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Dementia poses a great challenge for health care systems worldwide, with the 
population of affected people over the age of 60 estimated to reach 152 million by 
the year 2050.  
Dementia is acknowledged as being one of the strongest determinants of entry into 
residential care in people aged over 65 and it is estimated that nearly 70% of 
residents have dementia. 
Medication remains the most frequently used intervention for dementia patients, 
and pharmacists are arguably the nation’s experts on medication. In Great Britain, 
they are easily accessible and provide services to care homes as an enhanced 
service in the pharmacy contract. This research sought to establish the role and 
impact of community pharmacists on the pharmaceutical care of people living with 
dementia in care homes. 
 
Methods 
The research was conducted in four stages employing qualitative and quantitative 
methodology.  A qualitative study was conducted with community pharmacists 
who provided services to care homes for residents living with dementia in Essex 
and in Kent. This was followed by a quantitative survey of a wider population of 
community pharmacists across England.  
Qualitative interviews with care home staff explored their views about pharmacy 
services provided to residents with dementia. Finally, a dementia intervention tool 
to support pharmaceutical care through comprehensive medication reviews was 
developed and tested among a focus group of pharmacists. 
 
Results  
My research revealed that pharmacists mainly provided medication supply 
services to residents with dementia. Barriers to optimal pharmaceutical care 
included time, knowledge, communication, and access to patient records. 
Care staff revealed a desire for timely supply of medication, and help dealing with 
residents’ challenging behavior including refusal to take medications. Better 
e 
 
communication between MDTs and training of care home staff would improve 
patient care.  
The dementia medication review intervention toolkit was deemed useful by the 
focus group of pharmacists following preliminary testing. 
 
Conclusion 
Participating pharmacists considered their service provision as meeting 
contractual obligations despite structural barriers.  A tool to facilitate effective 
medication review was deemed useful as an aide-memoire. Further feasibility 
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1.1 Introduction and chapter overview  
Dementia affects about 7.1% of adults over the age of 65 and about 1 in 6 people 
over 80 years of age (Alzheimer’s Society, 2014).                                                                              
With continuous improvement in healthcare around the world, and consequent 
rise in life expectancy there is increasing prevalence of chronic diseases such as 
dementia (Alzheimer’s Disease International, 2015). An exponential surge in 
research within this area over the last few decades has thus ensued. This can be 
attributed to an increasing awareness of the rising global prevalence of dementia; 
knowledge of its progressive nature, the current lack of a cure together with 
progress in the understanding of the genetics and neuro-pathophysiology of 
dementia, as well as its current and future economic impact.  
Dementia may be caused by a range of diseases; these may be neurodegenerative 
(e.g. Alzheimer’s disease, Dementia with Lewy bodies, Frontotemporal dementia) 
or secondary to another disease condition (e.g. Vascular dementia, Parkinson’s 
disease dementia) (Gelder, Harrison and Cowen, 2006). Knowledge of the 
underlying cause of dementia (or its subtype) as well as early detection is key in 
the prognosis and treatment of the condition. This is not always easy because of its 
insidious and variable onset (Burns and Lliffe, 2009), with people sometimes 
presenting with symptoms of more than one type of dementia. 
While scientists grapple with the challenges of finding a cure for dementia, current 
strategies for dealing with the illness largely involve the use of medication to delay 
disease progression and manage symptoms, and at the same time, provide carers 
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with help in coping with the increased physical dependency of people with 
dementia as the disease progresses. 
Pharmaceutical care encompasses the responsibility to ensure medicines safety, 
appropriateness and clinical effectiveness of medicines use as well as the provision 
of advice on medicine administration, a responsibility that often falls to 
pharmacists amongst other healthcare professionals. 
This chapter presents a definition of dementia, a brief history of the disease 
condition, its prevalence in the UK and worldwide, epidemiology, and an 
examination of its current impact within the UK society and worldwide.                 
The concept of pharmaceutical care is defined and its application to care for people 
living with dementia will be discussed. 
The role of pharmacists in the care of people living with dementia and current 
service provision will also be discussed in this chapter. This will be followed by a 
presentation of the research question, aims and objectives of my research. 
1.2 Definition 
Dementia is a broad generic term used to describe a range of progressive, 
degenerative, terminal organic brain diseases all characterised by continuous 
deterioration in cognitive function (Burns, 2009). 
Neurologists have over the years, tended to define dementia as impairment in 
higher intellectual function manifesting itself usually as memory loss, difficulty 
with orientation to time, place, or person, decreased fund for general information, 
difficulty with performing tasks of abstract reasoning such as calculations, 
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similarities and differences, as well as lack of judgement (Feigenson, 1978).  
However, this earlier definition does not fully encompass the spectrum of mental 
states resulting from the variable causes of dementia.  
The Diagnostic and Statistical Manual (DSM-IV) (American Psychiatric Association, 
2000) and International Classification of diseases (ICD-10) (World Health 
Organisation, 1992) both propounded different criteria for dementia, with no 
common core definition of dementia. Both required impairment in two or more 
cognitive domains (memory, language, abstract thinking and judgement, praxis, 
personality and social conduct), representing a decline in previously higher level of 
functioning that is sufficiently severe to interfere with social or occupational 
functioning.  
However, the DSM-V (American Psychiatric Association, 2013) renamed dementia 
as a “major cognitive disorder” and modified the criteria such that impairments in 
learning and memory were no longer necessary for diagnosis, but at the same time 
recognising less severe forms of cognitive impairment (mild neurocognitive 
disorder). This reclassification was aimed at reducing stigma associated with 
dementia and aligning the diagnostic guidelines with current clinical practice 
(Dementia Australia, 2018) and delineating specific aetiological subtypes. 
The drawback with differing sets of criteria defining the same condition is that 
clinicians selectively use the criteria to meet their own clinical judgement of the 
concept of dementia (Breitner, 2006). This potentially influences diagnoses and 
prevalence studies of dementia.  
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An all-inclusive definition of dementia would differentiate it from delirium (similar 
to, and sometimes coexistent with dementia, but characterised by alterations in 
levels of consciousness) and other cognitive syndromes (like in the DSM-V), whilst 
describing its course and severity (like in ICD-10). The World Health Organisation 
(WHO 2019) definition of dementia comes close to achieving this: 
“Dementia is a syndrome – usually of a chronic or progressive nature – in which there 
is deterioration in cognitive function (i.e. the ability to process thought) beyond what 
might be expected from normal ageing. It affects memory, thinking, orientation, 
comprehension, calculation, learning capacity, language, and judgement. 
Consciousness is not affected. The impairment in cognitive function is commonly 
accompanied, and occasionally preceded, by deterioration in emotional control, 
social behaviour, or motivation”. (Dementia, WHO 2019) 
1.3 History 
Solon (ca 630-560BC), considered by some as the father of modern-day thinking, 
wrote about the impairment of judgement in humans through `physical pain, 
violence, drugs, old age or the persuasion of a woman'(Freeman 1926).                                
In medieval times, not much was recorded due to attribution of many medical 
conditions to mysticism, as a result of the proliferation of religions in this time 
period, but senile dementia became a disease in the 19th century when affected 
individuals were treated by medical practitioners called ‘alienists’ (Assal, 2019). 
Present day understanding of dementia follows on from early observations of 
scientists such as Aretaeus of Cappadocia in the second century A.D., Phillipe Pinel 
(1745-1826), Jean Etienne Esquirol (1772-1840) and much later in 1907, Alois 
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Alzheimer (Boller, Bick and Duyckaerts, 2007). The word ‘dementia’ is derived 
from the Latin root ‘demens’ (being out of one’s mind) and verbal usages of the 
word can be found before the 18th century (Berrios, 1987). 
Although dementia was brought to the world’s attention by the German 
neuropathologist and clinician, Alois Alzheimer, who is generally accepted to have 
discovered the condition that bears his name (Alzheimer’s disease) (Ramirez-
Bermudez, 2012); the diseases that can produce dementia existed long before the 
last century, and probably date as far back as the beginning of mankind itself 
(Boller and Forbes, 1998). Use of the term “dementia” is traceable back to 1381 in 
France, but it wasn’t until 1797 that Phillippe Pinel (1745-1826) who is credited 
with the discovery of modern psychiatry, first provided a sound description of 
dementia (Boller, Bick and Duychaerts, 2007). The six conceptual strands that 
shape the concept of dementia (a disorder of cognition, any age group affected, 
results in behavioural incompetence, potential complication of both a functional 
and psychiatric disorder and the fact that it could be acquired or congenital) were 
brought together in the 18th century (Berrios, 1987).  
 As a result of the heterogeneity of the dementia syndrome, the term “dementia” 
was dropped by DSM V (American Psychiatric Association 2013) in favour of 
“major cognitive disorders” as earlier discussed. 
1.4 Incidence, prevalence and global burden of dementia 
Epidemiological studies of dementia can be characterised by immense diversity 
with high levels of clinical and methodological variations (Kiejna et al. 2011). As 
the risk of developing dementia is often associated with ageing, lifestyle and 
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cardiovascular health (Nowrangi, Rao and Lyketsos, 2011), there is a need to 
design studies that determine country-specific dementia incidence and prevalence 
taking into consideration population specific lifestyles, diets and genetic 
dispositions, in a bid to develop preventive strategies and plan for future care.  
Determination of the incidence and prevalence of dementia is not an exact science 
(Kukull and Bowen, 2002), mainly because of difficulties in defining and detecting 
dementia in varying populations.  A case in point is the United Kingdom (UK) 
where determining the exact number of people living with dementia has remained 
a challenge (Knapp et al 2014). It has been suggested that difficulties with 
updating prevalence and incidence data on dementia could be partly due to the 
considerably high economic costs of door-to-door surveys or questionnaire-based 
studies (Pojoan et al 2019). 
As age is a main known risk factor for the disease, dementia constitutes one of the 
major causes of disability in later life and according to a World Health Organisation 
report (Dementia: A public health priority 2012), prevalence doubles for every 
five-year increment in age after 65. This is a huge concern, considering that the 
population of people over the age of 60 increased from below 500million in 1950 
to over a billion in 2009, and is estimated to be over 2 billion in 2050 (World 
Population Ageing, 2009). Furthermore, dementia does not affect only older people 
and an estimated 9% of total dementia cases are attributed to people with young 
onset dementia (which is defined as dementia where onset of symptoms occur 
before the age of 65) (Alzheimer’s Disease International and WHO, 2017). 
By 2010, the number of dementia sufferers worldwide was 35.6million, with 
projected increases over 20 years to 65.7 million, reaching 115million by 2050 
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(World Alzheimer’s Report 2009). The total number of new cases of dementia is 
nearly 7.7million each year, worldwide, giving an alarming estimate of one new 
case every four seconds (WHO, Dementia: a public health priority, 2012).  These 
estimates have changed over the years and the number of people now living with 
dementia worldwide in 2018 was 50million, set to rise by 204% to 132million by 
2050 (WHO Dementia Fact Sheet 2017). More recent figures indicate that number 
of people living with dementia by 2050 will be an estimated 152 million 
worldwide (WHO 2019). 
A Delphi consensus study commissioned by the World Health Organisation in 2005 
(Ferri et al, 2005) to determine prevalence of dementia in 14 of its world regions 
(based on geography), revealed that China and its developing western-pacific 
neighbours had the highest number of people living with dementia followed by 
Western Europe. It projected that Africa and Latin America will experience a 235-
393% surge in their numbers by 2040. 
However, when Prince et al (2013) conducted a systematic review and meta-
analysis of global prevalence in dementia, they concluded that there was little 
variation in age-specific prevalence of dementia between world regions.    
Although this study was meticulously designed to include only studies with 
sufficient sample sizes and robust designs, becoming one of the few available 
evidence bases for policy formulation with regards to dementia care at the time, it 
had poor coverage of evidence base from many world regions (particularly Africa) 
and considered only papers published in PUBMED and MEDLINE databases. This 
limited the generalisability of their conclusions. 
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In the UK, dementia was considered the most common psychiatric disorder in the 
community, affecting: 1 in 1400 of those aged 40-64, 1 in 100 of those aged 65-69, 
1 in 25 in those aged 70-79, and 1 in 6 in those aged over 80 years, altogether 
amounting to over 800,000 dementia sufferers. This was deemed likely to rise to 
1.7million by the year 2021 (Alzheimer’s Society, 2011). Additionally, it was 
estimated that dementia accounted for 60,000 deaths in the UK every year, with 1 
in 3 people over the age of 65 likely to die from dementia. By 2014, the total 
number of people living with dementia was an estimated 850,000 predicted to rise 
to 2million by 2050 (Prince et al 2014). These figures and predictions were 
maintained by Alzheimer’s Research UK in 2018 (Dementia Statistics Hub 2018). 
The prevalence of dementia is higher in women; this could be partly due to their 
greater longevity, but as most epidemiological studies show increasing incidence 
rate for women, their longer lifespan cannot be the only factor, and other 
explanations could be related to the confounding effects of education and 
hormonal influences (NICE-SCIE Dementia guideline, 2007). 
Of relevance to management and care strategies, is the prevalence of the range of 
diseases that cause dementia. Studies indicate that Alzheimer’s disease accounts 
for 50-60% of dementia cases, closely followed by Vascular Dementia (20-25%) 
and Dementia with Lewy bodies (10-15%), with Frontotemporal dementia 
underlying around 7% of later life dementia (Gelder, Harrison and Cowen, 2006) 
Despite the difficulties in determining incidence and prevalence of dementia, it is 
clear that dementia causes substantial global burden (Mathers and Leonardi, 
2000) and significantly affects those who suffer from it, their family and friends, on 
personal, financial and emotional levels. It is important that every society 
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understands the costs of dementia and how these impact upon families, health and 
social care services (Alzheimer’s Disease International 2016).                       
The total global societal cost of dementia was estimated to be US $818 billion in 
2015 corresponding to 1.1% of global gross domestic product, and it was predicted 
that by 2030, the cost of caring for people with dementia will exceed US $2 trillion, 
a figure which could potentially undermine global socio-economic development 
and overwhelm health, social services as well as long term care services (WHO 
2015).  
In the UK, the annual cost of dementia was an estimated  £23 billion per year, set to 
rise to £50billion by 2038, and the consequent impact on family and friends, in real 
terms, means that over 25million people will be affected by dementia (Alzheimer’s 
Society, 2012). Additionally, there’s an estimated 670,000 carers of people with 
dementia in the UK with family carers saving the government over £8 billion a 
year. Nonetheless the cost to the taxpayer is still considerably high since over a 
third of those suffering from dementia live in care homes (Alzheimer’s society, 
2012). 
There are low levels of understanding about dementia with symptoms being 
perceived differently in different parts of the world, leading to various 
misconceptions and resulting in stigma prevalent in most countries at various 
levels (Batsch et al 2012). The lack of awareness and understanding of dementia 
that results in stigmatisation has been blamed for the worldwide under-diagnosis 
of dementia and fragmentation of long-term care pathways for people living with 
dementia (WHO 2017). 
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The World Health Organisation in its “Global action plan on the public health 
response to dementia” (WHO 2017) proposed that when addressing the global 
challenges posed by dementia, an expansion of health and social care workforce 
with appropriate skill mixes, availability of necessary interventions and services 
were all essential for the prevention, timely diagnoses, treatment and care for 
people living with dementia. To this effect, in February 2015, the UK government 
published “The Challenge on Dementia 2020” (Powell and Baker 2019), in which 
the then Prime Minister, David Cameron, set key objectives for dementia care in 
England: The plan was to achieve the best support in the world for people with 
dementia, their carers and families and for England to be the best place in the 
world for them to live in. To achieve this, the challenge set many objectives; 
including increasing public awareness about dementia risks, enabling equal access 
to dementia diagnosis as for other conditions, ensuring that every person 
diagnosed with dementia received meaningful care according to NICE Quality 
Standards (NICE QS184 2019), and ensuring all hospitals and care homes became 
dementia friendly health and care settings, amongst other objectives. 
Involving pharmacists in all care settings to deliver pharmaceutical care to people 
with dementia was deemed essential, in order to achieve these goals (NHS 
Scotland 2014). 
1.5 Pharmaceutical care and its application to care of people with 
dementia 
In 1975, pharmaceutical care was considered “the care that a given patient requires 
and receives which assures safe and rational drug usage” (Mikael et al, 1975). 
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However the concept in its modern sense was defined as the “determination of the 
drug needs for a given individual and the provision not only of the drug required but 
also the necessary services (before, during and after treatment) to assure optimally 
safe and effective treatment” (Brodie, Parish and Poston 1980). 
In the ensuing decades, other definitions of pharmaceutical care have been 
advanced, with the most frequently cited being that of Hepler and Strand (1990) as 
“the responsible provision of drug therapy for the purpose of achieving definite 
outcomes that improve a patient’s quality of life”.   This definition was further 
expanded to include a “patient-centred approach” in which pharmacists assumed 
responsibility, and were held responsible for a patient’s medication-related needs 
(Cipolle, Strand and Morley, 1998). Later, the Pharmaceutical Care Network 
Europe (PCNE 2014) systematically reviewed the various definitions of the 
concept over the years, and came to a consensus that “Pharmaceutical Care is the 
pharmacist's contribution to the care of individuals in order to optimize medicines 
use and improve health outcomes”. 
Ensuring appropriateness and clinical effectiveness of medicines use as well as the 
provision of advice on medicine administration are all dimensions of 
pharmaceutical care. But more central to this philosophy, is the social 
responsibility, patient-centeredness and provision of care through the 
establishment of therapeutic relations that lead to better clinical outcomes for 
patients (Awaisu and Mottram 2018). 
As a working methodology for health professionals involved in the medication 
process, pharmaceutical care is essential for improving the safe use of medicines 
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and contributes to the optimisation of outcomes from medicines while preventing 
harm and inappropriate use (Cousins et al 2012).  
People living with dementia are often prescribed medication to manage the 
symptoms of the disease, to control the behavioural and psychological symptoms 
of dementia, or frequently to manage co-morbid conditions such as depression or 
epilepsy (Jordan et al., 2015). Healthcare professionals including pharmacists have 
a responsibility to ensure that the extent to which dementia compromises quality 
of life in sufferers is limited, and that their medication and other co-morbid 
conditions do not impact negatively on their overall functioning. Approximately a 
third of patients over the age of 65 in developed countries are prescribed five or 
more medicines a day (Qato et al 2008) and incidentally, most people living with 
dementia fall within this age group. The consequences of potentially inappropriate 
prescribing, especially in the older adult population with co-morbidities such as 
dementia, include functional and cognitive impairment, which can worsen health 
outcomes (Hilmer & Gnjidic, 2008). 
Medication can be inappropriately used or prescribed when the risks associated 
with its use surpass the clinical benefit for which they are prescribed (Eshetie et al 
2019).  
Evidence from an increasing number of research studies have shown that people 
with dementia are commonly prescribed potentially inappropriate medication 
(Banerjee 2009, Parsons 2017, Gnjidic et al 2018, Eshetie et al 2019). It is 
recognised that managing medication for people with dementia is a complex 
process which can result in medication errors and medication-related hospital 
admissions (Smith et al 2017). Initiation of acetylcholinesterase inhibitors for 
14 
 
treatment of dementia has also been linked to sequential polypharmacy to treat 
adverse drug reactions such as diarrhoea, syncope and bradycardia that are 
related to these drugs (Gill et al 2005, Park-Wyllie et al 2009, Gill et al 2009, 
Rochon et al 2018). Furthermore, polypharmacy is common in people living in care 
homes, who are often prescribed five medications or more across Europe 
(Bronskill et al 2012) and on average eight medications each in the UK (Barber et 
al 2009). This has been attributed to the care home population (at least 70% of 
which are living with dementia) being made up predominantly of frail elderly 
people more prone to multiple long-term conditions (Payne and Duerden 2015). 
Pharmaceutical care is invaluable for managing people with long term conditions; 
in dementia it would entail applying its conceptual principles to assessment of the 
person with dementia as well as all their drug therapies to optimise their 
treatment. This would ensure that medication prescribed is appropriate 
(identification of all co-morbidities and ascertaining that there is a clinical 
indication for each medication prescribed). The effectiveness of their medication 
(best drug at sufficient dose), its safety (consideration of adverse drug reactions) 
and any issues with compliance are also addressed (Cipolle, Strand and Morley 
2004), in order to identify drug therapy problems and create an individualised 
pharmaceutical care plan for each patient. 
Pharmaceutical care is thus an exemplar model of patient−centred pharmacy 
practice that involves the pharmacist taking responsibility for all a patient's 




There is an overwhelming need for a bespoke model of pharmaceutical care for 
people with dementia that can respond to local opportunities and local patients’ 
needs as well as contribute to the achievement of defined public health goals. A 
pharmaceutical care service, if expertly provided, may lead to a decrease in drug-
related problems and help in lowering care costs by reducing the number of these 
patients admitted into hospitals from care homes as a result of adverse drug 
events.  
For people with dementia resident in care homes, delivering healthcare 
interventions, including pharmaceutical care can be challenging, since these 
environments serve the dual purpose of catering for the needs of people with 
complex long term needs, as well as being a home for them (Hughes 2019).  
While it is recognised that care homes which accommodate a large population of 
physically and cognitively impaired residents require comprehensive and holistic 
pharmaceutical care (Lapane et al 2011), the impact of pharmaceutical care 
interventions, usually medication reviews, on outcomes such as reductions in falls, 
hospitalisations and mortality have been limited (Alldred et al 2016, Hughes 
2019). 
1.6 Care homes 
Care homes are long –term care facilities offering accommodation and personal 
care to people who need help and support in their daily lives. The Care Standards 
Act 2000 (Part 1, Section 3) considers an establishment a care home if it provides 
accommodation, together with nursing or personal care, for any of the following 
persons: persons who are or have been ill, persons who have or have had a mental 
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disorder, persons who are disabled or infirm, persons who are or have been 
dependent on alcohol or drugs (DOH 2003). This does not include hospitals, 
independent clinics or children’s homes. 
Facilities providing long term care are referred to using different terms around the 
world: in the United States, they are known as “long term care facilities”, in 
Australia “aged-care facilities” and in the UK, “care homes” (Alldred et al 2016).  
However, for clarity in my research, the term “care homes” will be used 
throughout. 
In the UK, care home services are predominantly provided by independently 
(privately) owned facilities. These establishments all provide accommodation and 
personal care, but are registered for different purposes: Care homes (offer 
personal care, help with washing, dressing, taking medication), nursing homes 
(offer personal care plus care from qualified nurses), care homes with dementia 
(designed to accommodate people with dementia and make them feel comfortable 
and safe), and dual-registered care homes that accept individuals that need 
personal care and or nursing care (Age UK 2019). 
The NHS (NHS UK 2019) advises consideration of a care home when an individual 
is struggling to live alone despite assistance from family, friends, or paid carers, or 
has a complex medical condition that needs specialist attention. 
Residents of care homes differ in terms of their healthcare requirements, but in the 
UK, the average care home inhabitant is likely to have over six clinical diagnoses, 
taking more than seven medications and living with physical disabilities, mental 
infirmity or cognitive impairment (Gladman et al 2015).  Over half of the care 
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home population in the UK is aged 85 and above and suffer from dementia 
(Gladman et al 2015, Hoffman et al 2014). Medication use amongst this population 
has been the focus of much research (Hughes 2019) owing to the high prevalence 
of polypharmacy (Jokanovic et al 2015) and its consequences which include drug-
drug interactions and/or drug-disease interactions (van Marum 2017).  
Inappropriate prescribing of medication, and polypharmacy are more prevalent 
amongst people living with dementia in care homes than in their community 
dwelling counterparts (Shah et al 2011). They also usually have at least four other 
active medical diagnoses (Patterson et al 2010) indicating that careful monitoring 
and medicines optimisation is required in these environments.  
1.7 Role of pharmacists  
Pharmacists began moving away from their traditional roles of compounding and 
supply of medicines as far back as the 1990s, and are now recognised as 
professionals with the skills and knowledge to improve the outcomes of drug 
therapy, focusing not only on the services they provide, but also on the effect of 
their services on patients’ quality of life (Penna 1990, Wiedenmayer et al 2006). 
Acknowledging that community pharmacies are the most frequently visited 
healthcare destinations has led policymakers to advocate extension of community 
pharmacists’ roles to accommodate growing public healthcare demands (DOH 
2008, Eades et al 2011, NHS England 2013). 
This shift in roles is fortuitous for people living with dementia in their own homes 
or in care homes, as pharmacists can play a significant role in supporting them 
through various clinically focused roles (Stafford 2015). These include but are not 
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limited to: help with managing adherence, as people with dementia reportedly do 
not take their medication as intended (Arlt et al 2008, Luzny, Ivanova and 
Jurickova 2014), managing symptoms of dementia and optimising drug therapy. 
The dementia syndrome is characterised by symptoms of cognitive decline such as 
loss of memory and orientation, and the development of behavioural and 
psychological symptoms of dementia (BPSD) such as aggression, agitation, 
wandering, hallucinations and sexual disinhibition (Cerejeira, Largato and 
Mukaetova-Ladinska 2012). These can lead to challenging behaviour in patients 
and elicit prescribing of psychotropic drugs that are deemed harmful to them in 
the long run (Banerjee 2009, Brechin et al 2013, Brooker et al 2016).   
Furthermore, significant differences in the pathology and clinical progression of 
various dementia sub-types directly impact their pharmacological management, 
each sub-type having a distinct pathology (Madhusoodanan and Ting 2014.) 
 Thus, when a pharmacist is dealing with prescriptions for dementia patients, there 
are many key points to consider:  
• the classification of sub-type 
• appropriateness of the prescribed medicine 
• impact of potential adverse effects of the drugs on the patients’ cognition 
• medicines optimisation 
In the UK, managing medication for people with dementia was emphasised in the 
National Dementia Strategy issued by the Department of Health in 2009, focusing 




Since the publication of the Banerjee Report (Banerjee 2009) highlighting 
inappropriate prescribing of antipsychotics to people with dementia and the harm 
that can be caused by this practice, pharmacists in the UK have been involved in 
reviewing anti-psychotic prescribing to patients with dementia, including those in 
care homes (Ballard et al. 2009, Redmond and Cavan, 2011, Child et al. 2012; 
Gadhia 2014, Maidment et al. 2016). While these interventions have led to a 
reduction in anti-psychotic prescribing amongst patients with dementia, 
medication management in general is still recognised as the missing link in 
dementia interventions and there are concerns that singularly targeting 
antipsychotics may result in clinicians reverting to prescribing alternatives like 
benzodiazepines which also have serious side effects (Maidment et al. 2011).  
To this effect, pharmacists’ involvement in medication management/review for 
people with dementia has focused more broadly on identifying potentially 
inappropriate prescribing (Pfister, Jonsson and Gustafsson 2017, Bala et al 2019, 
Eshetie et al 2019) and patient-centred care for dementia patients has been 
advocated (Blagburn 2017) especially with regards to managing behavioural and 
psychological symptoms of dementia. 
Person centred care is a term often used in relation to people with dementia which 
can mean different things to different people or healthcare services. It can be 
considered as a concept which encompasses four key elements: valuing people 
with dementia and those who care for them, treating people with dementia as 
individuals, looking at the world from their point of view, and having a positive 
social environment in which they can live relatively well (Brooker 2003). 
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In a patient-centred approach to dementia care, clinical pharmacists can be 
instrumental in the identification and management of under-treatment, ineffective 
medication, unsuitable dosage forms/regimens and proposal of non-
pharmacological approaches, all of which could lead to reduced healthcare costs 
and improvement in care quality (Zwietering et al 2018).  
Pharmacists can team up with other healthcare professionals to educate 
staff/carers of people living with dementia about clinical features of different 
forms of the disease, names of medications prescribed and their benefits/side 
effects, whilst also helping them look beyond medication by  sign-posting where 
appropriate to other services such as physiotherapists and optometrists (Riachi 
2016). 
Community pharmacists are amongst the most easily accessible healthcare 
professionals in primary care. They are highly visible and frequently form long-
standing relationships with their patients (Chang et al 2015), so they play an 
essential role in the overall health and wellbeing of the community in which they 
practise. People living with dementia both in the community and in care homes can 
benefit from the expertise of community pharmacists, who are trained to 
understand how medicines affect cognitive function.  
In 2013, the ‘dementia friends’ initiative was launched to increase awareness of 
dementia in communities, promote understanding of the disease and the ‘small 
things’ that can make a difference to people living with dementia (Dementia 
Friends 2013). The idea is to train ordinary people to become ‘dementia friends’ or 
‘dementia friends champions’ within communities. Community pharmacists have 
been encouraged to become more dementia friendly (Bearman 2013) with the 
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current community pharmacy contractual framework for 2019/20-2023/24 
requiring pharmacies to complete “dementia friendly environments” checklists 
(DOH 2019).  
There has been research leading to proposals about the role community 
pharmacists can play in managing medication for people living with dementia in 
the community (Maidment et al 2016). For people with dementia in care homes, 
clinical pharmacy input has mainly been provided by specialist dementia 
pharmacists (Maidment et al 2018), care home independent prescribing 
pharmacists (Inch et al 2019) or medicines optimisation pharmacists in care 
homes (Andalo 2014, Copeland 2016, NHS England MOCH Programme 2018).  
There is a paucity of published academic research concerning community 
pharmacist-led services targeting people with dementia in care homes in England. 
The increasing work load of community pharmacists (Gidman 2011), potential lack 
of adequate knowledge and skills in the field of dementia, lack of access to patient 
care records and inadequate communication with prescribers have all been 
suggested as possible reasons why an optimal pharmaceutical care service could 
not be provided by community pharmacists to people with dementia in general 
and those in care homes in particular. In fact, some researchers have opined that 
the ability of community pharmacists to contribute to chronic disease management 
is limited, and that policy initiatives aimed at developing a clinical role for 
community pharmacists in dementia care are unlikely to succeed (Maidment et al 
2017). 
However, in acknowledgement of the uniqueness of the medication-related needs 
of people living with dementia, NHS Education for Scotland (NES) published a 
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resource pack entitled ‘Pharmaceutical Care of People with Dementia’, designed to 
meet the education and training needs of pharmacists and pharmacy technicians 
delivering services to people with dementia, their families and carers (NES 2014).  
The extent to which this resource pack has been used has not been tested. 
The Alzheimer’s society (2016) asserted that overall care of people living with 
dementia in care homes was substandard. This view was echoed by Yeo et al 
(2017) with specific reference to pharmaceutical care, when they used the 
American Geriatric Society (AGS) Beers criteria (2015) to evaluate the quality of 
pharmaceutical care of people living with dementia in America. Based on their 
study which revealed that at least half of a large cohort of elderly dementia 
patients was receiving at least one potentially inappropriate medication, they 
concluded that this reflected poor quality pharmaceutical care in a patient 
population already deemed vulnerable.  This reiterated a need for a bespoke 
pharmaceutical care service to care homes with specific focus on people with 
dementia. 
In October 2016, NHS England (NHS Commissioning Pharmacy Integration Fund, 
2016 (PhIF)) confirmed that from April 2017, the PhIF would fund the deployment 
of pharmacy professionals in care homes, including development of the workforce 
through educational grants. This has led to the previously mentioned “Medicines 
Optimisation in Care Homes” (MOCH) programme (2018) that has seen pharmacy 
teams being funded to work in participating care homes till 2019/2020. This was a 
welcome development for care home residents, particularly those with chronic, 
progressive diseases such as dementia. 
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However, whilst deployment of clinical pharmacists in care homes could greatly 
improve disease management in residents (Royal Pharmaceutical Society (RPS), 
2016), this was a relatively small workforce and the service was not consistently 
offered in all care homes. In fact, NHS England announced in February 2018 that it 
would recruit 240 pharmacy professionals (including 180 pharmacists) into care 
homes by March 2019 but failed to meet this target by the deadline 
(Pharmaceutical Journal: News in Brief May 2019).  
The above implies that not all care homes are benefitting from pharmaceutical care 
services offered by specialist care home pharmacy teams, making current 
provision inadequate, particularly for the majority who are living with dementia. 
There have been suggestions that in addition to providing services through the 
national contract and locally commissioned services, community pharmacists 
could have direct contractual agreements with care homes either individually or in 
clusters (Webber 2015). Improvements of cognitive functioning of people with 
dementia in care homes, reduction in medication wastage and overall 
improvements in quality of life are outcomes that can inform the decision to 
involve community pharmacists more, and research is needed to explore their 
current capacity to do so.  
1.8 Research Rationale 
Dementia is a worldwide healthcare priority as determined by the World Health 
Organisation (2012), and as a result of its cost and burden, many countries have 
developed a strategy for managing the care of those suffering from it, in addition to 
supporting research on its prevention and treatment. 
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Within the last two decades, various schools of thought have explored the role 
community pharmacists could contribute to dementia care for people living with 
dementia in the community (Child et al 2012, Rubio-Valera et al 2014, McGrattan 
et al 2017), with one suggestion being for a wider role conducting medication 
reviews in patients’ homes (Oswald 2017). Other suggested roles include 
supporting people with dementia and their carers  to manage their medication 
better, and signposting them to other services that will enable them to live well 
with their condition (Lindauer et al 2017, Maidment et al 2017) 
There has been a push by professional bodies and governments to move 
community pharmacists towards fulfilling more clinical roles.                                   
For people with dementia, this would entail pharmacists being integrated with 
other healthcare providers to practice pharmaceutical care in its entirety, resulting 
in identification of drug therapy problems, and creation of care plans tailored to 
each patient, depending on individual need, ultimately leading to improved, 
measurable health outcomes. 
The British Medical Association (BMA) recognises this and recently pointed out 
that the direction of travel for community pharmacists is one focused on 
transitioning them from a business model to one which is more reliant on 
providing clinical services such as medication use reviews, enabling them to 
integrate better with the rest of the NHS (BMA and PSNC 2019). Whilst such 
services would be beneficial to people with dementia in the community, those in 
care homes where the services of dedicated care home pharmacists are not 
commissioned could also benefit from having their medication reviewed and drug 
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therapy problems addressed by local community pharmacists with knowledge of 
the disease, its features and appropriate management. 
The Alzheimer’s Society estimated that over 70% of care home residents in the UK 
are living with dementia; mostly because their disease has progressed to a point 
where they require more intensive support (Fix Dementia: NHS and Care Homes, 
Alzheimer’s Society 2016a). Often, the decision to be admitted into a care home is 
difficult for the person with dementia and this decision can be made easier if there 
is reassurance that once in the homes, residents receive the same or improved 
access to care services. This not the case; the report mentioned above by the 
Alzheimers’ Society concluded that dementia care in care homes was not 
sufficiently patient-centred, leading to damage to the health and wellbeing of 
dementia sufferers. The same report also concluded that the levels of pharmacy 
services were below the minimum needed, and supported the recommendation 
that “pharmacists should lead a programme of regular medicine reviews and staff 
training, working in an integrated team with other healthcare practitioners ensuring 
medicines safety” (The Right Medicine: Improving Care in Care Homes, RPS 2016). 
Each care home should have a dedicated pharmacist with responsibility for its 
overall medication management. 
In England, NHS England is the national commissioner for the NHS community 
pharmacy services to care homes. Through their local teams, NHS England 
commissions pharmacies to provide “advice and support to the residents and staff 
within the care home, over and above an essential dispensing service, to ensure 
proper and effective ordering of drugs and appliances, their clinical and cost 
effectiveness, storage, supply and administration, and proper record keeping” 
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(Pharmaceutical Services Negotiating Committee (PNSC 2005). However, clinical 
commissioning groups are also free to develop their own local services in response 
to identified local needs (PSNC 2019). Additionally, NHS England (NHS 
Commissioning Pharmacy Integration Fund 2016) only funded the deployment of 
pharmacy professionals in care homes for two years from March 2018, after which 
primary care networks were expected to continue (Andalo 2019), but how this will 
be implemented is currently unclear.  
What is clear from the above narrative is that some care homes will have more 
pharmacy input than others, as not all care homes will have a dedicated care home 
pharmacist, but community pharmacists are accessible to all.                                          
This realisation drove my desire to explore the possibility of community 
pharmacists expanding their role beyond the provision of essential services to care 
homes, to include targeted services for people with dementia in residential care.  
I thus set out to explore community pharmacists’ perspectives about the 
pharmaceutical care needs of people living with dementia in care homes; to 
examine their training needs in this domain and identify any barriers to the 
provision of the aforementioned targeted service. My research also explored the 
perceptions of care home staff about the medication-related needs of people living 
with dementia in this sector. 
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1.9 Research question, aim and objectives 
1.9.1 Research question 
What is the nature, role and impact of community pharmacists in the 
pharmaceutical care of people with dementia resident in care homes in England? 
1.9.2 Aim 
To explore the role of community pharmacists in the pharmaceutical care for 
people living with dementia in care homes, and to understand the barriers they 
face in an expanded role targeting this vulnerable patient group. 
1.9.3 Objectives 
• Review the literature on dementia, its subtypes, diagnosis and treatment and 
their implications for pharmaceutical care 
• Conduct a qualitative study utilising semi-structured interviews to explore the 
views and perceptions of community pharmacists about the pharmaceutical 
care needs of people living with dementia in care homes 
• Use the results of the qualitative study to develop a questionnaire survey for a 
wider audience of community pharmacists in England 
• Investigate the medication-related needs of people with dementia from the 
perspective of care home staff and explore their views about the services 
they receive from pharmacy. 

































2.1 Introduction and chapter overview 
There is a plethora of published literature on dementia, its prevalence, and global 
impact, risk factors for developing it, its diagnosis, pharmacological and non-
pharmacological management 
Existing literature was reviewed by searching specific healthcare databases: 
MEDLINE, EMBASE, PychInfo and PubMed.  
Relevant publications by the Department of Health (DOH), National Institute for 
health and Care Excellence (NICE) and Royal Pharmaceutical Society (RPS) were 
also reviewed for information regarding the role of pharmaceutical care to 
dementia diagnosis, risk factors, clinical features and sub-types. 
Hand searching of publications by experts in the field was also carried out, 
including publications in specific journals such as the ‘British Medical Journal’, 
‘Pharmaceutical Journal’ and ‘Age and Ageing’.   
The following search terms were used, alone or in combination:  
• Dementia, dementia care, drug therapy, medical care, pharmaceutical care, 
clinical pharmacist, community pharmacist, pharmacist attitude, Alzheimer’s 
disease, vascular dementia, frontotemporal dementia, dementia with Lewy 




Abstracts of retrieved articles were assessed for relevance to the study, duplicates 
were removed, and those not directly relevant to an overview of dementia, its 
identification, management and role of pharmacists were discarded.  
Chapter 2 presents an overview of dementia including its risk factors, clinical 
features and sub-types. The pathophysiology of each dementia sub-type and its 
relevance to therapeutic choice for each person with dementia is discussed. 
The behavioural and psychological symptoms (BPSD) of dementia and their impact 
on the therapeutic management of dementia is also addressed. 
There is a discussion about dementia diagnosis which includes a review of the 
assessment and detection of dementia in individuals referred for this purpose or 
are showing some level of cognitive decline. The potential role for pharmacists in 
care homes and the community in promoting early diagnosis is also considered. 
A critical review of current pharmacological and non-pharmacological 
interventions available for people with dementia is conducted.  
Finally, a summary of the knowledge gaps that set the scene for the rest of my 
research, a description of my chosen research methodology, followed by an outline 
of the ensuing chapters is included. 
2.2 Dementia Risk Factors and Clinical Features 
There are many neurodegenerative disorders that lead to dementia; thus the 
clinical features and risk factors of dementia may differ depending on the sub-type 
(cause) of dementia. However, there are some features that apply to most types of 
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dementia. This section presents some features that are common to most 
dementias. 
2.2.1 Risk Factors 
With current projections indicating an escalation in numbers of patients with 
dementia and an increased cost to the society, there is a need to examine the risk 
factors for dementia in order to identify ways in which individuals can make 
efforts towards prevention and mitigating risk. There is no way of definitively 
preventing dementia, but several key risk factors have been identified such as age, 
genetics, medical history (especially cardiovascular), lifestyle and environment 
(Alzheimer Scotland, 2011). While factors like age, genetics and gender, cannot be 
modified, it is possible to mitigate other risks and at least attempt to delay the 
onset of dementia. The Lancet Commission (Livingston et al 2017) estimated that 
an approximate 35% of dementia cases could be attributed to potentially 
modifiable factors like midlife hypertension, low education attainment, midlife 
obesity, hearing loss, late-life depression, diabetes, physical inactivity, smoking and 
social isolation. Risk factors associated with dementia are discussed here, but it 
must be noted that some risk factors can pre-dispose individuals more to one sub-
type of dementia than another; for example, age and genetic factors are most 
associated with Alzheimer’s disease whilst vascular risk factors are linked to both 
vascular dementia and Alzheimer’s disease (Larson 2019). 
Age 
Age is the biggest risk factor for dementia, and the effect of age ing is a consistent 
risk factor across various ethnic groups, with the risk of dementia increasing with 
age (Ferri et al, 2005, Prince et al, 2013). This is particularly true for Alzheimer’s 
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disease whose incidence approximately doubles every 10 years from the age of 60. 
In total, it is estimated that 85% of dementia cases are in the 75 and above age 
group (Niu et al 2017). 
Genetics 
A common genetic polymorphism, apolipoprotein E (ApoE) gene e4 allele greatly 
increases the risk of dementia but some people who have one or more copies of 
ApoE4 do not develop dementia, while others develop dementia without the gene 
at all. Some scientists have thus argued that the presence of the gene does not 
necessarily determine whether a person gets dementia, but rather when they get 
it, the presence of the gene being more predictive of late onset dementia 
(Alzheimer Scotland, 2011). 
The largest amount of data available on genetic risk factors is available for 
Alzheimer’s disease as it is the most prevalent subtype (Larson 2019), but a family 
history of dementia is commonly present in frontotemporal dementia too. It must 
be noted that the risk estimates taper off the older the parent is at diagnosis, 
meaning there is no risk to offspring if a parent is diagnosed after 80 (Wolters et al 
2017) 
Gender 
The female sex has been associated with increased risk of developing Alzheimer’s 
disease since the ApoE4 gene appears to have a greater deleterious effect on gross 
hippocampal pathology and memory in women than in men (Azad et al, 2007). 
However, the association between gender and dementia risk can be complicated by 
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lifestyle, ethnicity and other factors which need to be considered when exploring 
the link between sex and dementia risk (Chen, Lin and Chen 2009). 
Vascular risk factors  
Vascular risk factors such as hypertension, diabetes, lipid disorders 
(hypercholesterolaemia) are associated with increased risk of development of 
Alzheimer’s disease and vascular dementia (Sahathevan, Brodtmann and Donnan, 
2012). However, there exists a common vascular pathology to most causes of 
dementia, suggesting that early diagnosis and treatment of vascular disorders 
could modulate the onset of dementia, but epidemiological studies that group 
together all forms of dementia can hide individual patterns of risks, clinical 
manifestations and treatment success (Ritchie and Lovestone, 2002). Associations 
between vascular risk factors and dementia are best measured in midlife rather 
than later in life when multiple other factors have to be considered (Larson 2019). 
Lifestyle 
Smoking, excessive alcohol consumption, inflammation, a lack of physical exercise, 
lack of education, diet and environmental factors (aluminium, iron, copper, zinc in 
and obesity) have all been linked to increased risk of dementia (Chen, Lin and 
Chen, 2009).These environmental factors are thought to combine with genetic 
predisposing factors to cause cellular changes which result in progressive 
neuronal degeneration possibly involving mitochondrial dysfunction and failure of 
protein degradation machinery at the cellular level (Ghandi and Wood, 2005).   
With the upsurge in research activity in various aspects of dementia, many 
investigations are on-going, but so far there is no indication that the environmental 
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and lifestyle factors linked to dementia are fully understood. However, since 
prevalence and incidence of Alzheimer’s disease seem to be much lower in some 
developing regions, there may be some indication that some environmental risk 
factors are much less prevalent in these settings (WHO, 2006). 
Risk of dementia has been broadly associated with lifestyle components such as 
mental, physical and social activity, using various biologically plausible hypotheses 
including the cognitive reserve, vascular and stress hypotheses (Fratiglioni, 
Paillard-Borg and Winblad 2004). Of interest, is the theory that higher levels of 
education, combined with cognitive and social activity builds a cognitive reserve 
that reduces the impact of neurodegeneration on cognitive function. 
Others 
There have been links between a wide range of other factors and increased risk of 
dementia. These include depression chronic disease and medical illnesses, head 
trauma, depression, hearing loss, obstructive sleep apnoea and exposure to certain 
toxins (Larson 2019). 
A detailed examination of these risk factors is beyond the scope of this chapter. 
However an understanding of the aetiology and pathophysiology of the subtypes of 
dementia will help to shed light on how these factors play a role in the 
development of dementia. 
2.2.2 Clinical Features of dementia 
Clinical features of dementia may differ depending on the underlying cause and 
can be subjective depending on the individual’s premorbid personality, lifestyle, 
significant relationships and physical health (WHO 2006). 
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The presenting complaint is usually of memory loss (usually for more recent than 
more remote material), with forgetfulness usually being early and prominent, 
while impaired attention and concentration are common, non-specific features 
(Gelder, Harrison and Cowen, 2006). In more severe dementia, individuals may 
forget previously learned material including the names of loved ones, and have 
difficulty learning new material (Ameen, 2004).   
In general, the clinical features of dementia can be grouped into three different 
categories:  
➢ A first stage of cognitive impairments (including memory impairments, 
language difficulties), apraxia, aphasia and agnosia.  
➢ A second stage that comprises of neuropsychiatric features such as depression, 
paranoia, wandering, anxiety, (all known as behavioural and psychological 
symptoms of dementia or BPSD); 
➢ A third stage comprising deficits in activities of daily living such as self-neglect 
or diet (Grand, Caspar and Mcdonald, 2011). Disorientation for time, place and 
person, poor judgement and impoverished thinking can also occur, as well as 
distress, irritability, aggression, blunted emotional response and other 
behavioural problems (Gelder, Harrison and Cowen, 2006). 
It is worth noting that memory loss is no longer essential for dementia diagnosis as 
key clinical features can differ depending on the underlying cause of the dementia 
e.g. early deficits in attention and visio-spatial focus are more relevant in dementia 
with Lewy bodies, while in frontotemporal dementia, memory loss is absent or 
occurs later (Kester and Scheltens, 2009). 
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Behavioural and psychological symptoms of dementia (BPSD), a set of non-
cognitive symptoms (agitation, aggression, wandering, and psychosis) occur 
commonly in Alzheimer’s disease, especially in the middle and late stages of the 
disease (Turner 2014). These will be discussed in more detail later in this chapter 
as many potentially inappropriate medications are started in people with dementia 
as a result of BPSD. 
There is also recognition of a prodromal or transitional state for dementia called 
mild cognitive impairment (MCI), which is a phase between healthy ageing and 
dementia (Busse, Angermeyer and Riedel-Heller, 2006). This is relevant because 
up to 20% of people with MCI progress to dementia every year. 
The above core symptoms and signs can be balanced with additional specific 
features to form the basis for clinically differentiating between various causes of 
dementia. 
An awareness of the risk factors and clinical features of dementia enables 
community pharmacists to support community dwelling individuals with dementia 
and their carers in medication management and signpost them to appropriate 
services (Criddle 2014). 
2.3 Main Causes (sub-types) of Dementia, their pathophysiology, 
clinical presentations and implications for pharmaceutical care 
2.3.1 Introduction  
Distinctions have been made in the classification of dementia; these have 
implications for understanding the pathophysiology of each type of dementia. It is 
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important to understand the pathophysiology and the clinical presentations of 
various dementia subtypes in order to differentiate one type from another.  
Dementia cannot be assigned a single nosological entity; it can be grouped into 
different classes on the basis that each dementia type has a different 
neuropathophysiology. One such distinction is classifying dementia into cortical 
and subcortical dementias (Gelder, Harrison and Cowen, 2006).  The distinction 
between cortical and subcortical dementia is blurred, but subcortical dementia 
types (Parkinson’s disease dementia, Wilson’s disease, HIV associated dementia) 
are primarily characterised by movement disorders, slowness of thought, while 
cortical dementias (Alzheimer’s disease, Frontotemporal dementia) are 
characterised by memory impairment (Semple and Smyth, 2008).  
Another method of distinction for the dementias is differentiating between 
primary neurodegenerative dementias such as Alzheimer’s disease, dementia with 
Lewy bodies and frontotemporal dementia, from dementia secondary to another 
disease process such as HIV associated dementia.  However, as complex interactive 
effects of genetic predisposition, neurochemical changes and disease co-
morbidities of dementia become clearer with research, such simplistic distinctions 
are being revised (Ritchie and Lovestone, 2002). The cortical/subcortical 
dichotomy for example, has been revisited as subcortical deficits such as seen in 
Parkinson’s disease can also be found in cortical dementias such as Alzheimer’s 
disease and vice versa (Hickey et al, 2008). 
Histopathological studies have shown that different forms of dementia can share 
the same underlying pathologies and that mixed states where people present with 
the features of more than one type of dementia are more common than pure 
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dementia syndromes. This implies that grouping together all forms of dementia 
can mask individual patterns of risk, clinical manifestation, and treatment 
outcomes. 
A molecular based method for distinction emerged from the theory that 
neurodegenerative dementias involved two forms of abnormal proteins called 
synuclein and tau, resulting in classifications of dementia into synucleiopathies 
(Dementia with Lewy bodies, Parkinson Disease) and taupathies (Alzheimers 
disease, Frontotemporal dementia), which scientists found more useful (Hickey et 
al, 2008). Vascular dementia is a notable exception from this grouping as it is not 
neurodegenerative. It has also become increasingly clear that most 
neurodegenerative diseases that lead to dementia are characterised by processes 
that result in aberrant polymerisation of proteins. A small number of people with 
these diseases develop dementia as a direct result of the presence of mutations or 
polymorphisms in genes that influence these processes (Holmes, 2012). 
The relevance of understanding how clinical sub types of dementia correspond to 
underlying pathophysiology is that it becomes easier to assign patients to 
appropriate therapeutic protocols (Mesulam, 1985). 
Other distinctions have been made based on time of onset (early onset, late onset 
dementia) or severity (mild, moderate, severe), but these tend to apply mainly 
within each sub-type.  
The pathophysiologies of Alzheimer’s disease (AD) vascular dementia (VaD), 




2.3.2 Alzheimer’s disease (AD) 
Several diseases cause dementia, but by the far the most common cause is 
Alzheimer’s disease (AD) also called dementia of the Alzheimer type (DAT) (Plum, 
1986; Silvestrelli et al, 2006; Moreira et al, 2010). It accounts for almost 50-60% of 
dementia cases (Gelder, Harrison and Cowen, 2006, Alzheimer’s Research UK, 
2018). 
 Over 100 years ago in 1907, Alois Alzheimer reported the case of Auguste D, a 55-
year-old woman whose brain exhibited unusual neuro-pathophysiological 
features. Post-mortem examination showed a brain with an abnormally thin 
cerebral cortex and microscopic features of senile plaques and neurofibrillary 
tangles, but it was his colleague, Kraepelin who named the disease (Maurer and 
Maurer, 2003). In the years since, research has led to a better understanding of AD, 
but the cause of the disease remains unknown. Many case control studies have 
linked several risk factors such as age, family history, small head circumference, 
head injury, apolipoprotein (Apo E4) status, depression, hypertension, diabetes, 
high cholesterol, atrial fibrillation, presence of cerebral emboli, and low physical 
and cognitive activity to the disease (Burns and Illiffe, 2009).  
Advances in research have led to an understanding and characterisation of the 
hallmarks of AD earlier observed by Alzheimer (plaques composed of amyloid beta 
or Aβ, and tangles composed of hyperphosphorylated tau), and this knowledge has 
resulted in an appreciation of the complex nature of AD pathogenesis (Blennow, de 
Leon and Zetterberg, 2006, Keene, Montine and Kuller, 2019). These hallmarks 
need to be defined, in order to contextualise the theories that have been put 
forward by scientists to explain histological changes in AD pathology: 
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 In AD, the brain shrinks, and microscopic examination reveals the cardinal 
diagnostic features that are neurofibrillary tangles (NFT) and senile (amyloid) 
plaques in the cerebral cortex and many sub-cortical regions (Gelder, Harrison and 
Cowen, 2006). Amyloid plaques are deposits of insoluble proteins which occur 
together with degenerating neurites and glia, in the space between neurons. At the 
centre of the senile (amyloid) plaques, is a protein called β-amyloid (Aβ) which is a 
39-42 amino acid peptide. Production and accumulation of Aβ peptide is central to 
the pathogenesis of AD (Wood and Cummings, 2004). Isolation of Aβ  paved the 
way for the discovery of the amyloid precursor protein (APP) gene which was 
cloned in 1984, and led to the connection between Aβ and the protein from which 
it is derived (DeKosky, 2001). Aβ is a fragment cleaved from the full length of the 
APP, and Aβ has been found to be neurotoxic in vitro leading to cell death and the 
overexpression of human amyloid precursor protein in transgenic mouse models 
of Alzheimer's disease, which results in neuritic plaques similar to those seen in 
humans with Alzheimer's disease (Wood and Cummings, 2004). The other 
hallmark, NFT, are the remains of defective neurons where the centre of each cell 
is filled with remains of microtubules wrapped around each other to form highly 
ordered spirals called paired helical filaments. The filaments are then composed of 
several proteins including tau and Aβ. The presence of tangles leads to dysfunction 
and death of the neuron. NFT and amyloid plaques are found in the areas of the 
brain where neuronal loss is most severe. The density of filaments formed from tau 
proteins within the neurons in the brain is directly related to the severity of 
dementia (Silvestrelli et al, 2006). The number of plaques in the cerebral cortex is 
directly proportional to an individual’s intellectual function; so the greater the 
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incidence of plaque deposition, the more impaired is intellectual function. It is not 
yet clear whether tangles are linked to plaque formation.  
Many pathogenic hypothesis have been postulated based on Aβ, the more 
prominent being the amyloid cascade hypothesis, the genetic hypothesis and the 
inflammatory hypothesis. 
The amyloid cascade theory which resulted from research into APP has become 
predominant as the molecular model for AD. In this hypothesis, the central 
pathogenic event is the increased formation and deposition of β-amyloid (Aβ) 
protein (the main component of neuritic plaques), particularly the 42-amino acid 
variant, leading to formation of neurofibrillary tangles, cell loss and vascular 
damage leading to dementia (Hardy and Higgins, 1992). The amyloid precursor 
protein (APP) can be cleaved by one of three enzymes called secretases: α-
secretase, β-secretase, or ϒ-secretase. When α-secretase predominates, there is no 
formation of Aβ, but in AD, APP is predominantly formed via β-secretase and ϒ-
secretase pathways leading to increased β-amyloid formation hence dementia. 
Additionally, cholesterol metabolism is heavily implicated in liberation of Aβ. 
The implication of this for dementia care is that pharmacological treatments can be 
developed that inhibit β-secretase and ϒ-secretase leading to reduction in 
production of the toxic Aβ (Wood and Cummings, 2004). This also implies that 
statins can have a role in preventing AD.  
The genetic hypothesis of AD is based on research implicating various risk genes 
that have been isolated (Keene, Montine and Kuller, 2019). One such gene is the 
human apolipoprotein E (ApoE4), defined as a pleiotropic lipoprotein thought to 
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be involved in multiple cellular processes such as cholesterol transport, synaptic 
plasticity and immune regulation to name a few. 
The mechanism by which inheritance of ApoE4 increases AD risk is unclear; but a 
popular theory is that ApoE4 impairs clearance of Aβ from the cerebrum 
(Castellano et al 2011).  
The inflammatory hypothesis in relation to AD builds on evidence of the 
involvement of inflammatory processes in AD pathogenis documented over the 
years (Zotova et al. 2010). The inflammatory reaction referred to in this hypothesis 
is considered a downstream effect of accumulated amyloid beta (Aβ) and tau. 
According to this hypothesis, Aβ found in the CNS (central nervous system) brings 
about activation of microglia (resident phagocytes of the CNS) which initiates a 
pro-inflammatory cascade. This causes the release of substances such as cytokines, 
chemokines, reactive oxygen, nitrogen species and proteolytic enzymes which are 
potentially neourotoxic, and lead to degenerative changes to the neurons (Zotova 
et al. 2010, Heneka et al 2018). 
Despite evidence that inflammation is involved in AD pathogenis and exacerbates 
the course of the disease, the inflammatory hypothesis is mostly based on 
mechanisms observed in animal models, and the type of inflammation is not well 
defined in the human brain (Zotova et al. 2010). However, from a pharmaceutical 
perspective, there are implications that drugs with anti-inflammatory properties 





Pharmacotherapy of AD 
The neurotransmitter hypothesis of AD pathogenesis has great implications for 
development of therapeutic agents for treatment of the disease.  The cholinergic 
system is critical to normal memory and other cognitive functions and in AD, it has 
been discovered that there is selective loss of cells that produce acetylcholine 
(ACh) in the basal forebrain. Research in the field of AD in the 1970s identified the 
loss of the synthetic enzyme choline acetyltransferase (DeKosky, 2001) and as 
cholinergic function is required for short-term memory function, it was 
determined that cholinergic deficit in AD was responsible for much of the short 
term memory deficit. Loss of choline acetyltransferase (ChAT) is the most 
consistent finding in post mortem AD, and its deficit corresponds to loss of 
cognitive function (Keverne and Ray, 2008). The elucidation of this hypothesis led 
to the development of current symptomatic medications for AD, the 
acetylcholinesterase inhibitors, which prolong the half –life of ACh at the 
cholinergic synapse (DeKosky, 2001, Brodaty et al, 2001, Grossberg, 2003). 
Cholinesterase inhibitors reduce breakdown of ACh and have been found to 
enhance cognitive performance and improve behavioural symptoms of AD 
including depression, agitation and apathy. 
The neurotransmitter glutamate is also decreased in AD. Glutamate is the main 
excitatory neurotransmitter in the brain; loss of glutaminergic neurons as well as 
glutamate activity in AD patients correlates with severity of dementia, with the 
hypothesis that glutaminergic disruption may be involved in the cognitive 
symptoms of the disorder (Keverne and Ray, 2008). Overstimulation of NMDA 
receptors by glutamate is implicated in neurodegenerative disorders such as AD as 
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overstimulation may result in neuronal damage (Sylvestrelli et al, 2006). 
Glutamate stimulation of post synaptic receptors including NMDA has been 
implicated in memory processes, dementia and the pathogenesis of AD (Wood and 
Cummings, 2004). A therapeutic agent, memantine, a non-competitive NMDA 
receptor antagonist, reduces glutamate over stimulation and is currently widely 
used in the treatment of moderate to severe AD. 
Several other hypotheses have been advanced for the pathogenesis of AD, 
including inflammatory mechanism (Imbimbo, Solfrizzi and Panza, 2010), 
oxidative hypothesis, mitochondrial dysfunction (Moreira et al, 2010) and 
abnormalities in proteins regulating the cell cycle. However, even though these 
mechanisms contribute somewhat towards explaining AD pathogenesis, there is no 
knowledge yet of how they drive the neurodegenerative process (Blennow, de 
Leon and Zetterberg, 2006). Developing treatment strategies based on these can 
therefore be challenging.  
Even though knowledge and understanding of the pathophysiology of AD has 
grown in leaps and bounds in the past two decades, a cure for the dreaded disease 
remains elusive. It is hoped that with the availability of increasingly sophisticated 
neuro-imaging techniques and advances in molecular biology, enabling a better 
understanding of the underlying pathobiology of AD, medications can be 
developed to slow the progression of the disease more effectively, or even prevent 
its emergence. 
2.3.3 Vascular Dementia (VaD) 
Vascular dementia is the second most common form of dementia in the elderly 
after AD (Roman, 2002). The current prevalence of Vascular Dementia ranges from 
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4.5% to 39% in clinical studies (Jellinger, 2007). It is caused by cerebrovascular 
disease and was referred to in the past as “atherosclerotic psychosis” (Gelder, 
Harrison and Cowen, 2006). However, this dementia, which is insidious and slow 
progressing is not due to atherosclerosis. It was often associated with multiple 
infarcts, leading Hachinski et al (1974) to suggest the name “multi-infarct 
dementia”. This term is still sometimes used, but research has shown that patients 
with “multi-infarct dementia” are a subgroup of a larger group of patients who 
have dementia caused by vascular disease. 
To this effect, Vascular Dementia (VaD) can be classified according to the 
underlying mechanism into: dementia associated with ischaemic or haemorrhagic 
lesions, multi-infarct dementia, slowly progressing dementia and dementia with 
border zone infarction (Takahashi, 2006; Jellinger, 2008).  These classifications can 
however be misleading as they appear to indicate that VaD can result from distinct 
processes in isolation. In reality, the disease is best understood as a heterogeneous 
syndrome whose underlying cause is some form of cerebrovascular disease 
ultimately manifesting as dementia (Smith and Wright 2019).  
In VaD, whilst it is accepted that the pathogenic mechanisms of VaD are varied, 
there is generally a history of transient ischaemic attack (TIA), hypertension or 
stroke. This explains the current consensus that these pathogenic mechanisms 
include atherosclerosis and micro (infarcts) in addition to amyloid angiopathy 
(Wolters and Ikram, 2019). Vascular changes caused by these processes result in 
cognitive decline in a pattern consistent with models of disturbed cortical and 
subcortical circuits (Jellinger, 2008).  
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Despite advances in dementia research, it has been hard to get a widely accepted 
neuropathological criteria for vascular dementia because it is very difficult to 
define neuropathological thresholds for considering lesions as being causative of 
cognitive decline (Grinberg and Heinsen, 2010). Cognitive decline does not depend 
only on the amount of lesion in the strategic area, but is rather a complex equation 
involving the amount of tissue loss, location, and brain capacity for compensating 
the changes. It is therefore not rare to find descriptions of non-demented patients 
presenting with the same kind and severity of lesions found in demented patients 
(Grinberg and Heinsen, 2010). Further complications in defining criteria include 
the fact that AD can also be caused by cerebrovascular disease; Apolipoprotein E, 
which plays a role in AD, also has a role in the vessel pathology of the ageing brain. 
There is thus a high prevalence of VaD co-morbid with AD. 
Pharmacotherapy of VaD 
The therapeutic implication of these theories for VaD pathogenesis is that 
measures taken to reduce risk of developing cerebrovascular disease such as 
smoking cessation, control of diabetes, reduction of alcohol consumption and 
management of blood pressure, can be applied to preventing Vascular dementia.  
Another important aspect of VaD pathology is that neurochemical studies have 
shown abnormalities in key neurotransmitter systems, particularly in the basal 
forebrain cholinergic system which is related to diffuse white matter lesions. Since 
cholinergic mechanisms play a role in the regulation of cerebral blood flow, there 
are implications for VaD pathogenesis (Jellinger, 2008). Studies have also shown 
significant reductions in cholineacetyl transferase (ChAT) activity in the 
hippocampus of multi-infarct encephalopathy. The clinical implication of this is 
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that acetylcholinesterase inhibitors, currently used in AD pharmacotherapy, could 
play a role in VaD.                                                                                                       
Additionally, it is thought that hypertension may be the cause in up to 50% of cases 
of VaD (NES 2014), indicating that failure to take blood pressure tablets correctly 
could lead to worsening of dementia symptoms, creating a vicious cycle (Oswald 
2017). 
2.3.4 Dementia with Lewy Bodies 
Dementia with Lewy bodies (DLB) is a common form of dementia in old age which 
accounts for about 10-15% of cases seen in neuropathological studies (McKeith, 
2002), suggesting that it is one of the most frequent causes of dementia.  
DLB is characterised by the presence of cytoplasmic inclusions of α-synuclein in 
the cerebral cortex and nuclei of the brain stem (Rampello et al, 2004). The 
cardinal neuropathologic feature is the presence of Lewy bodies in the cerebral 
cortex. The Lewy body (an intracytoplasmic inclusion of a round hyaline mass) 
was first characterised as the neuropathologic hallmark for Parkinson’s disease 
(PD) in 1912(Ferman, 2000). Frederick Lewy described these bodies in the 
cerebral cortex and substantia nigra in 1923.  
DLB was often overlooked pathologically due to challenges in identifying cortical 
Lewy Bodies using histochemical stains. However with the advent of 
immunohistochemical stains, its prevalence is now better characterised, although 
distinguishing it from other degenerative dementias continues to be challenging 
(Latimer and Montine 2019) due to increased prevalence of concomitant AD 
neuropathological changes in DLB (Lemstra et al 2017). 
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In DLB, as with AD, amyloid plaques can be abundant, but neurofibrillary tangles 
are absent. Theories for formation of Lewy bodies include the postulation that they 
may form because α-synuclein becomes insoluble or are more able to aggregate for 
some reason, or abnormally processed by a dysfunctional proteasome system, 
producing toxic protofibrils (McKeith et al, 2004). 
The presence of Lewy bodies in the autonomic ganglia cause postural hypotension, 
possibly explaining the frequency of falls in patients with DLB. Their occurrence in 
the neocortex and limbic cortex produce cognitive failure and psychosis. DLB is 
also associated with widespread reduction in choline acetyl transferase (ChAT) in 
the neocortex, and loss of dopaminergic markers in the caudate nucleus. High 
incidences of psychiatric symptoms in DLB is associated with these neurochemical 
changes (Gelder, Harrison and Cowen, 2006). Many researchers associate the 
localisation and density of Lewy bodies with the severity of clinical syndromes. It is 
assumed that the presence of Lewy bodies in the brain stem is responsible for 
movement disorders; in the limbic system with psychosis and in the cortex with 
depression (Rampello et al, 2004). 
 
Pharmacotherapy of DLB 
The pathogenesis of DLB has many implications on its pharmacological 
management and in the pharmaceutical care of people living with it. As there are 
proven cholinergic deficits in DLB, acetylcholinesterase inhibitors (Galantamine, 
donepezil and rivastigmine) may be of use in improving cognition and decreasing 
apathy in some patients with DLB. 
49 
 
Due to dopamine depletion which is characteristic of DLB, patients with this 
condition are extremely sensitive to even the smallest doses of antipsychotics 
(Armstrong et al 2016), and the use of antipsychotics in this group of dementia 
patients can be fatal especially when the potential to cause neuroleptic malignant 
syndrome is considered. It is therefore very important to diagnose DLB early, as 
this will minimise the risk of exposing patients to potentially fatal treatments such 
as antipsychotics. 
In a web based survey of 962 caregivers of patients with DLB over a six month 
period, Galvin et al (2010) found that caregivers were often frustrated with their 
experiences with physicians who took considerable lengths of time and several 
visits to diagnose DLB, causing significant delay in initiation of therapy.  This study 
was limited by the fact that the researchers did not make any independent 
observations of patients’ medical notes, the need for education and training of 
caregivers, and any improvement of time to diagnosis by physicians. 
The implication of α-synuclein aggregation in how DLB manifests itself and 
progresses in human and animal cell models has led to research attempts to 
develop therapeutic strategies aimed at reducing α-synuclein in the brain, such as 
immunisation with antibodies which promote its degradation (Zang, Kim and 
Narayan 2015). 
2.3.5 Frontotemporal Dementia (FTD) 
Frontotemporal dementia (FTD) is the second most common type of pre-senile 
dementia and fourth most common type of senile dementia (Sjorgen and 
Anderson, 2006), underlying about 7% of late life dementias. FTD comprise a 
broader, more heterogenous range of clinical presentations than common 
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dementias, and it is the most frequent clinical phenotype under the spectrum of 
frontotemporal lobar degenerative diseases (FTLD),  further categorised by 
abnormal protein inclusions due to tau and other proteins (Lee 2019).  
FTD is now the preferred umbrella term for three presentations namely: two forms 
of primary progressive aphasia (PPA), and behavioural variant FTD (bvFTD). A 
clear distinction between the clinical and neuropathologic terminology is essential. 
BvFTD is the most common clinical subtype of FTD, its hallmark being a 
progressive change in behaviour and personality (Johnson et al 2005). 
In the majority of FTD cases, which are often sporadic in nature, the 
pathophysiology is unknown. In hereditary FTD, mutations of different tau 
proteins are implicated (Sjorgren and Anderson, 2006), where abnormal tau may 
lead to aggregation of tau or disruption of microtubules thereby severely 
impinging the intraneuronal transport system.  FTD differs from AD and DLB in not 
showing cholinergic deficits, and dopamine also appears to be unaffected.  All 
forms of FTD show gross atrophy of the temporal and frontal lobes, with neuronal 
loss, gliosis, spongiform changes in the cortex, and often ballooned cells and 
neuronal inclusions that stain for ubiquitin, tau and phosphorylated 
neurofilaments (Gelder, Harrison and Cowen, 2006). Tau protein involvement is 
central to the pathogenesis of FTD. Other hypotheses that have been proposed for 
pathogenesis of FTD include involvement of autoimmune mechanisms and 
involvement of cytoskeleton proteins (Sjorgen and Wallin, 2001). 
Due to its heterogeneous nature, FTD is difficult to diagnose despite existence of 
diagnostic criteria, and there are few investigations to aid diagnosis.  It has been 
reported that FTD is associated with movement disorders and studies have 
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provided evidence of Parkinsonism signs in familial cases due to mutations in tau 
proteins (Padovan et al, 2007). 
 
Pharmacotherapy of FTD 
The uncertainty about the pathophysiology and aetiology of FTD means no 
curative agents are available yet. Pharmacotherapy therefore involves 
symptomatic treatment with antidepressants and neuroleptic agents for control of 
behavioural symptoms. As a result of a hypothesis formulated by Constantinidis 
and Tissot (1981) who proposed that excess zinc is accumulated in the brains of 
patients with FTD, heavy metal chelators have been used to treat FTD resulting in 
clinical improvements in several frontal functions. Though there is cognitive 
dysfunction in FTD, it is not mediated via the cholinergic pathway, so theoretically, 
cholinesterase inhibitors will have little effect.  
2.4. Behavioural and psychological symptoms of dementia (BPSD) 
As dementia progresses, irrespective of subtype, functional and cognitive 
impairment worsens and individuals begin to suffer from a range of heterogeneous 
psychological and psychiatric symptoms often referred to as the behavioural and 
psychological symptoms of dementia (BPSD). These are also called 
‘neuropsychiatric disorders’ (Ritchie and Lovestone 2002), ‘challenging 
behaviours’, ‘non-cognitive symptoms’, ‘behaviour that challenges’ or ‘responsive 
behaviours’ (Finkel 2000, Dupius, Wiersna and Loiselle 2012). However, as the 




BPSD is defined as “signs and symptoms of disturbed perception, thought content, 
mood or behaviour” (Finkel et al 1997) manifested by people living with dementia. 
Mood disorder includes anxiety, depression, suicidal behaviour, and apathy and 
behavioural disorders exhibited often are agitation, disinhibition, perseveration, 
hypersexuality and eating disorders, whilst psychotic features include 
hallucinations and delusions (Ritchie and Lovestone 2002). 
It is essential to examine BPSD because it is estimated that between 80% (Mathys 
2018) and 97% (Steinberg et al 2008) of people with dementia will suffer from 
these symptoms, with subjective severity, as their disease progresses. BPSD are a 
source of significant morbidity in dementia patients and stress for their caregivers, 
leading to poor quality of life in both sets of individuals (Ryu et al 2011), and have 
an immense negative impact on both the physical and psychological wellbeing of 
both formal and informal caregivers (Ballad et al 2000). 
The causes of BPSD are complex and remain largely unknown, but they are thought 
to be an ineffective attempt by the person with dementia to cope with 
environmental or physiological stress factors (Cerejeira et al 2012).  Another 
theory postulated by Kales et al (2015) following a comprehensive literature 
review, was that neurodegeneration associated with dementia affected the ability 
of a person with dementia to interact with others and their environment,  and the 
resultant disruption in brain circuits for behaviour and emotion increased risks of 
developing BPSD. Other theories include changes in personality traits, physical 




Pharmacotherapy of BPSD 
The relevance of understanding BPSD in the context of pharmaceutical care is that 
aggressiveness and psychotic symptoms in people with dementia have been shown 
to result in a two-fold increase in their likelihood of being prescribed 
antipsychotics (Chui et al 2006). Though the effects of antipsychotics on the 
natural course of BPSD is unclear, their deleterious side effects in older adults are 
well documented (Maidment et al 2016, 2017) (Hernandez et al 2019). Due to the 
complex nature of BPSD aetiopathogenesis and multi-morbidity in sufferers, 
treatment is highly challenging. Emphasis is placed on non-drug measures, 
following a person-centred, caregiver-focused approach (Tible et al 2017), though 
the evidence for this is weak.  The use of antipsychotics is discouraged due to the 
increased risk of cerebrovascular events and mortality they pose to dementia 
patients. Pertinently, a qualitative study evaluating the role of community 
pharmacists in reviewing use of antipsychotics in BPSD found many barriers (lack 
of access to patient notes, lack of knowledge of dementia) limiting their ability to 
contribute to reduction of antipsychotic prescribing in dementia (Maidment et al 
2016). However, this study was a small qualitative study with limited 
generalisability. 
An understanding of the underlying causes of BPSD, the role of medication toxicity 
in precipitating them, as well as non-pharmacological therapies could significantly 
contribute towards effective management of the condition. Despite the general 
consensus that non-pharmacological methods are preferable, the concepts of 
person-centred care, considered the best approach when caring for people with 
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dementia (NICE NG97 2018), must be employed when considering treatment for 
BPSD in each person with dementia.  
In considering a pharmacological approach as an alternative to non-
pharmacological management of BPSD, a weighted analysis of the severity of BPSD 
against the risks and benefits of a medication based intervention,  is required so 
that an optimal pharmacological regimen can be implemented (Mathys 2018). 
2.5 Dementia Diagnosis 
2.5.1 Introduction 
As the prevalence of dementia increases worldwide, the need to develop effective 
treatments for the conditions becomes increasingly imperative. Similarly the 
developments of diagnostic strategies to improve early detection of the disease 
and define the different forms of dementia both selectively and specifically are also 
equally important. Significant benefits can be obtained for patients if diagnosis and 
therapeutics of dementia are combined, but since different syndromes make up the 
total picture of dementia, ensuring accurate diagnosis is vital. 
Whilst it is recognised that improved diagnosis of dementia and better treatment 
of mild cognitive impairment will help alter the grim picture painted by current 
predictions of the rising numbers of dementia sufferers, including increasing socio-
economic burden, diagnosing dementia is deemed a major challenge for many 
health care systems (Herloz, Perani and Morris, 2006). 
The Alzheimer’s Society UK (2014) statistics showed that about 46% of people 
living with dementia receive a diagnosis during their lifetime. Within these 
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statistics, the rate of diagnosis varied dramatically from as low as 35% in South 
West England to as high as 70% in parts of Scotland and Northern Ireland. The UK 
government pledged in 2013 (DOH 2013) to address the issue of people 
unknowingly living with dementia and launched a huge campaign to raise 
awareness of the condition. Diagnoses rates have improved significantly since 
then, though still widely variable: Wales, 53%; Scotland, 67%; England, 57.8% and 
Northern Ireland, 73% (Dementia Statistics Hub 2018). Concerns that many 
community dwelling people with dementia remain undiagnosed still exist (Eichler 
et al, 2015). 
The Alzheimer’s society reiterates the importance of a diagnosis, since without 
one, people with dementia cannot receive the support, information and treatment 
they need in order to live well with dementia, and services cannot be planned as 
needed [Alzheimer’s Society 2014). 
Early detection and diagnosis of dementia depends largely on patients or their 
carers/relatives recognising symptoms and making initial contact with health care 
professionals (Chrisp et al, 2012). It is important to understand the journey 
undertaken by people suspected to have dementia (and their carers) before a 
diagnosis is reached, as this helps health care professionals to formulate 
suggestions and strategies for improving the care experience for patients and their 
families. 
As the neuropathology of dementia starts before clinical symptoms manifest, often 
by several years, early detection and diagnosis form part of the key steps to 
mitigating the progression and burden of dementia (Henderson 2012). 
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The National Institute for Health and Care Excellence (NICE, 2018) proposes a 
pathway for diagnosis and assessment of dementia which involves an initial basic 
screen on first contact by the general practitioner, during which reversible causes 
of cognitive decline such as delirium, depression, medication are investigated and 
ruled out and if dementia is still suspected, it is followed by referral to a specialist. 
The specialist conducts a comprehensive assessment before making a diagnosis of 
dementia, followed by tests to determine the dementia sub-type. 
2.5.2 Assessment of Dementia 
Diagnosis of dementia is based on a patient’s history (including the use of 
information supplied by sources other than the patient), and clinical examination. 
At this stage, it is worth pointing out that cognitive decline is manifested in several 
ways which include memory loss, suspiciousness, inappropriate social behaviour, 
hoarding and perceptual distortions. Part of the average ageing process includes 
mild levels of cognitive inefficiency, but more significant impairment in the 
cognitive spheres of memory, language and judgement are often signs of a 
dementing disorder (Weiner and Lipton, 2012). As people age, impaired memory 
becomes more prevalent, so differentiating normal ageing from pathological 
cognitive decline is a significant part of the early detection of dementia. 
In summary, evaluation of cognitive impairment and dementia ideally consists of 
three stages:  
(1)-Recognition of deficits in cognition; 
(2)-an initial or basic screen to decide whether dementia is present and  
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(3)-determination of the cause of impaired cognition, once impairment is 
confirmed (Herholz, Perani and Morris, 2006).  
There are challenges at each stage, but it is necessary for all three to be completed 
in order to formulate an accurate diagnosis. 
The General Practitioner  
The first point of contact for a person who suspects they have dementia symptoms 
is their general practitioner (GP) (Alzheimer’s Society 2014).   
The GP puts the individual through a basic dementia screen that helps to 
differentiate true dementia from pseudo-dementia (ailments that mimic dementia 
such as delirium, depression, anxiety), and will seek to exclude other causes of 
cognitive decline such as normal age-associated memory changes, drug reactions, 
vision and hearing problems (de Souza et al. 2009, NICE 2018). 
Cognitive assessment is essential in order to make a clinical diagnosis of dementia. 
Cognitive impairment can be quantified using several standardised screening tools. 
NICE guidelines for dementia assessment (2018) recommend the use of brief 
structured cognitive instruments such as the 10-point cognitive screener (10-CS), 
the 6-item cognitive impairment test (6-IT), memory impairment screen (MIS) or 
the Mini-Cog. 
The most widely used is the Mini Mental State Examination (MMSE) developed by 
Folstein et al (1975). The MMSE is a 30-item cognitive screening test available in 
several languages that tests orientation, language, memory, attention, ability to 
follow commands and praxis. Use of MMSE which is under patent, is not 
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recommended by NICE (2018) when instruments of similar sensitivity are 
available for free.   
Following initial assessments, a general practitioner may feel the need to make a 
diagnosis of dementia (Alzheimer’s Society 2014) but the knowledge and expertise 
to determine the cause of dementia or make a sub-type specific diagnosis lies with 
specialists (NICE 2018).  Additionally, diagnostic uncertainty at early stages and 
feelings of embarrassment about conducting cognitive assessments as well as 
difficulty in communicating diagnosis pose serious obstacles for GPs (Van Hout et 
al. 2000).  In the United Kingdom, the National Institute of Health and Care 
Excellence (NICE Pathways, 2013) recommends memory assessment services 
(memory clinics) as the single point of referral for people with possible dementia. 
A Role for Pharmacists 
It has been suggested that community pharmacists could administer cognitive 
tests during medication reviews using simple standardised instruments such as 
the Mini-Cog or the General Practitioner test of cognition (GPCOG), to assist early 
detection of dementia in clients they suspect of showing cognitive decline (Elliot 
2018), but such a service has not been developed and tested in the UK. 
2.5.3 Memory Clinics 
Memory clinics, first described in the 1980s, have become accepted worldwide as 
useful for improving practice in the identification, investigation and treatment of 
memory disorders including dementia (Jolley, Benbow and Grizzell, 2006). Their 
aim is to facilitate referral from GPs, other specialists, or self-referral from patients 
or their families, helping to avoid the stigma associated with psychiatric services. 
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At the memory clinic, a fuller assessment of the person with suspected dementia is 
undertaken, including reviewing shared notes from the GP and extensive history 
taking for reasons described above under initial screening. The multi-disciplinary 
role of the memory clinic includes being a point of referral, performing specialist 
assessments and investigations, facilitating early diagnosis, education and 
counselling of patients and their carers and referral to other appropriate agencies 
(Passmore and Craig, 2004). 
Specialist memory clinics have the benefits of detailed neuropsychological 
assessments and brain imaging necessary to make a dementia diagnosis and 
determine the underlying cause, using standardised criteria. 
2.5.4 Diagnosing Dementia using standard criteria 
Dementia is a clinical diagnosis and various diagnostic strategies have been 
proposed for identification of individuals with dementia. Clinical assessments, 
aided by results of neuropsychological tests are the only in-vivo non-invasive 
screening and diagnostic tool for dementia (Herholz Perani and Morris 2006). In 
order to effectively treat dementia, an agreement on diagnosis is essential. 
However, due to the existence of various different classification systems, different 
diagnostic conclusions can be reached by different clinicians (Erkinjuntti et al. 
1997). Currently, criteria from the Diagnostic and Statistical Manual, 5th Edition 
from the American Psychiatric Association (2013) and the World Health 
Organisation (WHO) International Classification of Diseases, 10th Edition (ICD-10; 
World Health Organisation 1992) are used to determine a diagnosis of dementia. 
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The Diagnostic and Statistical Manual 5th Edition (DSM-V) (APA, 2013) is the 
widely used diagnostic scheme in Canada and the United States of America, hence 
commonly seen in many research.  
In the DSM-V, dementia is named “major neurocognitive disorder” allowing for 
recognition of less severe levels of cognitive impairment (mild neurocognitive 
disorder) so that less disabling syndromes which nonetheless cause concern can 
be diagnosed and treated.  The term neurocognitive disorder (NCD) was 
introduced in the DSM-V to address limitations of the term dementia, and to tackle 
the stigma associated with it, whilst at the same time capturing the many different 
causes and manifestations of significant cognitive impairment that can affect 
people of all ages (Dementia Australia 2012). 
A diagnosis of major NCD (dementia) requires evidence of significant decline in 
one or more cognitive domains, namely: complex attention, executive function, 
learning and memory, language, perceptual-motor function and social cognition. 
This decline must not be attributable to any other mental disorder, and loss of 
independent function differentiates major from mild NCD. 
The DSM-V criteria for dementia diagnosis further renames the main causes (sub-
types) of dementia as major or mild neurocognitive disorder due to Alzheimer’s 
disease, major or mild frontotemporal neurocognitive disorder, major or mild 
neurocognitive disorder with Lewy bodies and major or mild vascular 
neurocognitive disorder. 
ICD-10 diagnostic criteria are used often in the United Kingdom but do not often 
appear in research literature (Lejbak and Haugrud, 2010).  
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A diagnosis of dementia using these criteria would require in general: evidence of 
decline in memory and other cognitive abilities (characterised by deterioration in 
judgement and thinking), preserved consciousness, decline in emotional control 
and/or motivation, with symptoms (especially memory decline) lasting a 
minimum of six months. The diagnosis is further supported by evidence of damage 
to other higher cortical functions, such as aphasia, agnosia and apraxia. ICD-10 also 
includes specific criteria for diagnosing dementia sub-type.  
Even though there are some similarities between the two diagnostic schemes 
(DSM-V and ICD-10), using separate criteria to diagnose the same condition could 
lead to clinicians coming to different diagnostic conclusions depending on which 
scheme they apply. This was exemplified when Henderson et al (1994) surveyed 
1045 persons 70 years old or over and found that 3.2% were given a diagnosis of 
dementia based on the ICD-10 criteria and 7.3% when the third, revised edition of 
the DSM (DSM-III-R)(American Psychiatric Association 1987) was used. 
Whichever criteria are used, it is essential that each patient’s characteristics in 
relation to age, educational level, culture and language are taken into consideration 
when conducting assessments for the purposes of diagnosing dementia. 
 2.5.5 Diagnosis of Sub-types of Dementia 
NICE dementia guidelines (2018) recommend that diagnosis of sub-type of 
dementia be carried out in specialist dementia diagnostic services using 




Type of Dementia Recommended validated criteria for 
diagnosing dementia sub-type 
Alzheimer’s Disease National Institute on Aging (NIA) and a test 
of verbal episodic memory. 
Vascular Dementia NINDS-AIREN (National Institute of 
Neurological Disorders and Stroke and 
Association Internationale pour la 
Recherche et l’Enseignement en 
Neurosciences) 
Dementia with Lewy bodies International Consensus criteria for 
dementia with Lewy bodies 
Frontotemporal dementia International Frontotemporal Dementia 
Consortium for behavioural variant 
frontotemporal dementia 
Table 1: Recommended criteria for diagnosing dementia sub-type adapted from NICE clinical 
guidelines (NG97) 
 
In order to assist diagnosis of particular dementia sub-types and exclude other 
cerebral pathologies, NICE guidelines also recommend the use of structural 
imaging such as Magnetic Resonance Imaging (MRI) which is preferred or 
Computerised Tomography (CT) as an alternative. 
The sub-types of dementia in Table 1 above have more over-lapping signs and 
symptoms than defining ones, further complicating the prospects of successful 
differential diagnosis, but accurate diagnosis is important as each sub-type has 
unique prognostic and treatment considerations (Focht 2009).  
Further tests recommended in NICE guidelines (2018), where diagnosis is 
uncertain include: 
• Alzheimer’s disease: Fluorodeoxyglucose-positron emission tomography-CT 
(FDG-PET) or single-photon emission CT (SPECT) if FDG-PET is unavailable. An 
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examination of cerebrospinal fluid for either total tau or amyloid beta proteins 
is also a recommended alternative 
• Dementia with Lewy bodies: assessment of  the dopamine transporter in vivo 
with specific ligands, such as [123I]-2b-carbomethoxy-3b-(4-iodophenyl)-N-(3-
fluoropropyl) nortropane (123I-FP-CIT) single-photon emission CT (123I-FP-CIT 
SPECT) 
• Frontotemporal dementia: FDG-PET or perfusion SPECT 
• Vascular dementia: MRI or CT if MRI unavailable or contraindicated 
 
None of the dementia sub-types should be ruled out solely based on results of the 
structural or metabolic imaging tests recommended above. 
Pharmaceutical care 
From a pharmacy practice point of view, knowing the sub-type of dementia, 
through a precise diagnostic work-up is essential for accurate management and for 
prognosis. A case in point is DLB whose features include hallucinations, and 
misdiagnosis as another sub-type could lead to a prescription of an antipsychotic 
such as haloperidol, which can expose the sufferer to severe deterioration 
(McKeith et al 1992). 
2.5.6 Diagnosing Dementia in Care Homes 
Most people with potential dementia diagnosis live in the community (Ruths, 
Straand and Nygaard 2003) and are presumed to receive their diagnostic work up 
in primary care.  
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Typically, local health authorities plan healthcare needs by assessing people who 
live in their own homes, so people living in care homes may be neglected (British 
Geriatric Society 2012, Alzheimer’s Society 2016a) 
A great number of people receive their dementia diagnosis while in hospital 
suffering from a physical condition (Alzheimer’s society 2014). Within care homes, 
there is still no clear pathway for assessing potential dementia in residents.  
Lithgow, Jackson and Browne (2012) performed cognitive testing of 341 randomly 
selected nursing home residents in Glasgow, Scotland. They found that even 
though 58% of the sample already had a dementia diagnosis, 31.8% scored within 
the range of possible dementia (less than 24/30 in the MMSE) but had no diagnosis 
of dementia. 
Care home residents not yet diagnosed, but suspected of suffering from dementia 
are at a disadvantage because in most areas of the UK, diagnosis takes place in 
community locations which can be difficult to get to (Burns, 2014) and their access 
to GPs is limited or costly (Alzheimer Society 2016a). Ensuring that residents with 
dementia are diagnosed can improve their care as staff could better plan their care, 
inappropriate medication stopped and those who could still benefit from cognitive 
enhancers treated. Visiting GPs and geriatricians can play a leading role in 
identification and diagnosis of dementia in care home residents, and staff from 
memory clinics have been encouraged to develop in-reach services with care 
homes so that people living there can be assessed and diagnosed and have access 
to treatment (Alzheimer’s society, 2014). 
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There could also be consideration given to linking this to a national enhanced 
service for dementia (Burns, 2014). As some community pharmacists are already 
commissioned for the provision of enhanced services to care homes, their role in 
the domain of identification of residents with cognitive impairment and dementia 
could be explored. 
2.6 Pharmacological management of dementia 
Following nearly 36 years of biochemical and clinical/pathological studies, very 
little has changed in terms of available anti-dementia medication (Mukaetova-
Landska, 2018). Two classes of drugs approved for prescribing in the UK, for the 
purpose of combatting dementia symptoms remain the acetylcholinesterase 
inhibitors (donepezil, rivastigmine and galantamine) and the N-methyl-D-aspartic 
acid (NMDA) receptor antagonist (memantine) (Grand, Caspar and Macdonald 
2011, O’brien et al 2017, Pink et al 2018).  
Acetylcholinesterase inhibitors work by increasing cholinergic transmission and 
inhibiting the enzyme cholinesterase at the synaptic cleft, which provides some 
symptomatic relief in some people with dementia, particularly AD where reduced 
synthesis of acetylcholine causes impaired cortical cholinergic function (Press and 
Alexander 2019).  
Memantine, on the other hand, is thought to be neuroprotective as the NMDA 
receptor plays a role in memory and learning (Danysz and Parsons 1998). It has 
been shown to have some benefit in moderate to severe AD, but little or no benefit 
when used to treat mild AD (McShane et al 2019). 
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Though there are many agents in on-going trials with putative disease-modifying 
properties, no new drugs have been licensed for AD or other dementias (O’brien et 
al 2017). 
NICE guidelines (2018) advise that pharmacological treatments are initiated only 
on advice of clinicians with specialist expertise in the diagnosis and treatment of 
dementia.  
Alzheimer’s disease  
For Alzheimer’s disease (AD), donepezil, rivastigmine and galantamine are 
recommended for mild to moderate disease, with addition of memantine 
recommended for moderate to severe AD (NICE NG97 2018, Press and Alexander 
2019). 
Lewy body dementia  
NICE Guidelines (2018) recommend donepezil or rivastigmine for people 
diagnosed with mild, moderate or severe Lewy body dementia (DLB), and 
memantine if cholinesterase inhibitors are not tolerated. A combination of 
cognitive, neuropsychiatric, autonomic and motor features in people with DLB 
make management extremely challenging for clinicians (O’Brien et al 2017).  
Pharmacists with knowledge of the interplay of symptoms, mechanism of action of 
drugs for DLB and co-morbid medical conditions as well as consequences of 
prescribing medication that worsen these features are an essential addition to 
multidisciplinary teams dealing with dementia sufferers.  
Not everyone with a dementia diagnosis will benefit from AChEIs but there is 
research showing that 40-70% of people with dementia treated with these drugs 
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benefit from them, particularly reducing anxiety levels, and improvements to 
levels of confidence, memory and thinking observed (Alzheimer’s Society 2017).  
Vascular dementia  
There are currently no pharmacological treatments licenced for treating people 
suffering from vascular dementia (VaD), but cholinesterase inhibitors or 
memantine can be considered if it is co-morbid with AD, DLB or Parkinson’s 
disease dementia. Strategies for managing this heterogeneous condition focus 
largely on controlling cardiovascular and cerebrovascular risk factors. 
 
Frontotemporal dementia  
Cholinesterase inhibitors are not recommended for people with frontotemporal 
dementia (FTD), but there is evidence that serotonin re-uptake inhibitors may be 
useful in treating behavioural, though not cognitive features (O’Brien et al 2017). 
 
BPSD 
Pink et al (2018) in their summary of NICE (2018) dementia guidelines, highlight 
the recommendations for managing BPSD, emphasising that antipsychotics should 
only be offered if individuals living with dementia are at risk of harm to themselves 
and are experiencing agitation, hallucination or delusions which cause them severe 
distress. These agents are only to be used at the lowest possible dose for the 
shortest period of time. Antidepressants are not recommended for routine 






Stopping cholinesterase inhibitors  
A final note about when to stop cholinesterase inhibitors is necessary as there has 
been conflicting evidence, with some researchers recommending that when 
dementia is severe, sufferers no longer benefit from these drugs and there is 
increased risk of adverse outcomes (Gill et al 2009). However, another study 
(Howard et al 2012) demonstrated continued cognitive benefits from donepezil in 
people with severe dementia compared to placebo. To this end, NICE guidelines 
stress that cholinesterase inhibitors must not be stopped simply because of disease 
severity. 
 
Drugs in development 
With regards to drugs in development for dementia, octohydroaminoacridine is a 
novel cholinesterase inhibitor that showed a dose dependent significant 
improvement in cognition and behaviour in participants with AD during phase II 
trials, (Xiao et al 2017). The trial had limitations such as small numbers of 
participants and short duration (16 weeks). 
In a similar vein, two pharmaceutical companies working in collaboration, Biogen 
and Eisai, developed a monoclonal antibody Aducanumab® which they found dose-
dependently reduced amyloid deposition in six cortical regions of the brain, 
following phase III clinical trials (Alzforum 2019). Due to a prediction that the drug 
trials would not prove benefit compared to placebo, both companies decided to 
terminate further work on Aducanumab®. They later announced that a re-analysis 
had found the drug produced a significant reduction in decline on the primary 
endpoint at higher doses, so an application was made to the FDA in October 2019 
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for regulatory approval. It is thought that this move will lead to an opening of the 
floodgates for Alzheimer’s drugs (Selkoe 2019).  
Other agents that have been considered include gingko biloba, hormone 
replacement therapy (HRT), folate, vitamin B12 and therapeutic non-invasive 
brain stimulation (O’Brien et al 2017). None of these have resulted in any new 
treatments for dementia. 
2.7 Non-Pharmacologic treatment of dementia 
There has been much interest (Berg-Weger and Stewart, 2017, de Oliviera et al 
2015) in research exploring non-pharmacological interventions for managing 
dementia, either on their own or in conjunction with drug treatments (Grand, 
Casper and Macdonald 2011). Whilst the clinical efficacies of these treatments 
have not been fully evaluated, they are primarily aimed towards improving quality 
of life for people living with dementia. 
Two of the most widely used non-pharmacological approaches are cognitive 
training and cognitive rehabilitation techniques, usually applied during early 
stages of dementia and involve training of cognitive domains with emphasis on 
memory, attention and executive function (cognitive training) or geared towards 
enhancing functioning in everyday life (cognitive rehabilitation) (Clare et al 2003). 
Other non-pharmacological treatments include psychosocial therapies such as 
reminiscence therapy and validation therapy intended to bring about 
enhancements of self-esteem and wellbeing. Additionally, formal exercise 
programs have been suggested as a non-pharmacological approach since they may 
improve physical functioning, but they do not seem to improve cognitive 
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functioning in adults with dementia (Forbes et al 2015) so their benefits and those 
of other non-pharmacological interventions need further investigation. 
However, NICE guidelines for assessment and management of dementia (2018) 
does recommend that a range of activities to promote wellbeing, group cognitive 
stimulation and reminiscence therapy and cognitive rehabilitation be considered 
as interventions to promote cognition, independence and wellbeing in people with 
dementia. 
2.8 Prevention of Dementia 
Primary prevention of dementia involves adopting a lifestyle that reduces the risks 
of developing it, such as exemplified in a recent study that showed that a healthy 
diet (with daily portions of fruit and vegetables) is associated with a significant 
reduction in risk of dementia from middle age onwards (Lee et al 2017). 
Secondary and tertiary prevention techniques are geared towards preventing 
clinical progression in symptoms of dementia but pharmaceutical interventions 
being investigated for this purpose have been largely unsuccessful (O’Brien et al 
2017, Tipton and Graff-Radford 2018). 
There is as yet, no evidence in research that supports any single intervention that 
can be used to delay or prevent dementia, but there is some that supports the fact 
that modifying the risks and/or treatment with antihypertensive drugs, 
particularly in midlife (45-65 years) can potentially delay/prevent the rise of 
dementia cases worldwide (Gottesman et al 2014, Mogi 2019, Livingston et al 
2017). Additionally, when the profound individual and societal costs of dementia 
are considered, it is a sensible proposition that strategies to prevent or delay its 
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onset be made a public health priority in countries worldwide (Livingston et al 
2017). 
Pharmacists, as healthcare professionals at the hearts of communities they operate 
in, can play a pivotal role in promoting healthy lifestyles such as smoking 
cessation, exercise and primary prevention strategies, during medication review 
sessions. 
2.9 Summary and gaps in knowledge 
In summary deducing from the background and literature review I have 
expounded so far; dementia is highly prevalent and the trend of growth in 
numbers of those affected will continue to increase exponentially over the next few 
decades. As the population of older adults with chronic/long term conditions such 
as dementia increases, the number of those living in care homes will also snowball.  
There is a need to provide high quality healthcare that meets their complex needs 
and that includes pharmaceutical care. However, research shows that 
inappropriate prescribing is common in this population (Pfister et al 2017) and 
pharmaceutical care delivery to those with dementia is poor (Mehta et al 2017).  
We know that secondary care specialist pharmacists can deliver interventions to 
improve quality of prescribing in people with dementia (Dementia Alliance 2008, 
Maidment et al 2018). We also know that community pharmacists are the most 
accessible patient facing healthcare professionals who could play a big role in 
medicines optimisation for people with dementia living in the community 
(Maidment et al 2017).  
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There is research exploring the perspectives of family members of people with 
dementia in care homes (Cronfalk et al 2017), as well as research exploring 
attitudes of care home staff towards people with dementia (Lee et al 2013). 
Inappropriate prescribing in people with dementia has also been explored 
(Holmes et al 2008, Parsons et al 2012). However, despite existing research on the 
roles of various healthcare professionals in care of people with dementia resident 
in care homes, few qualitative and quantitative studies have addressed the exact 
role community pharmacists play in the care of people with dementia living in care 
homes. To this effect we sought to: 
• Explore the nature of services provided by pharmacists to people with 
dementia in care homes 
• Investigate Community Pharmacists’ knowledge of dementia and their ability 
to provide pharmaceutical care services to people with dementia 
• Examine any factors influencing pharmaceutical care provision to people with 
dementia in care homes 
• Explore the views of care home staff about the medication-related needs of 
residents with dementia and determine their views about the services they 
receive from community pharmacists contracted to deliver pharmaceutical 
services to their establishments. 
• Determine whether a tool designed to aid systematic review of prescriptions 
for people with dementia will be useful for pharmacists and assist them to 
improve quality of prescribing in people with dementia. 
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2.10 Methodological approach 
I approached this research with the intention of selecting the most suitable 
methods to answer the research question posed at the beginning (Sackett and 
Wennberg 1997).  Consequently, I decided to use pragmatism, a research 
philosophy which maintains that the point of research is to provide answers to the 
research question (Morgan 2014). 
Traditional research paradigms include positivism and interpretivism which are 
opposing notions: Positivism is associated with singular reality requiring the 
collection of measurable objective facts and aims to discover laws using 
quantitative methods (Bowling 2014, Morgan 2014). Interpretivism (also known as 
constructivism) on the other hand, is about studying people in their ‘natural’ 
settings and involves finding ‘meanings’ or constructed knowledge through 
qualitative research (Winit-Watjana 2016). 
Pragmatism provides a middle ground through which multiple philosophies can be 
used, if needed, to answer the research question, and values both quantitative and 
qualitative methods as approaches to conducting relevant, high quality research 
(Creswell and Clark 2017).  
This approach appealed to me as a pharmacist because of its focus on practicality, 
allowing me to select the most appropriate methods for my research, which was 
mixed methods. Using mixed methods research is a synthesis that can include 
findings from both qualitative and quantitative research, and this approach is 
increasingly used in pharmacy practice as it encourages methodological flexibility 
and encourages multi-disciplinary team working (Babar 2015). Additionally, for 
my research, combining qualitative and quantitative methods enabled both to be 
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used complementarily to address different aspects of the research question 
(O’Cathian et al 2007). 
2.10.1 Study design 
A sequential mixed methods design which involved collection of data on an 
iterative basis (data collected in one phase contributes to data collection in 
another phase) (Driscoll et al 2007) was employed for chapters 3, 4, 5, and 7. The 







                     = Qualitative  
                     = Quantitative 
                   = Chapter 6 describes the development of an intervention toolkit 
  
 
2.10.2 Outline of the rest of the thesis 
Chapter 3: Describes qualitative, face-to-face, semi-structured interviews 
exploring the knowledge, views and perceptions of pharmacists who provide 











SEQUENTIAL MIXED METHOD DESIGN 
Figure 1: Research outline 
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Chapter 4: A quantitative, questionnaire survey of a random sample of 
pharmacists in England, on the pharmaceutical care needs of people living with 
dementia  and the services they provide to care homes 
Chapter 5: Qualitative, face-to-face, semi-structured interviews exploring the 
views and perceptions of care home staff about the medication-related services 
provided to people living with dementia in care homes. 
Chapter 6: Based on findings from my research and up-to-date published evidence 
concerning appropriate pharmaceutical care in dementia, a practical, educational 
tool to be used in the clinical screening and systematic review of prescriptions for 
people living with dementia will be developed 
Chapter 7: Feasibility study of the DEMENTIAS intervention tool among a focus 
group of pharmacists, conducting a review of prescriptions for patients living with 
dementia 
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3.0   
 
3.1 Introduction and chapter overview 
There is a paucity of research exploring the perceptions of community pharmacists 
about their pharmaceutical care provision to people with dementia living in care 
homes. 
Though the majority of people who have dementia live in their own homes, many 
have to relocate to long term care facilities such as care homes due to their limited 
ability to self-care, or to their symptoms worsening to a point where they can no 
longer be cared for in the community (Corbet et al, 2013). 
This chapter encompassed the first stage of my research and involved a qualitative 
pilot study aimed at generating data to inform the development of a questionnaire 
for a wider population of pharmacists, that would broadly explore their knowledge 
and understanding of the pharmaceutical care needs of patients living with 
dementia in care homes in England. It also supported the identification of factors 
that may affect service provision.  
Additionally, I conceptualised that conducting interviews with a sample of 
pharmacists who provided services to care homes would yield some information 
about their awareness of the pharmaceutical care needs of care home residents in 
general and people with dementia in particular, and would identify training needs 




3.2.1 Aims and objectives 
3.2.1.1 Aims 
• To explore the views of pharmacists about the pharmaceutical care needs of 
dementia patients living in care homes  




• To investigate pharmacists’ awareness of the pharmaceutical care needs of 
dementia patients  
• To examine the nature of services provided by pharmacists to dementia 
patients in care homes 
• To seek pharmacists’ opinion about their knowledge and ability to provide 
pharmaceutical services to dementia patients  
• To determine the factors that influence the provision of pharmaceutical 
services to dementia patients 
• To use the responses from these pharmacists to inform the development of 
a survey instrument on pharmaceutical care in dementia. 
3.2.2 Study Design 
A qualitative study design utilising a face-to-face semi-structured interview format 
was employed to explore the views and perceptions of pharmacists who provide 
services to care homes that have people living with dementia. A qualitative 
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approach following the Consolidated Criteria for Reporting Qualitative studies 
(COREQ) guidelines (Tong et al 2007), was chosen to support in−depth exploration 
of issues from the perspective of research participants. Ethical approval was 
obtained from the Cross-Schools Research Ethics Committee (C-REC) at the 
University of Sussex (Appendix 3a).  
3.2.2.1 Participant recruitment 
Community pharmacists were invited to participate in two ways. A purposive 
sample, based on the selection of individuals with a particular characteristic for a 
study, is normally used in gaining understanding of complex issues and to generate 
a hypothesis. First, a purposive sample of all 17 care homes in the Thurrock 
(Essex) area that have dementia patients or a mixture of dementia and non-
dementia patients was identified by searching the website, www.carehome.co.uk  
(Care Homes Residential Homes UK Guide, 2015). Thurrock (Essex) and Kent areas 
were chosen for because of close geographical proximity to the researcher.  
The researcher contacted the homes identified to ascertain the main provider of 
their pharmaceutical services.  Pharmacists working in pharmacies identified by 
the care homes were contacted by the researcher and invited to participate in the 
study. Their contact details were obtained from the NHS Choices website (2014). A 
written letter of invitation including detailed information about the study was sent 
to the pharmacists identified (Appendix 3b). This was followed up by a phone call 
after five working days to ascertain the willingness of the pharmacist to 
participate. As there were 17 care homes to be contacted, there was a possibility 
that more than 10 pharmacists would be identified. The plan was that care homes 
would be ranked in order of the number of dementia beds per care home as 
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published on the website, carehome.co.uk.  Pharmacists delivering care to the 10 
care homes with the highest proportion of dementia beds would be initially 
selected and approached to participate in the pilot study. Where there was a 
failure to recruit 10 pharmacists providing pharmacy services to these care homes, 
recruitment would continue from the care homes lower down the list until 10 
pharmacists are recruited. 
10 pharmacists consented to participate. This was not a statistical sample based on 
a power calculation as these are thought to be inappropriate for qualitative 
research (Smith 2005), unlike quantitative studies, where power calculations are 
employed to determine a statistically appropriate sample size for a study. 
In a similar manner, 5 pharmacists were recruited from the Kent area, a different 
locality, to validate original findings from Thurrock and follow an iterative process.  
To ensure anonymity, pharmacists interviewed in Thurrock were designated P1 to 
P10 and those interviewed in Kent were designated K1 to K5. 
All pharmacists who agreed to participate were sent a participant information 




Figure 2: Study Flow Chart 
 
3.2.2.2 Inclusion criteria 
Pharmacists providing services to care homes with dementia patients or have a 
mixed clientele that include patients with dementia 
3.2.2.3 Exclusion criteria 
Locum or relief pharmacists who do not regularly provide services to care homes 
that have residents with dementia 
3.2.2.4 Informed consent 
Informed consent from pharmacist participants was confirmed by the receipt of a 
completed consent form by the researcher (Appendix 3d) 
3.2.2.5 Dissemination strategy 
Participants who indicated that they would like to be informed of the results were 




It was anticipated that the pilot study would span a period of 11 weeks (see study 
timetable in Appendix 3e) but the study took considerably longer due to a variety 
of unforeseen circumstances. Data was collected between June 2014 and May 
2015. 
3.2.2.7 Data Collection 
Semi-structured face-to-face interviews were carried out with consenting 
participants employing an interview schedule with fixed questions covering: 
• Number of care homes serviced 
• Proportion of dementia patients in these homes 
• Nature of services provided to them and  
• Perceived sufficiency of these services (See Appendix 3f for interview 
schedule).  
Furthermore, respondents were able to raise issues not covered by the interview 
schedule.  
The academic supervisor, a registered pharmacist, verified the schedule. 
Interviews were carried out and recorded by the researcher at a time of 
convenience for the participants, at their place of work. As these were face to face, 
the researcher used the opportunity to clarify any inconsistencies and probe for 
fuller responses. However, this approach had the disadvantage that it could be 
expensive and time consuming, and sometimes, interviewer bias could be 
introduced (Bowling 2009). In this study, the length of each interview varied 
between 10-30 minutes. 
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3.2.2.8 Data handling 
Interviews were digitally recorded, and the device stored safely in a locked filing 
cabinet at the research supervisor’s office at the University of Sussex. All data was 
securely erased from the digital device once transcribed. Verbatim transcripts 
were anonymised. 
3.2.2.9 Data analysis 
Following each interview, audio- tapes were reviewed for familiarisation with the 
data obtained. Interview tapes were transcribed verbatim and content analysis 
carried out using a thematic framework approach for sorting, categorisation and 
interpretation of recorded interviews (Bowling, 2009).  
The thematic framework included: 
• Analysis for emerging themes 
• Coding of emerging themes 
• Rearranging the data according to identified themes 
• Mapping and interpretation 
Transcripts were independently reviewed by the research supervisor, who met 
with the researcher for mapping, interpretation and comparison of findings to 




Figure 3: Data analysis process 
3.3 Results 
In Thurrock, 10 pharmacists participated in the study, six male and four female 
pharmacists who have been qualified in the UK between 3 years and 40 years. 9 
pharmacists supplied services to care homes with dementia patients and the 10th, a 











P1 F 2010 High Street Community 
P2 F 1974 Shopping Mall Community 
P3 F 2009 High Street Community 
P4 M 2002 High Street Community 
P5 M 2012 Town Centre Community 
P6 M 2007 High Street Community 
P7 M 2005 High Street Community 
P8 M 2005 High Street Community 
P9 M 2005 Town Centre Community 
P10 F 1981 CCG Primary Care 
Table 2: Demographics of pharmacists interviewed in Thurrock (Essex) 
 
In the Kent arm of the study, six pharmacists initially consented to participate but 
one subsequently dropped out. One male and four female pharmacists who have 
been qualified in the UK between 3 years and 20 years participated in the study. All 
were community pharmacists working in a high street, health centre or shopping 
mall setting (Table 2). 
Pharmacist 
code 
Gender Year of 
qualification 
Nature of Pharmacy Practice setting 
K1 F 2010 Shopping Mall Community 
K3 M 2001 High Street Community 
K4 F 2012 Health Centre Community 
K5 F 1995 Shopping Mall Community 
K6 F 1996 Shopping Mall Community 
Table 3: Demographics of pharmacists interviewed in Kent 
 
A focused analysis of the interview transcripts was performed by exploring the 
responses provided with consistencies and variances being highlighted.               
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Data saturation (no new information forthcoming) was achieved by the 10th 
interview in Thurrock and the sixth in Kent. This fact was verified by the 
researcher and confirmed by the research supervisor. Appendix 3g shows COREQ 
guidelines (Tong et al 2007) followed for this study. 
The emergent themes were reviewed for patterns and connections within and 
between the categories, deriving four main overarching themes, which were 
independently verified by the research supervisor. These were:  
• Services.  
• Conceptual understanding of pharmaceutical care (knowledge and confidence);  
• Barriers to pharmaceutical care provision and  
• Pharmacist education and training. 
 
3.3.1 Services 
3.3.1.1 Medication supply 
The main pharmaceutical service provided by pharmacists in both locations 
involved the dispensing of medication in monitored dosage systems (dosette 
boxes) with subsequent delivery to the care home. 
“…we only blister their medication, that’s the only service that we provide, then once a year, 
we’ll go and do a ‘care home visit’ (P3). 
 
“…we provide nomads (dosette boxes)…..we prepare the medication and then deliver to 
them” (K3) 
 
Expanding further on the clinical nature of the supply service provided, other 
pharmacists stated: 
 “…we monitor their medication. Where there are changes, we check with the doctors…..we 




 “…checking medication to be delivered monthly, as well as intra-medication they may 
request between their monthly instalments” (K5) 
The consensus amongst participants in Thurrock was that they could do little with 
care homes beyond supplying their medication and offering medicines-related 
advice when required to. This was what they were contracted to do and they did 
not have the funding or resources to offer more.  
One pharmacist explained this by stating: 
“I think it is quite difficult for the pharmacist to input beyond making sure the medication is 
in the dosette…..it is quite difficult for the community pharmacist to do anything other than 
maybe enable the person to have things they can easily open” (P10) 
 
In contrast, pharmacists interviewed in Kent, supplied more than prescription 
medicines to their care homes under contract. Their service model extended to 
include minor ailments management and the provision of pharmaceutical advice, 
which involved reviewing storage and management of medication supplied:  
“Apart from the usual repeat dispensing and obviously getting their monthly medications for 
them, we also offer pharmacist advice visits, where we go there and just look into standards, 
regulations and standards on how to manage medication in care homes” (K1) 
 
“I go like once a month to ensure that they’re taking their medication on time, and then if 
they have any issues or any problems, then they can discuss with me” (K3) 
 
“…sometimes when they have minor ailments, we are able to provide them with things like 
paracetamol and medicines for constipation, just the little things that will take their doctors’ 
time…” (K4) 
 
This showed recognition of their role as medicines experts, in the provision of 
medication-related advice as part of an integrated team of healthcare 
professionals, freeing up GPs to focus on medical issues.  Though resources and 
service specifications may play a role on service delivery, pharmacists’ attitudes 
also matter in determining positive outcomes for pharmaceutical services 
provided to care homes. 
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3.3.1.2 Medication reviews 
A medication review is defined as a critical examination of a patient’s medication 
with a view to reducing medication-related problems, optimising impact of 
medicines and reducing waste (Primary Care Pharmacy Association, 2013). 
Amongst the Thurrock study participants, only one pharmacist conducted 
medication reviews in care homes. Other participants did not provide this service 
because their local clinical commissioning group (CCG) did not commission it.  
“We don’t get paid for it, so we don’t do it” (P2) 
 
P2 however elaborated that in some areas, trained pharmacists are commissioned 
to visit care homes and review medication, especially antipsychotics prescribed to 
people living with dementia: 
“They do have a team of people who are employed by the CCG to go out and do a lot of 
medicines optimisation. So where I could do anti-psychotics audits, they’re normally done for 
me…..” (P2) 
 
The other study participants from Thurrock did not provide medication review or 
medicines optimisation services to their care homes and did not know whether the 
homes received these services from specially commissioned pharmacists. They 
considered it to be the responsibility of the local clinical commissioning group to 
commission the service.   
“We haven’t offered any because of the simple reason that I don’t think the PCT will allow it” 
(P7) 
 
Participants in Kent however used the opportunity of supplying medication to care 
homes, to conduct medicine use reviews, without indicating whether this service 
was specifically commissioned: 
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“…I do like, medicine use reviews there, to see whether there are any compliance issues or any 
problems; then we go from there. It’s for the GP then.” (K3) 
 
Another community pharmacist participant in this location expanded that he went 
the extra mile to follow work-based protocols and check residents’ medication: 
“If they were on antipsychotic medication, there’s this separate set of protocols to look 
through to make sure that it’s being used properly. For dementia medication, it would be like 
any other: checking dose, side effects, history, interactions with what else they are taking, 
that they’re being administered correctly, just as you would in any normal medicine use 
review” (K5) 
 
This demonstrates that some pharmacists consider medication reviews to be 
integral to the provision of pharmaceutical care, though community pharmacists 
are not currently remunerated for this service by clinical commissioning groups 
(CCGs). 
3.3.1.3 Care home Staff Training 
One of the intended outcomes of the NHS community pharmacy contractual 
framework, for pharmacies offering the care home enhanced service, is the 
provision of training to help improve the skills of care home staff including 
ordering, storage, administration, disposal and record keeping of medicines (PSNC 
2005). 
Only half of the participants interviewed in the Thurrock area confirmed fulfilling 
this part of the contract (P1, P2, P3, P4, and P7) 
“…Basically we train on administrations, importance of MAR sheets, how to read medication 
labels and what a prescription looks like and what the controlled drug is…”(P7) 
 
The other participants did not provide any form of training to their care home 
staff, with one stating that they themselves were not trained to do this: 




In the Kent study, two pharmacists indicated that this part of the contract was 
fulfilled; one pharmacist stated that care home staff were trained by a pharmacy 
technician when a contract to provide services was signed with a care home: 
“So anytime we sign up, we draw a contract with the care home and before we start issuing 
medication to them, she goes there to train all the staff, just for them to understand our 
policy” (K1) 
 
“There is a lead in the care home unit who, if a request is put in for some training or some 
advice, they would go and do that, and also there is an internet site for care home staff to 
access on different aspects of care home procedure and illnesses and I believe dementia is one 
of them” (K5) 
 
The other pharmacists did not provide training support to care homes for various 
reasons. 
“I can’t because I don’t have the time” (K3) 
 
Pharmacist K4 didn’t have it in her remit, while K6 was not personally involved in 
training and was unsure of what her establishment offered their care homes in 
terms of training. 
3.3.1.4 Adequacy of services provided to care homes 
All participants were asked to comment on whether the pharmaceutical services 
they provided to care homes were sufficient to meet the needs of the residents. 
A majority of the community pharmacists interviewed in Thurrock acknowledged 
that the services they provided did not fully meet the pharmaceutical care needs of 
patients in the care homes, including dementia patients; however they were 
willing to do more, recognising their role in highlighting and resolving drug-
therapy problems.  
“Personally, I would love to see more involvement of pharmacists in dementia care. That’s 




“I think we can help train up carers to some extent in terms of communication, what 
medication they need to take. The education aspect can be better” (P9) 
 
It is clear that an extension in the role of the community pharmacist was supported 
by some participants, despite the constraints of the contractual framework pointed 
out by P1 above. 
In contrast, 3 participants stated that the services they supplied were sufficient 
and in line with their contractual obligation. 
“We are not specifically trained to provide services for dementia patients, but we do provide 
services within the framework that we have, which is the supply them, and what happens 
beyond supply is beyond our control” (P1) 
“When you’re working in the pharmacy, you’re working on your own. So it’s very hard to 
leave” (P4) 
 
In Kent, 3 pharmacists expressed the belief that the services they provided were 
adequate, while two expressed their opinion that the services they provided did 
not fully meet the pharmaceutical care needs of patients in care homes, including 
people with dementia. 
Interestingly, those who said they were providing an adequate service focused 
solely on medication supply and responding to medication queries: 
 
“…they are satisfied with the service because we do deliver to them on time…..” (K3) 
 
“Yeah, well, we deliver to them when they need it, so, yeah, definitely. It’s sufficient for their 
needs” (K4) 
 
“I think so, yes…..we’re also chasing them on medication they haven’t ordered, that the homes 
may have forgotten or have overlooked…” (K6) 
 
However, an extension in the role of the community pharmacist was supported by 




“I think there is a lot we can do…..medicine reconciliation and also a lot of audits…..I don’t 
think we are doing enough. More involvement, pharmacists being involved more in their care 
can really help” (K1) 
 
3.3.2 Conceptual understanding of pharmaceutical care in dementia: 
Knowledge and confidence 
3.3.2.1 Pharmaceutical care 
Participants were asked what they believed were the pharmaceutical care needs of 
people with dementia. 
Of the 10 pharmacists interviewed in Thurrock, 9 indicated that the 
pharmaceutical care needs of dementia patients generally involved ensuring these 
patients were taking the correct medication in a formulation suitable for their 
individual needs, and monitoring the patients to ascertain compliance (achieved 
through reviewing medication administration records (MAR)).  
 Two were unsure what the pharmaceutical needs of people with dementia were, 
stating: 
 “It is difficult for me to know because I don’t see them; usually I don’t see them so it’s difficult 
for me to really know what their needs are”. (P8) 
 
 “I don’t think we have time for our patients to sit down and talk about their needs” (P3) 
 
 
Of the 5 pharmacists interviewed in Kent, 2 (K1, K4) indicated that they thought 
the pharmaceutical care needs of dementia patients generally involved ensuring 
these patients were taking the correct medication, in a timely manner. 
The others expressed concern about the amount of medication being given to 
people with dementia without rigorous needs assessment (K5, K6) and highlighted 
the importance of identifying drug therapy problems such as drug interactions and 
side effects (K1,K3) as well as ensuring symptoms are diagnosed correctly before 
initiating drug treatment in dementia patients (K5). 
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 “…you ask about any interactions, and like, say, any problems, any side effects…” (K3)  
 
One pharmacist was concerned about the inappropriateness of medication 
prescribed for dementia patients, stating: 
 “We give out these medications that the doctor prescribes but it worries you the amount of, 
you know, certain medications that go out and ones that are there to relax them and make 
them go off to sleep and you think, actually, is that appropriate?”(K6) 
 
In comparison, participants in the Thurrock arm of the study were more aware of 
key aspects of pharmaceutical care such as, ensuring that a patient gets the right 
medication at the right time in a suitable dosage form, and are compliant with it. A 
fundamental principle of pharmaceutical care, to ensure that the patients’ 
medications are safe as well as effective (Hepler and Strand, 1990, Alleman et al 
2014) was not mentioned by either group of pharmacists. 
The debilitating nature of dementia both in patients within the community and in 
care homes, usually means care is delivered through an intermediary in the form of 
a carer (family member, social worker, care home staff). Perhaps these are further 
confounding factors that community pharmacists have to navigate in order to 
provide a multi-faceted pharmaceutical care service.  
Strand et al (2004), describing pharmaceutical care practice and its positive 
outcomes over 25 years of practice, provided services only to patients in 
ambulatory clinics who were considered to be easier to access and to communicate 
with. 
Use of Compliance Aids 
The issue of dementia patients forgetting to take their medication and requiring 
prompts was pointed out by all 10 pharmacists interviewed in the Thurrock arm of 
the study, as a pharmaceutical care need. 
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Four pharmacists shared opinions about the type of monitored dosage systems 
(dosette boxes) patients were supplied with, to remind them to take their 
medication on time: 
Pharmacist P10 insisted that the four-weekly disposable dosette boxes were 
“probably the worst innovation of all time” in reference to community dwelling 
dementia patients, since there was no way of knowing if the medicines were 
actually taken or not.  
Though this was mentioned in reference to the practice of community pharmacists 
supplying multiple compartment compliance aids to dementia patients in the 
community, the view that patient safety may be compromised by the use of these 
aids is not unique to this participant as poor use of monitored dosage systems was 
highlighted as one of the causes of medication errors in care homes (Barber et al, 
2009). 
Two pharmacists elaborated on a system that incorporated an alarm to alert 
patients/carers of medication times. Another was investing in the Biodose © 
system, a monitored dosage system that accommodates both liquid and solid 
dosage forms in a patented unit (Biodose® 2015). 
While each monitored dosage system has its advantages and disadvantages, their 
provision to care homes is a substantial unfunded service provided by community 
pharmacists to help care homes improve their management of residents’ 
medicines (Barber et al, 2009). 
3.3.2.2 Pharmacist knowledge of the pharmaceutical care needs of people with 
dementia 
More specific questions were put to the participants about medicines dispensed 
specifically for the treatment of dementia. These included probing questions 
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concerning their knowledge of adverse effects of medicines and their clinically 
significant interactions, which are key components of pharmaceutical care 
provision. 
While the main adverse effects of dementia medicines were not clearly identified 
by the pharmacists when asked during the interviews, they were confident of 
where to find such information. From the pharmacists in Thurrock: 
“I always make sure I go through the leaflet” (P3) 
 
“To be honest, I wouldn’t know without looking at the BNF” (P5) 
 
Similar responses were obtained from the pharmacists in Kent: 
 
“I always check the BNF and look at other medications” (K5) 
 
“…I always check that in the BNF” (K4) 
 
With regards to knowledge of any clinically significant interactions relating to 
dementia medicines, none of the Thurrock participants could think of any.  Most, 
like other healthcare professionals, rely on their computer programs to flag up any 
interactions of concern. 
“Looking at Donepezil as a classic example, no major interactions have come to my 
attention” (P1) 
 
“Only what the machines are able to throw up at us” (P2) 
 
Whilst it is correct that pharmacy computer systems are programmed to flag up 
clinically significant drug-drug interactions, it is important for pharmacists to note 
that knowledge of the disease condition and how it affects patients is critical in 
managing dementia patients.  
Antipsychotics, for example, may not be flagged up on dispensing software as 
interacting with some dementia medication such as rivastigmine, but these drugs 
have been shown to increase the cholinergic burden in dementia patients, which is 
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associated with increased mortality in this patient group (Prentice and Wright, 
2014). 
Kent pharmacists did not display much knowledge on dementia medication-
related interactions either: 
“I’m not sure, to be honest. That for me, there would be a lack of knowledge” (K6) 
 
“I’m just going blank, I don’t know why” (K1) 
 
This is in contrast with some of the participants in the Thurrock arm of the study 
who indicated that they would rely on computer programmes to flag up clinically 
significant interactions. It is important to note that an underlying knowledge base 
of the disease condition and how it affects patients is critical in ensuring 
appropriate, safe and effective drug therapy in these patients.  
Another Kent participant when asked what clinically significant interactions she 
would consider when dispensing medication for dementia responded: 
“Clinically significant interactions, with those ones that are like the anticholinesterase ones, I 
would say a significant one would be because they can cause dry mouth and things like that, 
so that’s the only one I can think of at the moment” (K4) 
 
This particular pharmacist thus mixed up adverse drug reaction and drug 
interaction, and confused acetylcholinesterase inhibitors (anti-dementia 
medication) with anticholinergic drugs. Anticholinergic drugs are drugs from 
various classes indicated in treatment of many ailments such as depression, 
allergies, Parkinson’s disease and epilepsy, amongst others (Richardson et al 
2018).  
However, one participant who displaying a deeper perspective, and correctly 
highlighted the anticholinergic side effects of antihistamines,  opined that several 
dementia patients were burdened with many medications they did not need, or 
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medication for physical conditions which in turn caused deterioration in their 
cognitive function:  
“Most people have dry skin and it itches and because of that we give them an antihistamine 
and it affects their cognition…..and sometimes things like bladder control medicines affect 
cognition. I look at polypharmacy because a lot of times a person would be on medication 
which could be of limited value” (P10) 
 
This could be attributed to the fact that this participant had prior experience of 
working with primary care trusts to conduct medication reviews in care homes. 
Knowledge of the Behavioural and Psychological Symptoms of Dementia 
Knowledge of behavioural and psychological symptoms of dementia (BPSD) in 
dementia is essential to support pharmacists’ ability to challenge inappropriate 
prescribing of antipsychotics to people with dementia.  
In the Thurrock arm, a majority of pharmacists understood BPSD, stating some of 
the symptoms, with agitation being the most mentioned.  However, some training 
needs were evident. 
For the Kent arm one participant, demonstrating a clear understanding of BPSD, 
outlined succinctly, his opinion on how pharmacists could play a role in helping 
care homes manage patients with BPSD by suggesting that alternatives to 
medication should be tried: 
“….most people, when I speak to them, they say because they’ve got a very idle lifestyle and 
they feel really lonely…..that’s when the symptoms are more prominent. When they 
interact….then the symptoms are less” 
 
“….there are quite a few support therapies in dementia and so normally, I advise to try that 
first”… (K3) 
 
In support of this view, Corbett et al (2014) discourages the routine use of 
antipsychotics to treat aggression in dementia patients who have BPSD and 
recommends non-pharmacological strategies as first line treatment. 
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3.3.3 Barriers to Pharmaceutical Care 
Participants estimated that the proportion of dementia patients in their care 
homes ranged from 10% to 85%. Lack of time, poor inter-professional 
communication and funding for services were cited by most as clear barriers to 
pharmaceutical care and patient safety. While all participants had engaged with 
continued professional development (CPD), the majority had not undertaken any 
training in the field of dementia in the past one year. Judging from this, it could be 
deduced that lack of training was another barrier. 
3.3.3.1 Time constraints 
Participants in Thurrock, Essex shared the opinion that current community 
pharmacy practice made it difficult to provide optimised care to patients in care 
homes.  
“There is need for a change of working approach. If you are a dispensing machine, you don’t 
have time” (P10)  
 
Like the participants interviewed in Essex, Kent participants shared the opinion 
that current community pharmacy practice made it difficult to provide better care 
to patients in care homes.  
“I need to go during my lunchtime and then I speak to them so time is very limited because I 
am the only pharmacist here and I should be here working, I don’t get any cover, so it’s only 
during my lunchtime I tend to fit in the visit…” (K3) 
 
“Time. Time, because sometimes they give you time to go there and come back and most of 
the time I realise that whenever you get there, other activities take away your time and by 
the time you realise it, it’s time for you to get back to the pharmacy so you just do everything 
very quickly instead of really taking your time…..” (K1) 
 
This sentiment was echoed by Barber and Wilson (2013) who recommended a 
“step shift away from a service regarded as ‘dispensing of prescriptions’ to one 
99 
 
where its main focus is providing NHS pharmaceutical care and an increased 
emphasis on providing direct care to patients” 
This lack of time to deliver a focused service to people with dementia and other 
long-term conditions could potentially be linked to the increased workload for 
community pharmacists that arose as a result of the new pharmacy contractual 
framework implemented since 2005. 
3.3.3.2 Access to care records 
None of the Essex participants in the study had access to patient care records in 
the care homes for which they provided services, though some shared the view 
that the level of service they currently provided did not require access to patient 
records. 
Of concern was the fact that pharmacists only saw records of the medicines they 
dispensed regularly to patients. Care homes are not obliged to use their regular 
pharmacy for new one-off prescriptions for their residents, outside of the monthly 
repeat dispensing cycle; it is therefore possible that a pharmacist would not have 
the full picture of what the patients in their care homes are prescribed. 
This was described succinctly by a participant in the Thurrock arm of the study: 
“I think what it is, is the pharmacy gets allocated a care home or recruit a care home and all 
you know is their allergies, what their medication is and that’s it. But what we find a lot, 
what was happening in some of our care homes is that we do their regular medication and if 
they do have an acute prescription, they’ll take it somewhere else. The biggest barrier is, we 
have no access to health records to what they’ve had in between. It could clinically be a 
danger as well in terms of, if there’s an interaction with their normal medication, the new 
pharmacy hasn’t got a clue what they’re on.”(P3) 
 
Two pharmacists in the Kent arm of the study indicated they could, on request, 
access patient care records in the care homes they provided services to; one was 
unsure and the other two didn’t have access. Their views about the disadvantage of 
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not having access to patient records were expressed as well as the benefit access 
would afford: 
“….it’s only with the medication that we dispense in the pharmacy. I can only have those 
records so I can only go by that…..it is very difficult because they can’t always tell what extra 
medication they’re taking and things like that.” (K3) 
 
“I think it will really help because then we know all the medications they are on…..but you 
know, the clinical side of things and if they’ve had blood tests, and the history of their past 
medications and everything so that we can see if there will be any interactions or adverse 
reactions” (K1) 
 
This showed an awareness by some participants, of the need to have a complete 
picture of a patient’s medical conditions as well as their medication history in 
order to provide comprehensive pharmaceutical care. 
3.3.3.3 Absence of a diagnosis 
 Another point raised during the study was that pharmacists were not privy to the 
diagnosis of dementia in many of the patients they catered for, and only became 
aware if the patient had an anti-dementia medicine on their prescription. 
This means that for a care home resident diagnosed with dementia, this 
information is not routinely shared with the pharmacist dispensing their 
medication.   If this patient is not on an anti-dementia medication, which would 
give a pharmacist an indication of their dementia diagnosis, they could potentially 
be given medicines that could worsen their cognition, as the pharmacist would 
have no reason to raise concern. One Essex Pharmacist opined that: 
 “It is very very difficult to get doctors to put a diagnosis of dementia on some people” (P2) 
 
Lack of a diagnosis in care home residents taking anti-dementia medication was 
not specifically raised as a concern by the Kent pharmacists interviewed, unlike 
their Essex counterparts. 
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However, one participant did admit that their service included audits for patients 
prescribed dementia medication, to ascertain the presence of a diagnosis, but more 
time would be required to deliver an effective service:  
“We do have audits that we are meant to do for the patients that are taking…that are being 
prescribed medication for dementia. We are trying to improve on that. I mean, have some 
time to go there, and do those kind of, I mean audits to see if they have been diagnosed” (K1) 
 
The issue here is that a lack of communication concerning the diagnosis of a care 
home resident with dementia, limits the pharmacist’s role in optimising the 
patient’s therapy. 
3.3.3.4 Lack of communication with other healthcare professionals 
Lack of communication with hospitals and other health care professionals, 
specifically GPs regarding medication changes and other medicine-related issues 
for individual patients was considered by most participants in the study, to be a big 
obstacle for care. This issue was highlighted by participants in both arms of the 
study. 
In Essex: 
“Another thing is the communication even between hospital and community or GP and the 
community.  While you are dealing with a dosette box, patient has gone into hospital and you 
don’t even know about it, the patient comes out and the medication has changed, and then 
you have to find ways to get to know what has changed. It is a huge problem” (P8) 
 
“Looking at it, the barriers basically maybe related to not having a forward and backward 
kind of interaction with the prescribers” (P1) 
 
This account was corroborated by the findings of Barber et al (2009) in the ‘Care 
Homes Use of Medicines Study”. The study highlighted the need for improved 
communication between doctors and pharmacists, doctors and care homes, care 
homes and pharmacists as well as hospitals and community pharmacists. 
In Kent: A lack of communication was considered to be an obstacle to care by two 
participants in the study: 
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“If I see duplications on my sheet and second medications that I might think are not really 
necessary for the patient taking this, and they do tell me that it is a doctor that said to 
prescribe it, I want to know the reason behind it, so sometimes I do get their care plans and 
go through the visits the doctor has had with the patient to get further understanding” (K1) 
 
This is a laborious process for a pharmacist with limited time schedule to visit a 
care home. In the absence of pharmacists having access to computerised care 
records of patients, one model to consider would be to have a pharmacist-doctor 
communication book in the care home, where the doctor annotates any changes 
they have made on each visit, thus making it easier for a visiting pharmacists to 
evaluate medication changes. 
This, coupled with access to patient records could improve patient care and reduce 
medication error arising from poor communication within the healthcare system 
3.3.4 Education and Training 
Participant opinion was sought as to what knowledge and skills would be required 
for them to provide a comprehensive pharmaceutical care service to people with 
dementia. Most participants asserted that a dementia specific training course, 
which would enable them to understand the disease better, would be helpful, in 
addition to attending talks on dementia.  
One of the pharmacists interviewed in Essex bemoaned the absence of a system 
wide training standard in England:  
 “There’s no sort of national ‘you’ve got to do this, you’ve got to do that’, maybe that needs to 
be reviewed for the future” (P2) 
 
Kent pharmacists expressed more views on this subject, acknowledging gaps in 
their knowledge: 
“I need more in-depth knowledge….especially with prescription of antipsychotics. I need to 




“I think we need to know more about the personality of the individual patients as well, so 
that we can, rather than just managing with medication, getting lots of other support 
therapies that will do a lot to improve the condition…” (K3) 
 
“You have to have up to date knowledge of the drugs and how they’re used, any local 
protocols of administration and how they should be diagnosed. Being aware of interactions 
or at least having the facility to check interactions of their medication and give care homes 
guidance on dementia itself…”(K5) 
 
 This showed that participants understood the need for pharmacists to regularly 
evaluate their learning needs and undertake relevant education and training to be 
able to deliver consistently high standards of care to patients.  
3.4 Discussion 
 
The views and perceptions on various aspects of pharmaceutical care to people 
with dementia in care homes were captured, particularly with respect to the 
services they provided, their understanding of pharmaceutical care and what it 
meant for people with dementia, and aspects of everyday practice they considered 
as barriers to providing a comprehensive pharmaceutical service to this patient 
group. 
Services 
In this study, the community pharmacists interviewed, delivered pharmaceutical 
services to care homes ranging from 1 care home in the case of one participant, to 
over 70 care homes in the case of another. Whilst all participants in this study 
considered supply of medication to be the main service they provided to care 
homes, a few undertook medication reviews and some trained care home staff as 
part of their pharmaceutical service.  Though all the participants were selected for 
the study expressly for their involvement in delivering services to care homes that 
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had people living with dementia, the services provided were for the care home 
residents in general, none specifically for residents with dementia. 
Dispensing (supply) and repeat dispensing of medicines is an essential service 
offered by all pharmacy contractors in England, Scotland and Wales (PSNC 2014, 
Community Pharmacy Wales 2014).  
This supply role historically established the image of community pharmacy as a 
profession in which dispensing, and sales of medication dominates (Varnish 1998). 
This has led to the perception of pharmacists as the least visible healthcare 
professionals within the primary care network when compared to roles played by 
doctors, dentists, midwives, optometrists and nurses (Hassel et al 2011). Following 
a review of research evidence, the same authors, Hassell et al. (2011), concluded 
that community pharmacists spend most of their time dispensing prescriptions.  
Consequently, over the last three decades, steps have been taken by pharmacy 
professional bodies and the Department of Health in the UK to expand the role 
played by pharmacists (DOH 2008, RPS Wales 2016, and BMA&PSNC 2019, RPS 
Scotland 2019). This led to the incorporation of advanced and enhanced services 
into the community pharmacy contractual framework (PSNC 2014). Pharmacists 
began to offer services such as smoking cessation, weight management, appliance 
use reviews, NMS (New Medicine Service) amongst a myriad of other advanced 
and enhanced services, to patients/service users in the community (Wright 2016).  
However, involvement of pharmacists with other pharmacy-based commissioned 
services requiring their physical presence on their premises limits their capacity to 
provide more than an enhanced supply role to care homes in general, and 
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dementia sufferers in particular. This was highlighted by one of the participants in 
the current study, who pointed that in order to do more with care homes; they 
would have to squeeze in the time during their lunchtime. Additionally, expanding 
the role of community pharmacists and range of services offered such as minor 
ailment schemes has contributed to significantly increased workload and resultant 
workplace stress (Jacobs, Johnson and Hassell, 2014). This may be one of the 
factors that contributed to many pharmacists in this study offering a basic level 
service of dispensing and supply of medicines, and not medication reviews which 
they pointed out they were not remunerated for. 
While the previous service specification for community pharmacy services to care 
homes does not cover medication reviews, it has been suggested that community 
pharmacists can ‘build a compelling case to improve medicine management’ in 
care homes by doing just that (Barber et al 2009, Lau 2014, Anderson 2016,).  
Barry et al (2013) asserted that not only are pharmacists amongst the first 
healthcare professionals that a person with dementia in the community would 
encounter before seeking out their general practitioner, pharmacists are also 
expected to provide pharmaceutical services to patients in advanced stages of 
dementia living in care homes, which would include reviewing medication. 
However, in a review of community pharmacy services commissioned by the Kings 
Fund, Murray (2016) highlighted that existing contractual mechanisms for 
pharmacy are complex and poorly understood, in addition to poor integration 
between community pharmacists and GPs that have led to slow progress as well as 
patchy utilisation of community pharmacists in the development of new clinical 
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roles or adoption of extended roles in management of long term conditions. This 
included roles in community as well as in care homes. 
In welcoming the announcement of a £42 million-pound Pharmacy Integration 
Fund (PhIF) by NHS England in October 2016 (NHS England 2016), the Chief 
Pharmaceutical Officer for England, Dr Keith Ridge, acknowledged that community 
pharmacy will have to change the way it works. He asserted that there will be a 
shift from the old-fashioned view of the pharmacist as dispensers, with integration 
into a greater NHS role in helping patients.  
According to proposals in the Community Pharmacy Contractual Framework for 
2016-2018 (DOH 2016), the PhIF will support community pharmacy as it develops 
new clinical pharmacy services. Part of these will be the deployment of 
pharmacists into care home settings from April 2017. This was in line with 
recommendations by the Royal Pharmaceutical Society (2014), that pharmacists 
should be responsible for medicines and their use in care homes, and that every 
care home should be assigned to a community pharmacist and GP practice to 
ensure the provision of co-ordinated care to a consistently high standard.  
The PhIF also financed a medicines optimisation in care homes programme (NHS 
England 2018) intended to support the deployment of 240 pharmacy staff into 
care homes over two years. Local commissioners had to commit to funding half of 
the costs of pharmacists/pharmacy technicians to work in care homes as well as 
continuing the pathway after two years. Whilst this programme also funds 
education and training of specialist pharmacists and technicians to work in 
reducing waste and medication errors in care homes, there is no clarity about how 
community pharmacists delivering services to care homes with no dedicated care 
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home pharmacist could be supported to provide a comprehensive pharmaceutical 
care service. 
In July 2019 a new Community Pharmacists Contractual Framework was agreed 
(DOH 2019) with a 5-year life span. This new contract further promotes 
community pharmacy as an integral part of the NHS delivering clinical services, 
and requires that all premises complete a dementia-friendly environmental 
checklist, but it no longer specifically mentions care homes. It is not yet certain 
how the newly created Primary Care Networks (PCNs) will deploy clinical 
pharmacists previously dedicated to care homes, or how these organisations might 
integrate community pharmacists into new models of care so that they can provide 
more extensive pharmaceutical services to care homes (Taachi 2019). 
Pharmaceutical care  
The philosophy of pharmaceutical care practise requires that pharmacists engaged 
in the provision of a comprehensive pharmaceutical care service, must ensure the 
safe and effective use of medicines in all disease conditions, acute or chronic 
(Strand et al, 2004). This includes, but is not limited to: 
• Making ethical decisions on behalf of patients 
• Collaborating with patients, their families and with other healthcare 
professionals  
• Contributing to the professional development of their peers  
• Acquiring up to date knowledge in pharmacology, pharmacotherapy and 
pharmaceutical care practice 
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In a pharmacist’s guide to implementing pharmaceutical care, van Mil (2019) 
summarises that the ultimate goal of pharmaceutical care, which should exist in all 
practice settings, is optimising medicines use and improving health outcomes.  The 
same guide indicates that this goal is achieved by performing two major functions: 
identification of potential pharmacotherapy problems (also known as drug related 
problems or DRPs) and in collaboration with other healthcare professionals 
resolving these problems for patients in a manner that prevents the potential 
problems from becoming real for the patient and their therapy outcomes (van Mil 
2019).   
The role of the pharmacist in medicine optimisation for dementia patients, 
theoretically, is being able to review treatment regimens and identify improper 
drug selection, adverse drug reactions and drug interactions. They are also well 
placed to be involved in multidisciplinary teams, encouraging the correct use of 
cholinesterase inhibitors (donepezil, galantamine, rivastigmine) in mild to 
moderate dementia and memantine in severe dementia. They can also support 
prescribing decisions around treatment of BPSD which can be complex, often 
involving starting antipsychotics in an already frail population, further exposing 
them to serious adverse effects (Locca et al 2008, Maidment et al 2016). 
 There has been a drive to reduce prescribing of antipsychotics in dementia 
patients, with many initiatives targeting the care home population, a majority of 
who are estimated to suffer from dementia (Prentice and Wright 2014). Although 
most of the reviews of antipsychotic prescribing in care homes are currently 
carried out by pharmacists trained for this purpose, this task can also be carried 
out by community pharmacists, especially in the context of the expanding roles of 
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community pharmacists in managing long term conditions (DOH 2008) (DOH 
2019). 
In the current study, participants correctly highlighted that the pharmaceutical 
care needs of people with dementia in care homes involved ensuring they had the 
right medication in the right formulation, whilst some expressed concern about 
inappropriate prescribing and polypharmacy experienced by this vulnerable 
group. However, despite this recognition, participants showed limited knowledge 
about medication used for dementia and raised many issues representing barriers 
that prevented them from delivering a comprehensive pharmaceutical care service 
to care homes in general and to people with dementia in particular. 
From another angle, a review by Hughes et al (2010) showed that pharmaceutical 
care provision from community pharmacies across Europe is still limited because 
pharmacists are not regularly engaging in patient-centred professional activities 
such as implementation of therapeutic objectives and monitoring treatment plans.  
In France, community pharmacists are encouraged to listen, support, orientate and 
reassure patients with dementia by building confidential relationships with 
persons needing help (Dreux 2009). However, French pharmacists, as well as other 
pharmacists across Europe, also need to be motivated to participate in structured 
continuing training to adequately assist persons suffering from dementia and other 
neurodegenerative diseases (European Foundation Initiatives on Dementia 2016).  
This indicates a need for policy makers to address some of the barriers highlighted 




Despite the aforementioned professional capabilities of community pharmacists to 
extend their clinical expertise to care homes, thus benefitting people with 
dementia in these care settings, participants in this study revealed barriers to such 
provision including remuneration, time pressure, knowledge, access to resident 
care records, lack of dementia diagnosis and lack of communication with other 
healthcare professionals involved in the care of residents within individual long 
term care settings. 
Specific knowledge of medication used in dementia, adverse effects and 
implications were poorly displayed in this study, though two participants did 
highlight concern about the prescribing culture in care home residents with 
dementia.  
This concern was justified, and pharmacists dispensing medication to people with 
dementia in care homes should be aware of the effect of factors such as physical 
health problems (infections, constipation, undetected pain or discomfort) as well 
as side effects of medication on the wellbeing of people with dementia (NES 2014). 
Pharmacists in the current study were not unique in their limited dementia-
specific knowledge.  
In the USA, Marvanova and Henkel (2017a) surveyed community pharmacists and 
found that 50% of participants in the specified research location could not mention 
a single adverse effect of donepezil and inappropriately recommended insomnia 
aids to a person on rivastigmine. In a second study, the same authors (2017b) 
found that participating pharmacists had limited knowledge of Alzheimer’s disease 
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and did not consistently access continuing pharmacy education resources related 
to dementia. 
Building up community pharmacists’ knowledge and confidence in providing 
adequate medication related support to dementia patients and their carers within 
the community as well as in care homes must be a prime objective. This would 
require a service specification that ensures that pharmacists are trained and 
empowered to provide a structured and safe pharmaceutical care service to 
dementia patients, whether living in care homes or in the community. 
Other barriers highlighted by study participants were the lack of access to patient 
records and inadequate communication links with GPs and other healthcare 
professionals. 
 In this light, a joint statement by the Royal Pharmaceutical Society and The Royal 
College of General Practitioners, Scotland (RPS 2011) contained a recommendation 
for an integrated care record including medicines prescribed by GPs and dispensed 
by pharmacies to be developed that will help in management of long-term 
conditions. The Royal Pharmaceutical Society in Scotland in a recent publication 
calling for pharmacists to lead on provision of pharmaceutical care to care homes, 
recommended that all pharmacy team members directly involved in residents’ care 
should have full read/write accesses to residents health and care records (RPS 
Scotland 2019).  
This recommendation had been partially realised when community pharmacists 
were afforded access to summary care records which contain key clinical 
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information on what medication the patient is taking, and the indication being 
managed (Health and Social Care information Centre 2015). 
RPS Scotland (2019) also recommended that pharmacists involved in providing 
care to residents in care homes, should be required to develop competences in care 
of the elderly, dementia and palliative care. These recommendations further 
included the drive to build sustainability into care home contracts with community 
pharmacists to enable continuity of care, long term planning and investment into 
staff education and training. 
If these recommendations were to be implemented, it would support the delivery 
of a pharmaceutical care service to dementia patients in care homes as well as help 
to improve communication with general practitioners and other prescribers, 
leading to improved patient care outcomes. 
A relevant service level agreement requires that all pharmacists and staff who are 
engaged in providing services to care homes be fully trained in all aspects of 
providing such a service. However, there is no national standard for the level of 
training required for the provision of pharmaceutical care to patients with 
dementia by community pharmacists.  To this effect, RPS Scotland (2019) stated 
that an enabler to ensuring safe and effective pharmaceutical care to residents of 
care homes would be for NHS Education Scotland to develop a national education 
framework which will support approved standardised, competency-based training 
for all pharmacists and pharmacy technicians delivering pharmaceutical care to 
people living in care homes.  Development and implementation of such standards 
could be implemented across the four countries of the United Kingdom, which will 
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go a long way towards eliminating variation in care for care home residents, 
particularly those with dementia. 
Another deterrent to optimal pharmaceutical care highlighted by participants in 
the current study was the absence of a dementia diagnosis in residents’ records. 
However, many GPs are still not confident in making dementia diagnoses 
(Alzheimers Society 2016) and many residents do not have a formal diagnosis of 
dementia even though they may have clear symptoms (National Collaboration 
Centre for Mental Health 2018). It would be beneficial for memory clinics to 
develop out-reach services with care homes so that people living there can be 
assessed and diagnosed and given access to treatment (Alzheimer’s society 2013).  
Such services, together with an integrated system of sharing patient records 
between primary and secondary care, would help pharmacists to improve 
pharmaceutical care services provided to dementia patients in care homes. 
A view put forward by the Royal Pharmaceutical Society (Anderson 2016) is that 
there should be one named community pharmacy and one GP practice aligned to a 
care home to enable care co-ordination and consistently high standards of care for 
all residents. 
To offer consistently high standards of pharmaceutical care to care homes, and 
address medication safety, a novel model of care has been suggested for care 
homes in which every care home has an on-site pharmacist integrating with 
nursing staff to improve quality of use of medicines (Kosari et al 2018). This model 
is similar to the Medicines Optimisation in Care Homes project (NHS England 
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2018) which saw pharmacists assigned to care homes across England, but this is 
coming to an end.  
If community pharmacists are to contribute to supporting safe and efficient 
management services in care homes, commissioning of their services must be 
standardised alongside the aforementioned standardised education and training 
framework. It could be argued that the sub-optimal use of pharmacists caused by 
complex commissioning of cognitive pharmaceutical services by CCGs (Wright 
2016, RPS 2016, Murray 2016), contributes to a potential de-skilling of highly 
trained healthcare practitioners (Hindi, Jacobs and Schafheutle, 2018) who have a 
lot to contribute to improved patient outcomes . This de-skilling is underpinned by 
a contractual framework that is still heavily linked to prescription numbers and 
scepticism from community pharmacists about getting involved in offering 
extended services (Hall et al 2018), despite community pharmacy contracts 
consistently trying to move away from a supply-centric service through linking 
pharmacy quality schemes to more clinical services from community pharmacies 
(NHS England Community Pharmacist Contractual Framework 2019). 
This study identified the current nature of services provided by community 
pharmacists to people living with dementia and other morbidities in care homes; it 
has also identified areas where pharmacists’ roles could be expanded for example, 
in the training of care home staff and in the provision of medication reviews in care 
homes. It also established that several barriers currently prevent this from 
happening. Further research is required to establish whether adequate 
commissioning and remuneration of pharmacists for these enhanced services 
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would improve their participation and lead to better outcomes for people living 
with dementia in care homes. 
3.5 Study limitations 
This was a small qualitative study, and as such, the findings are not generalizable 
to the wider community. 
The interviews were conducted in community pharmacy consultations rooms but 
there were constant interruptions as participants often had to stop recording to 
deal with queries and conduct clinical checks of prescriptions within the 
pharmacy. This could have disrupted their thought processes and contributed to 
less than comprehensive answers.  The ideal setting for the interviews would have 
either been a quiet room booked for the purpose. Alternatively, if the participant 
preferred to be interviewed in their pharmacy premise, there should ideally have 
been a second pharmacist to maintain continuity whilst the participant pharmacist 
was being interviewed. 
3.6 Conclusions 
Analysis of semi-structured interviews with 10 pharmacists revealed that the 
pharmaceutical care provision by community pharmacists to dementia patients in 
care homes was limited to mainly medication supplies, in accordance with the 
contractual framework agreed between local authorities and the community 
pharmacy contractors.  
However, the precise pharmaceutical care needs of people living with dementia in 
care homes still need to be clearly defined. This is necessary to support the 
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development of a comprehensive evidence-based service framework that 
underpins a cognitive, transformative and well-defined pharmaceutical service, 
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4.0  
4.1 Introduction and chapter overview 
In chapter 1, the background to the research described the concepts of 
pharmaceutical care and its potential importance to improving outcomes in people 
living with dementia.  
Chapter 2 presented a comprehensive review of dementia, its causes, diagnosis, 
treatment and the relevance of these to pharmaceutical care of people who suffer 
from the condition.  
However, despite recommendations for pharmacists to become more involved 
with the pharmaceutical care of people with dementia (DOH 2009, NES 2014) 
together with evidence that pharmacist-led medication reviews in care homes can 
improve quality of prescribing, reduce drug costs and reduce drug burden for 
elderly residents (Brulhart and Wermeille 2011, Burns and Nair 2014, Lee, Mak 
and Tang 2019), there is a dearth of research on pharmaceutical care delivery by 
community pharmacists who are contractually responsible for supplying 
medication and appliances to people living in care homes. 
Chapter 3 described a qualitative pilot study with community pharmacists, 
exploring their views during face to face semi-structured interviews. Themes 
generated from this study were used to develop a questionnaire survey tool. 
The current chapter represents phase 2 of my research and involves a 
questionnaire survey of a wider population of community pharmacists, 
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systematically selected across England.  It explores the views of a larger group of 
community pharmacists about the nature of pharmaceutical care services provided 
to people living with dementia, with emphasis on those residing in care homes, and 
includes further investigation of barriers to care identified from findings of the 
qualitative study, and from published research.  
Additionally, using the results of the survey, a structural equational modelling 
technique was applied to evaluate the relationships between knowledge, barriers, 
understanding and confidence of pharmacists providing services to people living 
with dementia in care homes. 
4.2 Methods 
4.2.1Aims and objectives 
4.2.1.1 Aims 
• To assess the nature and extent of pharmaceutical services provided by 
community pharmacists to people living with dementia in care homes in 
England. 
• To investigate their confidence and knowledge base in providing 
pharmaceutical care services to this patient group in and identify any 
training needs, which can later be used to design an intervention tool 
4.2.1.2 Objectives 




• To explore the knowledge and confidence of pharmacists in relation to 
dementia medications and ascertain their expertise in identifying and 
resolving drug therapy problems 
• To identify the barriers to provision of effective pharmaceutical care for 
people living with dementia in care homes 
• To determine whether there is a relationship between knowledge, 
understanding and confidence of pharmacists, using structural equational 
modelling (path model) 
4.2.2 Study Design 
A quantitative research design was used for this phase of the research. 
Quantitative research involves counting “things” such as people, opinions, 
behaviours and medicines. It is different from qualitative research which involves 
either observing, interviewing participants or reading what they write with the 
aim of gaining understanding of their feelings, attitudes or views on specific topics 
(Babar 2015).  
Quantitative research methods complement qualitative research methods in 
pharmacy practice by providing estimates of frequency, commonness and size 
(Babar 2015), and use of self-administered questionnaires has several advantages: 
easier to get information from a larger number of respondents with less pressure 
to respond immediately, data analysis is more straightforward. Researcher bias 
can be reduced through ensuring responders are anonymous (Bowling 2005). The 
disadvantage of this method is that response rate may be low depending on length 
of the questionnaire, language used and literacy of respondents; use of tick boxes 
can limit information gathered (Bowling 2014). 
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Ethical approval was obtained from the Cross-Schools Research Ethics Committee 
(C-REC) at the University of Sussex in January 2016 (Appendix 4a).  
Self-completion postal questionnaires with prepaid envelopes were sent out to 
participants between January 2016 and April 2016; this was repeated twice 
between April 2016 and October 2016 following an extension to the study due to a 
poor response rate.  
4.2.2.1 Questionnaire development 
The questionnaire comprised of 6 sections. Each section required participants to 
respond to a specific set of questions (Appendix 4b).  The questionnaire design 




• Modifications and printing 
Planning 
The questionnaire planning stage involved deciding what topics would be included 
in the questionnaire. The topics of interest were informed by the overall aims and 
objectives of the research in both the qualitative and quantitative studies of 
pharmacists as both arms had the aim of establishing the nature of pharmaceutical 
care services provided by community pharmacists to people with dementia in care 
homes and objectives relating to investigating pharmacists’ awareness of 
pharmaceutical care needs of people with dementia, their knowledge and 
confidence in delivering these services, barriers encountered, and education and 
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training needs.   The qualitative study revealed themes (services, knowledge and 
confidence of pharmacists in pharmaceutical care of people with dementia, and 
education and training), which guided the choice of topic areas to focus on when 
planning the questionnaire. Table 4 depicts topics of generated using data from the 
qualitative study: 
A. Characteristics of participant pharmacists (demographics) 
B. Pharmaceutical services provided to care homes 
C. Pharmacist knowledge: prescriptions for dementia medication 
D. Pharmacist understanding and confidence: Pharmaceutical care of people with 
dementia 
E. Barriers to pharmaceutical care provision 
F. Education and training undertaken 
Table 4: Topics of interest for questionnaire 
Design 
As part of the design phase, a literature search for a suitable validated 
questionnaire that covered the topics identified was conducted in healthcare 
databases (PubMed, MedLine, PsychInfo, EMBASE, CINAHL). It also sought to 
ascertain whether there was a consensus process for the design of pharmacy 
practice research questionnaires.  
Two studies were identified that had utilized a questionnaire survey tool to study 
community pharmacist populations about services to care homes or to people with 
dementia. 
• Barry et al (2013) explored community pharmacists’ views, knowledge and 
attitudes to people with dementia, but this study was mainly focused on the 
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views, experiences and knowledge of community pharmacists about pain 
management for people with dementia.  
• Schweizer and Hughes (2004) developed a questionnaire and surveyed 
pharmacists in Northern Ireland about the pharmaceutical care services 
provided to care homes, but they focused purely on contractual services with 
no focus on dementia. 
A decision was therefore made by the researcher to design a questionnaire 
specifically for this study. Expert academic publications on designing healthcare or 
pharmacy practice research questionnaires (Bowling 2014, Gillman 2007, Smith 
2010) described best practice for questionnaire design but there was no consensus 
on the design and conduct of questionnaire surveys. 
A questionnaire was thus designed specifically for this study, with consideration of 
factors such as: 
• Format 
• Number of sections (these matched the selected topics) 
• Language (English), phrasing and length of questions 
• Scales for responses (Likert scales chosen) 
• Number of questions in each section (they varied) 
• Illustration  
• Free text boxes for participants to add their own comments. 
The content of the questionnaire was built from the results of the qualitative study 
(chapter 3 of this thesis). However, inspiration was sought from NHS Education 
Scotland (NES, 2014) publication entitled “The Pharmaceutical Care of People with 
124 
 
Dementia”, as well as NICE Guidelines for dementia (NICE CG42, 2006) because 
both publications described knowledge required by pharmacists and other 
healthcare professionals to deliver comprehensive pharmaceutical care to people 
with dementia. Most of the questions utilised were closed questions requiring a 
tick on a Likert scale, since this was a self-administered postal questionnaire; most 
respondents do not bother to write down replies to open-ended questions. 
However, there were open-ended questions following the closed questions in 
sections A, C and F which required free typing to give the respondents the 
opportunity to include their own comments.  
The resulting questionnaire was discussed with and reviewed by the academic 
supervisor who suggested improvements in structure, punctuation, and sentence 
construction. 
 Table 5 depicts the format and contents of the resulting questionnaire and the full 




Section Content Required response 
Part A Six questions gathering the socio-
demographics of respondents and their 
employing community pharmacies  





Four questions about pharmaceutical 






Nine statements about respondents’ 
knowledge of prescriptions for people 
with dementia 
 
Level of agreement with 
each statement on a 3-
point Likert Scale with  





Seven statements regarding 
respondents’ understanding and 
confidence in providing a 
comprehensive pharmaceutical service 
to people with dementia 
 
Level of agreement with 
each statement on a 5-
point Likert scale 
1=Strongly agree, 
2=Agree, 3= neither agree 
nor disagree, 4=disagree, 




Twelve statements about perceived 
barriers of respondents to 
pharmaceutical care provision 
 
Level of agreement with 
each statement on a 5-
point Likert scale 
1=Strongly agree, 
2=Agree, 3= neither agree 
nor disagree, 4=disagree, 




Three questions about respondents’ 
education and training on the subject of 
dementia  
 
Tick box, Yes/No and free 
text. 
Table 5: Format and content of pharmacists' questionnaire 
 
Piloting and validation 
For validation and to ensure reliability, the questionnaire was pre-piloted with 5 
professional colleagues in the department of pharmacy, and 5 community 
pharmacists purposively sampled in the researcher’s geographical area. 
Reliability refers to tests carried out on a survey instrument to ensure that scale 
items measure the same construct and do not change over a period in which it is 
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not expected to change (Bowling 2014). The questionnaire developed for this 
study was tested for reliability during pre-piloting with 5 colleagues in the 
department. The questionnaire was sent to colleagues by email and returned with 
comments regarding suggested improvements. The process was repeated a week 
later after the suggested changes were implemented. This process was repeated 
twice, and consistency in responses noted. 
Validity is assigned to a questionnaire after it has been tested satisfactorily in the 
populations for which it is designed and is defined as the extent to which it really 
measures the concepts it was designed to measure (Calnan 2007). There are many 
forms of validity but the relevant ones to this study were face validity, content 
validity, criterion, internal and external validity. The 5 community pharmacists 
who piloted the questionnaire were interviewed to ensure the questions in the 
instrument were clear and understandable, and to evaluate their use of the Likert 
Scales. Comments on the format, questions and scales were sought. The following 
aspects of validity were assessed: 
Face validity was established by the researcher and research supervisor who 
checked the general format, presentation and relevance of the questions to the 
research objectives. 
Content validity, which refers to the extent to which the content of the 
questionnaire appears to examine and include the full scope of the domain 
intended to measure (Bowling 2009), was assessed by the researcher consulting 
with the research supervisor and reviewing comments from colleagues who pre-
piloted the questionnaire. 
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Criterion validity refers to the degree of convergence of a proposed instrument 
with existing, tried and tested indicators of the concept (Calnan 2007). This could 
not be assessed, as my research questionnaire study did not correlate with any 
existing tools. 
Internal validity was established after satisfactorily pre-piloting and piloting the 
questionnaire as described above; external validity, which is the degree of 
generalisability of the findings to a wider population of community pharmacists 
was assessed at the conclusion of the study. 
Modifications and printing 
Modifications suggested by the research supervisor were grammatical corrections 
and sentence structure, as well as wording of the statements in section E of the 
questionnaire (Barriers to pharmaceutical care). Colleagues and community 
pharmacists who piloted the questionnaire made suggestions about the format, 
indicating that it should be on double sided A4 paper to ensure that there were not 
too many sheets to complete as this could seem daunting to the respondent. Font 
size was set at between 12-14 to improve readability (from 10-12 in initial 
questionnaire). Since there were many boxes to tick in sections C, D and E, 
suggestions were made to include alternate shading so each question would stand 
out, and respondents would identify items on the scale and match them to the 
questions more easily. 
No changes to the actual content of the questionnaire or the format were made, so 
these were not modified. However, after receiving responses from the first round 
of posting the questionnaires, it was noted that Section C had a three point Likert 
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Scale (agree, not sure, disagree) whilst sections D and E offered a wider, 5-point 
scale (agree, strongly agree, neither agree nor disagree, disagree, strongly 
disagree). This could not be changed for the second round of posting and was 
addressed during data analysis. 
4.2.2.2 Setting and participants 
The country setting of the study was England, the researcher’s practice base.  
Focusing on one country out of four that make up the United Kingdom ensured 
that the pharmacists who responded were practising under the same community 
pharmacy contractual framework. 
Contact details of registered pharmacy premises in England were obtained from 
the General Pharmaceutical Council’s website. A postal questionnaire and detailed 
information about the study were sent to the pharmacies identified by the 
sampling method described below. This was followed up by a phone call after five 
working days to ascertain the receipt of the questionnaire and the willingness of 
the pharmacist in charge to participate. Pharmacists who wished to participate 
were instructed to respond to the questionnaire and return directly to the 
researcher in a pre-paid envelope addressed to the Pharmacy Department at the 
University of Sussex. Participants were reassured in the information form sent out 
with the questionnaires that they could contact the researcher at any time for 
further information or clarification of any issues. Participants were informed that 
they could withdraw from the study at any time by contacting the researcher. They 
were also assured in writing (as part of the participant information form) that 
neither they, nor their premises would be identifiable in the study. 
129 
 
4.2.2.3 Sampling strategy 
For this arm of the research, involving a survey of a wider sample of community 
pharmacists, it was deemed necessary to use a probability sampling technique 
which ensures every pharmacist working in a registered pharmacy premise in 
England at the time of the study had an equal chance of being selected, in order to 
make the study more generalisable. 
Choice of probability sampling methods as summarised by Showkat and Parveen 
(2017) included 
• Simple random sampling (obtained through activities such as tossing a coin 
or throwing a dice) 
• Systematic random sampling (this requires complete details of the 
population under study, arranged randomly to ensure the same error rate. 
Following selection of the first unit, others are drawn at equal intervals 
until the full list is sampled). 
• Stratified sampling (creation of subgroups of the population under study, 
then randomly selecting from within the groups) 
• Cluster sampling (dividing the population into random clusters and 
randomly selecting from chosen clusters) 
For this study, a systematic sampling method was used as it is one of the simplest 
sampling methods which allows for selection of a representative sample. 
The sampling frame was community pharmacists practising in England, identified 
via the General Pharmaceutical Council list of community pharmacy registered 
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premises (since it was not possible to get person identifiable details of individual 
pharmacists). 
According to the Health and Social Care information Centre (2014), trading as NHS 
Digital (from 2017), there were 11,647 registered pharmacies in England on the 
31st of March 2014. A sample size calculation based on 5% confidence interval and 
95% confidence level, gave a sample size of 372. This calculation was done using a 
website with embedded sample size calculator. 
https://surveysystem.com/sscalc.htm (Creative Research Systems, 2012). 
Systematic sampling entails selection from every kth unit from the complete list of 
units in the population to produce a random sample where k = quotient or 
sampling interval.  
The sampling interval    (𝑘) =
𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑖𝑧𝑒
  and, for this study, k =
11647
372
 = 30 
Therefore systematic  random selection of the first pharmacy premise in the 
randomly arranged list of community pharmacy premises in England, then the 
30th, and  subsequent selection of every 30 pharmacies thereafter (30, 60, 90...) 
until 372 pharmacies had been selected  resulted  in systematic sampling of the 
population (Aparasu 2011). 
4.2.2.4 Inclusion criteria 
Community pharmacists providing contractual services from registered pharmacy 
premises in England, who respond to the questionnaire survey 
4.2.2.5 Exclusion criteria 




4.2.2.6 Informed consent 
A participant information form (Appendix 4b) was sent to every participant along 
with the questionnaire. Informed consent was assumed when pharmacists 
returned their completed questionnaires.  
4.2.2.7 Timescale 
Ethical approval for this study was obtained from the University of Sussex Cross-
schools Research Ethics Committee (C-REC) (Appendix 4a) on the 29th of January 
2016. Data was collected over several months, with the researcher resending 
questionnaires twice between April 2016 and October 2016 to improve the 
response rate. Final questionnaires were received in October 2016. 
4.2.2.8 Data Collection 
The questionnaire was piloted amongst my peers in the university pharmacy 
department, corrections made and reviewed by the main research supervisor.  
Each questionnaire was given a serial number corresponding to the pharmacy it 
would be posted to so that responses could be followed up. 
After the first mailing of 372 questionnaire packs, only 33 responses were 
received. These were ticked off the list and reminder calls made. Further copies 
were sent to pharmacies where the pharmacist in charge had indicated non-receipt 
of the original questionnaire. Another 60 responses were received after the first 
reminder and then a further 11 responses after the second reminder. Two 
questionnaires were excluded because they were returned blank, one with no 
explanation and the second with a note explaining that the premises had a 
registered pharmacist but dealt only with veterinary prescriptions. 
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4.2.2.9 Data handling  
Returned questionnaires were collected from the university postage box and 
stored in a locked filing cabinet at the School. Once data collection ended, 
responses were coded and entered on to SPSS software package version 24 and the 
paper copies stored securely. 
4.2.3 Data analysis 
The questionnaire design contained a mixture of nominal and ordinal data. The 
Likert scale (Likert 1932) was used as it is a psychometric item-scoring technique 
popularly used when attempting to measure the attitudes and opinions of 
individuals on various issues (Bishop and Herron 2015). 
Using SPSS Version 24 (IBM Corp 2016), the analysis was initially conducted using 
Kolmogorov Smirnov test to assess for normality. This is often used to satisfy the 
assumptions of parametric statistics and gives an indication of whether the data 
distribution as a whole deviates from comparable normal distribution (Field 
2009). If the test is not significant (meaning p≥0.05), then the sample distribution 
does not differ significantly from a normal distribution. If p≤0.05, the sample 
distribution differs significantly from normal. 
This study contained both continuous variables (such as age of participants) and 
categorical variables (such as gender, pharmacist’s role) 
Categorical variables were analysed using Pearson Chi Square for goodness of fit 
when comparing the observed sample distribution with the expected distribution. 
For example, in this study, where there were 102 respondents who were male or 
female, the expected distribution would be 51 male pharmacists and 51 females. 
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The Chi Square test determines how closely the actual distribution of samples in 
the study mimic this expected distribution. 
 Data were weighted according to their frequencies and the following tests applied: 
• Pearson Chi Square for independence was used for cross tabulation. 
• Fishers’ Exact test was used when the frequency in each cell was below five and 
the percentage of answers with value below five was higher than 20% 
• Cronbach’s alpha (α) was used for assessing the internal reliability 
(consistency) of the 3-point-Likert scale questions for each domain 
(knowledge, understanding/confidence, and barriers).  
Median and the interquartile range (IQR) were reported for continuous variables 
which were non-normally distributed. Interquartile range (IQR) estimates where 
the middle 50% of the data set is and is often used instead of the median when the 
difference between the smallest data point and largest data point per variable is 
too wide. 
The Likert scale questions were grouped according to their different 
parts/domains (pharmacists’ knowledge, understanding and confidence, barriers 
to pharmaceutical care) and for uniformity, ease of analysis and reporting, the 5-
point Likert scale in questions (Q12) and 13 (Q13) were reduced to a 3-point scale 
by merging “strongly agree” with “agree” to form “agree” and merging “strongly 
disagree” with “disagree” to form “disagree”. The middle point remained the same, 
representing “not sure” / “neither agree nor disagree” 
New variables were created for each domain called score variables and these score 
variables were calculated by adding up all the scores of each domain and dividing 
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this score by the number of items of each domain. The median and IQR was 
calculated for this variable as well. An optimal scaling method, called 
correspondence analysis (CA), which is a quantification used to reveal any 
relationships existing between and within two groups of variables (Hao 2019) was 
used to treat multivariate (categorical) data.  Abdi and Béra (2014) suggested that 
CA transform data into two sets of variables called factor scores, which are 
obtained as a linear combination of rows and columns. These factors provide the 
best representation of the similarity of the structure and are plotted as visual maps 
that display the information in the original table. Furthermore, Sourial et al (2010) 
suggested that CA is a useful tool to uncover the relationship among categorical 
variables. A p-value <0.05 was considered significant for all tests. 
To evaluate the three domains of knowledge, understanding/confidence and 
barriers, it was considered relevant to use another statistical technique called 
‘structural equation modelling’ (SEM). Among the variance-based structural 
equation models (SEM), partial least square (PLS) path modelling is regarded as 
one of the more fully developed. PLS is a technique developed by Herman Wold 
(1975) for use in econometrics and chemometrics but has since spread to other 
disciplines such as marketing (Albers, 2010) and social science research (Jacobs et 
al 2011). 
Hensler et al (2009) statement that “PLS path modelling is recommended in an early 
stage of theoretical development in order to test and validate exploratory models”, is 
why it was of interest to apply to the current study. 
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The aim was to design a basic, simple model for the evaluation of path coefficients 
among the domains (also called variables or latent variables) to identify any 
significant correlations.  
Due to the small sample size and non-parametric data, analysis was conducted 
using Smart-PLS (v.3.2.7) (Ringle et al 2015) which involves a series of ordinary 
squares regressions and bootstrapping recommended for assessing the statistical 
validity (p<0.05) of non-normal variables with 500 iterations and t>1.96. The 
variables with loading coefficient <0.5 were eliminated from the model. 
4.3 Results 
4.3.1 Response rate 
Completed questionnaires were received from 102 pharmacists, providing a 
response rate of 27.4% (102/372). 
4.3.2 Socio-demographic details of the participants 
56.9% (n=58) were female and 43.1% (n=44) were male. The gender split did not 
show a statistically significant difference (p<0.166). The age groups most 
represented were the 25-29 (23.5%) and 30-34 (19.6%), while the least 
represented was the 55-59 (4.9%). A statistically significant difference was found 
among the age groups (see Table 2) (p<0.001). Seventy-six (74.5%) were 
pharmacy managers, 11 (10.8%) locum; five (4.9%) second pharmacist. 
 There were 2 superintendent pharmacists in the 25-29, 35-39, 40-44 and 55-59 
age ranges. Locum seemed the most popular choice in the 45-49 and 50-54 age 
ranges (see Table 6). Manager and sole pharmacists appeared to be chosen by the 
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vast majority of pharmacists between 20-44 years of age (n=63; 61.7%). The 
number of pharmacists who held a post-graduate qualification were one in the age 
range 20-24 and 50-54, two in the 55-59, three in the 30-34, four in the 25-29 and 
45-59, six in the 40-44 and seven in the 35-39. Seventy-four (72.5%) did not hold a 
post-graduate qualification (p<0.001). The correspondence analysis presented in 
Figure 4 shows three quadrants, North West, North East and South East where 
there is a pattern between age range and role, where pharmacists aged between 
20-24 years, 25-29 and 30-35 are second pharmacists or pharmacy managers, 
whilst older pharmacists 45-49, 50-54 and 55-59 are locum pharmacists or 









Female 58 56.9 
 
Male 44 43.1 
 




25-29 24 23.5 
 
30-34 20 19.6 
 
35-39 14 13.7 
 
40-44 11 10.8 
 
20-24 10 9.8 
 
45-49 9 8.8 
 
50-54 9 8.8 
 
55-59 5 4.9 
 








Locum 11 10.8 
 
Superintendent 10 9.8 
 
Second Pharmacist 5 4.9 
 
    




No 74 72.5 
 
Yes 28 27.5   
Table 6: Pharmacist demographic data 
 
 




Figure 5: Pharmacist role vs age range 
 
4.3.3 Year of registration 
Figure 6 shows a bubble chart indicating the pharmacist’s year of registration with 
the pharmacy regulatory body, compulsory for any pharmacist practising in the 
UK. The bubble size represents the number of pharmacists who registered in each 
of the years represented on the chart; therefore, a larger bubble means a higher 
number while a smaller bubble represents a lower number. Since the bubbles with 
the larger sizes tended to be concentrated between 2000-2016, it indicated 
pharmacists who responded mostly registered after the year 2000. 
In fact, the year of registration presented a wide range, with some respondents 
registered in 1980 (n=2) and others 36 years later in  2016 (n=2) so the year-
range was 36 (2016-1980), the median year of the registration was 2007 and the 
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IQR (where 50% of participants were represented) was 1998-2012. The 
percentage of pharmacists registered between 1980-2000 was 33.3 (n=34), and 
from 2001-2016 it was 66.7% (n=66)  
 
 
Figure 6: Pharmacists' year of registration 
 
4.3.4 Service provision 
Thirty-two (31.4%) pharmacists delivered services to care homes, while 70 
(68.6%) did not. 
Pharmacists could select more than one option for service provision. The most 
common services provided were monitored dosage system and medication supply, 
provided by 25 pharmacists. These were followed by medication delivery service 
(n=23). Medication reviews and medicines management training were provided by 
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eight pharmacists (25% of those who worked with care homes). The types of 
services provided by pharmacists are summarised in Figure 7.  
Pharmacists could also indicate by free typing, other services they provided which 
were not listed in the questionnaire. Though this question required that 
participants indicate in writing what “other” services they provided, 5 pharmacists 
ticked the box but did not enter the name of service they provided that was not 
listed in the survey. 
 
Figure 7: Pharmacists' services to care homes 
 
4.3.4.1 Care home visits 
Care home visits were provided by 31% of pharmacists (n=32) participating in this study. 
Only 3 of the 32 pharmacists who said they provided services to care homes visited 
frequently (every three months or less). 8 pharmacists visited the care home every three 
to six months and 7 pharmacists once a year. 
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19 pharmacists provided services to residents living with dementia in care homes. All 19 
pharmacists indicated that they believed the services they provided were sufficient to 
meet the pharmaceutical care needs of these residents with dementia. 
Table 7 depicts pharmacists’ visits and number of Care Homes with residents with 
dementia. 
Care home visits N % 
How often do you visit the care home 
  
Never 20 52.63 
Every three to six months 8 21.05 
Once a year 7 18.42 





Does the care home have residents with 
dementia? 
  
Yes 19 51.35 
I don't know 14 37.84 





   
Are the services you provide sufficient to 
cater for their pharmaceutical care needs? 
  
Yes 19 52.78 
Not sure 8 22.22 
Partially 6 16.67 





Table 7: Care Home Visits and number of Care Homes with residents with dementia 
 
4.3.4 Knowledge of pharmacists about prescriptions for people with 
dementia 
Nine statements with a 3-Point-Likert scale were used to assess pharmacists’ 
knowledge of dementia. The internal reliability (Cronbach’s alpha) was 0.678. As a 
rule of thumb, a Cronbach’s alpha score of 0.7 and above indicates acceptable 
consistency and reliability (Gliem and Gliem 2003). This shows that the was 
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internal reliability in the knowledge domain of the questionnaire since the value of 
0.678 can be rounded up to 0.7.  
82.4% of pharmacists (n=84) agreed that they needed more training to provide 
improved pharmaceutical care services to patients living with dementia; while 
7.8% were not sure and 9.8% disagreed.  
Only 50% of pharmacists (n=51) agreed they could confidently identify drug 
interactions in prescriptions for people with dementia, however 61.8% confirmed 
that they had knowledge of the major side effects of drugs used as cognitive 
enhancers in dementia patients. Pharmacists’ responses to these statements are 
depicted in Figure 8. 
Pharmacist knowledge about the behavioural and psychological symptoms of 
dementia (BPSD) and drugs that cause cognitive impairment appeared strong 
(86.3% and 68.6% agreed respectively) but only 39.3% agreed they knew what 
drugs should be avoided in people with dementia and just 32.4% agreed that they 
could recommend interventions to optimise dementia medicines to GPs. This 
would explain why 82.4% indicated they required more training to provide better 




Figure 8: Pharmacists reported Knowledge on Prescriptions for People Living with Dementia 
 
4.3.5 Pharmacists’ perceived understanding and confidence in 
providing Pharmaceutical care for people living with dementia (Q12) 
 
Seven statements with a 3-Point-Likerts scale were used to assess pharmacists’ 
understanding and confidence when providing services for dementia patients. The 
internal reliability was 0.805 (Cronbach-alpha) which indicates good consistency.               
The score variable for this domain presented a median value of 2.57 (IQR; 2.85-
2.14); 83.2% of the scores were between 3-2 and 16.8% was between 1.86-1.00.  
The statements and correspondent response are depicted in Figure 9. 
51% of pharmacists asserted that they could use summary care records to improve 
pharmaceutical care for people with dementia and an equal proportion agreed that 
they could contribute significantly to multidisciplinary teams providing care, but 
the rest were unsure or disagreed.  
144 
 
Pharmacists expressed their lowest level of confidence (46%) when asked about 
their ability to make recommendations for stopping medication that was 
unnecessary or potentially harmful, but a good number (73.6%) felt they could 
identify drug interactions. This appears contradictory to the response given in the 
previous question about knowledge (Q11), where only 50% agreed with the 
statement “I can confidently identify drug interactions in prescriptions for 
dementia patients”. 
74.5% reported feeling confident in signposting people with dementia and/or their 
carers to relevant services for help and support, and an equally high percentage of 
pharmacists (71.6%) reported feeling confident in dealing with prescriptions for 
care homes. 
 
Figure 9: Comprehensive pharmaceutical care including confidence in dealing with prescriptions for 




4.3.6 Barriers to provision of pharmaceutical care services (Q13) 
Building on the results obtained from the qualitative study in Chapter 3 of this 
thesis, as well as evidence from published research, 12 statements on a 3-Point-
Likerts scale were presented to pharmacists to  assess the potential barriers to the 
provision of pharmaceutical care services to people with dementia.  
The internal reliability was 0.748 which indicates a reasonable consistency. The 
score variable for this domain presented a median value of 2.75 (IQR; 2.91-2.58); 
97.8% of the scores were between 3.00-2.08 and 0.2% was between 1.75-1.58. Full 
statements and percentage responses are presented in Table 8 and charted in 
Figure 10. A large majority of pharmacists surveyed (over 80%) agreed with the 
first eight statements addressing the: 
• need for access to clinical notes,  
• improving their knowledge about geriatric medicines,  
• making time to visit care homes,  
• communicating better with GPs and other healthcare professionals,  
• involvement in reducing antipsychotic prescribing to residents with dementia,  
• attendance at multidisciplinary team meetings and  
• being informed of patient discharge from hospital. 
However, 36.3% of the respondent pharmacists were unsure about how the role of 
the community pharmacy contractual framework at the time of the survey, 
impacted on the care of people with dementia, though 59.8% agreed that the 
design of the contractual framework restricted care. They were equally equivocal 
about the role of clinical commissioning groups (CCGs) (31.4%) though 67.6% 
agreed that CCGs overseeing commissioning services to care homes led to non-
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uniformity of care services. At the time of this study, over half of the participant 
pharmacists (57.8%) indicated that they had access to summary care records, 
whilst over a third (35.3%) did not. 60.8% of the respondents thought that it was a 
good idea for each patient to have a named community pharmacist (like how each 
patient has a named GP). 
 
Table 8: Barriers to providing Pharmaceutical Care to People with Dementia in Care Homes (full 




Statetment Disagree Not sure Agree Total
Limited access to clinical notes hinders the 
identification of drug therapy problems 6.9 8.1 85 100
Pharmacists’ need to improve their knowledge of 
geriatric medicines 4.4 11.9 83.7 100
Pharmacists should have more time to visit care homes 3.8 13.1 83.1 100
The pharmacist should build better relationships with 
care home GPs in order to better communicate 
recommended interventions 3.1 11.9 85 100
Community pharmacists should be notified of 
patient discharge 4.4 3.1 92.5 100
Pharmacists should attend multi-disciplinary team 
meetings 0.6 13.8 85.6 100
Pharmacists should be actively involved in 
helping to reduce the use of anti-psychotics in 
dementia 2.5 10 87.5 100
Communication with other healthcare 
professionals would be facilitated by diarised 
patient medication reviews in care homes 1.3 19.5 79.2 100
The current community pharmacy contractual 
framework restricts level of care provided to 
dementia patients 3.8 37.5 58.7 100
Clinical commissioning groups (CCGs) determine what 
services are provided to dementia patients so care 
provision in non-uniform across the country 1.3 33.1 65.6 100
Every patient should have a named community 
pharmacist 17.5 21.3 61.2 100




 Figure 10: Barriers to providing Pharmaceutical Care Services to People with Dementia in Care Homes 
 
4.3.7 Education and Training  
The purpose of this part of the questionnaire was to determine how much 
dementia-related education and training each respondent had participated in. The 
percentage of pharmacists who had undertaken any training on prescribing or on 
medicine optimisation in dementia was 18.6 (n=19), whilst 81.4% (n=83) had not.  
The percentage of pharmacists interested in receiving training on dementia was 
91.2% (n=93); only 8.8% (n=9) were not interested. A cross tabulation between 
the two questions was performed but the Fisher’s Exact test did not demonstrate 
statistical significance (p=0.060). 
4.3.8 Barriers to undertaking training on dementia 
Pharmacists were asked to state the barriers preventing them from pursuing 
further dementia related training (free text). While most left this section blank, 48 
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respondents (47%) wrote down a range of barriers, with lack of time being the 
most frequently cited reason.  
These reasons are presented in Figure 11. 
 
Figure 11: Barriers to undertaking dementia training 
 
4.3.9 Path modelling using PLS (Partial Least Squares) 
The answers to the knowledge, understanding/confidence and barriers questions 
were computed into a structural equational modelling software package (Smart-
PLS®) (Ringle et al. 2015). In order to clarify the codes used in the model, and the 
variables analysed in the model, the questions included in the models and the 
corresponding percentage affirmative (agreed) responses are first presented in 
clearly labelled  bar charts (Figures 12-14), with the correspondent codes used in 
the models (Figures 15-16). 
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The aim of this technique is to determine the relationships between pharmacists’ 
knowledge of dementia, their understanding and confidence, and the perceived 
barriers to delivering pharmaceutical care to people with dementia in care homes. 
These relationships can be explored using structural equational modelling, which 
can be done using different computer software packages. In this study, SmartPLS® 
was used. 
Using the SmartPLS® software to perform structural equation modelling has some 
advantages (Sander and Lee 2015) 
• It offers a path model that describes the relationships between variables, for 
example, the relationship between pharmacist knowledge and barriers to 
pharmaceutical care in this study. 
• It can handle multiple co-linearity amongst independent variables 
• Can be used when the data sample is small, such as that in the current study 
 










Figure 14: Barriers to Pharmaceutical Care (Q13) 
 

















Figures 15 and 16 below summarise two types of information: Figure 15 shows the 
path coefficients, Figure 16 the level of statistical significance. In Figure15 the 
black bold lines show the most relevant relationships. The loading coefficient with 
values <0.5 were eliminated from the model as values have to be > 0.5 for good 
convergent validity. 
Results of Path Modelling:  
• A negative effect of the standardized path coefficient (β= -0.151) was found 
between knowledge and barriers. This indicates that as knowledge increases, 
barriers decrease. 
• Another negative effect of the standardized path coefficient (β= -0.098) was 
found between barriers and understanding/confidence indicating that when 
barriers increase, the understanding /confidence decrease.  
• A positive effect of the standardized path coefficient (β= +0.672) was found 
between knowledge and understanding-confidence; highlighting that where 
knowledge increases, understating/confidence increase as well (Figure 15).                 
• A statistically significant linear relationship was only found between 
knowledge and understanding and confidence (t=12.70; p<0.001).  
• The model explained 48.1% (R2=0.481) of the variance of the 
understanding/confidence domains (variable).  
• The average-variance-extracted (AVE) was >0.451 for knowledge, 0.565 for 
barriers and 0.544. AVE is a measure used to express how much of the variance 
of its items are explained by the constructed model. An AVE score of 0.5 or 
more indicates that the construct explains at least 50% of the variance of its 
items (Hair et al 2019). 
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• The composite reliability (CR) was >0.8 for all the three variables, Cronbach 
alpha >0.77.     Rho (R) =0.788 for knowledge, 1.143 for barriers, and 0.863 for 
understanding / confidence.  
• The standardized root mean squared residual (SRMR) was 0.091 meaning an 
acceptable fit. 
   
 
 
Figure 15: Path coefficients and R values generated using PLS algorithm 
 Loading coefficients are reported for each variable; path coefficients are overlapping the connecting lines. R2 are 






Figure 16: Path model analysis using the complete bootstrapping algorithm with 500 iterations 
P values are ported for each loading coefficient; path coefficients are overlapping the connecting lines and their p 
values are reported in brackets. The only statistically significant path coefficient is represented by 0.672 
(p<0.001) which is located between knowledge and understanding/confidence. 
 
In summary, a statistically significant linear relationship was only found between 
knowledge and understanding/confidence (t=12.70; p<0.001). 
The path model provided relevant information regarding the positive and 







A questionnaire survey was used for this study as questions can be used to assess 
the attitudes and beliefs of respondents. It was administered via postage mail as 
mailed questionnaires provide on average, a better response rate than web 
administered survey modes (Cho et al 2013). 
The response rate of 27.4% was less than that returned by a similar study (Barry 
et al 2013) which had a response rate of 34% from community pharmacists 
surveyed, and fell short of the 30%-90% range found by Smith (1997) to be typical 
of community pharmacists. The response rate might have been improved by 
offering incentives (Hardigan et al 2016) and/or reducing the length of the 5-page 
questionnaire but doing this may have compromised the value brought by 
additional questions included (Sahlqvist et al 2011). 
Demographic data 
More female pharmacists responded (56.9%) than males (43.1%) but the split was 
not statistically significant. 
Most respondents (66.7%) were registered as pharmacists between 2001 and 
2016, with more participation from those who registered around 2010 onwards 
(figure 2).  It is possible that this might be as a result of key publications on 
dementia during that time period such as, Dementia UK: The full report 
(Alzheimer’s Society 2007), Living well with dementia: A National Dementia 
Strategy (DOH 2009), and the Banerjee Report (Time for Action, an independent 
review of the use of antipsychotics in elderly people with dementia) (Banerjee, 2009). 
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These publications and a series of subsequent ones (such as the Prime Minister’s 
challenge on dementia 2012 and 2015) have kept dementia on the national 
agenda, raising awareness about the condition, its prevention and living well with 
dementia, being areas of focus. 
The study data also showed that most respondents between the ages of 20-44 
(61.7%) were managers/sole pharmacists, whilst older participants were locums 
or superintendent pharmacists. There are no studies linking choice of employment 
contract within community pharmacy in the UK to age, but it is possible that 
younger pharmacists choose managerial roles for job stability and to gain 
experience. 
Service provision 
Of 102 pharmacists surveyed, 32 (31.4%) said they provided services to care 
homes, whilst the others didn’t answer yes to providing services to care homes but 
did supply medication to care homes.  The proportion of pharmacists providing 
services to care homes in this study was lower than that of a study by Barry et al 
(2013) in Northern Ireland, which had 40% respondent pharmacists delivering 
services to care home services, but closer to an estimate by the Royal 
Pharmaceutical Society (RPS 2012) which contended that less than 20% of 
community pharmacists were involved with care homes.  Half of those delivering 
pharmaceutical services to care homes (59.4%) said their care homes had people 
living with dementia. 
The services presented to participants to choose from were provision of monitored 
dosage systems, medication supply, delivery of medicines, prescription 
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interventions, care home staff training, medication reviews, medicine management 
training. They had the option of stating other services they provided but none did.  
These services were based largely on the NHS Community pharmacy contractual 
framework for enhanced services for care homes (PSNC 2005). This template 
remains mostly unchanged and is used by various commissioning groups across 
England for services community pharmacies contracted to deliver pharmaceutical 
services to care homes are expected to provide.  
The service outline (Figure 13) briefly outlines the enhanced services community 
pharmacies with care home contractual arrangements are expected to deliver, in 
addition to providing the essential dispensing of medication, and promoting 
patient safety by a professional focus on ordering, storage, administration and 
disposal of medicines. 
In addition to the services outlined in Figure 13, community pharmacies in 
England, according to the pharmacy contractual framework, can provide 
signposting, support for self-care and promotion of healthy lifestyle services to 
care homes (NHS 2013) but the practicalities of how these are delivered to care 
homes are unclear. 
The survey did not include all the services outlined in the framework (such as 
audit, advice on medicine policy, and medication waste disposal). This was to curb 
the length of the questionnaire as lengthy questionnaires can reduce response rate 
























Figure 17: Section 3 of the NHS community pharmacy contractual framework (enhanced service)-Care homes 
Adapted from the NHS Community Pharmacy Contractual Framework Enhanced Service – Care Home (support 
and advice on storage, supply and administration of drugs and appliances) at 
https://psnc.org.uk/wpcontent/uploads/2013/07/en5__care_home_support1.pdf 
 
People with dementia are often prescribed complex medication regimes that are 
difficult to manage, and research has found that they are often prescribed 
statistically significant higher number of medicines than patients of the same age 
3. Service outline 
3.1 The pharmacy will have an agreement with the care home to provide this service. 
 
3.2 The pharmacy contractor has a duty to ensure that pharmacists and staff involved in the 
provision of the service have relevant knowledge and are appropriately trained in the operation of 
the service. 
 
3.3 The pharmacy contractor has a duty to ensure that pharmacists and staff involved in the 
provision of the service are aware of and operate within local protocols. 
 
3.4 The pharmacy should maintain appropriate records to ensure effective ongoing service 
delivery and audit. 
 
3.5 The initial visit should include provision of advice on safe and effective ordering, storage, 
clinical and cost effective use, administration and disposal of medicines and appliances and record 
keeping. Advice will also be provided on the medicines policies and procedures which the care 
home should have in place. 
 
3.6 Follow up visits will be undertaken to monitor systems at least every six months. 
 
3.7 Pharmacists will ensure that they are aware of any medicines related issues which were raised 
at the most recent care home inspection organisation visit to the home. 
 
3.8 Records are maintained by the pharmacist of interventions and advice given during visits. 
Copies of any action plans agreed with the care home should be retained for review at future 
visits. 
 
3.9 The pharmacist will be responsible for the provision of training for care staff on medicines 
issues, on an opportunistic basis during regular visits and also at least once a year on a formal 
basis. 
 
3.10 The pharmacist will advise the care home on the content of their medicines related policy 
documents, including the administration of medicines for acute conditions, use of ‘homely 
remedies’ and procedures when there are alterations to residents medication regimens. 
 
3.11 The PCO will need to provide a framework for the recording of relevant service information 




without dementia (Clague et al 2017). It stands to reason that they would benefit 
from cognitive pharmaceutical services such as regular medication reviews. 
A cognitive pharmaceutical service is defined as “any activity in which the 
pharmacist would use their professional knowledge and abilities to improve 
pharmacotherapy and disease management by means of interacting with the patient 
or other healthcare professionals” (Cipolle, Strand and Morley 2004). Simply put, 
cognitive pharmaceutical services are “pharmacy services related to the 
pharmacists’ use of specialized knowledge and abilities to help patients achieve 
effective and safe pharmacotherapy” (Lakic et al 2017) 
Benrimoj et al (2010) devised a hierarchical model for classification of cognitive 
pharmaceutical services based on clinical decision-making, and the degree of shift 
needed from community pharmacists’ traditional roles in order to provide these 
services (Table 8).  
A comparison of the services listed in this model (Table 8) to the service 
specification for community pharmacists delivering services to care homes (Figure 
17) as well as what the community pharmacy contract in England covers, shows 
only some similarities (medicine information, medication use reviews, medicines 
reviews). 
This study included two services from the hierarchy (prescription intervention and 
mediation reviews) which would benefit care home residents particularly those 
with chronic long-term conditions such as dementia. 
None, of the survey participants fully complied with the contractual obligations. Of 
the 32 who  indicated that they provided services to care homes, only 25 carried 
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out medication supply (an essential service), 11 provided prescription 
interventions (service outline 3.8 in Figure 17), and 9 provided training of care 
home staff (section 3.9). Medication reviews, which can be carried out by the 
community pharmacist during routine, contractual visits or by a designated clinical 
pharmacist, were only carried out by 8 pharmacists in total. Additionally, the 
requirement to visit care homes a minimum of every six months was met by 11 
pharmacists, whilst 7 said they visited once a year. This would indicate a risk to 
patient safety unless care homes had service provision from specialist pharmacists. 
 
1 Medication information 
2 Compliance, adherence and/or concordance 
3 Disease screening 
4 Disease prevention 
5 Clinical intervention or identification and resolving drug related problems 
6 Medication use reviews 
7 Medication management/medication therapy management 
a. Home medication reviews 
b. Residential care home medication reviews 
c. Medication reviews with continuance follow up 
8 Disease state management for chronic conditions 
9 Participation in therapeutic decisions with medical practitioners 
a. In clinical setting 





Table 8: Hierarchical model of cognitive pharmaceutical services (Benrimoj et al 2010) 
 
The role of community pharmacists contracted to provide services to care homes 
in England therefore remains mainly dispensing and supply of medication, and 
advice on storage and medicine administration. Similarly, Schwiezer and Hughes 
(2004) reported that community pharmacists delivering services to care homes in 
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Northern Ireland, were typically involved in medication supply, giving advice on 
compliance devices, advice on storage and also advice on appropriate dosage 
forms of medicines such as liquids rather than tablets. They pointed out that these 
were in line with traditional roles associated with community pharmacists. Earlier 
in the decade, Furniss et al (2000) had also reported that community pharmacists’ 
involvement with care homes was primarily that of “supply and provision of basic 
advice about documentation and storage”. 
The fact that this study has reached the same conclusions shows that not much has 
changed between community pharmacists and care homes over the last few years 
despite the much-reported shift in community pharmacists’ roles towards more 
patient –oriented cognitive services.   
In the UK, there is a legal requirement for a pharmacist to be present at community 
pharmacy premises during their opening hours, so it is difficult to see how 
pharmacists could leave their pharmacies to visit or be more involved with care 
homes, unless they are assigned a second pharmacist or locum. This is uncommon 
practice and has cost implications (Schweizer and Hughes 2004). 
The RPS (2016) highlighted the need for consistency in medicines optimisation in 
care homes. This is particularly important for people with dementia who are often 
subjected to polypharmacy and complex medication regimes (McGrattan et al 
2017). 
It was noted in the current study that 25 pharmacists (78% of those providing 
services to care homes) supplied medication in monitored dosage systems (MDS), 
a practice well established in care homes, advocated because it saves staff time and 
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standardises processes within the care home, and might improve adherence 
(Bhattacharya 2005). However, concerns have been raised about this practice as 
many medicines are not suitable for MDS and there is a high risk of drugs packed 
together interacting with each other (Webber 2015). This would put patient safety 
at risk, particularly frail elderly people with long-term conditions such as 
dementia. Furthermore, pharmacists supplying medication in this manner require 
robust processes for accuracy checking. 
Knowledge of pharmacists about prescriptions for people with dementia 
Pharmacists in England providing pharmaceutical services to care homes are 
required to have the knowledge and confidence the service requires (PSNC 2005) 
but the exact competencies are not specified. However, the framework for 
enhanced health in care homes (NHS England 2016) emphasises the importance of 
conducting medication reviews for people with dementia, focused on reduction in 
polypharmacy. The framework advocates a multidisciplinary approach to 
medication reviews, with the incorporation of a pharmacist as part of the team.  
Research evidence indicates that specialist pharmacist-led interventions can lead 
to improvement in prescribing in older adults living in the community (O’Riordan 
et al 2016) and in reduction of items prescribed in care homes (Furniss et al 2000). 
This may be due to their possession of specialist knowledge to conduct 
comprehensive drug reviews in this group of patients. Conversely, not many 
studies have investigated outcomes of medication reviews in care homes 
conducted by community pharmacists and explored their roles in other sectors 
such as intermediate care services. Bryant et al. 2009 reported that community 
pharmacists who had completed some form of postgraduate study or were in the 
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process of completing one, were significantly more likely than pharmacists who 
had not, to consider the delivery of clinical services. Increased knowledge is clearly 
important since pharmacists with postgraduate qualifications said they had the 
competency required. This is an important finding, as in the current study, 72.5% 
of respondents had not undertaken any postgraduate study. There is also an 
implication here for universities offering undergraduate pharmacy courses, as the 
question of whether pharmacists graduate fully equipped with the knowledge 
required to deal with contemporary shift in community pharmacist roles must be 
considered. Another research article succinctly addresses this by stating that 
contemporary pharmacy practice requires individuals with problem solving skills, 
who are able to apply both moral and technical authority (Waterfield 2010), 
confirming the view that pharmacy curricula should engage with more reflective, 
problem based practice (Droege 2003). Whether this has been addressed in more 
recent years throughout undergraduate pharmacy training is beyond the scope of 
my thesis. However my research results show that in terms of cognitive 
pharmaceutical services being provided to care homes, and to people with 
dementia, the gaps between theoretical and practical knowledge as well as 
contractual requirements have not been bridged. 
In Wales, an enhanced service model from community pharmacies to care homes 
exists. It is structured into three tiers which allow community pharmacists to 
select from a level 1 service involving systematic review of medicines management 
processes in the care home; level 2 involving pharmaceutical scrutiny of 
prescribing practices in the care homes; and level three where pharmacists are 
expected to work with care home GPs to conduct comprehensive medication 
reviews (NHS Wales 2017).  To offer a level 3 service in this model, pharmacists 
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are required to be competent and knowledgeable in identifying and taking action 
to minimise harm to residents from side effects, interactions, therapeutic 
duplication and inappropriate medication doses (NHS Wales 2017).  
In the current study, only 50% of pharmacists indicated they were confident that 
they could identify drug interactions in prescriptions for people with dementia, 
though a higher percentage (61.8%) said they knew about the major side effects of 
drugs used as cognitive enhancers.   
However, pharmacist knowledge of dementia has been found to be poor by 
researchers in other parts of the world: Marvano and Henkel (2017) found that 
half of pharmacists they surveyed in a Chicago (USA) study could not name a single 
side effect of Donepezil, a drug popularly prescribed to people with mild to 
moderate dementia, and over a quarter of them readily made inappropriate drug 
therapy recommendations for a person with Alzheimer’s disease taking 
Rivastigmine (another anti-dementia drug). Similarly, Zerafa and Scerri (2016) 
investigated the level of knowledge of community pharmacists in Malta, using an 
Alzheimer ’s disease Knowledge Scale and found their knowledge about risk 
factors, care giving factors and pharmacological management of Alzheimer’s 
disease to be inadequate. Community pharmacist knowledge was also cited as a 
barrier in a UK based study by Maidment et al (2016) about how they could 
contribute to management of people with dementia in the community. 
The use of technology to support community pharmacist activities has been 
around for over thirty years (Goundrey-Smith 2018) when it was used primarily to 
facilitate ordering of drugs from wholesalers. However, advances in technology,  
particularly with respect to bar code dispensing, means available software can 
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enable a prescription to be sent electronically to a pharmacy, scanned, checked for 
side effects and interactions against patient records and dispensed by robot 
without the input of a pharmacist (Moreton 2017). This is potentially deskilling as 
it means community pharmacists are not always called on to use their knowledge, 
and in order to continue to demonstrate specialist knowledge, particularly in areas 
such as dementia, pharmacists need to engage in reflective practice, using cross 
referencing, analysis and synthesis of information to contribute to high quality 
interventions that lead to consistently better outcomes for patients within the 
healthcare system. 
There was disparity between pharmacists’ response to their knowledge of drugs 
that cause cognitive impairment (68.6% agreed they had this knowledge) and the 
response to knowing which drugs people with dementia needed to avoid (only 
39.3% agreed). It would be expected that respondents would know that drugs that 
worsen cognition should be avoided by people with dementia, as indicated by NICE 
dementia guidelines (2018) which cautions against use of certain medication, 
including over the counter medication such as antihistamines, which can worsen 
cognition in this patient group. However, changes in question wording, even when 
both pose the same question can result in differences in respondents’ responses, 
and sometimes, the effect of this on results interpretation can be unpredictable 
(Gendall and Hoek 1990). One possible interpretation of the result obtained is that 
pharmacists’ knowledge of the effect of medication on cognition ranged from poor 
to moderate. 
According to their responses, pharmacists’  had good knowledge of BPSD since 
86.3% agreed to this, and this can be attributed to the plethora of publications 
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highlighting the superiority of non-pharmacological approaches to the 
management of behavioural and psychological symptoms of dementia (BPSD) over 
prescribing of antipsychotics which pose cardiovascular risks and other physical 
health risks to people with dementia (Prentice et al 2014, Furniss et al 2000, 
McGrattan et al 2017, Child et al 2012, Maidment et al 2016, Zerafa and Scerri 
2016). 
Conversely, only 32.4% of respondents to this questionnaire agreed they could 
recommend interventions to optimise medication therapy for people with 
dementia. This corroborates other results within this section of the survey which 
indicates pharmacists’ knowledge of dementia therapy was limited, and confirms 
conclusions by other researchers that community pharmacists’ require more 
training and support to provide cognitive pharmaceutical services to people with 
dementia (Barry et al 2013, Maidment et a 2016, McGrattan et al 2017). 
Understanding and confidence 
Questions in this section were worded differently, asking pharmacists what they 
“felt”.  
Confidence has been defined in psychological theory as comprising of four factors: 
practice experience, personal effort, amount of relevant information available and 
the act of decision making (Paese and Sniezek 1991).                                                                                 
In this context, the current study showed 51% agreed that they felt confident in 
their ability to contribute significantly to multidisciplinary (MDT) teams of 
healthcare professionals providing care to people with dementia. In another study, 
pharmacists have reported feeling that they lacked confidence in clinical decision 
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making (Butterworth et al 2017, Frankel and Austin 2013), whilst there has been 
suggestions that community pharmacists confidence can be improved by making 
them more accountable for clinical decision making, through taking on prescribing 
roles, with the right clinical knowledge (Inch et al 2019). 
Pharmacists expressed their lowest level of confidence in recommending stopping 
medication they felt was unnecessary or potentially harmful for people with 
dementia (46% agreed they could). This was in line with their responses in the 
previous section of the questionnaire when only 39.3% agreed they knew what 
drugs should be avoided by people with dementia, and even fewer (32.4%) agreed 
they could recommend interventions to optimise drug treatment in dementia. 
73.5% of respondents agreed they felt confident in identifying drug interactions, 
which seemed like a contradiction to the previous section where only 50% agreed 
they could identify drug interaction in prescriptions for people with dementia. This 
can be explained from the point of view that the statement in the previous section 
required certainty on the part of the respondent, whilst a similarly worded 
question in the confidence section only required that they indicate what they “felt” 
they could do. Additionally, pharmacists can access hard copy or online references 
for relevant information, which would explain their confidence in the ability to 
source relevant information when needed. 
51% of respondents felt they could use summary care records; a summary care 
record (SCR) is an electronic record a GP holds which has information on each 
individual patient’s medication, allergies and adverse drug reactions (Greenhalgh 
et al 2008) for use in unscheduled care or in emergencies. Accessing information 
on summary care records enables community pharmacists to avoid unnecessarily 
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referring patients on to other healthcare professionals (The Pharmaceutical 
Journal, 2015). More than half of the pharmacist respondents responding 
positively to this statement is understandable considering that summary care 
record access by community pharmacists was launched in 2015 and a roll out was 
on going around the time of data collection for this research (The Pharmaceutical 
Journal 2015). 
Community pharmacists have been advocated as key links between people with 
dementia and the services they require in order to live well with the disease, 
particularly with respect to up-do-date knowledge of local support services, 
memory clinics and other services they can signpost people with dementia and 
their carers to (Brown 2017, Oswald 2017, RPS and CPPE 2017), so it is 
encouraging that 74.5% of respondents agreed they were able to signpost people 
to relevant services. 
The role of the pharmacist independent prescriber in a care home has been proven 
to increase pharmacist confidence, and could alleviate pressure on GPs, with 
appropriately trained pharmacists. However pharmacists still feel that it would be 
challenging to accommodate this service given their current workloads (Inch et al 
2019) and a specific contribution to dementia care through this service still needs 
to be clearly defined. However, recently, the Pharmacy Defence Association (PDA 
2019) advised about the necessity for pharmacists to acquire required knowledge 




Barriers encountered by community pharmacists when providing pharmaceutical 
care to people with dementia in care homes were examined in the qualitative 
aspect of this research, reported in chapter 3, and were included in the current 
quantitative study, alongside other barriers identified in literature (Maidment et al 
2016, Barry et al 2013). Over 80% of participants agreed with the majority of 
barriers they were presented with. 
The lack of full read/write access to patients’ clinical notes for comprehensive 
medication related services is a well-known barrier for community pharmacists 
(Barber et al 2009, Murray 2016, Torjesen 2018, and The Pharmaceutical Journal 
July 2019). Though community pharmacists now have access to summary care 
records, the information included in these (name, NHS number, drug allergies, 
medication prescribed) is not considered sufficient to support clinical decision 
making (Pharmaceutical Journal July 2019).  
In the context of care homes, a pharmacist would still be unaware of medication 
related changes resulting from interventions by multiple healthcare professionals 
(geriatricians, GPs, community psychiatric nurses, district nurses). In support of 
this assertion, 86.3% of respondents in this study agreed that their limited access 
to clinical notes hindered the identification of drug therapy problems. 
85.3% of pharmacists agreed they needed to improve their knowledge of geriatric 
medicine, validating the results of previous sections of the questionnaire survey 




Other barriers confirmed by over 80% of respondent pharmacists included the 
need for more pharmacist visits to care homes as well as a recognition that 
pharmacists needed to build better relationships with care home GPs in order to 
better communicate recommended interventions. However, pharmacists can 
sometimes feel inadequate when interacting with general practitioners about 
clinical issues relating to medication (Bryant et al 2009). One study by Smith et al 
(2002) found that only 17% of GPs surveyed agreed that community pharmacists 
should be involved with designing treatment plans, their inadequate clinical 
knowledge being cited as a barrier (Krska and Veitch 2001). 
The use of antipsychotics for people with dementia is associated with many side 
effects including unwarranted weight gain, extrapyramidal symptoms, stroke and 
mortality (Gareri et al 2014), even though in some circumstances, antipsychotics 
may be required (Greenblatt and Greenblatt 2016). Thus it is no surprise that 
89.2% of this study’s participants agreed that pharmacists should be actively 
involved in helping to reduce the use of antipsychotics in dementia. However, a 
study of community pharmacists concerning their potential review of 
antipsychotic use in people living with dementia in the community (Maidment et al 
2016) again revealed knowledge deficits and a lack of access to patient records as 
barriers for this happening. 
In the current study 59.8% of respondent pharmacists agreed that the current 
pharmacy contractual framework restricts the level of care provided to people 
with dementia by community pharmacists, a view also expressed in an 
independent  review into community pharmacy services to care homes (Webber 
2015). Additionally, 67.6% agreed with the notion that clinical commissioning 
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groups (CCGs) determine what services are provided to people with dementia in 
care homes, which leads to non-uniformity of services provided. The RPS report 
(RPS 2016) also acknowledges that there are many stakeholders in this domain, 
including CCGs and various NHS organisations, and agrees with the assertion that 
this leads to non-uniformity of services across England. 
Respondents seemed uncertain about every patient having a named community 
pharmacist, since only 60.8% were in agreement with this notion, but this is to be 
expected, as even the chief pharmaceutical officer for England, Keith Ridge, 
expressed his doubts about this concept, declaring that pharmacists should work 
as part of an integrated care system without bypassing general practitioners 
(Praities 2018).  
Summary care records (SCR) were accessible to 57.8% of respondents in the study, 
35.3% had no access, with another 6.9% uncertain whether they had access or not.  
Conversely, there is recent evidence that shows that despite all community 
pharmacists being given access to the system in 2015, nearly 85% did not access 
this in a typical week, and 41% were still likely to ring the GP rather than access 
the SCR (Wilkinson 2018). Reasons cited for this included lack of time,and fear of 
the unknown. 
Education and training 
The final section of the questionnaire which asked participants about dementia -
related education and training, had only 18.6% responding that they had accessed 
some form of relevant training, with the remaining 91.2% agreeing that they 
required further training in this area of practice. Barriers to pursuing further 
171 
 
training mentioned were lack of time, paucity of local training events, available 
training coinciding with work hours, amongst others (Figure 7). 
There is online distance learning training on the pharmaceutical care of people 
with dementia, available via the Centre for Postgraduate Pharmacy Education 
(CPPE). A similarly named package developed by the NHS Education for Scotland 
(NES 2014) is also available. However, a recent systematic review evaluating 
targeted training that prepares pharmacists to deliver optimal pharmaceutical care 
services to care homes, found that there is limited information regarding training 
and accreditation processes for this service, though pharmacists require expert 
knowledge for clinical and therapeutic areas such as management of pain, 
dementia, cardiovascular and antipsychotic prescribing in care homes (Wright et al 
2019). These researchers corroborate the findings of the current study which 
showed that one of the barriers to pharmacists undertaking dementia training was 
the lack of available training. 
Increasing workloads and role overload for community pharmacists have been 
quoted as resulting in work related stress (Johnson et al 2014) and could impede 
pursuit of education and training in long-term conditions such as dementia. This 
can be overcome with the right discussions and the will to do so. 
Structural equational modelling using Smart-PLS 
Answers to the knowledge, understanding and confidence, and barriers to care, 
which had good internal validity, were entered into a structural equational model 
using Smart-PLS® to ascertain any significant correlations. The result was the 
establishment of a significant correlation between knowledge, understanding and 
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confidence, in which increase in knowledge showed increases in confidence and 
understanding. The path model also showed that increase in knowledge led to 
decrease in barriers.  
This is not the first time a structural equational model has been used to evaluate 
relationships in the field of pharmacy: A partial least squares (PLS) structural 
equation modelling (SEM) approach was used to establish a bidirectional link 
between job satisfaction and over-the-counter counselling in community 
pharmacy (Ubonas and Kubiliene 2016). Similarly, PLS path modelling was used to 
examine ease of use of electronic prescribing on community pharmacy outcomes 
(Peikari et al 2014). PLS using SmartPLS highlighted that pharmacists work stress 
greatly influenced their perception of working environments (Boyle et al 2016). 
It is the first time, to the best of the researcher’s knowledge that this has been used 
to link community pharmacists’ knowledge of dementia to their understanding and 
confidence in dealing with people with the disease, as well as establishing a link 
between knowledge and barriers to care in this subject area. 
These correlations, coupled with the responses from pharmacists indicating 
requirements for more knowledge, education and training in dementia, formed the 
basis of the development of a bespoke medication review tool for pharmacists later 
in my research.        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
4.5 STRENGTHS AND LIMITATIONS 
This study is the first to the researchers’ knowledge that has undertaken a holistic 
examination of the nature of services provided by community pharmacists to 
people with dementia living in care homes and combined their perceptions of their 
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own clinical knowledge with perceived barriers. It is also the first time an attempt 
has been made to establish correlations between pharmacist knowledge and 
barriers to care using structural equational modelling. 
An additional limitation of the study was that likely response rate was not factored 
in when calculating the sample size, and the actual response rate was low, and 
even though the study findings have been similarly highlighted by other 
researchers exploring the role of pharmacists in dementia care, the small sample 
size makes the results less generalizable.  
There are standardised questionnaires available in the literature for establishing 
attitudes to dementia, as well as knowledge of Alzheimer’s disease. The use of such 
validated tools could have made the knowledge and confidence sections of my 
study more robust. 
CONCLUSION 
The findings of this study highlight deficits in pharmacists’ knowledge of specific 
aspects of pharmaceutical care in dementia; it also shows that while some 
community pharmacists contracted to provide services to care homes fulfil their 
contractual obligations, only a small number of conducted medication reviews or 
visited the care homes. Both are services that are included in the service 
specification.  More research needs to be undertaken to explore how 




Additionally, many barriers exist that prevent more pharmacists from providing 
comprehensive pharmaceutical care services to care homes, including their role in 
dementia care for residents not being clearly defined. 
Community pharmacists could play a vital role in improving early diagnosis for 
residents of care homes who show early signs of cognitive impairment, but have 
not been assessed for a possible dementia diagnosis, and their role in medicines 
optimisation for people with dementia can be enhanced with more targeted 
training, funding and resources. This will expand their reach and improve 
medication related health outcomes for care home residents living with long term 
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5.1. Introduction and chapter overview 
Care homes have, over the years, provided accommodation and personal care 
(residential homes) plus nursing care (nursing homes) for a growing population of 
older adults over the age of 65 in the UK. The clientele is usually those who suffer 
from chronic illness, are disabled or have a mental health disorder that renders 
them incapable of caring for themselves (Dofournet et al 2019, Verbeek et al 
2012). 
People living with dementia become increasingly reliant on carers as their disease 
progresses, due to their complex needs (Poland et al 2014). Dementia has been 
identified as one of the biggest single health-related determinants of care home 
admission, with an estimation that 60-70% of care home residents have some form 
of dementia (Alzheimer’s Society 2016b). 
In the UK, dementia has overtaken heart disease as the leading cause of death 
(Office for National Statistics 2012), with the cost of providing care for people 
living with dementia currently set at approximately £23 billion a year and growing. 
Community pharmacists are required, as part of service provision to care homes, 
to ensure appropriateness and clinical effectiveness of medicines use as well as the 
provision of advice on medicine administration (PSNC 2019) but the exact nature 
of such services that target chronic illnesses such as dementia are not well defined, 
and the patterns of medication use in people living with dementia in care homes 
remain largely uncharacterised (Blass et al 2008). 
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People living in care homes are at high risk of, and more vulnerable to medication 
errors than their counterparts living in the community (Saeed and Stretch 2010). 
Care home managers are accountable for the day to day running of the homes and, 
along with care home staff, have a responsibility to provide safe, personalised care 
for residents. 
As part of providing personalised care, care home staff are required to identify and 
record individual residents’ medication related goals, needs and preferences 
(Sawan et al 2019) 
There is a paucity of research investigating the perceptions of care home staff 
about the medication related needs of people living in care homes with chronic 
conditions such as dementia, and even less information about their views on the 
quality of services they receive from pharmacists, or indeed their expectations 
from pharmacy services. 
The impact of specialist clinical pharmacists working in care homes to reduce 
potentially inappropriate prescribing of medication has been widely researched, 
but results of specialist cognitive pharmaceutical services geared towards reducing 
the number of medications prescribed have failed to show clear evidence that such 
services lead to improvements in adherence or cognitive functioning of residents 
(Saez-Benito et al 2013). 
A clear understanding of the relationships between co-morbidities, medication 
related needs and overall person-centred care of people with living with dementia 





This chapter presents a study that broadly explores the views of care home staff 
about pharmacy services provision to their care homes.  These staff are principally 
involved in medication administration and management in participants’ care 
homes. 
I contend that specifically designated care home staff members are best placed to 
comment through interviews, about the medication related needs of care home 
residents. Further exploration could reveal whether care home staff are aware of 
the specific needs of residents with dementia which can be relayed back to 
pharmacists looking to deliver enhanced pharmaceutical care services to these 
establishments. 
5.2 Methods 
5.2.1 Aims and objectives 
 Aims 
• To explore the views, perceptions and opinions of care home staff about the 
medication related services provided to care homes that have people living 
with dementia 
• To ascertain the knowledge of care home staff about the medication related 
needs of residents living with dementia 
Objectives 
• To investigate the awareness of care home staff about the medication related 
needs of people living with dementia in their care homes 
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• To explore the nature of medication-related services provided by community 
pharmacists and other health care practitioners to people living with dementia 
in care homes 
• To make recommendations for best practice in medication related services for 
residents living with dementia  
5.2.3 Setting 
Care homes located in Thurrock Council, Essex, England registered with the Care 
Quality Commission (CQC), with provision for people with dementia. 
5.2.4 Study design  
A qualitative approach, involving face to face interviews was utilised to explore the 
views and perceptions of care home staff caring for people with dementia. A semi-
structured interview schedule with fixed questions was used, but respondents 
were able to raise issues not covered by the schedule (Bowling 2009). 
The qualitative study design was chosen because it enabled an in-depth 
exploration of issues from the perspectives of the research participants. 
5.2.4.1 Research Governance and Ethics 
 
Ethics approval was obtained from the University of Sussex Cross-Schools 
Research Ethics Committee (CREC) before commencement of the study (Appendix 
5a) 
NHS ethics was not applied for, because when research involves NHS and/or social 
care staff recruited as research participants because of their profession, it is not 




5.2.4.2 Sampling, participant recruitment and informed consent 
A purposive sample of care homes in Thurrock, Essex, that have dementia patients 
was identified by searching the website 
https://www.cqc.org.uk/search/site/care%20homes?sort=default&distance=15&
mode=html&f%5B0%5D=im_field_popular_services%3A3668  (CQC) (2017). This 
website has a database of care homes within England and Wales by post code, as 
well as by the nature of services provided. The Thurrock area was selected for 
convenience sampling, and the CQC website chosen as opposed to the website used 
in phase 3 of this research (Chapter 3). This was because in addition to listing care 
homes in a similar manner, the CQC is the official regulator for health and social 
care services in the UK, therefore has inspection reports and ratings of each care 
home listed. 
Care home managers of the homes identified were contacted by the researcher and 
invited to participate in the study or to nominate a care home staff member 
charged with managing medication in the care home. A purposive non-random 
sampling approach which is based on selecting individuals with a particular 
characteristic for a study was used. 
There were 17 care homes that were listed as providing care for people with 
dementia in Thurrock at the time of the study. The researcher aimed to recruit 
staff from 10 of these. This was not a statistical sample based on a power 
calculation as this is not required for qualitative research. 
The 17 care homes were ranked in order of the number of dementia beds per 
home as published on CQC website and care home staff of the 10 care homes with 




A written letter of invitation (Appendix 5b) and participant information (Appendix 
5c) about the study were sent to each care home selected. This was followed by a 
phone call later to ascertain their willingness to participate. Participants were also 
provided with a consent form (Appendix 5d), and advised that even after agreeing 
to take part, they could withdraw from the study at any time by contacting the 
researcher. All information obtained was kept strictly confidential, with intention 
to remove all person identifiable material from the research report. 
  
5.2.4.3 Inclusion and exclusion criteria 
Staff of homes with dementia patients in the study setting were included, whilst 
those of care homes not registered to provide care for dementia patients were 
excluded. 
5.2.4.4 Research instrument 
Semi-structured interviews following a standard format (Appendix 5e) were 
carried out face to face with consenting care home staff at their place of work. A 
pilot was not carried out for this study, but the interview schedule was reviewed 
and approved by the study supervisor.  
5.2.4.5 Data handling and analysis 
Interviews were conducted in the care home at a time convenient for the 
participant, recorded digitally and recordings safely stored in a digital safe 
accessible only by the researcher. Data will be stored for five years following 




The recorded interviews were transcribed verbatim and content analysis carried 
out using a thematic analytical six step process involving familiarisation with the 
data, generating initial codes, searching, reviewing and defining themes and finally 
writing up findings (Braun and Clarke 2006).  
The researcher carried out the coding and identification of themes, and the 
academic supervisor also did the same independently. They then compared notes 
to identify common trends and define final themes. 
During theme development, staff perceptions of the adequacy of pharmacy 
services and challenges with providing fundamental care for people with dementia 
seemed like potential themes, but during data analysis, a more flexible approach 
and wider view of the data was adopted that enabled the realisation of the four 
main themes prevalent in the results. 
Findings were independently verified by the academic supervisor to assure its 
reliability and confirm data saturation, which was reached by the 10th interview. 
No person/premise identifiable data was included in the report. 
A COREQ (COnsolidated criteria for REporting Qualitative research) checklist was 
completed and can be found in Appendix 5f. 
5.3 Results 
11 participants were interviewed for this study as one care home recruited 
consisted of two wings operating independently of each other, both with varying 
proportions of people with dementia and varying diagnoses of dementia type 
(Table 9). 
Data were also collected about the qualifications of the care home staff participants 




The preliminary themes were characterised (Figure 18) and narrowed down to 





















C1 H1 Residential only 
(P) 
97% Majority before, 2 
or 3 after 
Some 
C2 H2 Residential only 
(P) 
95% Majority before Majority 
AD 
C3 H3 With Nursing (P) 99% All diagnosed 




C4 H4 Residential only 
(P) 
75% Majority before(4 
or 5 after) 
Yes  
C5 H5 With Nursing (P) 80% All diagnosed 








C7 H7 With Nursing (P) 70% Majority before No 
C8 H8 Residential only 
(P) 
95% Majority before No 
C9 H9 Residential only 
(P) 
25% All before Yes 




C11 H11 With Nursing (P) 50% Half diagnosed 
before 
Yes 
Table 9: Type of Care Home and proportion of people with Dementia 
 
AD=Alzheimer’s disease, VD=Vascular Dementia DLB=Dementia with Lewy Bodies FD=Frontotemporal Dementia; 














Staff Gender Qualification Number of years’ 
experience 
C1 Female RGN, NVQ2, NVQ3 5 
C2 Female Midwife 10 
C3 Female RGN 20 
C4 Female NVQ2 (Health and Social care) 4 
C5 Female RMA+ NVQ3 Assessor 25 
C6 Female NVQ4 23 
C7 Female RGN 7 
C8 Female Teacher, NVQ3 Health & Social 
care 
4.5 
C9 Female NVQ2+NVQ3 8 
C10 Female RGN 14 
C11 Female Not disclosed (Deputy Manager) 13 
Table 10: Participant information including qualifications and number of years’ experience 






















Figure 19: Major themes 
 
5.3.1 Resident and staff information 
Seven participating care homes provided residential care only (H1, H2, H4, H6, H8, 
H9, H10) while the other four (H3, H5, H7, H11) provided residential plus nursing 
care. The care homes in the study accommodated a varying proportion of residents 
with dementia from 25% (H9) up to 97% of residents (H1). 
 
The majority of residents with dementia had their diagnosis before admission into 
the care homes, but fewer were estimated to have the sub-types (causes) of 
dementia recorded in their notes. Most residents with the causes of dementia 
recorded had Alzheimer’s disease, some had vascular dementia and a few others 
Theme 1: Staff knowledge of dementia and 
resident experience
Theme 2: Medicine management and challenges
Theme 3: Relationship with and role of 
multidisciplinary team (MDT)




had dementia with Lewy bodies. One care home had a resident with 
frontotemporal dementia, which participating staff called “frontal lobal dementia”. 
Care home staff in the study were all females, and were qualified to various levels 
(NVQs, registered nurses, a midwife) with their number of years’ experience in 
care homes ranging from at least four years (C4) to 25 years (C5). 
 
5.3.2 Staff knowledge of dementia and residents’ experiences of its 
symptoms  
This theme focused on what staff knew about dementia, their subtypes and how 
residents experienced symptoms. 
Participants displayed some knowledge of dementia, the assessment process and 
dementia subtypes. The general view was that most residents with dementia were 
diagnosed before admission into care homes and depending on whether they had 
been seen by the memory clinic, had the sub-type recorded. One care home staff 
(C1) in response to the question of whether they were informed of the cause of 
residents’ dementia responded: 
 
“Not always-if they have come from the memory service/done scans, yes, if not, records say 
‘unspecified’” (C1) 
 
Similarly, C9 confirmed that their residents rarely had causes of dementia noted in 
their records: 
 
“Very rarely, sometimes you’ll only get dementia on the assessment form and care staff rely 
on relatives to tell them what type of dementia the resident has” (C9) 
 
There was also recognition that the sub-type of dementia impacted on the 




“We have to know what kind of dementia they’ve got because we need to know how we’re 
going to treat them. There’s Lewy Body and then Vascular dementia. You know their 
behaviour is different” (C5) 
 
References were made to person-centred care with some care staff expressing the 
opinion that irrespective of dementia sub-type, each individual resident behaved 
differently and should be treated as such. 
 
“Everybody’s behaviour is going to be different anyway, so regardless of what type they have 
got, you have to learn their behaviours and what they are like, and what they are going to be 
behaving like within the care home.”(C1) 
 
Additionally, staff demonstrated knowledge of the need to keep a close eye on 
residents, ensuring that they were eating properly, and generally have their 
physical health monitored especially if they noticed changes in resident’s 
behaviour: 
 
“We watch their mobility, their eating, obviously especially eating, because of obviously the 
weight loss….we monitor all…” (C3) 
 
 “We have daily notes that we fill every day, health records and everything, so if we think 
there’s a change in their behaviour or anything the we can monitor that then go through the 
correct people to let them know-doctors, consultants-to say what we think is happening” 
“(C9) 
 
Determining why a resident was resisting personal care, or behaving aggressively 
was a skill deemed necessary, partly to protect the staff and also to differentiate 
between behaviour resulting from other physical health conditions or behavioural 
and psychological symptoms of dementia. Of note, one care home shared her 
awareness and experience of aggressive behaviour being potentially due to 
fluctuating sugar levels rather than BPSD: 
  
“…with people’s behaviour…if they’ve got diabetes and they’re on insulin and metformin and 
whatever, you have to look whether this, even though they’ve got dementia, is it the dementia 





To this effect, care staff interviewed shared the view that it was important to have 
the mental capacity of residents assessed especially with regards to covert 
administration of medication. 
“If a resident continually refuses, we would usually get an MCA or deprivation to do it 
covertly” (C8) 
 
With respect to getting an “MCA”,  the participant (C8) was referring to the care 
home working within the principles of the Mental Capacity Act (MCA) (2005) 
which requires that the mental capacity of the resident be assessed and evidence 
obtained that they lack the capacity to make decisions about their own care, thus 
allowing the care home to legally make decisions in the residents’ best interest. 
“Deprivation” in this context was in relation to the Deprivation of Liberty 
Safeguards (DoLS), which the care home applies for, from their local authority 
which allows them to legally keep a resident in the home without the freedom to 
leave, because the resident lacks the capacity to consent to arrangements for their 
own care and treatment (Care Quality Commission 2017). Staff in care homes are 
required to know about these legislations so that the rights of residents are not 
violated during attempts to administer care or treatment. 
The importance of involving family or carers in decision making in these 
circumstances was also highlighted. 
 
“If it is early stages of dementia, you can communicate with your resident….but if it is 
advanced stage and they’re refusing medication, you can’t communicate with them, you need 
to communicate with the family” (C7) 
 
Keeping family members of residents informed about medication changes and 
adverse effects were routine practice in care homes, and it was recognised that 




“We inform the family. The residents are unable to know as they’ve got dementia. They’re 
unable to retain the information so we ring the family to say that some medication has been 
started, some medication has been stopped.” (C4) 
 
From experience, some staff participants alluded to non-pharmacological care of 
people with dementia, asserting that to improve quality of life for dementia 
sufferers in care homes, some level of continued interaction with people outside of 
care homes would be useful. 
 
“As much as we are trying to take our residents into the garden…..it is not the same as going 
and being in a group of, a different group of people, other than the same people they see on a 
day-to-day basis.”(C11)  
 
On the whole, staff interviewed displayed good knowledge about the needs of 
people with dementia especially with regards to developments arising due to 
disease progression; medication taking; families’ wishes, and how to deal with 
challenging behaviour in a person-centred manner. 
Staff views on residents’ medication related needs and pharmaceutical care 
services provided are discussed in-depth in the next section. 
5.3.3 Medicine Management and its Challenges 
This theme was derived from all the responses related to processes followed by 
care homes with regards to medication; staff views about medication related needs 
and challenges associated with caring for residents with dementia as well as staff 
perceptions about pharmacy service provision. 
 
Staff members interviewed were all involved in one way or another with managing 
medicines for residents, particularly ordering medication and its administration.  




• receiving medication from pharmacy,  
• booking in,  
• changing over the trolley for start of new month,  
• collecting interim prescriptions required within the month outside of repeat 
prescription requests and,  
• booking these in when delivered.  
Medication pre-packed for residents into medicine dosage systems such as dosette 
boxes or “pods” helped staff manage administration better. Residents missing 
medication doses was also an issue highlighted:  
 
“..The other thing is the medication administration by staff…I do counts and sometimes, in 
the odd occasion when somebody signs something and it’s not given, we get too many tablets 
left….there’s a signature missing, or there’s a signature there and the tablets have not been 
given. We tried to address that by having ‘pods’, which is working…instead of people having 
to select tablets out of each box, all the tablets are put into pods now. So they’ve got morning 
and lunch time, a bit like the dosette boxes…” (C6) 
 
Ordering medication and having it dispensed and delivered on time was ranked 
high when discussing the medication related needs of residents with dementia, 
particularly those with advanced dementia and receiving end of life care. 
 
When asked to comment on medication related needs of residents with dementia, 
interviewees highlighted facing challenges with residents who had difficulty with 
swallowing and therefore needed medication prescribed in formulations easy to 
swallow such as liquids, dissolvable tablets or patches. For residents with an 
agreement in place, the ability to conceal medication in food was almost 






“I would say it’s mostly around the form of the medication, a form that is easy to swallow. 
Some of the service users are receiving medication in a covert form, so it is all about 
prescribing medication that are easy to crush, medication that are easy to dissolve in their 
mouth, dispersible, oral solutions. I would say it is mostly around the form of medication, 
with dementia services” (C11) 
 
Staff also faced challenges with residents refusing medication and had clear 
procedures to manage refusal. This usually involved observation to ascertain the 
reason for refusal, liaise with GPs to re-evaluate the need for the medication and if 
swallowing was the problem, involving the SALT team. Care plans were put in 
place and updated to reflect these.  
 
“Yes, refusal, we get that quite a lot. Obviously when people get quite advance dementia, they 
tend not to like to take medication, so obviously in their best interest, we know they need to 
take medication, whether it be for blood pressure, or diabetes, but there is quite a lot of times 
they will just completely refuse to take it” (C10) 
 
“If medication refused three times on consecutive days, then we ask the doctor to review the 
medication and we ask the doctor if it should stop or continue” (C5) 
 
Cognitive deterioration resulted in some residents needing constant reminders to 
take their medication as they often forgot, and staff were on hand to offer prompts 
until taken. Refusal and forgetfulness led to medicine wastage. 
 
Medication related services were outlined as mainly involving prescribing by 
doctors; and dispensing and supply by community pharmacies. 
The main pharmacist involvement, in all but one care home visited was described 
as supplying medication, liaising with GPs to obtain repeat prescriptions, 
dispensing and delivery.  
 
“Pharmacy gets the prescriptions, put them into bubble packs and send them” (C9) 
 
Supply of medication from pharmacy was not without challenges, particularly with 
prescriptions sent over electronically, or when pharmacists went through repeat 
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prescriptions for a care home and noted medication not prescribed then had to 
chase doctors.  
 
“They supply all our medication. They will liaise with the GP now. We don’t so much get the 
green prescriptions anymore. We request the prescriptions and they go along electronically 
to the pharmacy, which can be a little difficult because sometimes we’re chasing up 
medication that we should have, and they’re holding it back for the monthly, not aware that 
sometimes we need it ASAP….”(C2) 
 
However, pharmacists were also involved in auditing in care homes (correct 
ordering procedures, storage, use of MDS and administration) as well as staff 
training on using the dosage systems they supplied. These audits were done 
annually or bi-annually. 
Care homes contacted pharmacists for help with verification of adverse effects of 
medication before going on to GPs for prescription amendments. In addition, 
pharmacists were quoted as being handy in responding to queries relating to 
dosage intervals, compatibility of medication with foods/liquids in case covert 
administration was advised.  
…”Pharmacy will advise us, with the doctor, on what medication can be crushed or what can 
be taken covertly, what can’t, and stuff like that….” (C10) 
 
Routine medication reviews were carried out mainly by GPs (intervals ranging 
from 6-weekly to every six months, or remotely over the phone, in response to 
phone calls from care homes). The dementia crisis team and dementia liaison 
nurse were involved in reviewing medication for residents with challenging 
behaviours.  
One care home had a visiting specialist care home pharmacist but this service had 
only just started so the staff could not comment on the impact of the service, 
though they did point out that there was lack of communication between the care 




“…the pharmacist that comes here and the pharmacist that does dispense the medication are 
two different people. They don’t communicate. If they were to communicate a bit more, they 
might find the system would be a bit better” (C3) 
 
The role of community pharmacy was deemed to be that of supply and delivery 
and when viewed this way, pharmacy services were considered satisfactory: 
 
“…they deliver the medication on time, especially if we need antibiotics and need that 
antibiotic today, you call the GP, he will do the prescription, send to pharmacy and they will 
deliver the same time”  (C7) 
 
“They save us time because the previous pharmacy we were with, we had to chase up 
prescriptions if they weren’t printed in time to get medication ready for the next cycle, 
whereas, they do all that for us now” (C6) 
 
A couple of participants conversely thought that pharmacists could do more, 
though conceding that pharmacists had time constraints: 
 
“They are well placed because they know the residents. They could do more, I feel, more than 
they do at the moment to support services, as with dementia, but no, at the moment, there is 
not much support from the pharmacy team” (C9) 
 
“I think medication need reviewing more often and obviously, I know they are quite busy as 
well, but maybe pharmacy staff could explain what those medication are, rather than just 
putting them in a pack and sending because that’s what is requested,” (C8) 
 
Staff did not think there were any pharmacy services tailored for people with 
dementia but acknowledged that the dementia liaison nurse and dementia crisis 
team reviewed medication, particularly in introducing or reducing antipsychotics 
for those with challenging behaviour. 
5.3.4 Relationship with/role of multidisciplinary team (MDT) 
This theme was about the contributions of healthcare professionals to care of 
people with dementia in the care homes visited, and the relationship staff had with 




Overall people living with dementia in care homes had input from a plethora of 
health care professionals, named by care home staff interviewed as: 
• Dementia liaison nurse,  
• community pharmacists,  
• nutritionists,  
• dementia crisis team,  
• speech and language therapy (SALT) team,  
• general practitioner (GP),  
• geriatrician,  
• district nurses,  
• chiropodists,  
• occupational therapists,  
• falls team,  
• physiotherapists,  
• Parkinson’s nurses and  
• podiatric team.  
“We have physios, we have Parkinson’s nurses, Alzheimer’s nurses. There is a geriatrician 
team that is involved, district nurses, community nurses…..that is part of the team looking 
after service users with dementia” C11 
 
The greatest input into care homes seemed to come from the dementia liaison 
nurse, dementia crisis team and GPs. Care homes relied on the dementia nurse and 
crisis team for advice on managing residents with challenging behaviour.  
“We get a doctor, a referral, and then we get this dementia crisis team. If the behaviour is 
changing, then we need the service of the dementia crisis team to help us out. They have their 
own doctor, and they can prescribe medication…..it is not our duty to prescribe medication, it 
is the dementia crisis team….when we get the prescription, it goes to the pharmacy and 




Not all healthcare professionals were available to all care homes,  and one declared 
that they only had the dementia nurse, crisis team and someone to help the home 
with general nutrition, but admitted that that they were able to access help when 
needed: 
“If we have any problems, we have got people we can contact….we tend to manage what we 
can manage in the home. Only when we have got a problem would we call outside services 
in…..If someone starts becoming really aggressive, so that you can’t manage their needs, and 
it gets to a point where you can’t cope anymore, then you would need advice and you would 
need help from outside” (C1) 
 
Whilst staff knew which member of the MDT to contact with various concerns, it 
wasn’t always the case that they would get a prompt response. 
“It is really difficult, though, because we try to refer them as quickly as possible and 
unfortunately, with the NHS system, they don’t always react to it quick enough sometimes 
and then we have to find another route and that’s usually when I bring M in (dementia 
nurse) especially when it relates to dementia and we troubleshoot it and try and find the best 
possible route to find the answer to our problem” (C6) 
 
Though healthcare professionals from many disciplines were quoted as available 
to help care homes, there was no indication during any of the interviews carried 
out, that these teams collaborated with each other in an integrated manner. 
Care homes dealt directly with individual services and updated care plans with the 
outcomes. This lack of collaboration could result in waste of resources since the 
same care home would also have a GP, geriatrician, crisis team doctor, and 
dementia nurse visiting to review medication. 
 
Pharmacists, seen in the traditional role of “suppliers” also needed to provide 
answers as to whether suspected side effects to medication were attributable to 
specific medication they had dispensed, and were also consulted to help doctors 
choose appropriate formulations to suit the needs of residents. However, 
doctors/GPs/geriatricians/dementia nurses were viewed as the professionals that 
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could “action” suggested solutions by prescribing alternative medication, stopping 
medication or giving advice to counter side effects. 
The role of pharmacists in the identification of drug therapy problems did not 
come out in the interviews, as they tended to be seen as adopting a reactive rather 
than proactive approach. Family or carers of residents were informed of changes 
to residents’ care plans (medication) retrospectively according to staff 
interviewed.  
   
“First of all, we would update the care plan; there is medication in the care plans, so that’s 
written there. Then in the professional notes, we would write it down, if the service user has 
capacity, we would discuss it with them. If not, we notify the next of kin to let them know 
there have been changes to medication.” (C11) 
 
In none of the care homes was there mention of families or carers being informed 
before decisions were made with regards to changes to medication of their loved 
ones, rather a phone call after the decision had been made to make medication 
related changes was the usual practice. This appears to reflect another gap with 
regards to integrated care, as a system where care homes occasionally held 
multidisciplinary team meetings would accommodate attendance by family 





5.3.5 Barriers and facilitators to care provision 
Having talked about challenges faced by staff in relation to medication related 
needs of residents with dementia, the next theme focused on the barriers they 
faced to providing care.  
Care staff recognised the importance of managing pain in people with dementia, 
with many interviewees pointing out that affected residents could not 
communicate their needs effectively. 
However, sometimes requests for painkillers from doctors would result in 
prescriptions being sent directly to the community pharmacy by the GP, and 
because of a lack of communication between the two regarding the reason for the 
prescription, the pharmacy would sometimes withhold the prescription till the end 
of the month for routine delivery. In addition to this, pharmacists often withheld 
prescriptions with the assumption that care homes were over-ordering, again 
without communication. Attempts by a particular care home to arrange a three 
way meeting between their pharmacist, home manager and GP failed. 
 
“…When they get a prescription electronically from the GP, they will keep hold of it. And they 
will think it is part of the monthly meds, and it’s not, we’ve requested it, we want it now…… 
 
“We’ve tried and tried. We had a meeting with the health centre a couple of months ago and 
pharmacy was meant to be there,  because we had a big issue with who was holding up 
medication, X Pharmacy did not turn up for the meeting” (C3) 
 
It is noted that care homes are unable to purchase over the counter painkillers for 
use in residents they know or suspect are in pain, due to company policies that do 
not allow ‘homely remedies’. 
 
 “If somebody is in pain, or they’ve got a bad head, you can watch their body language, you 
can see. If they are not prescribed PRN (as required) paracetamol, I can’t give anything. I’ve 




Staff opined that GPs could visit more frequently instead of issuing instructions 
over the phone or prescriptions electronically, since they sometimes did not know 
the particular needs of the individual they were prescribing for: 
“I think the GPs; they don’t always have the needs of the service users in mind when certain 
medications are prescribed….you can prescribe medication that is easy to swallow. Simple 
things like that, But I believe they have a big impact on the mental health and wellbeing of 
service users” (C11) 
 
To facilitate better care for people with dementia to ensure they continue to live 
well in an environment they are familiar with, one staff interviewed suggested that 
a consultant dementia specialist could visit the homes to see residents:  
“It would be nice to have somebody who specialises in dementia as a consultant, to come in 
and visit the homes and see the residents and what issues we’re having. We deal with as 
much as we possibly can, but it is a shame when you can deal with it no longer, they get 
shipped out to another care home, where they just strip them of their medication and start 
again, whereas they could probably provide the same sort of service here where they’re 
comfortable and where they know the environment” (C6) 
 
A lack of understanding of dementia by emergency care services was also raised as 
a concern, and participants shared the view that people with dementia should be 
treated with more dignity: 
“It think there needs to be better understanding because especially with hospitals, if 
unfortunately we have to send someone to A&E,, I think there’s very little understanding and 
I think because they’ve got dementia and they’re old, unless they’re loud and causing trouble, 
they’ll force them to wait, and it’s almost like that’s it, their life is over anyway..” 
“I don’t think because someone has got dementia and they’re in their 80s, you just put a DNR 
(do not resuscitate) in place and leave it at that, which is what tends to happen” (C8) 
 
“I do understand that from the moment they are diagnosed to the moment they pass away, it 
might even be up to 15 years, so you want them to have a good quality of life and you want 
then to be, you know fairly well and medically well.”(C11) 
 
Furthermore, when care homes themselves had to accept emergency admissions to 
care homes, they had no immediate access to patient records to determine what 
medication to prescribe: 
“If we have, let’s say emergency admissions of service uses, say there’s been an incident at 
home, and they have to be admitted to us, as an emergency patient, there is very little 
support. Very often, these service users are not medicated, we don’t have access to their 
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records, we don’t know what medication they are on, when they were seen. So there is 
potentially a lot of work to be done. (C11) 
 
This would indicate a gap for the provision of medicine reconciliation services by 
pharmacists to care homes.  This could be offered remotely if pharmacists were 
given full access to electronic patient records. 
Staff were also of the opinion that there were not enough services to help people 
with dementia stay active as part of enabling them to live well with their disease. 
Suggestions included more exercise, more activities and visits to day care centres. 
The facts that most of these care homes were privately owned coupled with lack of 
funding from councils were viewed as barriers to providing such services.  
 
“I think, and I mean I know, obviously, finances with councils and things like that are tough 
as it is for our bosses, they are private owners. I think a lot of people in dementia homes, 
there should be more facilities to stimulate them…that are tailored for them” (C8) 
 
Providing dental hygiene to people with dementia was mentioned as an area 
where care could be better.  
“I think with teeth, dentist; that would be something that would be beneficial, obviously 
taking them to the dentist, trying to get them to open their mouth, things like that. 
Something to be provided as well (because it is hard to actually brush their teeth sometimes), 
it would be nice if they made some kind of sweet tablet they could take to help clean their 
teeth” (C8). 
 
This was an example of a lack of standardisation of services provided to every care 
home since some care homes had visiting dental teams as part of the MDT 
supporting them. 
The streamlining and standardisation of approaches to provide support for people 
with dementia in care homes to live well is necessary. Every care home should 
have a list of essential services they have to provide to residents. This would go a 
long way towards improving the quality of life for this patient group and make care 




Resident demographics and care home characteristics 
This study was carried out in 11 care homes despite the initial intention to select 
only 10 care homes in the chosen frame. This was because one of the care homes 
operated as two care homes in one location with one home (named differently) 
operating as a residential only facility and the other with nursing care. 
All care homes selected had people living with dementia in them with proportions 
ranging from 25% residents with dementia (H9) to 99 %(H3).  
  
Varying proportions of people in care homes are reported to be living with 
dementia. Two thirds (approx. 66%) was the estimate by the Alzheimer’s Society 
(2007), 69% (Prince et al 2014), 70% (Matthews et al 2013), and more recently, 
70% (Alzheimer’s Society 2019a).  Another report estimated that approximately 
four in five residents of care homes in the UK had people living with some form of 
dementia (Alzheimer’s society 2013). 
The study did not record gender specific data, but on average, it is thought that 
53% of male and 71% of female residents of care homes are living with dementia 
(Prince et al 2014, Ballard et al 2018). 
This means that the proportions in some of the homes where staff were 
interviewed for this study were higher than national average, but this can be 
attributed to the fact that some care homes were dedicated to catering mainly or 




Most residents with dementia were reportedly diagnosed before admission into 
the care home, and by implication, this means dementia was the likely reason for 
the choice to seek residence in a care home. 
Research shows that there are many factors that inform an individual’s decision to 
transition into a care home. These can be linked to the Anderson behavioural 
model (Anderson and Aday 1978) which postulates that utilization of various 
health care services is sequential and a conditional function of the predisposition 
of individuals to use a service, their ability to secure the service (economic factor) 
and the need for the service (health related factors). 
People with dementia fall in with the third factor as their disease progresses and 
their ability to self-care reduces and leads to the need for various care services.                            
To this effect, it can be extrapolated that of the 500,000 people living in over 
20,000 care homes in the UK (Cousins et al 2016, Laing 2013), considering upper 
end of Alzheimer’s Society (2013) estimates, up to 400,000 may have some form of 
dementia, a sobering figure. 
Studies examining predictors for admission into care homes have shown that old 
age, gender (women), cognitive impairment and suffering from some other key 
chronic medical conditions are the highest risk factors (Sinclair, Stanford and 
O’Connor, 1988, Kasteridis et al 2016).  
Amongst long term conditions, dementia is independently associated with an 
increased risk of care home placement and though other conditions such as 
functional dependence and cerebrovascular disease are also associated with 
placement in care homes, dementia and cognitive impairment are main 





The care homes included in this study were all privately run, supporting the 
observation that for the last three or four decades, provision of residential 
accommodation and care has changed steadily from public to almost exclusively 
private (independent) provision (Lievesley, Crosby and Bowman 2011, Gage et al 
2012). Participants in the study were not asked about their opinion of the quality 
of care their residents received, but homes registered for-profit by small 
businesses catering for publicly funded residents have been judged to have lower 
standards than corporate for-profit homes holding specialist registration and 
charging higher fees (Gage et al 2009). 
Staff knowledge of dementia and residents’ experience 
Care home staff interviewed for this study listed their qualifications and years of 
experience, with the least number of years’ experience being four years, and the 
minimum disclosed qualification being NVQ level 2. Two care homes employed 
registered general nurses. The study did not seek to establish whether the number 
of years’ experience declared by care home staff were in the same care home or a 
variety of others. However, there is a high level of staff turnover in care homes 
(Royal College of Nursing 2012), even though recent trends show an increasing 
number of degree level nurses working in care homes which could potentially 
result in higher quality of care for care home residents (Backhaus et al 2015). 
Other researchers also found that having a dementia program or dedicated unit 
were associated with positive commitment towards staying in dementia care (Lee 
et al 2013). 
Additionally, though concerns have previously been raised about the quality of 
nursing care provided to people living in care homes (CQC 2014), this study did 
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not seek to establish a link between the level of staff qualification and/or 
experience to their knowledge of dementia and residents’ lived experience. 
However, considering that numbers of people with dementia living in care homes 
are continuously on the rise, the importance of health workers in the care home 
sector having specialist dementia knowledge cannot be over emphasised (Royston 
et al 2017). 
With regards to knowledge about dementia, staff in the current study displayed 
knowledge of the pathway for assessment and diagnosis of dementia, as well as 
knowledge of sub-types (causes) of dementia. They stated that most people with 
dementia in their care homes were already diagnosed before admission, but most 
didn’t have their sub-type recorded unless they came in via the memory clinic. 
This is in line with the NICE guidelines (2018) and NICE dementia overview and 
diagnosis pathway (2019) which have been discussed earlier in this thesis. The 
importance of determining the dementia sub-type, which affects the management, 
disease course, outcomes and treatment has also been stressed (Robinson et al 
2015. Characterisation of sub-type is also important for care planning purposes 
(Albretch et al 2019). Staff in the study specifically pointed out that people with 
vascular dementia behaved differently from those with Lewy Body Dementia, for 
example. 
In the interviews conducted, staff made many references to person-centred care, 
from pointing out that they needed to learn every individual’s behaviours, to 
expressing views about the need to monitor physical health of residents, and 
having an understanding of their rights under the mental capacity act for purposes 
of covert administration of medication, as well as managing challenging behaviour.  
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This demonstrates a recent focus of dementia care which has directed towards 
person-centred care since Kitwood (1997), described the necessity of putting the 
person first before the disease. The person-centred approach acknowledges that 
the focus of care delivery should be on the individual and their psychological 
needs, not the disease (Evardsson and Innes 2010).  
Though this approach can have a positive impact on staff wellbeing and lead to 
better job satisfaction, some researchers have shown that residents with dementia 
often live with many unmet needs (physical, emotional, environmental) which 
staff, in a bid to see the patient instead of the disease, sometimes struggle to 
address, sometimes leading to emotional stress for staff (Brownie and Nancarrow 
2013, Royston et al 2017). Despite this, staff in the study displayed great insight 
into factors involved in managing people with dementia, describing the necessity 
to decipher reasons why residents with dementia would resist personal care or 
behave aggressively, noting that other physical health conditions such as diabetes 
may affect sugar levels and cause aggression and agitation.  
This corroborates findings by Rapaport et al (2018) where the care home staff 
interviewed indicated that some of the challenging behaviours exhibited by people 
with dementia were expressions of unmet emotional, physical or environmental 
need. However, like highlighted above, this group of staff also struggled 
emotionally and sometimes felt frightened, powerless, and overwhelmed when 
attempts to alleviate residents’ distress did not work.  
From a medication point of view, staff demonstrated knowledge of medication 
taking needs of residents, stating that as their dementia advanced, people with the 
disease were increasingly unable to communicate and began to refuse medication, 
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to the extent that family needed to be involved for decision making about stopping 
or starting medication.  
This finding is similar to findings by Mjorud et al (2017) who interviewed 
residents in a nursing home and found that they had difficulty communicating 
their thoughts and feelings, and also described a sense of being lost. The impact of 
these feelings, along with other symptoms, is that 90% of people suffering with 
dementia, particularly those with moderate to severe disease suffer from 
neuropsychiatric symptoms also known as behavioural and psychological 
symptoms of dementia (BPSD) (Corbett et al 2012). The tendency has been to treat 
these symptoms with antipsychotics, which are associated with increase cognitive 
decline for people with dementia, along with increased risk of stroke and death 
(Banerjee 2009, Schneider, Dagerman and Insel 2005). 
Non-pharmacological methods have been advocated as the best approach to 
treating people with dementia suffering from behavioural and psychological 
symptoms (Livingston et al 2015). Staff in this study alluded to this, highlighting 
the fact that continued interaction outside of the care home would benefit 
residents with dementia and improve their quality of life.  It should be noted that 
with training, and support, care home staff are able to successfully implement 
psychosocial interventions in care homes (Surr et al 2019). 
Medicine management and its challenges 
Older adults with dementia often live with frailty, which presents many medication 
management challenges.  
Medication safety in various healthcare facilities is an important issue for policy 
makers both nationally and internationally, and the medicines management 
process needs to integrate accurate drug selection, prescribing, ordering, storage, 
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dispensing, administration and monitoring in order to ensure patient safety (Joos 
et al 2014). 
 
In the current study, when asked what was involved in managing medication in 
their care homes, staff interviewed listed a range of activities including receiving, 
booking in, storage, changing over trolleys for start of new months and 
administration of medication. This finding is consistent with that of the Care 
Homes Use of Medicines Survey (Barber et al 2009). They found that care home 
staff spent 40-50% of their time on medicines related activities, and that there was 
an error rate of approximately 8.4% during these activities. Another study 
suggested that these errors could be prevented through frequent intervention by a 
pharmacist to ensure that medication administration happens at the correct time, 
and to define clear processes for handling medicines (for example, splitting, 
crushing, mixing with food) (Silva et al 2015).  
Staff highlighted the issue of missed medication doses by residents, medication 
wastage as well as refusal of medicines by people with dementia, and expressed 
the opinion that receiving medication from pharmacies already pre-packed in 
multi-compartment compliance aids, also known as Monitored Dosage Systems 
(MDS) such as dosette boxes or “pods”, made it easier to administer.  
MDS are widely used in care homes, and their use remains a contentious issue 
(Centre for Policy and Ageing, 2011). Some pharmacists opine that MDS facilitates 
drug administration for care home staff (the staff in this study agreed with this 
view), whilst others maintain that their use is unsafe due to the inability of staff to 
identify various tablets in each compartment and the fact that “as required” 
medication as well as liquid medications have to be excluded from the devices, 
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whilst many medicines lumped together in them are incompatible with each other 
(Barber et al 2009, Alldred et al 2011).  The Care Quality Commission (CQC 2019a) 
also discourages the use of these devices, citing a Royal Pharmaceutical Society 
report (RPS 2016) that concludes that these do not improve outcomes for patients, 
and advocating alarms, tablet splitters and other methods for facilitating 
medication administration. 
Whatever the views of professional and regulatory bodies, judging from the views 
of participants in this study, this form of medicines administration remains 
entrenched in care homes and it is infinitely better to educate staff on best practice 
than to try and stop it entirely. 
Staff in the study considered the dosage form of medication the most important 
medication related need for people with dementia, citing difficulty swallowing as 
significant. This is expected, since dysphagia is an important symptom in dementia, 
is common in older adults, and an estimated 45% of people with dementia are 
thought to suffer from some form of swallowing difficulty (Horner et al 1994). 
Swallowing difficulties impact the effectiveness and safety of pharmacotherapy, 
and dosage adjustments are often required to improve clinical effectiveness, and 
therefore cognition for people with cognitive impairment and/or dementia 
(Mastrioanni and Forgerini 2018), since giving a patient the appropriate 
formulation to suit their needs would lead to improved adherence. 
Refusal of medication was also a challenge care home staff indicated they faced 
often, in this study. Participants interviewed were all aware of processes to follow 
in this situation, including contacting the prescriber, which is what is advocated by 
the Alzheimer’s Society (2019), who recognised this problem and advises that 
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alternate dosage forms such as liquids and patches where available be 
recommended when people with dementia refuse to take their medicines. 
However, staff also intimated that cognitive deterioration further complicated the 
process of medicines administration as individuals with advancing dementia often 
forgot they had to take medication or that they needed to swallow it. Training of 
staff to manage these situations is essential. 
Care home staff mostly rated the services they received from pharmacy as 
sufficient, as they quoted medication dispensing, supply, response to queries and 
advice on storage as the main pharmaceutical services they received. These 
findings are similar to those of other studies that have investigated pharmaceutical 
services to care homes (Bolaky et al 2010, Patel and Donyai 2013) who found 
supply as the main service community pharmacists delivered to care homes. 
People with dementia who are often prescribed complex medication regimens 
would need more pharmacy input, and some participants did express the opinion 
that pharmacists could do more, echoing Bolaky et al (2010) who highlighted the 
fact that care home managers would welcome greater pharmacy input especially 
with training of care home staff. De Witt et al (2013) also advocated an expansion 
in the role of pharmacists to include regular medication reviews in care homes. 
Due to the regular occurrence of swallowing problems and medication refusal, 
crushed medication and liquid formulations are often required, and these are 
associated with significantly increased odds of medication error (Van den Bemt et 
al 2009).  
Challenges faced by care home staff when administering medication to residents 
with dementia remain relatively under-researched.  Staff in nursing homes 
struggle with preparation, management and administration of medication to 
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people living with dementia, with those suffering from moderate to severe forms of 
the disease presenting even more challenges (De Witt et al 2013). Thus greater 
input from a pharmacist is clearly an outcome that will improve care for people 
with dementia in care homes (Lemay et al 2012, Ociaomh et al 2014). 
 
Relationship with/role of Multidisciplinary team (MDT) 
Multidisciplinary teams have been shown to improve health outcomes through 
collaboration between healthcare professionals (Social Care institute for 
Excellence 2018). 
In the context of this study, several healthcare professionals were quoted by 
participants as having input into the care of people with dementia, and the greatest 
input came from the dementia liaison nurse, dementia crisis team and GPs.  
 
The dementia liaison nurse role in assisting with management of challenging 
behaviours, conducting assessments and signposting for medication review 
demonstrated the importance of this role within a care home MDT, as emphasised 
by Jenkins et al (2016) who outlined that the specialist dementia nurse as part of 
MDT, played a central role in referring people with dementia for best care. Their 
role descriptor included referring staff to pharmacists for medication advice, to 
occupational therapists for activities and to GPs for assessment and treatment.  
 
Hibberd (2014) also stressed the importance of a specialist dementia nurse and 
even though she referred mainly to care in the community where the needs of 
people with dementia were deemed inadequately addressed, their role in 
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facilitating regular reviews of clinical care was invaluable. The participants in this 
study rated the services they got from the visiting dementia nurse very highly. 
 
Despite having the potential to obtain services from a diverse team of 
professionals, staff noted that responses could be tardy, leaving them with the 
option of having to improvise. This view is echoed by the Alzheimer’s Society 
(2016), whose survey based on 286 care homes with dementia residents, found 
that they failed to receive timely access to essential services such as podiatry, 
dentistry and physiotherapy. 
 
Whilst there was evidence of interdisciplinary collaboration within teams (the 
geriatrician team had their own nurses and other practitioners), the researcher 
saw no evidence that interdisciplinary collaboration occurred. This could 
contribute to wastage of resources through fragmentation and/or duplication of 
services. 
An interdisciplinary team approach to medication reviews in care homes including 
a consultant pharmacist, social service coordinator and psychologist saw a 44.5% 
drop in psychotropic use (Oakes et al 2010).  
Additionally, a pharmacist participating in case conferences alongside doctors and 
nurses was valued by other members of an MDT in another study (Halvorsen et al 
2011) which reported improvement in the quality of prescribing. However, this 
was offset by the reported inconsistency in pharmacist participation and 
uncertainty about their continued input into the MDT. In this study, pharmacists 
delivering pharmaceutical services to the care homes were consulted remotely to 
respond to medication formulation queries, but were not involved in medication 
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reviews, which shows that these care homes were not taking full advantage of 
pharmacists’ expertise, since their participation in MDT for medication reviews 
have been shown to improve patient safety through prevention of medication 
errors, prescribing advice and recommendations for discontinuing unnecessary 
treatments (Bondesson et al 2012, Desborough et al 2011, Ballard et al 2002, 
Chadborn et al 2019). 
 
A positive impact of having a pharmacist in MDTs could also include balancing 
adherence to treatment guidelines with adverse drug effects, and a pharmacist led 
medication review in a care home as part of a MDT, could result in improved 
monitoring of side effects and reduction of drug-drug interactions (Brulhart and 
Wermeille, 2011). However, some barriers exist to pharmacists performing this 
role satisfactorily as discussed in the previous chapter of this thesis, not least of 
which is the low numbers of pharmacists’ recommendations actioned by GPs 
(Maidment et al 2018) and the lack of competencies in therapy areas such as pain 
and dementia (Wright et al 2019). 
 
Other members of a MDT that would improve outcomes for care home residents 
are their family members. 
However this study showed that though staff communicated decisions to family 
members of individual residents, they were not seen as part of the MDT. 
This indicates that not much has changed in care home settings, as Manthorp 
(2008) in her evaluation of dementia care quality in care homes showed that 




Barriers and facilitators to care provision 
Staff experienced several barriers to providing optimal care to people with 
dementia in their care homes, one of the main ones being lack of communication in 
the three way relationship between care homes and community pharmacies, care 
homes and GPs, and between GPs and community pharmacies.  
This negatively impacted the care of residents particularly those in pain where 
acute medication could not immediately be made available either due to doctors’ 
not informing pharmacies of its urgency or pharmacies not recognising immediate 
need. 
 
NICE guidelines (2018) recommend that people living with dementia are regularly 
assessed for pain using structured observational pain assessment tools, and a step 
wise protocol which balances pain management with potential adverse effects of 
drugs used (Pink et al 2018). The needs driven dementia-compromised behaviour 
theory (Kovach et al 2005, Rapaport et al 2018) purports that people living with 
dementia would display challenging behaviour, often labelled as disruptive, as a 
result of unmet need that are related to physical factors (pain thirst, constipation) 
amongst others. 
 
Additionally, neuropathological changes in the brain affect how people with 
dementia experience pain and cognitive deficits impair their ability to portray their 
discomfort (Achterberg et al 2013, van Dalen-Kok et al 2017). 
Staff in this study recognised this, which explains their frustration at delays in 
promptly obtaining medication for residents. 
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Whilst one of the main benefits of electronic transmission of prescriptions has 
been touted as improved efficiency in handling prescriptions and in patient safety 
(Franklin et al 2014, Kauppinen et al 2017), the impact of prescription delays on 
residents of care homes due to communication breakdown have not been 
evaluated since electronic transmission of prescriptions was rolled out in the UK. 
 
Even though the need for care home staff to be better trained in assessing and 
managing pain in people with dementia has been frequently highlighted (Barry et 
al 2012, Carter 2015, Sawan et al 2019), staff in this study appeared well informed 
and expressed the desire to see real improvements through multidisciplinary team 
collaboration. They also lamented bureaucratic barriers that prevented them from 
keeping “homely remedies” in their care homes that would further empower them 
to manage residents with dementia better. 
 
Homely remedies are medication that do not require a prescription and can be 
purchased over the counter for use in managing minor ailments (Care Quality 
Commission, 2019b). NICE guidelines (SC1) (2014) for managing medication in 
care homes recognises the need for homely remedies and outlines guidance on 
their safe storage and administration. The absence of homely remedies in care 
homes in this study is not reflective of practice in all care homes across England, 
since some areas do have policies and guidelines to support self-care in residential 
care facilities as recommended by the Care Quality Commission (2019b). 
More frequent visits from GPs and a suggestion that consultant dementia 
specialists could visit care homes were advocated by participants in the study, as 
they saw this as a way of preventing residents being unnecessarily transferred as 
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well as dealing with specific needs of people with dementia such as prescribing 
appropriate medication formulations. 
Poor access to NHS services which results in people with dementia ending up 
bedbound and sedated has been highlighted by an Alzheimer’s Society report 
calling for parity of esteem for this vulnerable patient population (Alzheimer’s 
Society 2016a). The same report also quoted poor access to GP services leading to 
people with dementia experiencing unacceptably long waits for treatment and 
unnecessary hospital admissions.  
Access to mental health services by care homes was also advocated, which is a 
proposal similar to what respondents in this study have suggested. 
Staff on their part, could incorporate the recording of medication-related goals of 
care for each individual with dementia (Sawan et al 2019), to improve goal-direct 
pharmaceutical care and guide quick decision making when prescribers are 
required to recommend treatments for various ailments. 
 
Another deterrent to the wellbeing of people with dementia, expressed in the 
interviews with care home staff was their treatment by hospital staff when they 
visited hospital emergency rooms. They felt A&E staff had poor understanding of 
people with dementia, and this view is not unique to participants of this study. 
Another study noted impatience of emergency staff at hospitals with people with 
dementia, and explained this behaviour by citing bureaucratic (Parke and Hunter 
2017). According to these researchers, pressure caused by the need to meet 
targets made dealing with dementia patients challenging as they are unable to 
communicate their needs in a way that is quick to understand. It was suggested 
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that emergency services staff be provided with the dementia friends framework as 
well as training on person-centred care. 
It was also highlighted that emergency admissions of people with dementia into 
care homes lacked sufficient information regarding medication, and care homes 
did not have access to primary care patient records.  
 
Various methods can be employed to help care homes with medicines 
reconciliation at the point of admission of a resident. The most obvious is having a 
dedicated community pharmacist and GP assigned to each care home (RPS 2014). 
As community pharmacists have access to summary care records, they can provide 
a basic list of medication the new resident is on.  
The Royal Pharmaceutical Society (RPS, 2012) issued guidance in its publication 
“Keeping patients safe when they transfer between care providers-getting the 
medicines right” which has been adopted by many hospital and community sites 
across the UK. A standardisation of practice, where pharmacists designated to care 
homes take responsibility for medicines reconciliation when new residents are 
admitted or return to the homes following hospital admission would go a long way 
towards enhancing patient safety. 
 
Further barriers to care raised by staff in this study were the absence of services to 
stimulate residents with dementia, and in some care homes, lack of dental services. 
This indicates that care homes in the study were not fully compliant with NICE 
guidelines for dementia (2018) which recommend that sufferers be offered 
interventions to promote cognition, independence and wellbeing, such as cognitive 
rehabilitation and group reminiscence therapy. 
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Music therapy has also proven to be a cheap, safe, easy to deliver intervention that 
can have potential benefits in reducing anxiety, depression and agitated 
behaviours in elderly people with dementia (Blackburn and Bradshaw 2014).  
 
Poor oral health and hygiene is common in people with dementia (Marchini et al 
2019) and is often neglected by care home staff due to prevalence of other 
demands (Yi Mohammadi et al 2015). Staff in the current study highlighted the 
challenges they faced getting residents with dementia to open their mouths for 
oral cleaning and proposed the possible use of an oral cleaning tablet. Such a 
venture would need the input of a pharmacist to ensure that a tablet used in this 
manner will have no systemic effects nor interact with any medication a resident is 
taking. 
A holistic multi-disciplinary approach to health and wellbeing of people with 
dementia living in care homes is essential to achieve better oral health and 
comfort, and visits by dementia friendly dental hygienists to conduct dental 
examinations.  
Whilst the wellbeing of people with dementia cannot be guaranteed at all times, 
efforts need to be made by all involved in their care to ensure that they are as 
comfortable as can be and receive adequate medical and psychological treatments 
where needed. 
5.5 Conclusion 
Interviews carried out with care home staff revealed that though they faced 
several challenges with managing medication for people with dementia, they were 
satisfied with the dispensing and supply services provided by community 
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pharmacy, but improvements were needed in obtaining anticipatory medication 
for residents in end of life care, and gaining information on prescribed medication 
for emergency admissions.  
Improvements were needed for the improved functioning of multidisciplinary 
teams with better communication and integration between healthcare 
professionals advocated. 
 
This study preceded policy changes which saw more specialist pharmacists being 
placed in care homes from 2018, following implementation of the Medicines 
Optimisation in Care Homes (MOCH) scheme resulting from the establishment of 
the Pharmacist Integration Fund (PhIF). However, as this scheme only committed 
to providing funding for 218 pharmacists in care homes, with a stipulation that 
local commissioners take over after May 2019, it is clear that the role and impact of 
community pharmacists who remain part of the overall management of people 
with dementia in care homes through medication supply and medicines 
information, continue to require further exploration and definition.  
 
Incorporating a medication review tool for use by pharmacists integrated into care 
home MDTs, to encourage prescribing of required medication or de-prescribing of 
inappropriate medication could be useful in improving medication use in people 
living with dementia in long term care facilities. 
 
The next two chapters in this research describes the development and testing of 
such a tool. 
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5.6 Study limitations  
• This study was a qualitative study based in a small geographical area so the 
generalisability of the findings are limited  
• The interviews were conducted in care homes, where there were interruptions 
with participants being called out to attend urgent duties within the care home. 
This could have disrupted their thought processes leading to less 
comprehensive answers. 
• Questions regarding reporting of medication incidents were not asked, and this 
information would have been useful in evaluation of medication related 
practices in care homes visited, which would have increased the impact of the 
research. 
• Care home staff may have been reluctant to express opinions that were not 
complimentary about their care home. 
• For a few participants, English was not their first language and though they 
managed to convey what they wanted to say, eventually, transcripts tended to 
be much longer and some context may have been lost. 
• Though information was gathered about the extent of the experiences of care 
home staff in terms of the number years spent in the care home sector, this 
information was not correlated with knowledge in the data analysis. 
• Finally, this study was based on face to face interviews which raised the risk of 
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6.1 Introduction and chapter overview 
7 in 10 people living with dementia are also living with other medical conditions 
and potentially being prescribed multiple drugs (Brown 2017). Healthcare 
professionals, especially pharmacists, have the responsibility of ensuring that the 
treatments that follow the dementia diagnosis, are safe, effective, and can be 
accessed by all who need them (Kennedy and Sud, 2014). 
In chapters 3, 4 and 5 of this thesis, the role and impact of pharmacists in 
managing medication for people with dementia was examined, and a link between 
their knowledge and barriers to offering an optimal pharmaceutical care service to 
people with dementia was established. Pharmacists interviewed admitted that 
they needed to improve their knowledge on dementia, and the majority of those 
who participated agreed they would be interested in dementia related training. 
Pharmacists, given their extensive training on the use of drugs, should be able to 
ensure that medicines, prescribed to people living with dementia, whether in care 
homes or in the community, are monitored, reviewed regularly and stopped when 
they are no longer required.  
Prescribing is considered potentially inappropriate when its potential risks 
outweigh its potential benefits. A systematic review by Morin et al (2015) found 
that nearly 50% of nursing home residents are exposed to inappropriate 
medication use during their stay. Community pharmacists who supply medication 
to care homes have electronic records of residents’ medicines in the pharmacy and 
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are ideally placed to periodically screen for potentially inappropriate prescribing 
(Tommelein et al 2016).  
As discussed in previous chapters of this thesis, people with dementia often also 
live with other diseases, sometimes up to 4 or 5 other chronic conditions (Guthrie 
et al 2015), and if each of these conditions are treated according to their individual 
evidence based guidelines, it is to be expected that this will result in polypharmacy. 
Polypharmacy is defined as the use of five or more medications daily in one 
individual (Curtin et al 2019). It is common in older adults, and in many cases, may 
be clinically appropriate, but as older adults have decreased renal and hepatic 
function, it is important to identify inappropriate polypharmacy which puts them 
at increased risk of falls, adverse drug reactions, higher mortality rates, hospital 
admissions and other poor health outcomes (Masnoon et al 2017). In the Services 
and Health for Elderly in Long Term Care (SHELTER) project which evaluated 
prescribing for nursing home residents with advanced cognitive impairment, 
polypharmacy or excessive polypharmacy was observed in 67.6% of residents 
(Vetrano et al 2013). For people with dementia, this can be particularly 
problematic, impaired cognition being a hallmark of dementia, and drugs such as 
anticholinergics, several psychotropics and drugs for Parkinson’s can worsen 
cognitive decline. Additionally, dementia, a neurodegenerative disease, can lead to 
impairment of mobility, which could be further worsened by blood pressure 
lowering drugs e.g. alpha adrenoceptor blocking drugs (van Marum 2017). Other 
adverse effects of medication that are especially undesirable in people with 
dementia are myalgia (from drugs such as statins), Parkinsonism (caused by some 
antipsychotics) and diminished appetite which could lead to malnutrition (van 
Marum 2017).  
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Medication reviews and educational interventions can commonly be used to 
improve prescribing for people with dementia living in care homes (Liu et al 
2019). Medication reviews have been found helpful for carers of people with 
dementia (Maidment et al 2017) and are reported to result in a positive impact on 
patient health outcomes (Santos Silva et al 2019). 
Medication review, an integral component of the provision of pharmaceutical care 
by pharmacists, facilitates the identification of potentially inappropriate 
prescribing and highlights drug therapy problems.  It is defined as “a structured, 
critical examination of a patient’s medicines with the objective of reaching an 
agreement with the patient about treatment, optimising the impact of medicines, 
minimising the number of medicines related problems and reducing waste” 
(Taskforce on Medicines Partnership and The National Collaborative Medicines 
Management Service Programme 2002).  
The National Prescribing Centre’s “A Guide to Medication Review” (National 
Prescribing Centre 2008) describes three different types of review: 
➢ Type 1: Prescription review- addresses issues relating to the prescription of 
medicines (patient does not need to be present, nor does it require access to 
full notes) 
➢ Type 2: Concordance and compliance review – addresses issues relating to the 
patient’s medicine taking behaviour (e.g. medicines use review –MUR- by 
community pharmacists) 
Type 3: Clinical medication review: requires patient’s notes and addresses 




Medication reviews for people with dementia in care homes have to be conducted 
in a systematic manner, using a structured approach (van Marum 2017).  
Crucially, the stage of dementia has to be considered in any medication review 
process for people with dementia, and Maidment (2013) proposed a model in 
which cognitive enhancement is optimised in mild dementia, and people with 
moderate dementia are supported with medication adherence whilst those with 
moderate to severe dementia have any medication prescribed to manage 
behavioural symptoms (antipsychotics, hypnotics, anxiolytics) reviewed. In 
advanced stage dementia, common issues include constipation, continence 
problems, swallowing problems, infection, pain and breathlessness (NES 2014).  
It was envisaged that a simple toolkit purposely designed for use in people with 
dementia, by pharmacists working in collaboration with GPs and 
patients/caregivers, would facilitate pharmaceutical care and support a rational 
approach to prescribing. This toolkit would provide pharmacists with a framework 
for conducting structured, quality Type 3 medication reviews for people living 
with dementia. It could also be utilised by community pharmacists conducting a 
Type 2 review. 
6.2 Method/Results 
6.2.1 Aim 
• To design a dementia intervention toolkit to act as aide-memoire to 




• To use guidelines and evidence on medicines optimisation in dementia to 
develop a tool for conducting systematic medication reviews for people living 
with the condition. 
6.2.3 Process 
To develop the toolkit, a literature search was carried out to evaluate existing 
medication appropriateness tools, publications and guidelines.  
Medication appropriateness tools 
Though many tools have been developed to classify medication appropriateness in 
the elderly (Kaufman et al 2014), not many have been used to address potentially 
inappropriate medication use in people with dementia. Tools used frequently in 
literature not particularly targeting people with dementia include: 
• Beers criteria (American Geriatrics Society Beers Criteria 2019) 
• STOPP/START (O’Mahony et al 2015) 
• Medication Appropriateness Index (Hanlon et al 1992) 
• STRIP (Keijsers et al 2014) 
• WHO 6-Step approach to prescribing 
Recently developed: 
• Ghent Older People’s Prescriptions community pharmacy screening 
(GheOP3S) (Tommelein et al 2016) 
For people living with dementia, the consensus criteria developed by Holmes et al 
(2008) which categorised medication into ‘never’, ‘rarely’ ‘sometimes’ or ‘always’ 
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appropriate, remains the most significant development in literature (Parsons 
2016). However, this tool was developed for use in people with advanced dementia 
requiring a palliative approach. More recently, a tool was developed that looked at 
medication use in people with dementia and other co-morbid health conditions: 
• Medication Appropriateness Tool for Comorbid Health Conditions during 
Dementia (MATCH-D) (Page et al 2016). Though the development of this tool 
involved the consultation of a large group of experts, it has not yet been fully 
tested in a clinical setting. 
Following the review of available tools, the following were considered for use in 
the toolkit based on their widespread use in clinical settings and relevance to the 
current study: 
STOPP/START Criteria Version 2 
The Screening Tool of Older People’s Potentially inappropriate prescriptions 
(STOPP) and the Screening Tool to Alert doctors to Right Treatment (START) 
version 2 (O’Mahoney et al 2015) were included as resources in the toolkit for its 
applicability in reviewing prescriptions for older people with comorbid chronic 
conditions. The STOPP/START criteria publishers allow reproduction and re-use of 
the resource for non-commercial purposes as stated in 
https://doi.org/10.1093/ageing/afx178  as long as the resource is properly 
referenced. However, permission for its use in this toolkit was sought from the 






WHO six-step approach and the STRIP tool 
The WHO six step approach for rational prescribing (Figure 20) which is a useful, 
validated tool for teaching and ensuring appropriate prescribing for people in later 
life (de Vries et al 1994) and the Systematic Tool to Reduce Inappropriate 
Prescribing (STRIP) (Keijsers et al 2014) were used as guides to ensure that the 
toolkit incorporated all aspects required for consideration in a holistic approach to 
medication review and the provision of pharmaceutical care to people with 
dementia. However, whilst the WHO stepped approach can help doctors prescribe 
appropriately, it is insufficient on its own for judging the appropriateness of a 
medication regimen, a process which requires a systematic approach.  
The STRIP tool (Keijsers et al 2014) was developed in the Netherlands as a five 
step process, namely (1) drug history, (2) analysis of drugs, (3) treatment plan, (4) 
Patient preferences and (5) follow up and monitoring. Though this tool does not 
specifically target people with dementia, step 2 (analysis of drugs) is meant to 
prompt considerations about under-treatment, noneffective medication or over-
treatment, potential side effects, incorrect doses, contraindications or interactions. 
Of particular relevance is the pointers to “under-treatment” as people with 





Figure 20: adaptation of WHO 6-step approach to rational prescribing 
 
NICE guidelines (Dementia) 
Excerpts from NICE guidelines for dementia (CG42) were used, in part, as a 
resource. This is permitted by the NICE UK Open Content Licence which allows 
content to be used freely if the content is used in its original form and referenced. 
These excerpts were used for the tool in preference to the new updated guidelines 
(NG97) as they described in more detail, the management of non-cognitive 
symptoms of dementia, clearly separating pharmacological from non-
pharmacological approach, which was judged better by the researcher for use with 
a focus group of pharmacists 
Other considerations 
Anticholinergic medication: A medication review tool for a person with dementia 
requires a prompt to consider the anticholinergic burden of medication prescribed 
Patient's problem Diagnosis, symptoms, patient's characteristics)
Therapeutic objectives (defining the goals of therapy, be it curative, 
symptomatic, or preventive)
Treatment choice (verifying that the chosen treatment is suitable 
for individual, based on available evidence)
Start treatment (consider formulation choice, dosing intervals,  
dose timings)
Patient information (instructions and warnings, possible side effects, 
correct usage)




as people with dementia are particularly sensitive to adverse effects associated 
with high anticholinergic load (Sura et al 2013). 
Psychotropic medication: These include antipsychotics, hypnotics, antidepressants, 
anticonvulsants, and anxiolytics often prescribed to manage the behavioural and 
psychological symptoms of dementia (BPSD) also known as neuropsychiatric or 
non-cognitive symptoms (Thompson Coon et al 2014).   
To ensure the above two issues are considered in the systematic medication 
review pointers to determining the anticholinergic burden (Campbell et al 2010), 
were added and NICE guidelines CG42 for managing non-cognitive symptoms of 
dementia were also included as discussed earlier. 
A reference to the British National Formulary (Joint Formulary Committee 2019) 
was added so that drug interactions and side effects of medication prescribed can 
be considered, in line with advice from the STRIP tool highlighted earlier. 
The DEMENTIAS prototype toolkit 
A mnemonic was formed using the word “dementias”, since mnemonics can be 
used to enhance memory and maximise sound decision making (Bruno et al 2012, 
Sinopoulou et al 2017). Finally, a proforma for recording pharmaceutical care plan 
was included, styled on one proposed by Cipolle, Strand and Morley (2004). 
Permission was obtained from McGraw Hill publishers to include this proforma in 
this thesis (Appendix 6g). 









The main purpose of pharmaceutical care is to provide and optimise drug therapy 
in a way that leads to definite outcomes that improve the quality of life of 
individual patients. This toolkit was developed with a view to incorporating the 
principles of pharmaceutical care into the process of reviewing medication for 
people with dementia in manner that facilitates detection of drug therapy 
problems such as unnecessary drug therapy, need for additional medication, 
ineffective drugs, dosing issues or adverse drug reactions. 
The desire to reduce prescribing of potentially inappropriate medication to older 
adults, particularly those in care homes who are amongst the frailest patient 
groups, has led to the design of many medication review tools for this purpose, and 
their use during medication reviews can help promote rational prescribing. 
Appropriateness of medication can be measured by applying validated criteria 
developed to patients’ prescriptions and/or clinical data, and these criteria can be 
explicit (developed from literature reviews, expert opinion and consensus 
techniques) which contain drug lists or classes known to cause harm in older 
people, or implicit criteria (quality indicators of prescribing that can be applied to 
prescriptions by doctors or pharmacists) (O’Connor et al 2010). 
Examples of explicit tools include the Beers Criteria (American Geriatrics Society 
2019), the STOPP/START criteria (O’Mahoney et al 2015), and the ‘Discontinuing 
Inappropriate Medication in Nursing Home Residents’ (DIM-NHR) (Wouters et al 
2014). Other tools to manage medication appropriateness in older adults include 
the FORTA-USA (Fit fOR The Aged, Pazan et al 2019) which is a classification list 
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designed to support doctors in the USA with medicines optimisation and   for older 
adults, and the EURO-FORTA (Pazan et al 2018).    
Implicit tools in research include the Medication Appropriateness Index (MIA, 
Hanlon and Schmader 2013) and the Systematic Tool to Reduce Inappropriate 
Prescribing (STRIP, Keijsers et al 2014). Explicit tools can be applied to 
prescriptions without need for much clinical judgement, whilst implicit tools 
require clinical knowledge to administer, but explicit criteria can fail to take into 
account individual patient preferences, whilst implicit criteria though catering for 
patient preferences and disease, rely on clinicians’ medical knowledge and are 
time consuming to apply (O’Connor et al 2012) 
Though the tools discussed above were developed to address inappropriate 
prescribing in the older population in general, both the STOPP/START and Beers 
tools have criteria specifically for people with dementia such as concerning 
psychotropic and anticholinergic medication. There are few tools specifically 
designed to detect inappropriate prescribing in people with dementia, and these 
focus either on prescribing of psychotropic medication, such as the Appropriate 
Psychotropic drug use in Dementia (APID)( van Der Spek et al 2015) which is an 
implicit tool, or the Quality use of Medicines in Dementia (QUM-D, Peisah et al 
2015), an explicit tool. 
The DEMENTIAS toolkit developed in the current study aimed at targeting 
prescriptions for people with dementia specifically, combining aspects requiring 
clinical judgement and others needing consultation of appropriate criteria to 
improve prescribing for this patient group. 
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The toolkit starts with a pointer to consider drugs prescribed and their doses 
following medicines reconciliation to obtain drug history, as required by NICE 
guidelines for managing medication in care homes (NICE 2014). This is a similar 
step to the pharmacotherapy review advocated in the Systematic Tool to Reduce 
Inappropriate Prescribing (STRIP) (Drenth-Van Maanen et al 2017). 
Other steps in the toolkit include ensuring prescribing is evidence based, as well as 
consideration of co-morbidities for which other medication could be prescribed, 
with a reference to the STOPP/START (O’Mahony et al 2015) for lists of medication 
to avoid or commence in such circumstances. The STOPP/START criteria was 
chosen for comorbid health conditions, in preference to the Beers Criteria which is 
similar, because the latter focuses on USA prescribers and 50% of medicines 
included in it are unavailable in Europe, whilst the former has been used to 
optimise medication for people with dementia (Aziz et al 2018) and has been 
widely used in Europe (Snyder et al 2014, Nicieza-Garcia et al 2016, Oliviera et al 
2015). 
This tool also incorporates steps to review effectiveness, cost-effectiveness and 
side effects of prescribed medication, all of which are integral aspects of medicines 
optimisation (NHS Brent CCG 2014)). These are particularly important 
considerations for people with dementia when the impact of side effects such as 
increased risk of falls and reduced cognition from anticholinergic side effects are 
factored in (NICE NG97 2018). Furthermore, evidence that long term effectiveness 
of acetylcholinesterase inhibitors (anti-dementia medication) is not established, 
requires case by case evaluation of risk versus benefits of discontinuing treatment 
(Renn et al 2018). Cost effectiveness of prescribed medication for people with 
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dementia is also an important issue that needs to be addressed as part of 
medicines optimisation in dementia (Apampa and Navti 2014), and also 
highlighted by the House of Commons All Party Parliamentary Group on Dementia 
(2011) who quoted how much was spent prescribing food supplements for people 
with dementia because they were losing weight, when training staff to 
communicate better with dementia sufferers could yield better results. 
Additionally, with reference to anti-dementia medication, combinations of 
acetylcholinesterase inhibitors are increasingly being prescribed when the 
economic case for their benefit hasn’t been made (Knapp et al 2017). 
A separate step requiring assessing presence of and prescribing for 
neuropsychiatric symptoms (behavioural and psychological symptoms of 
dementia) was added to the tool, since the majority of people with dementia suffer 
from these at some point during disease progression (Mar et al 2019). The adverse 
effects of prescribing pychotropic medication to this patient group are well 
established (Coon et al 2014, Stocks et al 2017).  
The type of dementia suffered by an individual whose medication is being 
reviewed is important because symptoms across the dementia subtypes are 
heterogeneous and influence the individual’s capability to live well with the 
condition (Barret and Burns 2014). A step was added to the toolkit to account for 
this. 
People with dementia can be more susceptible to drug-drug interactions especially 
when they are prescribed medication such as antidepressants, psychotropic 
medication or gastrointestinal drugs such as omeprazole (Bogetti-Salazar et al 
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2016). Thus the identification of potential interactions, as well as determination of 
their clinical significance is useful when reviewing their medication. 
In an extension to the step considering medication side effects, a separate step 
emphasising review of anticholinergic burden of prescribed medication was added 
to the tool. It is well established that medication with cumulative high 
anticholinergic burden have many adverse outcomes in elderly people in general 
and those with dementia in particular (Fox et al 2011). These drugs also 
antagonise the effects of acetylcholinesterase inhibitors prescribed to slow down 
progression of dementia (EFjestad et al 2013).  
The final step of the tool was a decision-making one requiring the pharmacist to 
suggest simplifying, switching, or stopping reviewed medication as part of a 
pharmaceutical care plan which would be communicated to the patient’s GP and 
shared with the relevant multidisciplinary group, with an emphasis on involving 
the patient/family or carer in the decisions regarding any proposed changes to 
medication. 
6.5 Conclusion 
A toolkit was developed to provide pharmacists with a systematic approach to 
conducting medication reviews for people with dementia, as part of 
pharmaceutical care delivery to this patient group.  
This approach relies predominantly on the reviewer having the relevant clinical 
knowledge, but provides references to resources that can be used, for those less 
familiar with the subject area. Unlike most medication appropriateness tools 
available in research which state their purpose in their mnemonic e.g 
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STOPP/START (O’Mahoney et al 2015), this toolkit provides at a glance both the 
purpose, and the process that needs to be followed when addressing inappropriate 
prescribing in people living with dementia. This would work as a great reminder to 
any pharmacist taking up this important task. 
6.6 Limitations 
Though this toolkit has been developed using evidence from national guidelines, 
validated medication review processes and other implicit and explicit tools, it has 
not gone through a process of validation via consensus from experts in the field, 
nor has the process recommended by the Medical Research Council framework for 
developing complex interventions been applied to the process. 
Future research requires that this is done for it to be adopted widely. 
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7.1 Introduction and chapter overview 
As the prevalence of dementia has increased steadily over the past few years, and 
proportion of people with confirmed diagnosis of dementia has also gone up, the 
consequence has been that the number of people prescribed anti-dementia 
medication either on their own or in addition to other medication has also been on 
the rise. For people living with dementia, this represents an increase in the number 
of medicines prescribed, also known as polypharmacy (Maher et al. 2014). 
This highlights the need for pharmacists who routinely deal with prescriptions for 
people living with dementia to equip themselves with knowledge and skills to 
assist sufferers and/or their carers with managing their medication, and on the 
whole, become part of an integral system striving towards improving quality of 
care for people living with dementia. 
However, evidence from research carried out and reported in chapters 3, 4 and 5 
of this study shows that the main pharmaceutical care services delivered by 
community pharmacists in England to care homes (known to have high 
proportions of people with dementia), are the supply of medication, training of 
staff on medication administration and storage, and audit. One of the main barriers 
to community pharmacists providing optimal pharmaceutical care to people with 
dementia was insufficient knowledge of dementia and medicines optimisation in 
dementia, as less than half of the pharmacists interviewed agreed they could 
recommend interventions to optimise medicines use for people with dementia.  
The researcher theorized that pharmacists needed to engage in reflective practice, 
cross referencing and using analytical information to contribute to high quality 
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interventions for people with dementia. This led to the development of an 
intervention toolkit described in Chapter 6 to help pharmacists with this process of 
identifying inappropriate prescribing and optimising medication for people living 
with dementia. 
Though an association between polypharmacy and potentially inappropriate 
prescribing has been established across Europe and America (Blanco-Reina et al. 
2014, Tommelein et al. 2015), and a number of consensus criteria developed to 
address this amongst the elderly population, most of the tools developed do not 
focus on people living with dementia (Parsons, 2017).  
Chapter 6 described the development of a DEMENTIAS toolkit targeting 
pharmacists wishing to review or screen prescriptions for people with dementia 
and on the whole, improve pharmaceutical care delivery to this patient population 
as well as facilitate identification and reporting of drug therapy problems. The 
toolkit outlined a step by step approach, each step highlighting key issues for 
consideration by pharmacists when processing prescriptions for people with 
dementia. 
This chapter reports a feasibility study of the prototype toolkit developed in 
chapter 6 with the aim of testing its usability, acceptability, and applicability.   
Focus group methodology was selected for this arm of the study because this 
would enable participants to provide insights and comments in the course of 
discussions (Barbour, 2007), whilst interacting with each other and defending 
their views, and providing greater insight into their opinions (Oates, 2000) without 
use of a rigid framework. The expectation of the researcher was that the process 
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would lead to suggestions that would improve the toolkit. In future, the prototype 
can be piloted and tested amongst a larger cohort of health care practitioners that 
deliver care to people with dementia in care homes, such as geriatricians, crisis 
team, pharmacists and dementia liaison nurses. 
This study forms the concluding part of the living with dementia in care homes 
pharmaceutical care in dementia research, following qualitative face to face 
interviews with pharmacists, a quantitative questionnaire survey of pharmacists 
and face to face interviews with care staff working with people living with 
dementia. 
7.2 Method 
A qualitative research design involving a focus group of selected pharmacists was 
used. 
7.2.1 Aim 
• The aim of this study was to explore the views and opinions of pharmacists 
about the usability and applicability of the toolkit developed by the researcher, 
for improving pharmaceutical care for people living with dementia 
7.2.2 Objectives 
• To determine the feasibility of using the medication review toolkit for 
reviewing prescribing of medication for people living with dementia 
• To test the format of the prototype toolkit and determine whether it is 
comprehensible and appropriate for use by pharmacists  
• To determine whether the toolkit can be used to identify potential drug therapy 
problems in prescriptions for dementia patients 
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• To make amendments and revisions to the toolkit based on feedback from the 
focus group. 
7.2.3 Setting 
A conference room at a hotel within easy reach for participants, located in 
Thurrock, Essex was booked for the purpose of this study which took place in July 
2019. 
7.2.4 Study design 
A focus group qualitative research methodology was used.  
As a measure of content validity, the toolkit (described in chapter 6) was sent to 
the research supervisors and comments sought with regards to the structure, 
clarity of wording and to ensure that no essential areas had been missed out. 
Minor corrections were made to the toolkit by the researcher, in readiness for 
piloting with the focus group. 
The development of the toolkit used for this part of the study is described fully in 
chapter 6 of this thesis. 
 
7.2.4.1 Sampling, participant recruitment and informed consent 
Pharmacists working in the community pharmacy, care home or mental health 
sector were identified via NHS England Pharmacy Integration Programme, through 
The NHS Future Collaboration Platform 
(https://future.nhs.uk/connect.ti/system/login?nextURL=%2Fconnect%2Eti%2F
PharmacyIntegration%2Fgrouphome), where the researcher is a member. This 
forum was chosen because it was created purposefully to bring together 
healthcare professionals. There are pharmacists from various practice settings on 
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this forum and they are empowered to collaborate on projects aimed at delivering 
high quality health care services. 
A purposive non-random sampling approach was initially used. A purposive 
sample is that which is based on the selection of individuals with a particular 
characteristic for a study (Bowling, 2014). No assumptions were made that the 
participants were representative of the wider population of pharmacists.  
 
A call for participants was placed in the Future NHS Collaboration Integrated 
Pharmacists group. The purpose of the study was described. Pharmacists who 
expressed an interest were contacted via email and their job role and level of 
involvement with people suffering from dementia established.  
A target sample of 10 pharmacists were to be invited with a view to recruit 6 for 
the study. This number was chosen based on research that shows that the ideal 
sample size for a non-commercial focus group is 5 to 9 participants (Krueger and 
Casey, 2014). Where all 10 pharmacists invited agreed to participate, the 6 with 
the greatest number of years’ experience who fit the inclusion criteria would be 
selected to take part.  
Only two pharmacists were recruited in this manner, well short of the targeted 
number, so the rest of the participants were identified via snowball sampling.  
 
Snowball sampling is a convenience sampling technique where an initial set of 
suitable participants are called upon to refer relevant others who may be 
interested in the topic to be explored (Hutson and Hobson, 2008). 
Ethical approval for the study was obtained from the University of Sussex Cross 
Schools Research and Ethics Committee (Appendix 7a). 
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Six pharmacists who agreed to participate in the study, were sent an information 
pack that consisted of participant information about the study (Appendix 7b), 
consent form (Appendix 7c) and the researcher contact details at the University of 
Sussex.  
 
The recruited pharmacists were asked to return the signed consent form directly 
to the researcher in a pre-paid envelope addressed to the University of Sussex. 
They were advised that they could contact the researcher at any time for further 
information or clarification of any issues and that they could withdraw from the 
study at any time by contacting the researcher. Written assurance of the 
confidentiality of any information obtained during the study was included in the 
participant information letter. 
One of the 6 participants indicated a few days before the day booked for the study 
that they were unable to attend but recommended another pharmacist who met 
the criteria for selection and agreed to participate. However, on the day of the 
study, the pharmacist who had pulled out came along, so the final number of 
participants in this study was 7. The 7th participant received all relevant 
information as detailed above on the day of the study. 
 
Participants were given copies of the toolkit and asked to initially discuss its 
structure and write down comments about the tool length on an evaluation form 
provided. They were then asked to review prescriptions for two fictitious case 
studies prepared for the study by the researcher, as they would in routine practice, 
using the toolkit. The patient and medication details included in the case studies 
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were derived from the researcher’s detailed knowledge of previous patient cases 
obtained during her role as a mental health pharmacist.  
No person identifiable material was used in the case studies presented to the focus 
group.  
Discussions were audio recorded and recordings were sent for transcribing by a 
professional company that specialises in transcribing data from interviews and 
focus groups. 
7.2.4.2 Inclusion and exclusion criteria 
Inclusion criteria 
Pharmacists working in the community retail, care home or mental health sector 
as identified above in the sampling process described in the previous section. This 
was to ensure a diverse group with relevant experience that could be drawn on 
during evaluation of the toolkit. 
Exclusion criteria 
Pharmacists working in administrative, non-patient facing roles. 
7.2.4.3 Research instrument 
The ‘DEMENTIAS’ toolkit developed in Chapter 6 (Figure 20), along with the 
relevant appendices (Appendices 6b to Appendix 6f) were printed and distributed 
to all participants, along with two case studies (Appendix 7e) for testing the 
toolkit. 
7.2.4.4 Data Handling and Analysis 
Focus group discussions were digitally audio recorded following verbal and 
written consent by participants, and recordings safely stored in a digital safe 
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accessible only to the researcher. Data will be stored for five years following 
completion of the study to enable verification of findings if required.  
The recorded discussions were transcribed verbatim.  
In a similar manner to the approach reported in Chapter 5, content analysis was 
carried out using a thematic analytical six step process involving familiarisation 
with the data, generating initial codes, searching, reviewing and defining themes 
and finally writing up findings (Braun and Clarke, 2006), which enabled data to be 
described in detail. Codes and themes identified by the researcher were verified by 
the main research supervisor as described previously with the care home study 
reported in Chapter 5. 
Findings were independently verified by the academic supervisor to assure its 
reliability and confirm data saturation, which was clear when the participants had 
nothing more to add during their evaluation. No person/premise identifiable data 
was included in the report. 
 
7.2.5 Research Governance and Ethics. 
Ethics approval was obtained from the University of Sussex Research and Ethics 
Committee, the Cross-Schools Research Ethics Committee (CREC) before 
commencement of the study (Appendix 7a) 
NHS ethics was not required because the research involved NHS and/or social care 
staff recruited as research participants by virtue of their profession (Health 
Research Authority, 2016). Consolidated criteria for reporting qualitative research 
(COREQ) were completed for this focus group study as with previous qualitative 




There were 7 participants in total who took part in the focus group study. Their 
details are presented in Table 11. 
There was diversity in area of pharmacy practice of the participants, with most 
participants practising in more than one sector. One participant (AA) practised in 
an elderly ward within a community hospital, as well as in other areas of 
community health services. The other participants were care home pharmacists or 
mental health pharmacists/community pharmacists. 
During the discussion, participants commented on the ease of use of the toolkit, 
length, its applicability and suggested changes. The results of the study are 
presented here in sections comprising  
• demographic details  
• results of discussions about the toolkit 
• results from piloting the tool by using it on a couple of case studies 
• presentation of the written evaluations of the tool from the participants, and 
• final modifications to the toolkit based on focus group recommendations 
7.3.1 Pharmacist demographics 
Participants in the study were made up of 5 female and 2 male pharmacists with 
number of years of experience as pharmacists ranging from 5 years to 19 years 






Gender Sector Years of experience 
AA Female Community Health Services/Hospital 11 
BB Female Care Homes 10 
BA Male Hospital/Mental Health 5.5 
BT Female Community/Mental Health 16 
IM Male Care Homes 8 
IN Female Mental Health/Community 19 
OA Female Care Homes 5 
Table 11: Demographic details of participants and number of years' experience as 
pharmacists 
7.3.2 Results of discussions about the toolkit 
The researcher started the discussion by ensuring all consent forms had been 
completed and making sure the participants knew the objectives of the focus group 
study. Discussions on the toolkit began after participants had had a chance to 
review the toolkit. They started by expressing their general views about the 
instrument and progressed to talking about some of the appendices added to it. 
The main points discussed, following data review and thematic analysis, with the 
resulting main points and themes are presented in Table 12.  
The themes and main areas covered during the focus group discussion of the 
‘DEMENTIAS’ toolkit have been grouped under three overarching themes, namely:  
• Prescribing for people with dementia 
• Participants’ views about the toolkit 




Themes Main points considered Main themes 
Evidence from 
guidelines 
-NICE guidelines on 
dementia 




-guidelines on continued use 
of acetylcholinesterase 
inhibitors 
                  
 
 
               
Current prescribing 
practice 
-adherence to guidelines 
-shared care practice 
-responsibility for 
prescribing 
-changing role of 
pharmacists 
-antipsychotic prescribing 
-role of specialist clinics 
-diverging practices 
Toolkit Structure -simplicity 
-extent of areas covered 
-use as a checklist 
Toolkit usability -cost considerations 
-frequency of use 
-selective use of some 
aspects of tool 
-barriers to use (time, 




-relevance to pharmacists 
-relevance to other 
healthcare professionals 
-decision making from 
recommendations following 




-updates to appendices 
-NICE guidelines 
-ACB scale 
-Diagnosis and treatment of 
dementia 
-addition of other specialist 
clinics to recommendations 
Table 12: Main points and themes from 'DEMENTIAS' toolkit focus group discussion 
Participants’ views 
about the toolkit 
Improvements to the 
toolkit 





7.3.2.1 Prescribing for people with dementia 
Participants in the study discussed at length about the NICE guidelines on 
dementia (NICE CG42, 2006), particularly the recommendations for 
pharmacological management of the behavioural and psychological symptoms of 
dementia. 
Whilst most agreed that prescribers generally adhere to national guidelines and 
recommendations when prescribing antipsychotics to people with dementia, it was 
acknowledged that prescribing practice differed depending on the clinicians’ 
assessment of the individual with dementia, their disease severity and quality of 
life: 
“For example, care home residents: they might have challenging behaviour. They’ve factored 
in the risk, but they also look at quality of life of the resident.  So they say 6 weeks, but it goes 
on for a long period of time….because you’re trying to improve their quality of life…..My 
population, after about 16 months, we know that they’re going to pass away, average. So 
you’re trying to make the best life possible for that person. They could be on it for a long 
time….” BB (care home pharmacist) 
There was uncertainty about what the guidelines said with regards to continuing 
anti-dementia therapy (acetylcholinesterase inhibitors) in people with severe 
dementia, when they are no longer considered to be of any benefit to the sufferer. 
The evidence base for the prescribing of anti-dementia medication was queried, 
but participants concluded that these medications could prevent further 
deterioration of the individual with dementia.  
Some participants pointed out that prescribing practice could vary depending on 
local guidelines or local prescribing formularies, and shared experiences of 
consultant psychiatrists diverging from prescribing guideline recommendations, 
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especially with respect to prescribing antipsychotics to elderly people with 
dementia: 
“The BNF says ‘short-term treatment up to six weeks. Well, sometimes, in ward rounds, the 
consultant would say they’re not using it for aggressive behaviour of the patients. They feel 
the patient is psychotic. Because you can’t go above, I think, two milligrams, they go under 
the cover of…..the reason why they want to increase is because they actually feel the patient 
is psychotic….and not for the aggression” BT (Community/Mental health pharmacist) 
Responsibility for prescribing was also discussed, with some participants 
explaining that when certain medication for people with dementia was started in 
secondary care, some GPs did not feel obliged to continue these once patients were 
discharged back into their care.  The practice of shared care protocols for such 
medication was highlighted, as well as the role of GP practice pharmacists in 
scrutinizing such prescriptions. 
“Certain medications…..it might be a dementia medication that they prescribed and a GP 
doesn’t prescribe that, or isn’t familiar with that. Or a GP would not want to continue 
because of cost, for instance. So, they might request a shared care guideline for the GP to say 
‘yes, I’ll follow on with treatment for the patient’” AA (Community health service 
pharmacist) 
“Another thing, from working in the community, I notice that with the GPs…..because there 
are a lot of GPs now with a pharmacist working at the GP practice; if the consultant is trying 
to change medication and they (the patient) are not stable, they (practice pharmacists) tend 
to push it back….. “BT (community/mental health pharmacist) 
 
Aside from GPs and consultant psychiatrists, a view was put forward that there 
were instances where responsibility for prescribing and medication review was 
with the memory clinic:  
“The thing is, if someone is on medication for dementia, sometimes they might be under the 
memory clinic, who then do review that medication every six months, do a pulse rate and 
Mini Mental State” …IM (care home pharmacist) 
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Involving family/carers in decision making about prescribing of antipsychotics to 
people with dementia was highlighted as a positive by one of the care home 
pharmacists, who went on to express concern about the lack of physical health 
monitoring offered to these patients following such prescribing: 
“…they will have to do that with the family; letting them know all the risks that are involved. 
I don’t know if it happens across all areas. But we’ll have to let the family know because there 
are risks of stroke, prolonged QT, sudden death and all that stuff…..and then it is prescribed. 
So, it will be like a best interest type of discussion….” BB (care home pharmacist) 
From the above discussions amongst participants in this study, it can be deduced 
that though only one set of NICE guidelines and NICE quality standards are 
available for all prescribers to refer to for guidance on prescribing for people with 
dementia, there is some level of divergence depending on local guidelines, which 
clinician initiates prescribing for an individual with dementia, and whether the 
person with dementia is under a memory clinic or remains with their GP practice. 
All these issues are relevant for a pharmacist wishing to undertake systematic 
medication reviews or prescription screening for someone with dementia as any 
drug related problems will need to be reported to the right clinician. 
Discussions within the focus group around varying prescribing practices were 
interspersed with participants sharing their views about the prototype toolkit. 
7.3.2.2 Participants’ views about the toolkit 
Participants were complimentary about the structure of the toolkit and the level of 
detail covered: 
“I feel it is quite extensive. For someone who has very little mental health background, I feel 
like it covers a lot of stuff that, in physical health, we look at, which maybe could be 





“I think it is well structured. It’s quite simplistic. It follows step by step. It has sections which 
are particular to dementia review….IM (Care home pharmacist) 
 
“I think it helps to cover everything because there’s a structure. There is a checklist to make 
sure ‘have I done this’, ‘have I thought about this, and done all that?’ That way, you won’t 
miss anything in the medication review” BT (Community/Mental health pharmacist) 
Participants also opined about the ease of use and relevance of the toolkit to their 
practice: 
“…I think it’s a full holistic review….for example, if I’m in a care home and I’m doing general 
reviews, I can utilise this, especially when there is a patient with dementia, and there is high 
population of that in that setting….” IM (care home pharmacist) 
“…It’s very comprehensive. I feel like I wouldn’t miss anything out with this tool” BB (Care 
home pharmacist) 
Two participants shared a view that the toolkit could be useful to other healthcare 
professionals such as mental health nurses and geriatricians, indicating that it was 
versatile. 
…”If there is an area whereby they don’t have the resources, such as a pharmacist or as in my 
area they have a mental health nurse that goes to the care homes…if they don’t have that 
then this would be a good tool for the GP to use….” BB (Care home pharmacist) 
 
…”Can I just say I second what BB just said, because in respect to the ward I cover….it is very 
highly medical. Now, if a consultant had this, he would be happy to use it…because once a 
week we get a mental health doctor to come and review all patients who have dementia…. 
But me as a pharmacist, it’s also quite good for me because we’re all about optimising 
medicines…” AA (Community health service [CHS]/hospital pharmacist)  
 
Due to the existence of local prescribing guidelines and formularies that already 
advocate cost effective prescribing, one participant did not think the toolkit would 
add much value as a means of reducing medication costs: 
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…”When you consider the local guidelines, they would usually cover it already with regards 
to the cost of this [sic] particular medicine…” OA (care home pharmacist) 
 
A few drawbacks to using the toolkit in practice were mentioned, with all the 
participants agreeing that it would be time consuming to go through the steps.  
“…I have to fit it in….you want to do it, but how do you fit it in?”…AA (CHS/hospital 
pharmacist) 
…”Yeah, I was going to say…it would be hard to…with this tool, you’re going to be referencing 
quite a bit. You wouldn’t need everything” BB (care home pharmacist) 
 
A few dwelled on the lack of communication between healthcare professionals 
especially when patients transfer settings, but the fact that many pharmacists were 
becoming independent prescribers was thought to be a positive, as it would mean 
they could make some of the warranted changes themselves, following discussions 
with the responsible clinicians. 
“…Between primary and secondary care…even within the same primary care 
unit…communication is a challenge because we don’t let the GP know what you have done. 
They are not magicians…they won’t know what has happened to the patient and by the time 
the information gets there, something has happened. Especially when you also go between 
secondary care to intermediate care before you go back to the GP……anything can 
happen….communication is key” BT (community/mental health pharmacist) 
 
One participant highlighted the importance of communicating not just with the GP 
but also with the patient themselves depending on their capacity, or with their 
family. According to this participant, becoming a pharmacist prescriber has helped 
with decision making regarding making recommendations following the final step 
of the toolkit. 
“…Maybe this is exclusive to where I am…you’ve spoken to the doctor in one area, then you’ve 
spoken to the nurse in one area, then you’ve got the information together, and you, in your 
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capacity can prescribe. The last piece of the puzzle, maybe, is to speak to resident or their 
family to see whether they are okay…” BB (care home pharmacist) 
Participants also completed a written evaluation of the toolkit in which they rated 
its layout/format, appendices included and length, and made comments, some 
about how to improve the toolkit. These are presented in Table 13. 
7.3.2.3 Improvements to the toolkit 
The participants made a few suggestions both during the focus group discussion 
and in their evaluation forms. 
One of the first issues of note was the inclusion of an excerpt from NICE guidelines 
(CGG42, 2006) as an appendix in the tool. This was included to aid decision making 
about the pharmacological and non-pharmacological management of non-cognitive 
symptoms of dementia. The guidelines seemed to contradict themselves according 
to one participant: 
…”There is a line here that says ‘Alzheimer’s disease, vascular dementia, mixed 
dementias’….people with those should not be prescribed anti-psychotic drugs because of the 
possibility of increased risk obviously of vascular events….then two bits after that, it says they 
should not, but then there’s a line that says they can…”  BA (Hospital/Mental health 
pharmacist) 
A discussion ensued about this leading to another participant suggesting that in 
terms of evidence, NICE dementia quality standards and local guidelines should be 
added to the tool. It should be noted that current NICE guidelines for dementia 
(NG97, 2018) does not have this ambiguity and the recommendations for 
pharmacological/non-pharmacological management of dementia have been 
simplified and placed in one section, so one amendment to the tool would be to 
include these instead of the previous version. 
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In light of the contribution from another participant that some people with 
dementia were reviewed by memory clinics, another suggestion was to include 
memory clinics amongst the list of healthcare professionals to share interventions 
with, at the end of the medication review process, using the toolkit. However, the 
final agreement, after consideration that there may be other specialist services 
linked to the person with dementia, it was agreed that “specialist clinic” be added 
to this information sharing list, instead of “memory clinic”. 
One participant had some suggestions relating to the flow of the steps within the 
toolkit, opining that the “E” for evidence came before “sub-Types”, indicating that 
time would have been wasted going through the steps of the toolkit before finding 
out what type of dementia they had or whether they even had a diagnosis of 
dementia: 
“… sorry, just taking it back to what might be the issue with this: as opposed to being 
a flow chart, as it is….because in my head, you’re looking at the evidence before you 
actually determine what kind of dementia they have… 
 
…rather, you establish what kind of dementia it is or if they have a diagnosis before 
you start to look at evidence”…OA (care home pharmacist) 
 
A second participant was concerned about ruining the flow of the toolkit by 
moving steps around as suggested above: 
…”Another way you could do it…that “D”…like she said…so you don’t mess up….you can 
remove the ‘drugs’ then put diagnosis, then under ‘T’, ‘therapy’/’treatment’” IN 




After further debate with the researcher, it was agreed that a “D” for diagnosis 
should be added at the beginning of the toolkit, and an arrow drawn linking this to 
the sub-type. 
Other suggestions for improving the toolkit were made when the participants 
completed their evaluation forms as seen in Table 13. 
The written evaluations were like those shared during the discussion session, with 
all participants rating the toolkit’s format, length, and its appendices between 
‘good’ and excellent. Overall, the participants wrote that it was useful, well-
structured, comprehensive and useful. There were suggestions for improvements 
to the toolkit but most of those had already been discussed earlier, such as 
addition of a “D” for diagnosis at the beginning of the toolkit, addition of ‘specialist 
clinic’ and ‘patient/carer’ to the list of individuals/services to communicate 
medication review results to and removal of NICE guidelines (dementia) excerpts, 
and replacing with a link, plus explicit guidance on managing behavioural and 
psychological symptoms of dementia (BPSD). 
Another suggestion was to potentially change the order of the toolkit, following 
discussions about the evaluating evidence before becoming aware of diagnosis or 








Toolkit evaluation (poor, average, good, very 
good, excellent) Comments 




Very Very good 
-very extensive and quite 
comprehensive 
-found it useful 
-could be very handy in my practice 
BA Excellent Very good Good 
-Well-structured and user friendly 
-Considered removal of appendices 
but presence makes them easier to 
refer to e.g. STOPP/START tool 
-To add explicit recommendations 
for antipsychotic therapy for BPSD, 
or at least the relevant NICE 
guidelines 
-NICE guideline excerpts can be 
removed, and links provided instead 
BB Excellent Excellent Excellent 
-Comprehensive and useful for that 
are already prescribed 
antipsychotics 
-Great tool which incorporates 
‘holistic approach’ and person-
centred approach 
-Potentially could change order of 
acronym 
-communication section to refer to 
carer or patient 
BT Very good Excellent Excellent 
-Very useful 
-add diagnosis at the top and 
connect to type of dementia 
-communication: add ‘specialist 
clinic’ 
IM Excellent Very good Very good 
-Well-structured 
-very useful, in-depth 
-to add: whether patient is under 
specialist clinic and last review 
 
IN Excellent Excellent Excellent 
-Very useful as it has compressed a 
wealth of information ensuring 
every aspect is covered 
-can be tailored exactly to patients’ 
needs 
-to add: local guidelines 
OA Very good Very good Excellent 
-useful for people with dementia 
-very detailed tool and very relevant 
-to add: signposting to relevant 
updated information for ACB score 
-Consider rearranging/re-wording 
flow chart 
Table 13: Results from written evaluation of 'DEMENTIAS' toolkit 
 
7.3.3 Result of toolkit pilot using two case studies 
The participants were split into two groups with Group 1 discussing case study 1 
and Group 2 discussing case study 2. 
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Case studies and the possible drug therapy problems that could have been 
identified using the toolkit, by both groups can be seen in Appendix 7e. 
Group 1, case study 1 
The case study discussed by Group 1 had seven potential drug therapy problems to 
be identified using the toolkit, and they were expected to use the following aspects 
of the toolkit: 
• Drugs prescribed (D). 
• Evidence for prescribing them (E). 
• Comorbidities (M). 
• Side Effects of medication prescribed (E) 
• Neuropsychiatric symptoms (N) 
• Dementia sub-type (T) 
• Interactions (I).  
• Anticholinergic burden of medication prescribed (A).  
• Opportunities to suggest stopping or switching therapy in their pharmaceutical 
care plan (S). 
The group lead (BA) admitted that they had first read over the case and discussed 
it amongst themselves before consulting the toolkit. 
They consulted NICE Guidelines for dementia, though they used their own 
judgement for considerations regarding the comorbidities of the person with 




With regards to the drug therapy problems identified by this group, despite not 
using all expected aspects of the toolkit (see Appendix 1), they used a combination 
of their own clinical judgement and aspects of the tool to identify 4 out of the 7 
possible drug therapy problems. 
“We did check the tool. Atenolol/beta-blockers doesn’t give you any cognitive side effects. 
Salbutamol for asthma is fine as well, so we’ll leave that, although SIGN (*Scottish 
Intercollegiate Guidelines Network) do recommend a corticosteroid as well as a Beta-2….but 
NICE still says if a patient has not used a PRN inhaler, you can keep them on just that….” 
(BA) 
 
The four potential drug therapy problems the group used the toolkit to identify 
were drug interactions, initiate an acetylcholinesterase inhibitor, recommend 
stopping a drug with a high anticholinergic burden, and recommend alternative 
hypnotic for the patient’s sleep problem.  They also considered the cost effectiveness 
of switching an acetylcholinesterase inhibitor for another based on identified 
interactions. They missed the fact that the patient’s asthma would need monitoring 
since the proposed addition of a cholinesterase inhibitor could cause worsening 
control of asthma symptoms (British National Formulary 2019). 
“The toolkit also showed us interactions as well…so I would say it’s definitely good, whether 
you use it at the start or you could use it at the end to check everything…” (BA) 
 
However, the group suggested melatonin as an alternative hypnotic to consider for 
the case in review, though current NICE guidelines for dementia (NG97, 2018) do 
not recommend this.  
Additionally, they used the toolkit and found an interaction between the 
acetylcholinesterase inhibitor they recommended (donepezil), and fluoxetine 
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(antidepressant) the patient was already on and decided to switch the 
antidepressant instead of choosing a non-interacting cholinesterase inhibitor like 
rivastigmine. Their rationale was cost considerations. More detail needed here 
about cost comparison. 
The group also did not mention that they considered any physical health 
monitoring which is referenced in the tool, and would have been a significant drug 
therapy problem to note since prescribing of a beta-blocker (atenolol) and a 
cholinesterase inhibitor (donepezil) can exacerbate bradycardia. This is despite 
one of the participants in this group expressing worry about lack of physical health 
monitoring in the elderly population during discussions in part 1 of the study: 
“..Like, I'm worried. Because if you're on a mental health ward, if they're, let's say, 65…before 
you start an anti-psychotic you have to think about ECG, thinking about physical health if you 
can. But for the elderly population, none of that is factored in…” (BB) 
 
However, they did point out the absence of physical parameters in the case 
vignette, such as blood pressure and pulse rate, and the absence of a drug history, 
which indicates that they would have considered these in practice.  
When the researcher asked the group about completing the therapeutic care plan 
included with the toolkit, they indicated they felt they did not have enough 
information to complete one but would do so in practice. They felt they needed 
more details such as past medical history and physical health monitoring results 
(like blood pressure and weight) 





Group 2, case study 2 
Group 2 discussed a much more straight forward case (case study 2, see Appendix 
7e), that required them to go through all the steps of DEMENTIAS toolkit, 
considering the following: 
• Drugs prescribed as well as over the counter medication,  
• Evidence for prescribing antipsychotics,  
• Any possible co-morbidities (using STOPP/START),  
• Effectiveness of prescribed medication,  
• The patient’s neuropsychiatric symptoms,  
• Query type of dementia (even though they were not given this information),  
•  Anticholinergic burden of over the counter medication and  
• Stopping the antipsychotic prescribed based on the all the above 
considerations. 
 
The group did recognise that based on the case vignette, the patient with dementia 
had challenging behaviour. Considering NICE guidelines for non-cognitive 
symptoms as recommended on the toolkit, a non-pharmacological approach was 
deemed more appropriate than prescribing an antipsychotic (olanzapine in this 
case). 
They also used the toolkit to consider comorbidities, and possibility of side effects 
as well as switching a codeine-containing painkiller with paracetamol only, but 
admitted that the toolkit was more useful for more complex cases.  
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“I think it was applicable in the sense that you almost… because from the beginning, you kind 
of gathered that it was a non-pharmacological intervention. However, if we were going to 
prescribe olanzapine, would it be appropriate, if that makes sense? So, because we didn’t 
have all the information, we were like, “Oh, actually, will it be appropriate?” So, then we had 
to look at the evidence. But also, NICE guideline says that you can use it but we figured it was 
non-pharmacological. And we just went down to the neuropsychiatric symptoms and then we 
did find that we’ll definitely go and look at the non-pharmacological interventions. But we 
didn’t use it as extensively, definitely not, as the first (BB) 
 
“We looked at the comorbidities and we kind of like just thought maybe having a total 
review. She’s not on a lot of medication as per what we got presented with but things like 
initiating the STOPP/START, we looked at the pain relief, if she’s still in pain. Can she just go 
on paracetamol? Having the codeine….Codeine we know is a drug that metabolises into 
morphine, that kind of causes constipation. Again, is her behaviour due to the fact that she 
might have constipation going on, giving her all that aggression because she’s not able to 
verbalise her feelings per se? So, with regards to comorbidities, it was also quite effective” 
(AA) 
Despite not using the toolkit systematically, this group indicated that they still 
found the toolkit useful as a reminder of what to consider: 
“I guess, the other thing to think about is the fact that although we didn’t use the full tool, 
having that there was able to prompt us to look at certain things, like neuropsychiatric 
symptoms. It is part of the tool. So we’re not using the full tool, we’re using little bits of it” 
(OA)  
 
They needed prompting to consider the fact that the patient in the case study may 
have a co-morbid mood disorder. 
With regards to further corrections of the tool, the first group did not suggest any 
further changes following their case study, but one Group 2 participant made a 
suggestion that the anticholinergic burden scale (ACB) included with the toolkit 
should have a prompt to inform a potential user that these were not gold standard, 




“You know, say for antidepressants, one of the things that they use quite a lot in my patch is 
mirtazapine and it has a burden of one. But that isn’t on there. 
…” So, probably just ensuring that it is prompted that this is subject to change in different 
places…” (OA) 
 
The researcher asked the whole group at this point if there was anything else they 
would like to add regarding the whole study, but no one had any. 
Part 1 of the study (discussions on the toolkit) took about 40 minutes and part 2 
less than 20 minutes, but this was because recording was only done for actual 
discussions, not whilst participants were familiarising themselves with the toolkit 
or deliberating on the case studies. 
7.3.3.4 Changes to toolkit from a consideration of all participant comments 
Changes suggested by the focus group were discussed with the research 
supervisor and the following were made: 
• Addition of diagnosis to the first box in the flow diagram and connection 
between this and type of dementia  
• Addition of patients/carers and specialist clinic to list of individuals/teams to 
receive information from completed medication review 
• Removal of NICE guideline CG42 excerpts and replacement with relevant 
excerpts from NG97 (2018) (Appendix 7f) 
• Shortening of the pharmaceutical care plan template to reduce time spent 
completing it, by removing some of the non-essential demographic data 
required in initial toolkit (Appendix 7g) 
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• Addition of a link for pharmacists to obtain up to date anticholinergic burdens 
of drugs from http://www.acbcalc.com/ with permission from the lead author 
(King, R 2019) (Appendix 7h) 
• Removal of drug interactions of acetylcholinesterase inhibitors and memantine, 
as up to date information on these are best taken from latest BNF 
Figure 22 shows the results of the amendments and final toolkit developed 














This study convened a focus group of pharmacists to discuss and review an 
intervention toolkit developed to aid pharmacists in delivering pharmaceutical 
care to people living with dementia. 
The goal of pharmaceutical care is for pharmacists to work with patients and other 
healthcare professionals responsible for their care, to promote health, prevent 
disease, assess, monitor, initiate and modify prescribed medication to ensure that 
they are safe and effective, through patient-centred care (American Pharmacists 
Association 1995). When patients are prescribed medication, the principles of 
pharmaceutical care require that they are appropriate, safe, effective, and that the 
patient is compliant with the medication regimen (Cipolle, Strand and Morley 
2004). Failure to meet these principles results in drug therapy problems (DTP), 
and pharmacists, alongside other healthcare professionals, have a duty to prevent 
and/or resolve drug therapy problems (Cipolle, Strand and Morley 2004). 
Prescribing appropriately for elderly people is a complex issue which cannot be 
managed simply by following clinical guidelines (Molist Brunet et al 2016) and for 
those living with dementia, this is further complicated because the condition is 
commonly associated with other long term conditions such as diabetes, chronic 
cardiac failure, chronic obstructive pulmonary disease amongst others (Schubert 
et al 2006, Delgado et al 2020).  
Whilst polypharmacy in itself is not always equivalent to inappropriate 
prescribing, the added challenge of managing possible adverse side effects and 
potential drug interactions puts those prescribed multiple medications at higher 
risk of potentially inappropriate prescribing (Delgado et al 2020, Barry et al 2016) 
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with those living with dementia particularly affected (Parsons 2017). Despite this, 
people with dementia are more susceptible to polypharmacy and inappropriate 
prescribing than those without dementia (Kirstensen et al 2018). Inappropriate 
medication use is even more prevalent amongst people with dementia living in 
care homes, so it is essential to have a structured approach to managing 
medication for people with dementia resident in care homes, including conducting 
periodic medication reviews in a systematic manner with the purpose of 
evaluating appropriateness of all medication prescribed (van Marum 2017). 
Several tools have been developed over the years to help identity potentially 
inappropriate prescribing, mostly developed for the general older adult population 
(Delagado et al 2020, Luccetti and Lucchetti 2017) though Holmes et al (2008) did 
develop an integrated approach specifically targeting medication appropriateness 
in people living with advanced dementia. 
In this study, a focus group of pharmacists from various sectors of practice 
evaluated and tested a prototype toolkit developed to serve as a guide to a 
structured approach to conducting systematic, comprehensive medication reviews 
for people living with dementia, without specificity on the severity of the disease, 
though the expectation is that pharmacists should know that medication therapy 
for people with dementia progresses from preventive measures to symptom delay 
in mild to moderate disease, to palliative in advanced dementia. 
Focus group methodology is often employed in pharmacy practice research as it 
has the advantage that it provides a safe environment for participants to express 
their views, perceptions and opinions as well as support each other, compare 
views and revise opinions based on discussions with others (Minard et al 2016).  
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In the current study, the participants spent some time initially discussing 
prescribing practice for people with dementia, before discussing the toolkit 
specifically. The areas of convergence (use of national guidelines) and divergence 
(individual prescribers’ approach to prescribing psychotropic medication to 
people with dementia) were discussed.  
Prescribers were thought to make prescribing judgements based on a desire to 
maintain good quality of life in advanced dementia, with an assertion that most 
people with dementia died within 16 months of admission into care homes, which 
made the consultant reluctant to discontinue antipsychotics in this group of 
patients. The view that most residents of care homes with dementia die within 16 
months is backed by a systematic review exploring the clinical course of advanced 
dementia (Mitchell et al 2009); the study found that over half of care home 
residents with dementia died within 18 months of admission as a result of various 
co-morbid physical health disorders and frailty.  
Though there is a paucity of practical guidelines for prescribing in advanced 
dementia (Fox et al 2017), in part due to difficulties in conducting research in this 
population (Murphy et al 2016), palliative care guidelines for people with 
advanced dementia (NHS North West Coast Strategic Clinical Network Palliative 
Care Guidelines in Dementia 2018) cautions continued prescribing of medication 
such as antipsychotics. However, as with the views of participants in this research, 
many physicians are reluctant to discontinue antipsychotics in people with 
dementia (Parsons et al 2014). 
Pharmacists in this focus group study also cited uncertainty about what guidelines 
recommended with regards to continued prescribing of acetylcholinesterase 
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inhibitors in people with dementia as the disease advances, and were not sure if 
these drugs afforded any benefits to people with severe dementia. Their doubts are 
in line with research which shows that prescribers have little guidance on when to 
discontinue therapy with acetylcholinesterase inhibitors (Hermann and Gauthier 
2008, Renn et al 2018) even though adverse effects have been associated with 
discontinuation (Okazaki et al 2006, Shega et al 2009). Furthermore NICE 
guidelines caution against discontinuation simply based on level of cognitive 
decline (NICE NG97). 
Another issue of interest discussed in this focus group study, which informed their 
suggestion for the toolkit improvement, was the variation of prescribing as a result 
of local guidelines or formularies, as well as prescribers diverging from national 
guidelines with regards to prescribing antipsychotics to people with dementia.  
Whilst it is true that local prescribing guidelines can lead to variation in 
prescribing practice (Duerden et al 2011), recent research has also shown that 
ethnicity and social status of the person with dementia affects physicians’ 
prescribing decisions (Fortinsky et al 2010, Jones et al 2020, Szchepura et al 2016). 
People from deprived areas or from black or Asian backgrounds were more likely 
to receive less symptomatic dementia medication treatment and more likely to be 
prescribed antipsychotics for longer. For example, studies in Norway and Denmark 
found that people from minority ethnic backgrounds were not being prescribed 
anti-dementia drugs on an equal basis as those from majority ethnic groups 
(Alzheimer Europe 2018). Similarly, inequalities were found in a UK study which 
found that people with dementia from black and ethnic minority backgrounds 
were more likely to be prescribed antipsychotics for longer than white people 
(Jones et al 2020). 
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Considerations about where the responsibility for prescribing lies were discussed. 
This is salient as it explains some of the inappropriate prescribing in people with 
dementia since responsibility for monitoring and medication review is sometimes 
disputable, with GPs firmly believing that this should lie with the specialist 
clinics/prescribers (Illife et al 2006, Russ et al 2013).  
Involving family and carers in decision making was also deemed important in this 
study; this is also in line with recommendations for managing medication for 
people with advanced dementia (NHS North West Coast Strategic Clinical Network 
2018, Parsons 2017), showing that some of the participants in the focus group 
were knowledgeable about the subject. 
Participants’ evaluation of the toolkit during the focus group study were overall 
very positive, with most pointing out that it will be useful as a reminder to them 
and other healthcare professionals involved with care of people with dementia, 
particularly those who live in care homes, of important person centred issues to 
consider when reviewing prescriptions for people with dementia. They did 
comment on how time consuming completing the tool would be and wanted to 
know how often this process would need to be done for each person with 
dementia.  With respect to useability of the toolkit and its versatility, similar tools 
have been judged useful by pharmacists for identifying inappropriate prescribing 
in people with dementia (Tommelien et al 2016, Hanlon et al 2013) even though 
the impact of these on health related quality of life of people with dementia is 
difficult to quantify (O’connor 2017, Alldred et al 2016, Al Aqqad et al 2014). 
The point made that the toolkit was time consuming to follow in practice is a view 
shared by other researchers that have developed medication processes (De Bock et 
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al 2018). In answer to participants’ queries about how often a process such as that 
advocated by this toolkit could be carried out, NICE Quality Standard (QS85 2015) 
for medicines management in care homes recommends a multidisciplinary 
medication review for each resident, and the frequency guided by the residents’ 
needs. NICE quality standard (QS85 2015) also recommends that the maximum 
interval between medication reviews should be one year. 
Additionally, it has been suggested that a full review starting with medication 
reconciliation is invaluable in transitions of care such as hospital discharge (De 
Bock et al 2018). 
The frustration expressed by participants in this study over communication 
challenges between healthcare practitioners in primary and secondary care in the 
UK is reflected in other research, linked to poor patient outcomes (Forondo et al 
2016) and also demonstrated in the earlier part of this research, as expressed by 
staff of care homes with people living with dementia in Chapter 5. The care home 
study showed that many providers and healthcare professionals were involved in 
care of people with dementia in care homes, and research has shown that when 
many providers are involved in the medication process, there is need for regular 
communication of information between healthcare professionals to enable 
periodic review and adjustments of medication (Mahlknecht et al 2019), but, like 
found in both the care home study (chapter 5) and current study, this 
communication doesn’t happen regularly, thus the increased risk of potentially 
inappropriate prescribing (Spinewine et al 2007). There have been calls for better 
inter-professional communication (Olsson et al 2010). 
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Participants seemed to believe that expansion of pharmacists roles into 
independent prescribing would help in this domain as they would be able to action 
some of their own recommendations following medication review in care home 
environments. This is echoed by Hughes and Lapane (2011) who proposed the 
implementation of interventions by prescribing pharmacists. Indeed, it has been 
suggested that the assumption of full responsibility for overall management of care 
home residents’ medicines and monitoring, as well as authorisation of repeat 
prescriptions based on individualised pharmaceutical care plans by pharmacist 
independent prescribers, could lead to improved patient outcomes, as well as 
improved communication of resident specific prescribing decisions to staff, 
residents and GPs (Inch et al 2019). 
The comments made by participants during discussions and written evaluation 
suggested similar improvements to the toolkit some of which have been actioned 
(Figure 22). Of note was the suggestion to add family/carer to the list of people to 
communicate a pharmaceutical care plan to, in addition to the suggestion to add 
specialist clinics. This was a useful suggestion as family/carers often need to be 
involved in decision making about the care of their relatives with dementia since 
they often cannot participate in decision making once dementia is advanced 
(Parsons and Gamble 2019). The suggestion to add diagnosis at the top of the 
toolkit process was also considered useful as research has found that a dementia 
diagnosis increases the likelihood of potentially inappropriate medication 
prescribing, which is of clinical importance as it may help determine whether 
interventions to improve prescribing should be implemented following 
establishment of a dementia diagnosis (Gnjidic et al 2018). 
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The feasibility study of the toolkit using two case vignettes revealed that even 
though the toolkit could be used to identify drug related problems when 
conducting medication reviews for people with dementia, participants did not use 
all aspects of the toolkit, nor identify all possible drug related problems written 
into the vignettes.  
For the first case study, participants identified most of the drug related problems, 
but failed to note the need for physical health monitoring. The neglect of physical 
health monitoring for people living with dementia has been noted in research, with 
Cooper et al (2017) reporting that this group of people receive fewer physical 
health checks. This is despite one of the participants in this group expressing 
concern in earlier discussions in the focus study about precisely this, and in spite 
of national dementia strategies pushing for prioritisation of healthcare access for 
people with dementia, particularly those in care homes (Alzheimer’s Society 
2016a, Cooper et al 2017).  
The second case study which was more straight-forward still saw group 2 
participants demonstrate uncertainty about tackling low mood in the person with 
dementia. This could have been solved by consulting the START tool attached as an 
appendix to the toolkit under study (O’Mahonney et al 2015) as many people with 
dementia experience depression and social withdrawal during the course of the 
disease (Sury et al 2013). 
Pharmaceutical care plans embedded in the toolkit were not completed by either 
groups of participants since they considered that they weren’t furnished with full 
information to do so. Inability to access patient’s clinical information has been 
quoted as a barrier to using screening tools to structure medication use reviews in 
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another study (Cardwell et al 2018), and in addition, when full medication or 
diagnostic information is unavailable it is difficult to apply every section of a 
medication appropriateness tool, as pointed out by Hukins et al (2019) in their 
systematic review of tools for identifying potentially inappropriate prescribing in 
older people living with dementia. 
Overall, participants in this study did not use every aspect of the toolkit to identify 
drug therapy problems, and expressed the view that the toolkit was more useful 
for ensuring they remembered important aspects of person centred dementia care 
to consider, as well as for more complex cases. Researchers who developed the 
Discontinuing Inappropriate Medication in Nursing Home Residents (DIM-NHR) 
(Wouters et al 2017) to examine successful discontinuation of inappropriate 
medication and improve medication prescribing in nursing homes, found that 
whilst the tool proved useful for this purpose, they were in agreement with Craig 
et al (2008) that medication reviews conducted in multiple steps should be 
considered complex healthcare interventions. The toolkit under review in the 
current focus group study could therefore fall in the category of complex 
healthcare intervention. Consideration of the toolkit in this study as a healthcare 
intervention would require that a robust systematic approach to its development 
is adopted following the UK Medical Research Council complex intervention 
framework, in order for it to be valid for use in improving clinical practice (Craig et 
al 2008). The useability of the toolkit would also need to be tested using a valid 





A group of pharmacists from diverse sectors of practice participated in a focus 
group study to evaluate the prototype DEMENTIAS resource toolkit developed by 
the researcher and reported that they found it useful for practice as a checklist to 
prompt correct identification of issues to address during medication review, as 
well as a good tool for reviewing medication for complex patients. They made 
several suggestions for improvement of the tool, and in a feasibility study designed 
to apply the toolkit to case studies involving prescribing for people living with 
dementia, found the toolkit partially useful for this purpose.  
Further robust experimental design will need to be carried out using a valid 
framework for testing complex interventions, in order to confirm its useability and 
applicability in wider practice, especially amongst community pharmacists 
delivering pharmaceutical services to care homes for people living with dementia, 
as the toolkit was designed mainly to target this group of pharmacists. 
7.6 STUDY STRENGTHS AND LIMITATIONS 
Whilst this study describes one of the few intervention toolkits designed 
specifically for reviewing medication for people with dementia, and had the 
advantage of being evaluated by pharmacists with knowledge of the subject, there 
are some limitations, mainly based on the study design: 
• Majority of pharmacists who participated had working experience with people 
who had dementia either through working in care homes or in hospital 
environments. This counted as a strength in that they were able to critically 
evaluate the tool effectively, but the disadvantage of this is that they could use 
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their own judgement to review case studies presented in the feasibility study, 
making the toolkit which was the focus of the study less relevant 
• As this was a focus group, those with more confidence in the subject under 
discussion tended to contribute more to discussions, meaning the views of the 
less confident were not well represented 
• The testing of the toolkit did not use validated scales testing feasibility or 
usability and relied on views and judgement of the participants, which could 
have been biased. 
• It is a very small study so the views of the participants are not generalizable. A 
larger study with more participants, testing the tool with a large sample of 
people with dementia prescribed medication and following a standardised 
framework for testing interventions is needed in order to test whether the 
toolkit can be utilised in practice 
• It is assumed that by following the processes described in the toolkit, 
practitioners will apply the correct principles of care to people with dementia 
based on their disease severity, however, its usability based on various stages 














































This final chapter addresses the overall aims and objectives of the body of research 
undertaken on pharmaceutical care in Dementia by summarising and discussing its 
findings. 
Dementia, a worldwide health care priority as determined by the World Health 
Organisation (WHO) is a major cause of disability and dependency in the world’s 
older adult population (WHO 2019).  
Medicines play a key role primarily in managing the symptoms of dementia 
(Donegan et al 2017) and are often used in combination with medication 
prescribed for other comorbid health conditions. Thus, medication management 
can be very complex for people living with dementia and their carers (Smith et al 
2017). Medication is the most common intervention received by care home 
residents (Hughes et al 2013), and consequently multiple morbidity is associated 
with polypharmacy, which is particularly problematic for people with dementia, as 
many drugs worsen cognition, impair mobility or diminish appetite leading to 
malnutrition (van Marum 2017). The quality of prescribing to the vulnerable care 
home population is recognised as being poor (Hughes and Goldie 2009).  
Community pharmacists are trusted healthcare professionals whose accessibility 
means they are often the first to be encountered by people with dementia in the 
community, and thus they have many opportunities to provide pharmaceutical 
care to these people (Barry et al 2013). They play a vital role through offering a 
broad spectrum of services (medication advice, drug therapy management and 
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monitoring) to patients and their caregivers (Duong et al 2017). However, the role 
of community pharmacists in the pharmaceutical care of people with dementia 
living in care homes has not been widely explored in research and community 
pharmacists have, in the past been reported to be only minimally involved with 
people with dementia with regards to their medicines (Taylor 2009).  
Following a quality review in 2014, the Care Quality Commission produced a 
report on the care of people living with dementia in the UK (Cracks in the Pathway 
CQC 2014). 90% of care homes inspected were found to provide poor care to 
residents with dementia, particularly in areas such as: 
• Assessing their care needs  
• monitoring care quality  
• collaboration between care providers 
• Involving residents and their families in decision making  
• Planning and  
• Delivery of care.  
This report did not mention the role community pharmacists or pharmacies could 
play in the dementia care pathway, but Webber (2015) in a review specially 
commissioned by the General Pharmaceutical Council, recommended that the level 
of need for pharmacist involvement be considered when developing and defining 
the pharmacy professional’s role in supporting people with dementia living in care 
homes. People living with dementia are frequently prescribed potentially 
inappropriate medicines. This has been adduced as being reflective of potentially 




The overall aim of this research was to conduct an in-depth exploration of the role 
community pharmacists play in the pharmaceutical care of people living with 
dementia in care homes, establish any impact, and to foster an understanding of 
any barriers they face in the fulfilment of this role. 
In order to achieve this aim, objectives related to: a qualitative and quantitative 
exploration of community pharmacist views and perceptions of the pharmaceutical 
care needs of people with dementia in care homes, a qualitative exploration of the 
medication-related needs of residents with dementia from the perspectives of care 
home staff. 
8.2 RESEARCH FINDINGS 
8.2.1 The pharmacists’ study 
Methodology 
This two phase study involved semi-structured interviews with a purposive 
sample of 15 community pharmacists in the first instance, to explore their 
awareness of the pharmaceutical care needs of people with dementia and seek 
their opinion about their knowledge and ability to provide services that meet these 
needs. The views expressed in this phase were used in a second phase to design a 
questionnaire survey that was administered to a random selection of community 
pharmacists across England. The central focus of both was establishing community 
pharmacists’ awareness of the pharmaceutical care needs of people living with 
dementia, the services provided to those in care homes, pharmacist knowledge and 
confidence in delivering these services and understanding the barriers they face.  
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A similar study had been previously carried out in Northern Ireland (Barry et al 
2013) in which a quantitative questionnaire survey was used to evaluate the views 
of community pharmacists about their knowledge of pain management in people 
living with dementia. The survey tools used in that study could have been adapted 
for use in the current study since it had similar objectives and the questionnaire 
had been developed through comprehensive literature searches and the use of 
validated tools such as the Approaches to Dementia Questionnaire (Lintern et al 
2000). Alternatively, Mat Nuri et al (2017) used validated items from the 
Alzheimer’s disease Knowledge Scale (Carpenter et al 2009) to evaluate knowledge 
of clinical pharmacists in Malaysia on Alzheimer’s disease, which could also have 
been a useful tool to adapt to the current study. 
However, though existing questionnaire instruments have track record of 
reliability and validity, modifying or adapting them to a different study can lead to 
weakening of that validity (Nichter et al 2002). A formative approach whereby 
qualitative research is used to inform survey development, similar to that used by 
Nichter et al 2002 was therefore applied, which helped to inform the researcher 
about the perspectives of a selected group of community pharmacists of the 
pharmaceutical care needs of people living with dementia in care homes. The 
results obtained and issues identified from evidence-based research on dementia 
care, informed the development of the questionnaire which was distributed to a 
random sample of community pharmacists across England.  
The drawback to this approach was that whilst the qualitative study of 
pharmacists involved purposive sampling of pharmacists who delivered services 
to care homes, the quantitative survey utilised a convenience sample.  Community 
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pharmacists (n=372) were contacted via the register of pharmacy premises on the 
General Pharmaceutical Society website without assumption of service provision 
to care homes.  
This resulted in just over 31% of 102 respondents (n=32) affirming that they 
delivered services to care homes, a very small sample making generalisations 
difficult. There is no data on the percentage of community pharmacies that are 
involved in delivering pharmaceutical services to care homes in England (Webber 
2015). However, the Royal Pharmaceutical Society Scotland (RPS Scotland 2012) 
reported that less than 20% of community pharmacies in Scotland were involved 
in delivering services to care homes, a figure lower than the 31% of respondents to 
the questionnaire survey in this research. Whilst the figure for Scotland cannot be 
extrapolated to determine an estimate for England, it is reasonable to expect that 
the percentage of community pharmacies delivering services to care homes in 
England would be higher than in Scotland since the percentage of pharmacists 
working in a community setting are higher in England (62%) than in Scotland 
(55%) (General Pharmaceutical Council 2019). 
 
Pharmaceutical Care Services Provision 
The results obtained from the qualitative arm of my research study were like those 
from the questionnaire survey of community pharmacists in terms of 
pharmaceutical care services provided the following services in varying degrees: 
• Medication supplies to care homes 
• Delivery services 
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• Compliance aid service (monitored dosage systems) and to a lesser, variable 
extent,  
• Care home staff training  
• Audits 
• Medication reviews and  
• Prescription interventions. 
 
Pharmaceutical Care Needs  
When questioned about the pharmaceutical care needs of people with dementia in 
care homes during face to face interviews, pharmacists stated that these involved 
checking prescriptions for drug interactions and ensuring medication was taken 
correctly and in a timely manner, whilst others expressed concerns about 
polypharmacy and inappropriate prescribing in this patient group, without 
specifying what they would do about it. 
These views are partially in line with documented pharmaceutical care needs of 
patients in general (Hepler 2010, Hudgens and Chirico 2010) which are 
reportedly:  
• Timely, accurate responses to signs and symptoms 
• Access to safe and cost-effective medication 
• Planned professional follow-up, and the  







A review of the appropriateness of drug therapy through medication review and 
the detection of drug therapy problems are considered integral aspects of the 
pharmaceutical care process. This requires adequate and up-to-date clinical 
knowledge by the healthcare professional undertaking the process. 
Pharmaceutical care issues relevant to people living with dementia include 
minimising cognitive side effects from prescribed medication, appropriate 
prescribing of memory enhancing drugs, and management of behavioural and 
psychological symptoms of dementia (Paton 2009). This would entail integration 
of services, in which a pharmacist has the responsibility for the whole system of 
medicines supply and their use within a care home, alongside a GP (RPS 2016), the 
promotion of rational prescribing of antipsychotics to people with dementia and 
playing an enhanced role in pain management for people with advanced dementia, 
as well as those at the end of life (Thrave 2016). 
However, in the current study, when it came to the specific knowledge about 
medication used to treat dementia, their adverse effects or related side effects, 
pharmacists interviewed appeared to display a preference for checking reference 
books or relying on computer software to ascertain the appropriateness of their 
answers. This finding was consistent with that of the questionnaire survey where 
respondents displayed similar immediate knowledge deficits about drug 
interactions and interventions to optimise medication use in people with 
dementia. However pharmacists in all phases of my research were knowledgeable 
about behavioural and psychological symptoms of dementia and the detrimental 
effects of prescribing antipsychotics for people with dementia in care homes.  
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The issue of professional knowledge cannot be overstated, considering that the 
Patients Association (2019) recently launched a care home charter which states 
that any professional working in a care home must have the requisite knowledge 
and skills to assess, monitor, and review medication to ensure that residents 
receive medication safely and appropriately via the right route (British Geriatrics 
Society 2019). Though the existence of computerised clinical decisions support 
systems go a long way towards assisting pharmacists in identifying drug therapy 
problems and highlighting requirements for patient counselling, some systems are 
poorly designed and generate inappropriate medication alerts or fail to work 
completely (Sutton et al 2020).  Pharmacists considering extending their roles to 
offering targeted pharmaceutical care to people with dementia would need to 
embark on appropriate continued professional development (CPD) to complement 
their knowledge in this field. 
Education and Training  
Education and training were also an area of consensus for both arms of the study 
as in both cases, only a small fraction of respondents had pursued any dementia 
training, with most participants agreeing that they would welcome more. It has 
been suggested that to meet the challenge of making a difference to medicines 
management in care homes, pharmacists require extra training in topics such as 
dementia, palliative care and end-of-life care (Oxtoby 2014).  
Remuneration for Extended Roles 
Remuneration is an aspect of service provision that needs to be tackled through 
commissioning bodies, who in turn need to ascertain that any proposed enhanced 
service/role demonstrates value for money. While community pharmacists are 
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being encouraged to take on more clinical roles in managing long term conditions 
(Hall et al 2018), variations in commissioning has seen people with dementia in 
some parts of the country benefit from their input, whilst others have not 
(Maidment et al 2017).  
Some participants in the qualitative study of pharmacists admitted that lack of 
remuneration hindered their willingness to deliver a pharmaceutical service 
beyond supply to care homes. 
However, the fact that other participants within the same study did go the extra 
mile demonstrates the point that there are variations in how residents in care 
homes benefit from pharmacist input across England, and a more standardised 
commissioning pathway could help in ensuring every care home resident gets the 
pharmaceutical care they need. 
 
8.2.2 The care home staff study 
This phase involved an exploration of the views of care home staff about the 
medication related needs of people with dementia in residential and nursing care 
home settings, as well as their opinions of the pharmaceutical services they 
received.  
Pharmacists’ Impact on Dementia Care 
The care home staff study gave an indication of the impact of community 
pharmacists on care of people with dementia in the care home setting, stating that 
they mainly supplied their medication, and in some cases conducted audits, liaised 
with GPs about supply issues, and gave advice regarding side effects of medication 
287 
 
or the right medicine formulations for residents with swallowing difficulties or 
those refusing medication.  
 
Multidisciplinary team working 
Helmsley (2018) described care homes as a ‘healthcare blackhole’ owing to the fact 
that they can be seen as low priority even amongst GPs, a view shared by the 
Alzheimer’s Society (2016) in their ‘Fix Dementia Care: NHS and Care Homes’ 
report.  
Curiously, this arm of the study showed that medication reviews were being 
conducted solely by GPs, geriatricians and nurses, as opposed to pharmacists; at 
the time of the research, these care homes did not have access to clinical 
pharmacists who provide specialist services to care homes.  
Pharmacy-led medicines optimisation services which can lead to reductions in 
emergency hospital admissions from care homes and savings on drug costs 
continue to be advocated (Helmsley 2018). However, this will require pharmacists 
working as an integral part of multidisciplinary teams (Miller et al 2015), an 
occurrence found to be lacking in the current study. This clearly indicates a gap 
that can be filled by community pharmacists trained to fulfil the role, considering 
the British Medical Association called for GPs not to overstretch themselves when 
working with care homes (Chaplin 2016, Helmsley 2018). Furthermore, care home 
staff interviewed stated that they would welcome more input from pharmacists 
and advocated better communication between pharmacists and GPs.  
It is estimated that the care home population will grow by 15% by 2020/2021 
(Crawford, Read and Sim 2016) and in a report highlighting the need for 
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pharmacists to step up from performing a predominantly supply role in care 
homes, Chaplin (2016) describes expanding role of pharmacists in this sector, 
whilst pointing out that such a role will require pharmacists to be trained to 
deliver services essential for the wellbeing of care home residents, a majority of 
whom will suffer from dementia. 
In a cautionary note that acknowledges the suboptimal nature of medicines 
management in care homes in the UK, Wright (2016) asserted that an effective 
model proven to improve pharmaceutical care in care homes has not been 
identified; while the cost effectiveness of community pharmacist involvement 
remained unknown, the author conceded that they could improve the quality of 
prescribing and reduce future utilisation of NHS resources. The same report 
advocated that interventions with different elements be tested robustly for 
feasibility, to avoid implementation of services based on non-generalisable 
evidence. The utilisation of community pharmacists in an expanded role delivering 
comprehensive pharmaceutical care to people with dementia in care homes will 
therefore be a service that needs robust testing across the UK. 
Development of a pharmaceutical care prototype toolkit 
Given the partial knowledge and confidence of community pharmacists in regard 
to dementia care discovered in the pharmacist arms of this research, and their 
restricted level of involvement in care home medication reviews (care home staff 
study), a dementia intervention toolkit that would assist pharmacists who wish to 
conduct systematic, structured medication reviews for people living with dementia 
was considered useful. A prototype toolkit was therefore developed. It aimed to 
provide pharmacists with a systematic, stepped care approach to conducting 
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medication reviews, as part of pharmaceutical care provision for people with 
dementia. Though this was subsequently tested in a focus group of clinical 
pharmacists who mostly worked in care homes exclusively or worked in both 
community and secondary care sectors, the toolkit provides references directing a 
user less familiar with the subject area to useful resources to aid the process.  
8.2.3 DEMENTIAS Intervention Toolkit  
Several studies investigating inappropriate medication use in people with 
dementia, across disease severity, various settings and around the world have 
demonstrated high prevalence of polypharmacy and potentially inappropriate 
prescribing. These include: Colloca et al (2012) across Europe, Holmes et al (2008) 
in the USA, Parsons et al (2012) in the UK, Cross et al (2016) in Australia and 
Truter (2013) in South Africa. 
Parsons et al (2012) noted that inappropriate medication use was more prevalent 
in people with dementia living in care homes, and in a recent, comprehensive 
review of the topic (Parsons 2017) highlighted the necessity for the design of the 
development, testing and validation of tools to assess medication appropriateness 
specifically for people with dementia. 
Tommelien et al (2016) also highlighted the unique opportunities for community 
pharmacists, whilst dispensing and supplying prescriptions, to conduct periodic 
screening for potentially inappropriate prescribing of prescription only or over the 
counter (OTC) medication, and argued that such a process required an evidence 
based tool. 
Future models of care will include the necessity for pharmacists to carry out 
structured medication reviews in various settings of practice (Primary Care 
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Pharmacy Association 2019, NHS England GP Contract 2019,) with the likelihood 
of community pharmacists being drafted to into primary care networks to work 
alongside other healthcare professionals, following appropriate training. 
It is anticipated that the toolkit developed in the concluding part of this research 
study will be a useful inclusion to any training package for pharmacists delivering 
cross sector pharmaceutical care; providing appropriate pharmaceutical services 
to people living with dementia will be inevitable given its growing prevalence.  
 
8.3 Strengths and limitations of my research 
Strengths 
1. Pharmaceutical Care Needs 
a. To the best of the researcher’s knowledge, this is the first study in the UK that 
has explored the views of community pharmacists and established their 
awareness about the pharmaceutical care needs of people living with dementia 
in care homes in England.  
b. It has sought to understand and highlight the intersectionality of views of 
pharmacists and those of care home staff working in these establishments and 
make recommendations to optimise the current provision.  
c. The qualitative studies of community pharmacists and care home staff 
highlighted the challenges each group of healthcare professionals faced when 
contributing to care of people with dementia in care homes.  
d. A toolkit to support pharmacists wishing to conduct medication reviews to 
people with dementia was developed and piloted. 
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e. The study also triangulated data through the perspectives of two sets of 
healthcare professionals involved in the care of people living with dementia in 
care homes (community pharmacists and care home staff) based in different 
locations, achieving data saturation in both studies.  
2. Structural equation modelling  
a. Additionally, the use of structural equation modelling using PLS to find 
correlations between knowledge, confidence and barriers to care delivery 
amongst community pharmacists could be replicated in other areas of 
pharmaceutical care practice. 
b.  This could inform development of content for continuing education and 
training of pharmacists. 
Limitations 
There were several limitations to this study: 
a. Generalisability: The findings of the study have limited generalisability to the 
wider population of community pharmacists or care home staff because all 
arms of the study involved small numbers of participants and the sample frame 
was England only. 
b. Patient/Carer’s Voice: The views of people living with dementia in care homes 
or their family representative were not explored in this study. Thus their 
pharmaceutical care needs from their own/family’s perspectives were not 
investigated, which could have triangulated the findings. However, people with 
dementia in care homes are often suffering from more advanced forms of the 
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disease, with levels of cognitive decline that would have made carrying out this 
sort of investigation difficult and potentially unethical. 
c. DEMENTIAS Toolkit: The development and testing of the toolkit involved 
clinical pharmacists with experience of working in secondary care or care 
homes. Its applicability from the perspective of community pharmacists 
involved in supplying medication to care homes was not tested and is therefore 
not known. 
d. MRC Framework: The development and testing of the toolkit did not follow the 
MRC framework for developing complex interventions (Craig et al 2008). This 
was beyond the scope of my research. It is suggested that a future feasibility 
study would employ a collaborative approach between suitably trained teams 
of community pharmacists, care home GPs and care home staff/managers. It 
could also involve people with dementia in care homes still able to participate 
fully in decision making about their medication needs or their family 
member(s). 
 
8.4 Implications for Pharmacy Practice 
The Framework for Enhanced Health for Care Homes (2016) suggests the 
involvement of pharmacists in medication reviews in care homes, with specific 
reference to people living with dementia in these establishments. It also 
recommends collaboration between clinical commissioning groups, local 
authorities and care homes for the development of care home service 
specifications and outcomes.  
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Many studies have explored the role of community pharmacists in medication 
management for older people (Holland et al 2007, Tommelein et al 2015, Chau et al 
2016). Additionally, there is a vast amount of research exploring roles of specialist 
clinical pharmacists in carrying out clinical interventions to optimise prescribing 
for older people in care homes (Alldred et al 2016, Wouters et al 2017). There is 
limited research on roles of community pharmacists in medication management 
for people living with dementia in the community (Maidment et al 2016, Maidment 
et al 2017, McGrattan et al 2017). However, there is very little published research 
in the roles community pharmacists play in delivering pharmaceutical care to 
people with dementia in care homes, which is something my research sought to 
address. 
The changing landscape of policies in this field is exemplified by the community 
pharmacy contractual framework (NHS England 2019) which requires all 
community pharmacy patient-facing staff to become dementia friends, but the 
medicines optimisation in care homes scheme (NHS England 2018) which placed 
specialist clinical pharmacists in care homes, is ending. This is due to the re-
engineering of care home pharmacists roles under the newly created primary care 
networks, and plans for dedicated enhanced services such as structured 
medication reviews which are still to unfold (Farmer 2019). 
There remains a paucity of research exploring the roles of community pharmacists 
delivering care to people living with dementia in care homes. This research is 
timely in that it highlights the barriers that need to be overcome if community 
pharmacists are to be utilised in extended roles in care homes that have residents 
living with dementia.  
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My research successfully defines barriers (inadequate remuneration, limited 
clinical knowledge, time constraints, lack of access to patient care records) and 
facilitators (payment for medication review services, education and 
training)experienced by community pharmacists delivering pharmaceutical care 
services to people living with dementia in care homes.  
Finally, it is the researcher’s belief that given the barriers to undertaking further 
dementia related education and training which were highlighted by pharmacists 
participating in this study, considerations should be given to inclusion of  
undergraduate pharmacy students in projects to enhance healthcare education in 
dementia such as the “Time for Dementia” programme (Banerjee et al 2016, 
Alzheimer’s Society 2019b), which is designed to create healthcare professionals 
who have a raised awareness and understanding of dementia.  
Dissemination of my research through publications and conference abstracts in 
presented in Appendix 1 and 2 of this thesis. 
8.5 Recommendations for future research 
Whilst the capability of community pharmacists to deliver clinical services has 
been widely recognised by professional bodies, and supported by UK government 
policy changes, more research needs to be done to establish the cost benefit of an 
extension of their clinical roles to people with dementia in care homes. 
Further research on how community pharmacists could deliver patient-centred 
care to people with dementia through a comprehensive pharmaceutical care 
service delivered to care homes (particularly those without specialist pharmacists 
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in dedicated roles) still needs to be carried out. Positive outcomes anticipated 
would include: 
• Reduction in polypharmacy 
• Improved prescribing practice and  
• Reduction in use of potentially inappropriate medication 
Building in cost effectiveness and quality of health outcome measures into this 
research would ensure that the impact of such services could be easily evaluated.  
It should prove useful to policy makers and commissioners of community 
pharmacy services so that remuneration models can be appropriately evidence-
based incentivising pharmacists to update their clinical knowledge on dementia 
and expand their roles into becoming named pharmacists in care homes as 
proposed by the RPS (2016). 
The DEMENTIAS intervention tool developed and preliminarily tested amongst 
specialist pharmacists in the focus group arm of my research will need to be 
reviewed and further optimised in the context of the MRC framework for complex 
interventions. 
8.6 Conclusions 
Pharmacists interviewed and surveyed in my research acknowledged that the 
pharmaceutical care services to people with dementia in care homes provided by 
community pharmacists could be improved and shared their perceived barriers to 
improvement. The results were similar between the qualitative and quantitative 
arms. More research is required to identify the exact role fit for community 
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pharmacists within multidisciplinary teams in care homes alongside continued 
professional development.   
Care home staff showed good knowledge of the needs of people with dementia 
living in care homes. Whilst they expressed satisfaction with medication supply 
and medicines information services offered by community pharmacists, they 
revealed that overcoming challenges such as obtaining medicines out of hours and 
medicines reconciliation on admission to care homes would facilitate dementia 
care. They welcomed more involvement from pharmacists and better 
communication between pharmacists and GP practices working in care homes. 
While the medication review prototype toolkit was found useful by the focus group 
of pharmacists who completed reviews with the toolkit, it was reported as being 
time consuming to use; however a shortened version would be a great ‘aide-
memoire’ for both community pharmacists, care home pharmacists and other 
healthcare professionals wishing to review prescribing and promote rational use 
































Abdi, H. and Bera, M., 2014. Correspondence analysis. In: R. alhaji and J. Rokne, ed., 
Encylopedia of Social Network and Mining, 1st ed. [online] New York: Springer, 
p.275.  
Achterberg, W. P., Pieper, M. J., van Dalen-Kok, A. H., de Waal, M. W., Husebo, B. S., 
Lautenbacher, S., … Corbett, A. (2013). Pain management in patients with 
dementia. Clinical interventions in aging. 8, 1471–1482 
 
Age UK (2019) Types of care homes [online] available at 
https://www.ageuk.org.uk/information-advice/care/arranging-care/care-
homes/type-of-care-home/  [accessed 26/09/2029] 
 
Agüero-Torres,H., von Strauss,E.,Viitanen,M.,Winblad, B.  and Fratiglioni,L. (2001) 
Institutionalization in the elderly: The role of chronic diseases and dementia. 
Cross-sectional and longitudinal data from a population-based study, Journal of 
Clinical Epidemiology 54 (8), 795-801 
 
Al Aqqad, S., Tangiisuran, B., Chen, L., Shaffie, A. and Hassali, A., 2014. The use of 
potentially inappropriate medications and changes in quality of life among older 
nursing home residents. Clinical Interventions in Aging,9, 201-207 
Albers, Sönke (2010). PLS and success factor studies in marketing. Pp. 409-425 in 
Esposito, Vinzi V.; Chin, W. W.; Henseler, J.; & Wang, H., eds., Handbook of partial 
least squares: Concepts, methods, and applications. NY: Springer. Series: Springer 
Handbook of Computational Studies. 
 
Albrecht, J.S., Hanna, M., Randall, R.L., Kim, D., and Perfetto E.M. (2019). An 
algorithm to characterise a dementia population by disease subtype. Alzheimer’s 
Disease and Associated disorders 33(2), 118-123 
 
Alldred, D. P., Kennedy, M. C., Hughes, C., Chen, T. F., & Miller, P. (2016). 
Interventions to optimise prescribing for older people in care homes. The Cochrane 
database of systematic reviews, 2, CD009095. 
https://doi.org/10.1002/14651858.CD009095.pub3 
 
Alldred, D.P., Standage, C., Fletcher, O., Savage, I., Carpenter, J., Barber, N. et al 
(2011). The influence of formulation and medication delivery system on 
medication administration errors in care homes for older people, BMJ Quality and 
Safety 20(5), 397-401 
 
Allemann, S., van Mil, J., Botermann, L., Berger, K., Griese, N. and Hersberger, K.  
(2014). Pharmaceutical Care: the PCNE definition 2013. International Journal of 
Clinical Pharmacy, 36(3), 544-555. 
Alves, A.; Green, S.; James, D.H.(2019) Deprescribing of Medicines in Care Homes—




Alzforum (2019). Therapeutics: Aducanumab [online] available from 
https://www.alzforum.org/therapeutics/aducanumab  [accessed 28/10/19] 
 
Alzheimer’s Disease International. (2016). World Alzheimer Report. Improving 
healthcare for people living with dementia: Coverage, quality and costs now and in 
the future. London. [Online] available at 
https://www.alz.co.uk/research/WorldAlzheimerReport2016.pdf [accessed  
30/10/2017] 
 
Alzheimer’s research UK (2018). Numbers of people in the UK, Dementia Statistics 




Alzheimer Scotland (2011) Risk factors in dementia. Edingburgh. Available at: 
http://www.alzscot.org/downloads/IS40%20risk%20factors%20in%20dementia.
pdf. [Accessed 21/02/2013] 
 
Alzheimer’s Society. (2013). Low expectations: Attitudes on choice, care and 
community for people with dementia in care homes. Executive Summary. London, 
UK: Alzheimer’s Society.  
 
Alzheimer's Society (2014): Dementia 2014: Opportunity for change [online] 
available at: 
https://www.alzheimers.org.uk/sites/default/files/migrate/downloads/dementia
_2014_opportunity_for_change.pdf [accessed 17/10/19] 
 
Alzheimer’s society (2016a). Fix Dementia Care –NHS and Care Homes [online] 
available at 
https://www.alzheimers.org.uk/sites/default/files/migrate/downloads/fix_deme
ntia_care_nhs_and_care_homes_report.pdf [accessed 16/09/19] 
 
Alzheimer’s Society (2016b). Alzheimer's Society's view on demography [online] 
available at 
https://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=4
12 [accessed 11/04/2016] 
 
Alzheimer’s Society (2017) Effects of Alzheimer’s disease drugs [online] available 
at https://www.alzheimers.org.uk/about-dementia/treatments/drugs/effects-of-
alzheimers-drugs#content-start  [accessed 17/03/2017] 
 
Alzheimer’s research UK (2018). Numbers of people in the UK, Dementia Statistics 
Hub, available at  https://www.dementiastatistics.org/statistics/numbers-of-




Alzheimer’s Society (2019a). Refusing to take medication [online] available at: 
https://www.alzheimers.org.uk/get-support/daily-living/refusing-to-take-
medication  [accessed 31/12/2019] 
 




Alzheimer's Society (2019c). How Many People Have Dementia And What Is The 
Cost Of Dementia Care? [online]  Available at:  
https://www.alzheimers.org.uk/about-us/policy-and-influencing/dementia-scale-
impact-numbers [Accessed 20 March 2020]. 
 
Alzheimer's Association, 2017. 2017 Alzheimer's disease facts and figures. 
Alzheimer's & Dementia, 13(4), pp.325-373. 
Alzheimer's Disease International and WHO, 2017. Annual Report 2016-17. [online] 
Available at: https://www.alz.co.uk/adi/pdf/annual-report-2017.pdf [Accessed 16 
August 2019]. 
 
Alzheimer's Disease International. World Alzheimer's Report. London.: Alzheimer's 
Disease International.; 2015. 
 
Alzheimer's Research UK, 2017. Global Prevalence | Dementia Statistics Hub. 
[online] Dementia Statistics Hub. Available at: 
https://www.dementiastatistics.org/statistics/global-prevalence/ [Accessed 15 
May 2019]. 
 
Ameen, S. (2004) 'Dementia', in Organic Mental Health Disorders [Online] Available 
at: http://www.psyplexus.com/neuropsychiatry/dementia.htm. [accessed 
06/10/2014] 
 
American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015). 
American Geriatrics Society 2015 Updated Beers Criteria for Potentially 
Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics 
Society, 63(11), 2227–2246. https://doi.org/10.1111/jgs.13702 
 
American Geriatrics Society, 2019. American Geriatrics Society 2019 Updated AGS 
Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. 
Journal of the American Geriatrics Society, 67(4), pp.674-694. 
 
American Psychiatric Association (2013) Diagnostic and Statistical Manual of 
Mental Disorders, Fifth Edition (DSM-5®). Washington DC: American Psychiatric 
Association. 
 
American Psychiatric Association. Diagnostic and Statistical Manual of Mental 




Andalo, D. (2014). Pharmacists offer a clinical service to vulnerable care home 
residents. The Pharmaceutical Journal, 292, 313–314. Retrieved from 
http://dx.doi.org/10.1211/pj.2014.11135788 
 
Andalo, D. (2019) Medicines optimisation in care homes scheme to end in March 
2020. The Pharmaceutical Journal online | DOI: 10.1211/PJ.2019.20206389  
 
Andersen, R. and Aday, L., 1978. Access to Medical Care in the U.S.: Realized and 
Potential. Medical Care, 16(7), 533-546. 
Apampa, B., & Navti, B. (2014). Medicines optimization in the dementias. Nurse 
Prescribing, 12(11), 557-563 
 
Aparasu, R. (2011) Research Methods for Pharmaceutical Practice and Policy. 
Gurnee IL: Pharmaceutical Press; 2011. p192 (paperback) ISBN 9780853698807 
 
APhA Pharmaceutical Care Guidelines Advisory Committee (1995) Principles of 
practice for pharmaceutical care [online] available at 
https://www.pharmacist.com/principles-practice-pharmaceutical-care  [accessed 
17/02/2020] 
 
Arlt, S., Lindner, R., Rösler, A., & von Renteln-Kruse, W. (2008). Adherence to 
medication in patients with dementia: predictors and strategies for 
improvement. Drugs & aging, 25(12), 1033–1047. 
https://doi.org/10.2165/0002512-200825120-00005 
 
Armstrong, M. J., & Weintraub, D. (2016). The Case for Antipsychotics in Dementia 
with Lewy Bodies. Movement disorders clinical practice, 4(1), 32–35.  
 
Assal, F (2019) History of Dementia. Frontiers of Neurology and Neuroscience, 
44:118-126. 
 
American Psychiatric Association (1987): Diagnostic and statistical manual of 
mental disorders, 3rd ed. rev.: DSM-III-R. Washington D C: American Psychiatric 
Association. 
 
Awaisu A and Mottram D. (2018) Chapter 6- How Pharmacy Education Contributes 
to Patient and Pharmaceutical Care, in: Pharmacy Education in the Twenty First 
Century and Beyond-Global Achievements and Challenges, Editors: Ahmed Ibrahim 
Fathelrahman, Mohamed Izham Mohamed Ibrahim, Alian A. Alrasheedy Albert I. 
Wertheimer. Elsevier, 2018, pp61-77 
 
Aziz, V., Hill, N. and Kumar, S. (2018). Completed audit cycle to explore the use of 
the STOPP/START toolkit to optimise medication in psychiatric in-patients with 




BABAR, Z.2015) Pharmacy Practice Research Methods. 1st ed. [Place of publication 
not identified]: ADIS, pp.6-8, 109-114. 
Badger, F., Plumridge, G., Hewison, A., Shaw, K., Thomas, K. and Clifford, C., 2012. 
An evaluation of the impact of the Gold Standards Framework on collaboration in 
end-of-life care in nursing homes. A qualitative and quantitative evaluation. 
International Journal of Nursing Studies, 49(5), 586-595. 
Bala, S., Narayan, S. and Nishtala, P., 2018. Potentially inappropriate medications in 
community-dwelling older adults undertaken as a comprehensive geriatric risk 
assessment. European Journal of Clinical Pharmacology, 74(5), 645-653. 
Ballard, C. G. (2004) Definition and diagnosis of dementia with Lewy bodies 
Dementia and Geriatric Cognitive Disorders, 17, 15-24. 
 
Ballard, C., Corbett, A., Orrell, M., Williams, G., Moniz-Cook, E., Romeo, R., … Fossey, 
J. (2018). Impact of person-centred care training and person-centred activities on 
quality of life, agitation, and antipsychotic use in people with dementia living in 
nursing homes: A cluster-randomised controlled trial. PLoS medicine, 15(2), 
p.e1002500 
 
Ballard, C., Hanney, M., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., 
Gill, R., Juszczak, E., Yu, L. and Jacoby, R. (2009). The dementia antipsychotic 
withdrawal trial (DART-AD): long-term follow-up of a randomized placebo-
controlled trial. The Lancet Neurology, 8(2), 151-157. 
Banerjee S. (2009) The use of antipsychotic medication for people with dementia: A 
time for action. A report for the minister of state for care services. London: 
Department of Health; 2009 
 
Bangor, A., Kortum, P. and Miller, J. (2009) Determining What Individual SUS 
Scores Mean: Adding an Adjective Rating Scale. Journal of Usability Studies, 4, 114-
123. 
 
Barber, N., Alldred, D., Raynor, D., Dickinson, R., Garfield, S., Jesson, B., . . . 
Zermansky, A. G. (2009). Care homes’ use of medicines study: Prevalence, causes 
and potential harm of medication errors in care homes for older people. Quality 
and Safety in Health Care, 18(5), 341–346. Retrieved from 
http://dx.doi.org/10.1136/qshc.2009.034231 
 
Barber, S., Thakkar, K., Marvin, V., Franklin, B. and Bell, D. (2014). Evaluation of My 
Medication Passport: a patient-completed aide-memoire designed by patients, for 
patients, to help towards medicines optimisation. BMJ Open, 4(8), e005608-
e005608. 
 




Barrett, E. and Burns, A. (2014). Dementia Revealed: what primary care needs to 
know. Version 2, November 2014 [online] available at 
https://www.england.nhs.uk/wp-content/uploads/2014/09/dementia-revealed-
toolkit.pdf  [accessed 14/01/2020] 
 
Barry H.E., Parsons, C., Passmore, P, Hughes, C.M. (2012). An exploration of 
Nursing Managers’ Knowledge of and attitudes towards the management of pain in 
residents with dementia. International Journal of Geriatric Psychiatry 27:1258-
1266 
 
Barry, H., Cooper, J., Cristin, R. Passmore, A.P., Robinson, A.L., Molloy,G.J. et al 
(2016) Potentially inappropriate prescribing among people with dementia in 
primary care: a retrospective cross-sectional study using the Enhanced Prescribing 
Database. Journal of Alzheimer’s Disease 52 (4), 1503-1513 
Barry, H., Parsons, C., Passmore, A. and Hughes, C., (2013). Community pharmacists 
and people with dementia: a cross-sectional survey exploring experiences, 
attitudes, and knowledge of pain and its management. International Journal of 
Geriatric Psychiatry, 28(10), 1077-1085. 
Barry, H., Parsons, C., Peter Passmore, A. and Hughes, C. (2012). An exploration of 
nursing home managers' knowledge of and attitudes towards the management of 
pain in residents with dementia. International Journal of Geriatric Psychiatry, 
27(12),1258-1266. 
Batsch, N., Mittelman, M., & Alzheimer’s Disease International (2012). World 
Alzheimer’s Report2012: overcoming the stigma of dementia (p. 56). London: 




Bearman D. (2013) From little acorns-our communities need to be more dementia-
friendly. The Pharmaceutical Journal, 291, p122 | DOI: 10.1211/PJ.2013.11123665 
 
Berg-Weger, M., & Stewart, D. B. (2017). Non-Pharmacologic Interventions for 
Persons with Dementia. Missouri medicine, 114(2), 116–119. 
 
Berrios, G. (1989). Non-Cognitive Symptoms and the Diagnosis of Dementia. British 
Journal of Psychiatry, 154(S4),11-16. 
 
Bhattacharya, D. (2005) Indications for Multi Compartment Compliance Indications 
For Multi Compartment Compliance Aids (MCA) - Aids (MCA) - Also Known As 
Monitored Dosage Also Known As Monitored Dosage Systems (MDS) -Provision. 
[online] Available at: 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20ac
cess/Support/toolkit/indications-for-mds.pdf [Accessed 19/09/ 2019]. 
304 
 
BIODOSE, 2015. Biodose For Care Homes –[online] Biodose.co.uk. Available at: 
https://www.biodose.co.uk/biodose-for-care-homes/  [Accessed 29/10/ 2019]. 
Bishop, P. A., & Herron, R. L. (2015). Use and Misuse of the Likert Item Responses 
and Other Ordinal Measures. International journal of exercise science, 8(3), 297–
302. 
 
Blackburn R. and Bradshaw T (2014). Music therapy for service users with 
dementia: a critical review of the literature. Journal of psychiatric and mental 
health; 21 (10), 879-888 
 
Blagbourn, J. (2017). How pharmacy can provide patient-centred care for dementia 
patients. The Pharmaceutical Journal 299, 7905, online | DOI: 
10.1211/PJ.2017.20203385  
Blanco-Reina, E., Ariza-Zafra, G., Ocaña-Riola, R. and León-Ortiz, M. (2014).  2012 
American Geriatrics Society Beers Criteria: Enhanced Applicability for Detecting 
Potentially Inappropriate Medications in European Older Adults? A Comparison 
with the Screening Tool of Older Person's Potentially Inappropriate Prescriptions. 
Journal of the American Geriatrics Society, 62(7), 1217-1223. 
Blass, D., Black, B., Phillips, H., Finucane, T., Baker, A., Loreck, D. and Rabins, P., 
(2008). Medication use in nursing home residents with advanced dementia. 
International Journal of Geriatric Psychiatry, 23(5),490-496. 
Blennow, J., de Leon, M. J. and Zetterberg, H. (2006) Alzheimer's disease. Lancet, 
368, 387-403. 
 
Bogetti-Salazar, M., González-González, C., Juárez-Cedillo, T., Sánchez-García, S., & 
Rosas-Carrasco, O. (2016). Severe potential drug-drug interactions in older adults 
with dementia and associated factors. Clinics (Sao Paulo, Brazil), 71(1), 17–21. 
doi:10.6061/clinics/2016(01)04 
 
Bolaky D, Clark P, Ferrigan D, Patel R and Virdee D. (2010) Care home managers’ 
views of services provided by community pharmacies. The Pharmaceutical Journal; 
284, 139-140 
 
Boller, F. and Forbes, M., 1998. History of dementia and dementia in history: An 
overview. Journal of the Neurological Sciences, 158(2), pp.125-133. 
 
Boller, F., Bick, K. and Duyckaerts, C., (2007). They have Shaped Alzheimer Disease 
the Protagonists, Well Known and Less Well Known. Cortex, 43(4), 565-569. 
Bondesson, A., Holmdahl, L., Midlov, P., Hoglund, P., Andersson, E., &Eriksson, T. 
(2012). Acceptance and importance of clinical pharmacists’   LIMM-based   




Bowling A. (2005) Mode of questionnaire administration can have serious effects 
on data quality. Journal of Public Health, 27(3):281‐91. 
 
Bowling, A. (2009) Research Methods in Health. 3rd Edition edn. Maidenhead: The 
Open University Press. 
 
Bowling, A. (2014) Research methods in health: investigating health and health 
services. 4th edition, Maidenhead, GB. McGraw Hill; Open University Press. 
 
Boyle, T., Bishop, A., Morrison, B., Murphy, A., Barker, J., Ashcroft, D., Phipps, D., 
Mahaffey, T. and MacKinnon, N., (2016). Pharmacist work stress and learning from 
quality related events. Research in Social and Administrative Pharmacy, 12(5), 772-
783. 
Braun, V. and Clarke, V., (2006). Using thematic analysis in psychology. Qualitative 
Research in Psychology, 3(2), 77-101. 
Brechin, D., Murphy, G., James, I.A. and Codner, J. (2013). Briefing paper: 
Alternatives to antipsychotic medication: Psychological approaches in managing 
psychological and behavioural distress in people with dementia. Leicester: The 




th%20dementia%20%282013%29.pdf [accessed 20/01/2020] 
 
Breitner, J.(2006). Dementia—Epidemiological Considerations, Nomenclature, and 
a Tacit Consensus Definition. Journal of Geriatric Psychiatry and Neurology, 19(3), 
129-136. 
Brent CCG (2014) Medication Review Practice Guide [online] available at 
https://www.sps.nhs.uk/wp-content/uploads/2016/08/Brent-CCG-Medication-
Review-Practice-Guide-2014.pdf [accessed 31/10/2019] 
  
British Geriatrics Society (BGS) 2019: Patients association launches care homes 
charter [online] available at https://www.bgs.org.uk/policy-and-media/patients-
association-launches-care-home-charter  [accessed 11/02/2020] 
 
British Geriatric Society (BGS) (2012) Briefing Paper: Failing the Frail: – A Chaotic 
Approach to Commissioning Healthcare Services for Care Homes [online] available 
from 








British Medical Association (BMA) and Pharmaceutical Services Negotiating 
Committee (PSNC) (2019) The Community pharmacy: a guide for general 




Brodie, D. C., Parish, P. A., & Poston, J. W. (1980). Societal needs for drugs and drug-
related services. American journal of pharmaceutical education, 44(3), 276–278. 
 
Bronskill SE, Gill SS, Paterson JM, Bell CM, Anderson GM, Rochon PA (2012). 
Exploring variation in rates of polypharmacy across long term care homes, Journal 
of American Medical Directors Association 13(3), 309.e15-21 
 
Brooker, D., 2003. What is person-centred care in dementia? Reviews in Clinical 
Gerontology, 13(3), 215-222. 
 
Brooker, D., Latham, I., Evans, S., Jacobson, N., Perry, W., Bray, J., Ballard, C., Fossey, 
J. and Pickett, J. (2015). FITS into practice: translating research into practice in 
reducing the use of anti-psychotic medication for people with dementia living in 
care homes. Aging & Mental Health, 20(7), pp.709-718. 
Brown, J (2017). How can you encourage medicines optimisation to improve the 






Brownie S and Nancarrow S (2013). Effects of person-centred care on residents 
and staff in aged-care facilities: A systematic review. Clinical Interventions in Aging 
8, 1-10 
 
Brulhart, M. and Wermeille, J. (2011). Multidisciplinary medication review: 
evaluation of a pharmaceutical care model for nursing homes. International Journal 
of Clinical Pharmacy, 33(3), 549-557. 
Bruno, C., Ip, E., Shah, B. and Linn, W. (2012). A Mnemonic for Pharmacy Students 
to Use in Pharmacotherapy Assessment. American Journal of Pharmaceutical 
Education, 76(1), 16. 
Bryant, L., Coster, G., Gamble, G. and McCormick, R. (2009). General practitioners' 
and pharmacists' perceptions of the role of community pharmacists in delivering 
clinical services. Research in Social and Administrative Pharmacy, 5(4), 347-362. 
Burns, A (2014). ‘Dementia’ Blog: don’t let care home residents slip through the 
dementia net. 18 December [online] available at 




Burns, A. and Iliffe, S., (2009). Alzheimer's disease. BMJ, 33, b158-b158. 
Burns, A. and Nair, S (2014) New horizons in care home medicine, Age and 
Ageing;43 (1), 2–7, https://doi.org/10.1093/ageing/aft186 
 
Busse, A., Angermeyer, M. C. and Riedel-Heller, S. G. (2006) 'Progression of mild 
cognitive impairment to dementia: a challenge to current thinking', The British 
Journal of Psychiatry, 189(5), 399-404. 
 
Butterworth, J., Sansom, A., Sims, L., Healey, M., Kingsland, E. and Campbell, J., 
(2017). Pharmacists’ perceptions of their emerging general practice roles in UK 
primary care: a qualitative interview study. British Journal of General Practice, 
67(662), e650-e658. 
Cahir, C., Fahey, T., Teeling, M., Teljeur, C., Feely, J. and Bennett, K. (2010). 
Potentially inappropriate prescribing and cost outcomes for older people: a 
national population study. British Journal of Clinical Pharmacology, 69(5),543-552. 
Calnan, M. (2007) “Quantitative Survey Methods in Health Research” in Saks, K. & 
Alsop, J. (Eds) Researching Health: Qualitative, Quantitative and Mixed Methods 
Sage: 174-196 
 
Cardwell, K., Hughes, C. M., & Ryan, C. (2018). Community pharmacists' views of 
using a screening tool to structure medicines use reviews for older people: findings 
from qualitative interviews. International journal of clinical pharmacy, 40(5), 
1086–1095. https://doi.org/10.1007/s11096-018-0659-z  
 
Care Homes & Residential Homes UK – Care Home & Residential Home UK Guide. 
(2015). [online] available at  http://www.carehome.co.uk/care_search.cfm  
[accessed 15/10/2015] 
Care Quality Commission (CQC)(2019a). Treating minor ailments and promoting 
self-care in adult social care [online] available at 
https://www.cqc.org.uk/guidance-providers/adult-social-care/treating-minor-
ailments-promoting-self-care-adult-social-care  [accessed 08/01/2020] 
 
Care Quality Commission (CQC) (2019b). Using multi-compartment compliance 
aids (MCAs) in care homes [online], available at 
https://www.cqc.org.uk/guidance-providers/adult-social-care/using-multi-
compartment-compliance-aids-mcas-care-homes [accessed 27/12/2019] 
 
Care Quality Commission (CQC). (2014). Cracks in the pathway. [online] Available 
at 
http://www.cqc.org.uk/sites/default/files/20141009_cracks_in_the_pathway_fina




Carpenter, B. D., Balsis, S., Otilingam, P. G., Hanson, P. K., & Gatz, M. (2009). The 
Alzheimer's Disease Knowledge Scale: development and psychometric properties. 
The Gerontologist, 49(2), 236–247. https://doi.org/10.1093/geront/gnp023 
 
Carter, R. (2015). Poor training of care home staff leaving residents at risk, 
investigation finds. Community Care [online] available at 
https://www.communitycare.co.uk/2015/10/28/training-deficit-among-care-
home-staff-leaving-residents-risk-investigation-finds/ [accessed 16/11/2016] 
 
Castellano J.M, Kim J, Stewart F.R, et al (2011) Human apoE isoforms differentially 
regulate brain amyloid-β peptide clearance. Science Translational 
Medicine,3:89ra57 
 
Centre for Policy and Ageing (CPA) (2011). Managing and administering 
medication in care homes for older people [online], available at 
http://www.cpa.org.uk/information/reviews/Managing_and_Administering_Medi
cation_in_Care_Homes.pdf [accessed 21/11/2019] 
 
Centre for Policy on Aging (CPA). (2012). Managing and administering medication 
in care homes for older people. [online] Available at 
http://www.cpa.org.uk/information/reviews/Managing_and_Administering_Medi
cation_in_Care_Homes.pd [accessed 03/03/2017] 
 
Cerejeira, J,, Largato, L. and Mukaetova-ladinska E.B. (2012). Behavioural and 
psychological symptoms of dementia. Frontiers in Neurology 3(73),1-21 
 
Chadborn, N. H., Goodman, C., Zubair, M., Sousa, L., Gladman, J., Dening, T., & 
Gordon, A. L. (2019). Role of comprehensive geriatric assessment in healthcare of 
older people in UK care homes: realist review. BMJ open, 9(4), e026921. 
doi:10.1136/bmjopen-2018-026921.  
 
Chang, F., Patel, T. and Schulz, M. (2015). The “Rising Tide” of dementia in Canada. 
Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, 148(4), 193-
199. 
 
Chau, S. H., Jansen, A. P., van de Ven, P. M., Hoogland, P., Elders, P. J., & Hugtenburg, 
J. G. (2016). Clinical medication reviews in elderly patients with polypharmacy: a 
cross-sectional study on drug-related problems in the Netherlands. International 
journal of clinical pharmacy, 38(1), 46–53. https://doi.org/10.1007/s11096-015-
0199-8 
 
Chaplin, S., (2015). The Expanding Role of Pharmacists In Care Homes. [online] 
London: Prescriber.co.uk, p.1. Available at: https://www.prescriber.co.uk/wp-
content/uploads/sites/23/2016/07/The-expanding-role-of-pharmacists-in-care-




Child, A., Clarke, A., Fox, C. and Maidment, I. (2012) A pharmacy led program to 
review anti-psychotic prescribing for people with dementia. BMC 
Psychiatry 12, 155. https://doi.org/10.1186/1471-244X-12-155  
 
Chiu M.J., Chen, T.F., Yip, P.K., Hua, M.S., and Tang, L.Y., (2006). Behavioural and 
psychological symptoms in different types of dementia. Journal of the Formosan 
Medical Association 105, 556-562 
Cho, Y., Johnson, T. and VanGeest, J., 2013. Enhancing Surveys of Health Care 
Professionals. Evaluation & the Health Professions, 36(3), 382-407. 
Chrisp, A. C., Thomas, D., Goddard, A. and Owens, A. (2012) 'Dementia timeline: 
Journeys, delays and decisions on the pathway to an early diagnosis' Dementia, 
10(4), 570. doi: 10.1177/1471301211409375 
 
Christensen, D., Trygstad, T., Sullivan, R., Garmise, J. and Wegner, S. (2004). A 
pharmacy management intervention for optimizing drug therapy for nursing home 
patients. The American Journal of Geriatric Pharmacotherapy, 2(4), 248-256. 
 
Cipolle R.J, Strand L.M, Morley P.C. Pharmaceutical care practice. New-York: 
McGraw-Hill Companies. Inc.; 1998. 
 
Cipolle R., Strand, L., Morley, P. Pharmaceutical Care Practice. The Clinician’s Guide. 
2nd Edition. McGraw-Hill Medical Publishing Division, New York. 2004 
 
Clague, F., Mercer, S., McLean, G., Reynish, E. and Guthrie, B. (2016). Comorbidity 
and polypharmacy in people with dementia: insights from a large, population-
based cross-sectional analysis of primary care data. Age and Ageing 46(1):33-39.   
Clare L, Woods RT, Moniz Cook ED, Orell M, Spector A. (2003). Cognitive 
rehabilitation and cognitive training for early-stage Alzheimer’s disease and 
vascular dementia. Cochrane database systematic review 4:CD003260 
 
Colloca, G., Tosato, M., Vetrano, D. L., Topinkova, E., Fialova, D., Gindin, J., van der 
Roest, H. G., Landi, F., Liperoti, R., Bernabei, R., Onder, G., & SHELTER project 
(2012). Inappropriate drugs in elderly patients with severe cognitive impairment: 
results from the shelter study. PloS one, 7(10), e46669. 
https://doi.org/10.1371/journal.pone.0046669 
 
Community Pharmacy Wales, (2016). Care Home Support and Medicines 
Optimisation: Community Pharmacy National Enhanced Service. [online] Available 
at: http://www.cpwales.org.uk/getattachment/Services-and-
commissioning/Enhanced-Services/Pharmacy-Care-Home-Support-NES/National-





Cooper, C., Lodwick, R., Walters, K., Raine, R., Manthorpe, J., Iliffe, S., & Petersen, I. 
(2017). Inequalities in receipt of mental and physical healthcare in people with 
dementia in the UK. Age and ageing, 46(3), 393–400. 
https://doi.org/10.1093/ageing/afw208 
 
Corbett, A., Nunez, K and Thomas, A. (2013). Coping with dementia in care homes. 
Maturitas, 76(1),3–4.  
 
Corbett, A., Smith, J, Creese, B., Ballard C. (2012) Treatment of behavioural and 
psychological symptoms of Alzheimer’s disease. Current Treatment Options in 
Neurology 14(2), 113-25       DOI 10.1007/s11940-012-0166-9 
 
Cousins, D. H., Gerrett, D., and Warner, B. (2012). A review of medication incidents 
reported to the National Reporting and Learning System in England and Wales 
over 6 years (2005-2010). British journal of clinical pharmacology, 74(4), 597–604. 
https://doi.org/10.1111/j.1365-2125.2011.04166.x 
Cousins, C., Burrows, R., Cousins, G., Dunlop, E. and Mitchell, G. (2016). An 
overview of the challenges facing care homes in the UK. Nursing Older People, 
28(9), 18-21. 
Craig, P., Dieppe, P., Macintyre, S., Michie, S., Nazareth, I. and Petticrew, M. (2008). 
Developing and evaluating complex interventions: the new Medical Research 
Council guidance. BMJ (Clinical research ed.), 337, a1655 
Crawford, E., Read, C. and Sim, D. (2016). Care After Cure: Creating A Fast Track 
Pathway from Hospitals to Homes. [online] London: ResPublica, p.4. Available at: 
https://www.respublica.org.uk/wp-content/uploads/2016/02/Care-After-Cure-
final.pdf  [Accessed 10 January 2020]. 
Creative Research Systems (2012). Sample Size Calculator - Confidence Level, 
Confidence Interval, Sample Size, Population Size, Relevant Population - Creative 
Research Systems. [online] Available at: 
https://www.surveysystem.com/sscalc.htm [Accessed 21 February 2016]. 
Creswell, J. and Plano Clark, V. (2017). Designing and Conducting Mixed Methods 
Research. 3rd ed. Sage Publishing. 
Criddle, D. (2014). The role of pharmacists in the early detection of dementia. 
Australian Pharmacist 33, 38–41. 
 
Cronfalk, B.S., Ternestedt B, and Norberg A. (2017). Being a close family member of 






Cross, A. J., George, J., Woodward, M. C., Ames, D., Brodaty, H., Ilomäki, J., & Elliott, 
R. A. (2016). Potentially Inappropriate Medications and Anticholinergic Burden in 
Older People Attending Memory Clinics in Australia. Drugs & aging, 33(1), 37–44. 
https://doi.org/10.1007/s40266-015-0332-3 
 
Curtin, D., Gallagher, P.F, and O’Mahoney, D. (2019) Explicit criteria as clinical tools 
to minimize inappropriate medication use and its consequences. Therapeutic 
Advances in Drug Safety, 10: p1-10 DOI:10.1177/2042098619829431 
 
Danysz W, Parsons CG (1998). Glycine and N-methyl-D-aspartate receptors: 
physiological significance and possible therapeutic applications. Pharmacological 
Reviews, 50:597. 
 
De Bock, L., Tommelein, E., Baekelandt, H., Maes, W., Boussery, K. and Somers, A., 
2018. The Introduction of a Full Medication Review Process in a Local Hospital: 
Successes and Barriers of a Pilot Project in the Geriatric Ward. Pharmacy, 6(1), 21. 
de Oliveira, A. M., Radanovic, M., de Mello, P. C., Buchain, P. C., Vizzotto, A. D., 
Celestino, D. L., Stella, F., Piersol, C. V., & Forlenza, O. V. (2015). 
Nonpharmacological Interventions to Reduce Behavioral and Psychological 
Symptoms of Dementia: A Systematic Review. BioMed research international, 
218980. https://doi.org/10.1155/2015/218980 
 
De Vries T.P., Henning, R.H., Hogerzeil H.V., Fresle, D.A. (1994) Guide to good 
prescribing. WHO. Geneva 
 
De Witt, J. B., Parsons, C., and Huges, C. (2013) Administering medications to 
nursing home residents with dementia: A qualitative study. International Journal of 
Pharmacy Practice, 21: 43-44, 0961-7671 
 
DeKosky, S. T. (2001) 'Epidemiology and Pathophysiology of Alzheimer's Disease', 
Clincial Cornerstone, 3(4), 15-26. 
 
Delgado, J., Bowman, K. and Clare, L. (2020). Potentially inappropriate prescribing 
in dementia: a state-of-the-art review since 2007. BMJ Open, 10(1), p.e029172. 
Dementia Australia (2012). Diagnostic criteria for dementia [online] available from 
https://www.dementia.org.au/files/helpsheets/Helpsheet-DementiaQandA11-
DiagnosticCriteriaForDementia_english.pdf  [accessed 18/10/19] 
 
Dementia Australia (2018). Diagnostic Criteria for Dementia. [online] 
Dementia.org.au. Available at: 
https://www.dementia.org.au/files/helpsheets/Helpsheet-DementiaQandA11-
DiagnosticCriteriaForDementia_english.pdf  [Accessed 17 May 2019]. 
Dementia fact sheet December (2017) World Health Organisation [available from 
dementia statistics hub: https://www.dementiastatistics.org/statistics/global-




Dementia Overview (2019). NICE Pathway (online) available at   
http://pathways.nice.org.uk/pathways/dementia  [accessed 01/07/2019] 
 
Dementia statistics hub (2018): Diagnoses in the UK [online] available from 
https://www.dementiastatistics.org/statistics/diagnoses-in-the-uk/  (updated 
17/10/2018) [accessed 18/10/2019] 
 
Department of Health (2013) Dementia diagnosis to be overhauled [online] 
available from https://www.gov.uk/government/news/dementia-diagnosis-to-be-
overhauled   [accessed 18/10/2019] 
 
Department of Health (DOH) (2003) Care Homes for Older People-National 
Minimum Standards [online] available at 
https://webarchive.nationalarchives.gov.uk/20130124064446/http://www.dh.go
v.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasse
t/dh_4135403.pdf  [accessed 09/03/2020] 
 
Department of Health (DOH) (2008). Pharmacy in England: Building on strengths-
Delivering the Future. London: Department of Health. 
 
Department of Health (DOH) (2009) Living well with dementia: A national dementia 
strategy. London: HMSO. 
 
Department of Health (DOH) (2019). The Community Pharmacy Contractual 
Framework for 2019/20 to 2023/24: supporting delivery for the NHS Long Term 
Plan [online] available from: 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/at
tachment_data/file/819601/cpcf-2019-to-2024.pdf  [accessed 24/10/2019] 
 
Department of Health (DOH), 2016. Community Pharmacy In 2016/17 And Beyond: 
The Final Package. London: Department of Health and Social Care, pp.17-18. 
 
Department of Health (DOH). (2003). A vision for pharmacy in the new NHS. 
London: Department of Health 
 
Department of Health (DOH). (2014). Dementia Revealed: What Primary Care 
Needs to Know. London: Department of Health, available at: 
https://dementiapartnerships.com/wp-content/ uploads/sites/2/dementia-
revealed-toolkit.pdf  [accessed 27/11/2017] 
 
Desborough, J., Houghton, J., Wood, J., Wright, D., Holland, R., Sach, T., Ashwell, S. 
and Shaw, V., (2011). Multi-professional clinical medication reviews in care homes 
for the elderly: study protocol for a randomised controlled trial with cost 
effectiveness analysis. Trials, 12:218 
313 
 
Disalvo, D., Luckett, T., Bennett, A., Davidson, P. and Agar, M., (2019). Pharmacists’ 
perspectives on medication reviews for long-term care residents with advanced 
dementia: a qualitative study. International Journal of Clinical Pharmacy, 41(4), 
950-962. 
Donegan, K., Fox, N., Black, N., Livingston, G., Banerjee, S. and Burns, A. (2017). 
Trends in diagnosis and treatment for people with dementia in the UK from 2005 
to 2015: a longitudinal retrospective cohort study. The Lancet Public Health, 2(3), 
e149-e156. 
Drenth-van Maanen, A., Leendertse, A., Jansen, P., Knol, W., Keijsers, C., Meulendijk, 
M. and van Marum, R. (2017). The Systematic Tool to Reduce Inappropriate 
Prescribing (STRIP): Combining implicit and explicit prescribing tools to improve 
appropriate prescribing. Journal of Evaluation in Clinical Practice, 24(2), pp.317-
322. 
 
Dreux, C., (2009). La maladie d’Alzheimer et les pharmaciens en contact avec le 
public. Annales Pharmaceutiques Françaises, 67(2), 104-115. 
 
Driscoll, David & Appiah-Yeboah, Afua & Salib, Philip & Rupert, Doug. (2007). 
Merging Qualitative and Quantitative Data in Mixed Methods Research: How To 
and Why Not. Ecological and Environmental Anthropology. 3(1), 18-28 
 
Droege, M. (2003) The Role of Reflective Practice in Pharmacy. Education for 
Health: Change in Learning & Practice, 16(1), pp.68-74. 
Duerden M, Millson D, Avery A, Smart S: The quality of GP prescribing: an inquiry 
into the quality of general practice prescribing in England. (2011), London: The 
King's Fund 
 
Dufournet, M., Dauphinot, V., Moutet, C., Verdurand, M., Delphin-Combe, F., Krolak-
Salmon, P., Krolak-Salmon, P., Dauphinot, V., Delphin-Combe, F., Makaroff, Z., 
Federico, D., Coste, M., Rouch, I., Dorey, J., Lepetit, A., Danaila, K., Vernaudon, J., 
Bathsavanis, A., Sarciron, A., Guilhermet, Y., Gaujard, S., Grosmaître, P., Moutet, C. 
and Verdurand, M., (2019). Impact of Cognitive, Functional, Behavioral Disorders, 
and Caregiver Burden on the Risk of Nursing Home Placement. Journal of the 
American Medical Directors Association, 20(10), 1254-1262. 
Duong, S., Patel, T. and Chang, F. (2017). Dementia. Canadian Pharmacists Journal / 
Revue des Pharmaciens du Canada, 150(2), 118-129. 
Eades, C., Ferguson, J. and O'Carroll, R. (2011). Public health in community 
pharmacy: A systematic review of pharmacist and consumer views. BMC Public 
Health, 11(1). 
Efjestad, A., Molden, E. and Øksengård, A. (2013). Pharmacist-Initiated 
Management of Antagonistic Interactions between Anticholinergic Drugs and 
Acetyl cholinesterase Inhibitors in Individuals with Dementia. Journal of the 
American Geriatrics Society, 61(9), 1624-1625. 
314 
 
Elliot, R (2018). Cognitive screening during pharmacist medication reviews (letter 
to the editor). Journal of Pharmacy Practice and Research, 48 (1) p102 
Eshetie, T., Nguyen, T., Gillam, M. and Kalisch Ellett, L. (2019). Potentially 
inappropriate prescribing before and after initiation of medicines for dementia: An 
Australian population‐based study. Geriatrics & Gerontology International, 
19: 654– 659. https://doi.org/10.1111/ggi.13686 
European Foundations’ Initiative on Dementia (EFID), 2016. Dementia-Friendly 
Communities Case Studies Across Europe. [online] London: EFID, pp.14,26,54-55. 
Available at: http://www.efid.info/wp-content/uploads/2016/06/Collection-of-
DFC-case-studies-across-Europe.pdf  [Accessed 16 March 2020]. 
Farmer D (2019) NHS Improvement and NHS England: HJ Medicines Optimisation 
and the LongTerm Plan (LTP) [online] available at: https://www.sps.nhs.uk/wp-
content/uploads/2019/06/HJ_Medicines_Optimisation_and_the_Long_Term_Plan_
DF_Sept_2019.pdf  [accessed 02/02/2020] 
 
Fiegenson, J., 1978. Letters to the Editor. Stroke, 9(5), pp.523-523. 
 
Ferri, C., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., 
Hasegawa, K., Hendrie, H., Huang, Y., Jorm, A., Mathers, C., Menezes, P., Rimmer, E. 
and Scazufca, M., (2005). Global prevalence of dementia: a Delphi consensus study. 
The Lancet, 366(9503), 2112-2117. 
Field A (2009) Discovering statistics using SPSS. 3rd Ed. London. Sage 
 




Finkel S. (2000) Introduction to behavioural and psychological symptoms of 
dementia (BPSD). International journal of geriatric psychiatry 15(S1): S2-S4. 
 
Finkel, S., Costa e Silva, J., Cohen, G., Miller, S. and Sartorius, N., (1997). Behavioral 
and Psychological Signs and Symptoms of Dementia: A Consensus Statement on 
Current Knowledge and Implications for Research and Treatment. International 
Psychogeriatrics, 8(S3) .497-500. 
 
 
Focht, A. (2009) Differential diagnosis of dementia. Geriatrics, 64(3), 20-6. 
 
Forbes D, Forbes, S.C, Blake, C.M, Thiessen. E.J, Forbes, S (2015). Exercise programs 
for people with dementia. Cochrane Database Systematic Reviews:CD006489. 
 
Foronda, C., MacWilliams, B. and McArthur, E (2016). Interprofessional 





Fortinsky, R.H., Zlateva, I., Delaney C., Kleppinger A. (2010) Primary Care 
Physicians’ Dementia Care Practices: Evidence of Geographic Variation, The 
Gerontologist, 50(2)179–191, https://doi.org/10.1093/geront/gnp106 
 
Fox, C., Richardson, K., Maidment, I., Savva, G., Matthews, F., Smithard, D., Coulton, 
S., Katona, C., Boustani, M. and Brayne, C. (2011). Anticholinergic Medication Use 
and Cognitive Impairment in the Older Population: The Medical Research Council 
Cognitive Function and Ageing Study. Journal of the American Geriatrics Society, 
59(8), pp.1477-1483. 
 
Fox, S., FitzGerald, C., Harrison Dening, K., Irving, K., Kernohan, W. G., Treloar, A., 
Oliver, D., Guerin, S., & Timmons, S. (2017). Better palliative care for people with a 
dementia: summary of interdisciplinary workshop highlighting current gaps and 
recommendations for future research. BMC palliative care, 17(1), 9. 
https://doi.org/10.1186/s12904-017-0221-0 
 
Frankel, G. and Austin, Z. (2013). Responsibility and confidence. Canadian 
Pharmacists Journal / Revue des Pharmaciens du Canada, 146(3), 155-161. 
Franklin, B., Reynolds, M., Sadler, S., Hibberd, R., Avery, A., Armstrong, S., Mehta, R., 
Boyd, M. and Barber, N. (2014). The effect of the electronic transmission of 
prescriptions on dispensing errors and prescription enhancements made in 
English community pharmacies: a naturalistic stepped wedge study. BMJ Quality & 
Safety, 23(8), pp.629-638. 
 
Fratiglioni, L., Paillard-Borg, S. and Winblad, B. (2004) An active and socially 
integrated lifestyle in late life might protect against dementia. The Lancet 
Neurology, 3(6), pp.343-353. 
 
Freeman, K (1926) The Work and Life of Solon. University of Wales Press, 
 
Furniss, L., Burns, A., Craig, S., Scobie, S., Cooke, J. and Faragher, B (2000). Effects of 
a pharmacist's medication review in nursing homes. British Journal of Psychiatry, 
176(6), 563-567 
Gadhia, S (2014) Reducing antipsychotics in dementia. The Pharmaceutical Journal, 
292, No 7795, p124 | DOI: 10.1211/PJ.2014.11133564 
 
Gage H., Knibb W., Evans J., Williams P., Rickman N., Bryan K. (2009) Why are some 
care homes better than others? An empirical study of the factors associated with 
quality of care for older people in residential homes in Surrey, England. Health and 






Gage, H., Dickinson, A., Victor, C., Williams, P., Cheynel, J., Davies, S., Illife, S., 
Froggat, K., Martin, W., and Goodman, C. (2012) Integrated working between 
residential care homes and primary care: a survey of care homes in England. BMC 
Geriatrics 12, 71 doi:10.1186/1471-2318-12-71  
 
Galvin, J. E., Duda, J. E., Kaufer, D. I., Lippa, C. F., Taylor, A. and Zarit, S. H. (2010) 
'Lewy body dementia: The caregiver experience of clinical care', Parkinsonism and 
Related Disorders, 16, 388-392. 
 
Gandhi, S. and Wood, N (2005). Molecular pathogenesis of Parkinson's disease. 
Human Molecular Genetics, 14(18), 2749-2755. 
Gareri, P., De Fazio, P., Manfredi, V. and De Sarro, G. (2014). Use and Safety of 
Antipsychotics in Behavioral Disorders in Elderly People with Dementia. Journal of 
Clinical Psychopharmacology, 34(1), 109-123. 
Gelder, M., Harrison, P. and Cowen, P. (2006) Shorter Oxford Textbook of Psychiatry. 
5th Edition edn. Oxford: Oxford University Press. 
 
Gendall, P and Hoek, J (1990) A question of wording. Marketing Bulletin,1, 25-36, 
Article 5 
 
General Pharmaceutical Society (GPhC)(2019) GPhC Survey of pharmacy 
professionals 2019 [online] available at: 
https://www.pharmacyregulation.org/sites/default/files/document/gphc-2019-
survey-pharmacy-professionals-summary-infographics-report-december-2019.pdf   
[accessed 01/03/2020] 
 
Ghadia, S. (2014). Reducing antipsychotics in dementia. The Pharmaceutical 
Journal, 292(7795), p.124. 
Gidman, W. (2011). Increasing community pharmacy workloads in England causes 
and consequences. International Journal of Clinical Pharmacy, 33(3),512-520. 
Gill, S.S., Mamdani, M., Naglie, G., Streiner, D.L., Bronskill, S.E., Knopp, A., Shulman, 
K., Lee, P.E. and Rollion, P. A. (2005) A Prescribing Cascade Involving 
Cholinesterase Inhibitors and Anticholinergic Drugs. Archives of Internal Medicine, 
165(7), 808–813. doi:10.1001/archinte.165.7.808 
 
Gill, D., Almutairi, S. and Donyai, P. (2017). “The Lesser of Two Evils” Versus 
Medicines not Smarties: Constructing Antipsychotics in Dementia. The 
Gerontologist, 59(3), .570-579. 
317 
 
Gill, S., Anderson, G., Fischer, H., Bell, C., Li, P., Normand, S. and Rochon, P. (2009). 
Syncope and Its Consequences in Patients with Dementia Receiving Cholinesterase 
Inhibitors. Archives of Internal Medicine, 169(9), 867. 
Gillham, B. (2007) Developing a Questionnaire 2nd edition: Continuum 
 
Gladman, J., Harwood, R., Conroy, S., Logan, P., Elliott, R., Jones, R., Lewis, S., Dyas, J., 
Schneider, J., Porock, D., Pollock, K., Goldberg, S., Edmans, J., Gordon, A., Bradshaw, 
L., Franklin, M., Whittamore, K., Robbins, I., Dunphy, A., Spencer, K., Darby, J., 
Tanajewski, L., Berdunov, V., Gkountouras, G., Foster, P. and Frowd, N., 2015. 
Medical Crises in Older People: cohort study of older people attending acute 
medical units, developmental work and randomised controlled trial of a specialist 
geriatric medical intervention for high-risk older people; cohort study of older 
people with mental health problems admitted to hospital, developmental work and 
randomised controlled trial of a specialist medical and mental health unit for 
general hospital patients with delirium and dementia; and cohort study of 
residents of care homes and interview study of health-care provision to residents 
of care homes. Programme Grants for Applied Research, 3(4), 1-410. 
Gliem J.A. and Gliem R.R. (2003) Calculating, Interpreting, and Reporting Cronbach’s 
Alpha Reliability Coefficient for Likert-Type Scales. 2003 Midwest Research to 
Practice Conference in Adult, Continuing, and Community Education, Columbus, 
82-88.  
 
Gnjidic, D., Agogo, G., Ramsey, C., Moga, D. and Allore, H. (2018). The Impact of 
Dementia Diagnosis on Patterns of Potentially Inappropriate Medication Use 
Among Older Adults. The Journals of Gerontology: Series A, 73(10), 1410-1417. 
 
Gottesman RF, Schneider AL, Albert M, Alonso A, Bandeen-Roche K, Coker L, 
(2014). Midlife hypertension and 20-year cognitive change: the atherosclerosis 
risk in communities’ neurocognitive study. JAMA Neurology 71:1218–27. 
 
Gottesman, R., Schneider, A., Albert, M., Alonso, A., Bandeen-Roche, K., Coker, L., 
Coresh, J., Knopman, D., Power, M., Rawlings, A., Sharrett, A., Wruck, L. and Mosley, 
T. (2014). Midlife Hypertension and 20-Year Cognitive Change. JAMA Neurology, 
71(10), 1218. 
Goundrey-Smith, S. (2018). The Connected Community Pharmacy: Benefits for 
Healthcare and Implications for Health Policy. Frontiers in Pharmacology, 9(1352), 
1-10. 
Grand HG., Casper S, Macdonald S.W.S (2011). Clinical features and 
multidisciplinary approaches to dementia care. Journal of Multidisciplinary 




Greenblatt, H. and Greenblatt, D., 2016. Use of Antipsychotics for the Treatment of 
Behavioral Symptoms of Dementia. The Journal of Clinical Pharmacology, 56(9), 
1048-1057. 
 
Greenhalgh, T., Stramer, K., Bratan ,T., Byrne, E., Russell J, Hinder, S, et al. (2010) 
The devil’s in the detail: final report of the independent evaluation of the Summary 
Care Record and Health Space programmes. University College London. 
 
Grossberg, G. T. (2003) 'Diagnosis and treatment of Alzheimer's disease', Journal of 
Clinical Psychiatry, 64(Suppl 9), 3-6. 
 
Guthrie, B., Payne, K., Alderson, P., McMurdo, M.E.T., and Mercer, S.W. (2012) 
Adapting clinical guidelines to take account of multimorbidity. BMJ 345: e6341.  
 
Hachinski, V. C., Lassen, N. A. and Marshall, J. (1974) 'Multi-infarct Dementia: A 
cause for mental deterioration in the elderly', Lancet, 304(7874), 207-209. 
 
Hair, J., Ringle, C. and Sarstedt, M., 2011. PLS-SEM: Indeed, a Silver Bullet. Journal of 
Marketing Theory and Practice, 19(2), 139-152. 
Hair, J., Risher, J., Sarstedt, M. and Ringle, C. (2019), When to use and how to report 
the results of PLS-SEM, European Business Review,31(1), 2-24. 
https://doi.org/10.1108/EBR-11-2018-0203 
Hall, N., Donovan, G. and Wilkes, S., 2018. A qualitative synthesis of pharmacist, 
other health professional and lay perspectives on the role of community pharmacy 
in facilitating care for people with long-term conditions. Research in Social and 
Administrative Pharmacy, 14(11), 1043-1057. 
Halvorsen K.H, Stensland P, Granas AG (2011). A qualitative study of physicians' 
and nurses' experiences of multidisciplinary collaboration with pharmacists 
participating at case conferences. International Journal of Pharmacy Practice 19(5), 
350-7 
 
Hao J (2019) Correspondence Analysis: What is it, and how can I use it to measure 
my Brand? (Part 1 of 2) [online] available at 
https://www.qualtrics.com/eng/correspondence-analysis-what-is-it-and-how-
can-i-use-it-to-measure-my-brand-part-1-of-2/  [accessed 14/02/2020] 
 
Hardigan, P., Popovici, I. and Carvajal, M., 2016. Response rate, response time, and 
economic costs of survey research: A randomized trial of practicing pharmacists. 
Research in Social and Administrative Pharmacy, 12(1), 141-148. 
Hardy, J. A. and Higgins, G. A. (1992) 'Alzheimer's disease: the amyloid cascade 




Hassell, K., Seston, E., Schafheutle, E., Wagner, A. and Eden, M. (2011). Workload in 
community pharmacies in the UK and its impact on patient safety and pharmacists’ 
well-being: a review of the evidence. Health & Social Care in the Community, 19(6), 
561-575. 
Health and Social Care information Centre (NHS Digital) (2014). General 
Pharmaceutical Services in England - 2004/2005 to 2013/2014[online] available 
at https://digital.nhs.uk/data-and-information/publications/statistical/general-
pharmaceutical-services/general-pharmaceutical-services-in-england-2004-05-to-
2013-14  (accessed 05/06/ 2015) 
 
Health Research Authority (2016). Research involving staff as participants [online] 
available at http://www.hra.nhs.uk/resources/before-you-apply/research-
requiring-nhs-rd-review-but-not-ethical-review/  [accessed 11/04/2016] 
 
Hemsley, S. (2018). Medicines optimisation in care homes: the role of the 
pharmacy professional. The Pharmaceutical Journal, [online]. Available at: 
https://www.pharmaceutical-journal.com/careers-and-jobs/careers-and-
jobs/career-feature/medicines-optimisation-in-care-homes-the-role-of-the-
pharmacy-professional/20205072.fullarticle?firstPass=false [Accessed 23/07/ 
2019]. 
Henderson, T. (2012). The diagnosis and evaluation of dementia and mild cognitive 
impairment with emphasis on SPECT perfusion neuroimaging. CNS 
Spectrums, 17(4), 176-206. doi:10.1017/S1092852912000636. 
Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Brosseron, F., Feinstein, D. 
L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., Herrup, K., Frautschy, 
S. A., Finsen, B., Brown, G. C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., 
Halle, A., Petzold, G. C., … Kummer, M. P. (2015). Neuroinflammation in Alzheimer's 
disease. The Lancet. Neurology, 14(4), 388–405. https://doi.org/10.1016/S1474-
4422(15)70016-5 
 
Henseler, Jörg; Ringle, Christian M.; & Sinkovics, Rudolf R. (2009). The use of 
partial least squares path modeling in international marketing. New Challenges to 
International Marketing Advances in International Marketing, 20, 277–319 
 
Hepler, C., 1990. The Future of Pharmacy: Pharmaceutical Care. American 
Pharmacy, 30(10), 23-29. 
 





Herholz, K., Perani, D., Morris, C. (2006) The Dementias: Early Diagnosis and 




Hernandez M.H., Mestres C., Modamio, P., Junyen, J., Costa-Tutusaus, L., Lastra, C.F., 
and Marino, E.L. (2019). Adverse Drug Events in Patients with Dementia and 
Neuropsychiatric/Behavioural, Psychological Symptoms, a One-Year Prospective 
Study. International Journal of Environmental Research and Public Health, 16 
(934),1-11 
 
Herrmann, N. and Gauthier, S. (2008). Diagnosis and treatment of dementia: 6. 
Management of severe Alzheimer disease. Canadian Medical Association Journal, 
179(12), 1279-1287. 
Hibberd, P. (2014). The role of the specialist dementia nurse and why it matters in 
home care. Community Care [online] available at: 
https://www.communitycare.co.uk/2014/03/07/role-specialist-dementia-nurse-
matters-home-care/  [accessed 27/12/2019] 
 
Hickey, C., Chisholm, T., Passmore, M. J., O'brien, J. D. and Johnston, J. (2008) 
'Differentiating the dementias. Revisiting synucleinopathies and tauopathies.', 
Current Alzheimer Research, 5(1), 52-60. 
Hilmer, S. and Gnjidic, D., 2008. The Effects of Polypharmacy in Older Adults. 
Clinical Pharmacology & Therapeutics, 85(1), 86-88. 
Hindi, A., Jacobs, S. and Schafheutle, E., (2018). Solidarity or dissonance? A 
systematic review of pharmacist and GP views on community pharmacy services in 
the UK. Health & Social Care in the Community, 27(3),565-598. 
Hoffmann, F., Kaduszkiewicz, H., Glaeske, G., van den Bussche, H. and Koller, D., 
2014. Prevalence of dementia in nursing home and community-dwelling older 
adults in Germany. Aging Clinical and Experimental Research, 26(5), 555-559. 
 
Holland, R., Desborough, J., Goodyer, L., Hall, S., Wright, D., & Loke, Y. K. (2008). 
Does pharmacist-led medication review help to reduce hospital admissions and 
deaths in older people? A systematic review and meta-analysis. British journal of 




Holmes, C. (2012) 'Dementia', Medicine, 40(11), 628-631. 
 
Holmes, H., Sachs, G., Shega, J., Hougham, G., Cox Hayley, D. and Dale, W., 2008. 
Integrating Palliative Medicine into the Care of Persons with Advanced Dementia: 




Horner, J., Alberts, M.J., Dawson, D.V., Cook, G.M. (1994) Swallowing in Alzheimer’s 
Disease. Alzheimer Disease and Associated Disorders; 8(3), 177-189 
 
House of Commons All-Party Parliamentary Group on Dementia (2011). The £20 
billion question: An inquiry into improving lives through cost-effective dementia 




the_all-party_parliamentary_group_on_dementia.pdf  [accessed 14/01/2020] 
 
 
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., 
Dening, T., Findlay, D., Holmes, C., Jones, R., Jones, R., McKeith, I., Macharouthu, A., 
O'Brien, J., Sheehan, B., Juszczak, E., Katona, C., Hills, R., Knapp, M., Ballard, C., 
Brown, R., Banerjee, S., Adams, J., Johnson, T., Bentham, P. and Phillips, P.(2015). 
Nursing home placement in the Donepezil and Memantine in Moderate to Severe 
Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. The 
Lancet Neurology, 14(12), 1171-1181. 
Hudgens, J. and Chirico, M. (2010). A Course Introducing the Principles of 
Pharmaceutical Care. American Journal of Pharmaceutical Education, 74(7),131. 
Hughes C.M. (2019) Implementation of Pharmaceutical Care in Nursing Homes. In: 
Alves da Costa F., van Mil J., Alvarez-Risco A. (eds) The Pharmacist Guide to 
Implementing Pharmaceutical Care. Pp225-233 Springer, Cham 
Hughes, C., Hawwa, A., Scullin, C., Anderson, C., Bernsten, C., Björnsdóttir, I., 
Cordina, M., Costa, F., Wulf, I., Eichenberger, P., Foulon, V., Henman, M., Hersberger, 
K., Schaefer, M., Søndergaard, B., Tully, M., Westerlund, T. and McElnay, J. (2010). 
Provision of pharmaceutical care by community pharmacists: a comparison across 
Europe. Pharmacy World & Science, 32(4), 472-487. 
Hukins, D., Macleod, U. and Boland, J. (2019). Identifying potentially inappropriate 
prescribing in older people with dementia: a systematic review. European Journal 
of Clinical Pharmacology, 75(4), 467-481. 
Huston, S. and Hobson, E., 2008. Using focus groups to inform pharmacy research. 
Research in Social and Administrative Pharmacy, 4(3),186-205. 
IBM Corp. Released (2016). IBM SPSS Statistics for Windows, Version 24.0. 
Armonk, NY: IBM Corp. 
 
Iliffe, S.,Wilcock,J. Haworth, D (2006) Obstacles to Shared Care for Patients with 





Imbimbo, B. P., Solfrizzi, V., and Panza, F. (2010). Are NSAIDs useful to treat 
Alzheimer's disease or mild cognitive impairment? Frontiers in aging 
neuroscience, 2, 19. https://doi.org/10.3389/fnagi.2010.00019 
 
Inch, J., Notman, F., Bond, C., Alldred, D., Arthur, A., Blyth, A., Daffu-O’Reilly, A., Ford, 
J., Hughes, C., Maskrey, V., Millar, A., Myint, P., Poland, F., Shepstone, L., Zermansky, 
A., Holland, R. and Wright, D. (2019). The Care Home Independent Prescribing 
Pharmacist Study (CHIPPS)—a non-randomised feasibility study of independent 
pharmacist prescribing in care homes. Pilot and Feasibility Studies, 5(1). 
Jacobs, N., Hagger, M., Streukens, S., De Bourdeaudhuij, I. and Claes, N. (2011). 
Testing an integrated model of the theory of planned behaviour and self-
determination theory for different energy balance-related behaviours and 
intervention intensities. British Journal of Health Psychology, 16(1),113-134. 
Jacobs, S., Johnson, S. and Hassell, K., 2017. Managing workplace stress in 
community pharmacy organisations: lessons from a review of the wider stress 
management and prevention literature. International Journal of Pharmacy Practice, 
26(1),28-38. 
 
Jellinger, K. A. (2007) 'The enigma of Vascular cognitive disorder and Vascular 
dementia', Acta Neuropharmacologica, 113, 349-388. 
 
Jellinger, K. A. (2008) 'Morphological diagnosis of "vascular dementia"-A critical 
update', Journal of the Neurological Sciences, 270, 1-12. 
 
Jenkins, C., Keenan, B. and Ginesi. L. (2016) Dementia 4: The nurse’s role in caring 
for people with dementia. Nursing Times; 112: (27/28)20-23. 
 
Johnson, J. K., Diehl, J., Mendez, M. F., Neuhaus, J., Shapira, J. S., Forman, M., Chute, D. 
J., Roberson, E. D., Pace-Savitsky, C., Neumann, M., Chow, T. W., Rosen, H. J., Forstl, 
H., Kurz, A., & Miller, B. L. (2005). Frontotemporal lobar degeneration: 
demographic characteristics of 353 patients. Archives of neurology, 62(6), 925–
930. https://doi.org/10.1001/archneur.62.6.925 
 
Joint Formulary Committee (2019) BNF 77: March 2019-September 2019. London: 
Pharmaceutical Press. 
 
Jokanovic, N., Tan, E., Dooley, M., Kirkpatrick, C. and Bell, J. (2015). Prevalence and 
Factors Associated with Polypharmacy in Long-Term Care Facilities: A Systematic 
Review. Journal of the American Medical Directors Association, 16(6), 535.e1-
535.e12. 
Jones, M. E., Petersen, I., Walters, K., Bhanu, C., Manthorpe, J., Raine, R., Mukadam, 
N., & Cooper, C. (2020). Differences in Psychotropic Drug Prescribing Between 
Ethnic Groups of People with Dementia in the United Kingdom. Clinical 




Joos, E., Mehuys, E., Bocxlaer, J.V., Remon, J.P., Winckel, M.V., and Boussery, K. 
(2014) Medication Management in Belgian Residential Care Facilities for 
Individuals With Intellectual Disability: An Observational Study. Journal of Policy 
and Practice in Intellectual Disabilities; 11(1) pp 27–33 
Jordan, S., Gabe-Walters, M., Watkins, A., Humphreys, I., Newson, L., Snelgrove, S., & 
Dennis, M. (2015). Nurse-led medicines’ monitoring for patients with dementia in 
care homes: A pragmatic cohort stepped wedge cluster randomised trial. Plos One, 
10(10), e0140203. [online] Available at 
http://dx.doi.org/10.1371/journal.pone.014020314 [accessed 17/03/2017] 
Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H. P., & van den Bussche, H. 
(2005). Cholinesterase inhibitors for patients with Alzheimer's disease: systematic 
review of randomised clinical trials. BMJ (Clinical research ed.), 331(7512), 321–
327. https://doi.org/10.1136/bmj.331.7512.321 
Kales, H., Gitlin, L. and Lyketsos, C. (2015). Assessment and management of 
behavioral and psychological symptoms of dementia. BMJ, 350, h369-h369. 
Kalsekar, I., Sheehan, C. and Peak, A. (2007) Utilization patterns and medication 
adherence in patients with type 2 diabetes: Variations based on type of pharmacy 
(chain vs independent). Research in Social and Administrative Pharmacy, 3(4), 378-
391. 
Kasteridis P, Mason A, Goddard M, Jacobs R, Santos R, Rodriguez-Sanchez B, et al. 
(2016) Risk of Care Home Placement following Acute Hospital Admission: Effects 
of a Pay-for-Performance Scheme for Dementia. PLoS ONE 11(5): e0155850. 
https://doi.org/10.1371/journal.pone.01558 
 
Kaufer, D. I. (2001) 'Long-Term Care in Dementia: Patients and Caregivers', Clinical 
Cornerstone, 3(4), 52-62. 
 
Kauppinen, H., Ahonen, R, and Timonen, J. (2017). The impact of electronic 
prescriptions on medication safety in Finnish community pharmacies: A survey of 
pharmacists. International Journal of Medical Informatics 100:56-62 
 
Kaur, S., Mitchell, G., Vitetta, L. and Roberts, M. (2009). Interventions that can 
Reduce Inappropriate Prescribing in the Elderly. Drugs & Aging, 26(12), pp.1013-
1028. 
Keene C.D, Montine T.J., and Kuller L.H. (2019). Epidemiology, pathology and 







splay_rank=1  [accessed 01/05/2019] 
 
Keijsers, C. J., van Doorn, A. B., van Kalles, A., de Wildt, D. J., Brouwers, J. R., van de 
Kamp, H. J., & Jansen, P. A. (2014). Structured pharmaceutical analysis of the 
Systematic Tool to Reduce Inappropriate Prescribing is an effective method for 
final-year medical students to improve polypharmacy skills: a randomized 
controlled trial. Journal of the American Geriatrics Society, 62(7), 1353–1359. 
https://doi.org/10.1111/jgs.12884 
 
Kennedy, S., and Sud, D. (2014). A guide to prescribing anti-dementia medication. 
Nursing Times 110. No.23 
 
Kester, M. I. and Scheltens, P. (2009) Dementia: the essentials, Practical neurology, 
9(4), 241-51. 
 
Keverne, J. and Ray, M. (2008) Neurochemistry of Alzheimer's disease, Psychiatry, 
7,6-8. 
Kiejna, A., Frydecka, D., Adamowski, T., Bickel, H., Reynish, E., Prince, M., Caracciolo, 
B., Fratiglioni, L. and Georges, J., (2011). Epidemiological studies of cognitive 
impairment and dementia across Eastern and Middle European countries 
(epidemiology of dementia in Eastern and Middle European Countries). 
International Journal of Geriatric Psychiatry, 26(2), 111-117. 
King, R. and Rabino, S (2019) ACB calculator [online] available at 
http://www.acbcalc.com/ [accessed 01/02/2020] 
 
Knapp, M., Black, N., Dixon, J., Damant, J., Rehill, A., Tan, S. (2014) Independent 
assessment of improvements in dementia care and support since 2009. London: 
Policy Innovation Research Unit and NIHR School for Social Care Research. London 
 
Knapp, M., Park, A. and Burns, A. (2017). Medications for treating people with 
dementia: summary of evidence on cost-effectiveness. PSSRU, London School of 
Economics and Political Science v4 23 July 2017 [online] available at 
https://www.england.nhs.uk/wp-content/uploads/2018/01/dg-medications-for-
treating-people-with-dementia.pdf  [accessed 14/01/2020] 
 
Kosari, S., McDerby, N., Thomas, J. and Naunton, M., 2018. Quality use of medicines 
in aged care facilities: A need for new models of care. Journal of Clinical Pharmacy 
and Therapeutics, 43(4),591-593. 
Kovach, C., Noonan, P., Schlidt, A. and Wells, T., 2005. A Model of Consequences of 




Kristensen, R., Nørgaard, A., Jensen-Dahm, C., Gasse, C., Wimberley, T. and 
Waldemar, G., (2018). Polypharmacy and Potentially Inappropriate Medication in 
People with Dementia: A Nationwide Study. Journal of Alzheimer's Disease, 63(1), 
383-394. 
Kröger, E., Wilchesky, M., Marcotte, M., Voyer, P., Morin, M., Champoux, N., Monette, 
J., Aubin, M., Durand, P., Verreault, R. and Arcand, M. (2015). Medication Use 
Among Nursing Home Residents with Severe Dementia: Identifying Categories of 
Appropriateness and Elements of a Successful Intervention. Journal of the 
American Medical Directors Association, 16(7), 629.e1-629.e17. 
Krska, J. and Veitch, G. (2001). Perceived factors influencing the development of 
primary care-based pharmaceutical care in Scotland. International Journal of 
Pharmacy Practice, 9(4), 243-252. 
Krueger, R. A. & Casey, M. A. (2015). Focus groups: A practical guide for applied 
research. 5th edition. Thousand Oaks, CA: Sage. 
Kukull, W. and Bowen, J., (2002). Dementia epidemiology. Medical Clinics of North 
America, 86(3), 573-590. 
Laing, W. (2013). Care of elderly people UK market survey 2012/2013. London, 
UK: Laing Buisson. 
Lang, L., Clifford, A., Wei, L., Zhang, D., Leung, D., Augustine, G., Danat, I., Zhou, W., 
Copeland, J., Anstey, K. and Chen, R. (2017). Prevalence and determinants of 
undetected dementia in the community: a systematic literature review and a meta-
analysis. BMJ Open, 7(2), .e011146. 
Lapane, K., Hughes, C., Christian, J., Daiello, L., Cameron, K. and Feinberg, J., 2011. 
Evaluation of the Fleetwood Model of Long-Term Care Pharmacy. Journal of the 
American Medical Directors Association, 12(5), 355-363. 
Larson, E (2019). Risk Factors for cognitive decline and dementia. In J. L 




_rank=1  [accessed 03/05/2019] 
Larson, E., 2017. Prevention of Late-Life Dementia: No Magic Bullet. Annals of 
Internal Medicine, 168(1), 77. 
Latimer, C. and Montine, T (2019). Epidemiology, pathology and pathogenesis of 






ectedTitle=3~60&usage_type=default&display_rank=3  [accessed 14/10/2019] 
 
Lau, M. (2014). Care homes are better off with local pharmacies. The 
Pharmaceutical Journal, 293(7922/3). 
 
Launer, L. (2019). Statistics on the burden of dementia: need for stronger data. The 
Lancet Neurology, 18(1), 25-27. 
Lee, A.T.C, Richards, M., Chan, W.C, Chiu, H.F.K. Lee, R.S.Y., Lam, L.C.W. (2017). 
Lower risk of incident dementia among Chinese older adults having three servings 
of vegetables and two servings of fruit a day. Age and Ageing 46(5), 773-9 
 
Lee, J., Hui, E., Kng, C., & Auyeung, T. (2013). Attitudes of long-term care staff 
toward dementia and their related factors. International Psychogeriatrics, 25(1), 
140-147. doi:10.1017/S1041610212001512 
 
Lee SE (2019). Frontotemporal Dementia: Clinical features and diagnosis. In J 




tle=1~150&usage_type=default&display_rank=1 [accessed 14/10/19] 
 
Lee, A., Richards, M., Chan, W., Chiu, H., Lee, R. and Lam, L. (2017). Lower risk of 
incident dementia among Chinese older adults having three servings of vegetables 
and two servings of fruits a day. Age and Ageing, 46(5), 773-779. 
Lee, D. R., McKeith, I., Mosimann, U., Ghosh-Nodyal, A. and Thomas, A. J. (2013) 
Examining carer stress in dementia: the role of subtype diagnosis and 
neuropsychiatric symptoms, International Journal of Geriatric Psychiatry, 28(2), 
135-41. 
Lee, J., Hui, E., Kng, C. and Auyeung, T. (2012). Attitudes of long-term care staff 
toward dementia and their related factors. International Psychogeriatrics, 25(1), 
140-147. 
Lee, S., Mak, V. and Tang, Y. (2019). Pharmacist services in nursing homes: A 
systematic review and meta‐analysis. British Journal of Clinical Pharmacology, 
85(12), 2668-2688. 
Lejbak, L. and Haugrud, N. (2010) Clinical Guidelines and Related Research for 





2010.pdf  (Accessed: 17/04/2013) 
Lemay C, Foy, S., Mazor, K., Harrold, L. Donovan, K. Kanaan, A., et al (2012). 
Knowledge of and perceived need for evidence-based educational materials about 
antipsychotic medication safety by nursing home staff. Journal of American 
Geriatrics Society; 60 (S167-S168), 0002-8614 
Lemstra, A., de Beer, M., Teunissen, C., Schreuder, C., Scheltens, P., van der Flier, W. 
and Sikkes, S., 2016. Concomitant AD pathology affects clinical manifestation and 
survival in dementia with Lewy bodies. Journal of Neurology, Neurosurgery & 
Psychiatry, 88(2), pp.113-118. 
Lievesley N., Crosby, G, Bowman C., (2011). The changing role of care homes. 
London: Bupa© and Centre for Policy and Ageing. 
Likert R. A. (1932) Technique for the Measurement of Attitudes. New York: Archives 
of Psychology. 
Lim, R. and Sharmeen, T. (2018). Medicines management issues in dementia and 
coping strategies used by people living with dementia and family carers: A 
systematic review. International Journal of Geriatric Psychiatry, 33(12),1562-1581. 
Lim, X.Y.; Yeo, Q.Q.; Kng, G.L.L.; Chung, W.L.; Yap, K.Z. (2018) Validation of a Drug-
Related Problem Classification System for the Intermediate and Long-Term Care 
Setting in Singapore. Pharmacy, 6, 109. 
 
Lindauer, A., Sexson, K. and Harvath, T., (2017). Medication Management for 
People with Dementia. AJN, American Journal of Nursing, 117, S17-S21. 
Lintern T., Woods, R., Phair, L. (2000). Before and after training: a case study of 
intervention. Journal of Dementia Care; 8, 15– 17. 
Liu, E., Dyer, S., Whitehead, C., O'Donnell, L., Gnanamanickam, E., Harrison, S., Milte, 
R. and Crotty, M. (2019). Patterns of medication prescription by dementia 
diagnosis in Australian nursing home residents: a cross-sectional study. Journal of 
Pharmacy Practice and Research, 49(1), 33-40. 
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S., Huntley, J., Ames, D., 
Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., Cooper, C., Fox, N., Gitlin, L., 
Howard, R., Kales, H., Larson, E., Ritchie, K., Rockwood, K., Sampson, E., Samus, Q., 
Schneider, L., Selbæk, G., Teri, L. and Mukadam, N., (2017). Dementia prevention, 
intervention, and care. The Lancet, 390(10113), pp.2673-2734. 
Locca, J., Büla, C., Zumbach, S. and Bugnon, O. (2008). Pharmacological Treatment 
of Behavioral and Psychological Symptoms of Dementia (BPSD) in Nursing Homes: 
Development of Practice Recommendations in a Swiss Canton. Journal of the 
American Medical Directors Association, 9(8), 611-611.e10. 
328 
 
Lucchetti, G. and Lucchetti, A. (2017). Inappropriate prescribing in older persons: 
A systematic review of medications available in different criteria. Archives of 
Gerontology and Geriatrics, 68, 55-61. 
Lužný, J., Ivanová, K., & Juríčková, L. (2014). Non-adherence in seniors with 
dementia - a serious problem of routine clinical practice. Acta medica (Hradec 
Kralove), 57(2), 73–77. https://doi.org/10.14712/18059694.2014.43 
Ma, Z., Zhang, C., Cui, X., and Liu, L., (2018). Comparison of three criteria for 
potentially inappropriate medications in Chinese older adults. Clinical 
interventions in aging. 14, 65–72. doi:10.2147/CIA.S190983 
 
Madhusoodanan, S., and Ting, MB., (2014). Pharmacological management of 
behavioural symptoms associated with dementia.  World Journal of Psychiatry. 
4(4), 72-79. 
Maher, R., Hanlon, J. and Hajjar, E., (2013). Clinical consequences of polypharmacy 
in elderly. Expert Opinion on Drug Safety, 13(1), pp.57-65. 
Mahlknecht, A., Krisch, L., Nestler, N., Bauer, U., Letz, N., Zenz, D., Schuler, J., 
Fährmann, L., Hempel, G., Flamm, M., and Osterbrink, J., (2019). Impact of training 
and structured medication review on medication appropriateness and patient-
related outcomes in nursing homes: results from the interventional study. 
InTherAKT. BMC geriatrics, 19(1), 257. https://doi.org/10.1186/s12877-019-
1263-3 
 
Maidment, I. D., Aston, L., Moutela, T., Fox, C. G., and Hilton, A., (2017). A qualitative 
study exploring medication management in people with dementia living in the 
community and the potential role of the community pharmacist. Health 
expectations: an international Journal of Public Participation in Health care and 
Health Policy. 20(5), 929–942. https://doi.org/10.1111/hex.12534 
 
Maidment, I. D., Damery, S., Campbell, N., Seare, N., Fox, C., Iliffe, S., Shaw, R., 
(2018). Medication review plus person-centred care: a feasibility study of a 
pharmacy-health psychology dual intervention to improve care for people living 
with dementia. BMC psychiatry. 18(1), 340. doi:10.1186/s12888-018-1907-4 
Maidment, I., (2013). Medication -related adverse events in older people with 
dementia-possible causes and solutions. PhD Thesis Aston University. [online] 
available at https://publications.aston.ac.uk/id/eprint/21396/1/Studentthesis-
2013.pdf  [accessed 14/03/2020]. 
Maidment, I., Aston, L., Hilton, A., Iqbal, N., Child, A. and Shaw, R., 2016. Role of 
community pharmacists in the use of antipsychotics for behavioural and 




Maidment, I., Aston, L., Moutela, T., Fox, C. and Hilton, A., 2017. A qualitative study 
exploring medication management in people with dementia living in the 
community and the potential role of the community pharmacist. Health 
Expectations, 20(5), 929-942. 
 
Maidment, I., Damery, S., Campbell, N., Seare, N., Fox, C., Iliffe, S., Hilton, A., Brown, 
G., Barnes, N., Wilcock, J., Randle, E., Gillespie, S., Barton, G. and Shaw, R., 2018. 
Medication review plus person-centred care: a feasibility study of a pharmacy-
health psychology dual intervention to improve care for people living with 
dementia. BMC Psychiatry, 18(1). 
Maidment, I., Fox, C., Boustani, M. and Katona, C., 2011. Medication management-
the missing link in dementia interventions. International Journal of Geriatric 
Psychiatry, 27(5),.439-442. 
Malek, N., and Greene, J., (2014). Cognition enhancers for the treatment of 
dementia. Scottish Medical Journal. 60(1), 44–49. Retrieved from 
http://dx.doi.org/10.1177/0036933014561948. 
Mar, J., Arrospide, A., Soto-Gordoa, M., Iruin, Á., Tainta, M., Gabilondo, A., Ibarrondo, 
O., (2019). Dementia-related neuropsychiatric symptoms: inequalities in 
pharmacological treatment and institutionalization. Neuropsychiatric disease and 
treatment. 15, 2027–2034. doi:10.2147/NDT.S209008 
Marchini, L., Ettinger, R., Caprio, T. and Jucan, A., 2019. Oral health care for patients 
with Alzheimer's disease: An update. Special Care in Dentistry, 39(3), 262-273. 
Marvanova, M. and Henkel, P., (2017a). Community pharmacists' knowledge of 
Alzheimer disease care in high- and low-income Chicago. Journal of the American 
Pharmacists Association, 57(5), 596-600.e1. 
Marvanova, M. and Henkel, P., (2017b) Community Pharmacists’ Knowledge 
Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia 
for Persons with AD. Pharmacy, 5(4), 42. 
Masnoon, N., Shakib, S., Kalisch-Ellett, L., and Caughey, GE., (2017). What is 
polypharmacy? A systematic review of definitions. BMC geriatrics. 17(1), 230. 
doi:10.1186/s12877-017-0621-2. 
Mastroianni, PC., and Forgerini, M., (2018). Drug administration adjustments for 
elderly patients with dysphagia: A case report. Dementia and Neuropsychologia. 
12(1), 97-100. 
Mat Nuri, TH., Hong, YH., Ming, LC., Mohd Joffry, S., Othman, MF., and Neoh, CF., 
(2017). Knowledge on Alzheimer's Disease among Public Hospitals and Health 
330 
 
Clinics Pharmacists in the State of Selangor, Malaysia. Frontiers in Pharmacology. 8, 
739. doi: 10.3389/fphar.2017.0073. 
Mathers, C. and Leonardi, M. (2000) Global burden of dementia in the year 2000: 
summary of methods and data sources, Geneva: World Health Organisation. 
Mathys, M., (2018). Pharmacologic management of behavioural and psychological 
symptoms of major neurocognitive disorder. The Mental Health Clinician. 8(6), 
284-293. 
Matthews, F., Arthur, A., Barnes, L., Bond, J., Jagger, C., Robinson, L. and Brayne, C., 
(2013). A two-decade comparison of prevalence of dementia in individuals aged 65 
years and older from three geographical areas of England: results of the Cognitive 
Function and Ageing Study I and II. The Lancet, 382(9902), 1405-1412. 
Maurer, K. and Maurer, U. (2003) Alzheimer: The life of a physician and career of a 
disease. New York: Columbia University Press. 
McCormack, B., (2017). Person-centred cultures: Valuing all persons. Care Home 
Nursing Journal. 1(1), 4–5. 
McGrattan, M., Ryan, C., Barry, H. and Hughes, C., (2017). Interventions to Improve 
Medicines Management for People with Dementia: A Systematic Review. Drugs & 
Aging, 34(12), pp.907-916. 
McKeith, I. G. (2002) 'Dementia with Lewy bodies', The British Journal of Psychiatry, 
180, 144-147. 
McKeith, I., Fairbairn, A., Perry, R., Thompson, P., and Perry, E., (1992). Neuroleptic 
sensitivity in patients with senile dementia of Lewy body type. BMJ. 305, 673-678 
 
McKeith, I., Mintzer, J., Aarsland, D. B., Chiu, H., Cohen-Mansfield, J., Dickson, D. and 
al, e. (2004) 'Dementia with Lewy bodies', The Lancet Neurology, 3, 19-28. 
 
McShane, R., Westby, MJ., Roberts, E., Minakaran, N., Schneider, L., Farrimond,  LE., 
Maayan,  N., Ware, J., Debarros,  J., (2019). Memantine for dementia. Cochrane 
Database of Systematic Reviews. (3), Art. No.: CD003154. DOI: 
10.1002/14651858.CD003154.pub6. 
Mehta, H., Sura, SD., Raji, M., Holmes, H., Kuo, Y., Aparasu, R., and Goodwin, JS., 
(2017). Quality of pharmaceutical care in dementia patients. Innovation in Aging. 
1(Suppl 1), 905. doi:10.1093/geroni/igx004.3244. 
 
Mental Capacity Act., (2005). [Chapter 4]. TSO: Norwich [online] available at: 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/at





Mesulam, M. M. (1985) 'Dementia: its definition, differential diagnosis, and 
subtypes', JAMA, 253(17), 2559-61. 
Mikeal, R., Lazarus, H., Vinson, M. and Brown, T., 1975. Quality of pharmaceutical 
care in hospitals. American Journal of Health-System Pharmacy, 32(6), 567-574. 
Miller, L., Williams, J., Marvell, R. and Tassinari, A., 2015. Assistant Practitioners in 
the NHS in England. British Journal of Healthcare Assistants, 9(4), pp.194-195. 
Minard, LV., Deal, H., Harrison, ME., Toombs, K., Neville, H., Meade, A., (2016). 
Pharmacists' Perceptions of the Barriers and Facilitators to the Implementation of 
Clinical Pharmacy Key Performance Indicators. PLoS ONE. 11(4), e0152903. 
doi:10.1371/journal.pone.0152903. 
Mitchell, G., Cousins, C., Burrows, R., Cousins, G., (2017). A review of safe‐staffing 
models and their applicability to care homes. Journal of Nursing Management. 25, 
157– 162.  
Mitchell, S. L., Teno, JM., Kiely, DK., Shaffer, ML., Jones, RN., Prigerson, HG., Volicer, 
L., Givens, JL., and Hamel, MB., (2009). The clinical course of advanced dementia. 
The New England Journal of Medicine. 361(16), 1529–1538. 
https://doi.org/10.1056/NEJMoa0902234 
Mjørud, M., Engedal, K., Røsvik, J., and Kirkevold, M., (2017). Liv ing with dementia 
in a nursing home, as described by persons with dementia: a phenomenological 
hermeneutic study. BMC health services research. 17(1), 93. doi:10.1186/s12913-
017-2053-2. 
Mogi, M., 2019. Could Management of Blood Pressure Prevent Dementia in the 
elderly? Clinical Hypertension, 25, 27. https://doi.org/10.1186/s40885-019-0135-
7 
Molist Brunet, N., Espaulella Panicot, J., Sevilla Sánchez, D., Amblàs Novellas, J., Solà 
Bonada, N., Torné Coromina, A., et al., (2016). A Patient-Centered Prescription 
Model assessing the appropriateness of chronic drug therapy in older patients. 
International Journal of Integrated Care. 16(6), A29. DOI: 
http://doi.org/10.5334/ijic.2972. 
 
Moreira, P. I., Carvalho, C., Zhu, X. W., Smith, M. A. and Perry, G. (2010) 
'Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology', 
Biochimica Et Biophysica Acta-Molecular Basis of Disease, 1802(1), 2-10. 
 
Moreton, R.C., (2017). Is the future of pharmacy under threat from technology? The 
Pharmaceutical Journal. 299 (7905), [online]DOI: 10.1211/PJ.2017.20203135. 
Morgan, D., (2014). Pragmatism as a paradigm for mixed methods research. In 
Morgan, D. Integrating qualitative and quantitative methods (25-44). 55 City Road, 




Morgan, D.l., and Scannell, A.U., (1998). In: Planning Focus Groups, Vol 2. Thousand 
Oaks: Sage Publications. 
 
Morin, L., Laroche, M., Texier, G. and Johnell, K., 2016. Prevalence of Potentially 
Inappropriate Medication Use in Older Adults Living in Nursing Homes: A 
Systematic Review. Journal of the American Medical Directors Association, 17(9), 
862.e1-862.e9.. 
Morley, JE., Ouslander, JG., Tolson, D., Vellas, B., (2013). Nursing home care. USA. 
McGraw-Hill Education. 
Mukaetova-Ladinska, E., 2018. The therapeutic ‘make-over’ of dementias—an 
introduction. Age and Ageing, 47(3).331-333. 
Murphy, E., Froggatt, K., Connolly, S., O'Shea, E., Sampson, EL., Casey, D., Devane, D., 
(2016). Palliative care interventions in advanced dementia. Cochrane Database of 
Systematic Reviews. (12), Art. No.: CD011513. DOI: 
10.1002/14651858.CD011513.pub2 




National Collaboration Centre for Mental Health, 2018. Dementia Care Pathways. 
[online] London: Royal College of Psychiatrists. Available at: 
https://www.rcpsych.ac.uk/docs/default-source/improving-
care/nccmh/dementia/nccmh-dementia-care-pathway-full-implementation-
guidance.pdf?sfvrsn=cdef189d_6 [Accessed 20 March 2020]. 
National Institute for Health and Care Excellence., (2018). Dementia - assessment, 
management and support for people living with dementia and their carers (NICE 
guideline NG97). Available from www.nice.org.uk/guidance/ng97  [accessed 
16/10/2019]. 
National Institute of Clinical Excellence (NICE)., (2006). 'DEMENTIA: A NICE-SCIE 
guideline on supporting people with dementia and their carers in health and social 
care'. London.  
NHS Commissioning Pharmacy Integration Fund., (2016). [online] from 
https://www.england.nhs.uk/commissioning/primary-care-
comm/pharmacy/integration-fund/  [accessed 27/09/19]  
 
NHS Digital., (2019). Clinical pharmacists vital to patient care in five-year GP deal. 
https://www.england.nhs.uk/2019/01/clinical-pharmacists-vital-to-patient-care-




NHS Education Scotland (NES)., (2014). The pharmaceutical care of people with 
dementia. [online] available at:  
https://www.nes.scot.nhs.uk/media/4104909/pharmaceutical-care-of-people-
with-dementia-2014.pdf  [accessed 11/09/2019]. 
 
NHS England (2017). Framework for Enhanced Health In Care Homes. [online] 
England.nhs.uk. Available at: https://www.england.nhs.uk/wp-
content/uploads/2016/09/ehch-framework-v2.pdf [Accessed 23/03/2020]. 
 
NHS England., (2013). Improving Health and Patient Care Through Community 
Pharmacy-A call to Action. London: NHS England 
 
NHS England., (2018). Medicines optimisation in Care Homes (MOCH.) [online] 
available at https://www.england.nhs.uk/wp-
content/uploads/2018/03/medicines-optimisation-in-care-homes-programme-
overview.pdf  [accessed 28/09/19] 
NHS England., (2019). When to consider a care home. [online] available at 
https://www.nhs.uk/conditions/social-care-and-support-guide/care-services-
equipment-and-care-homes/care-homes/  [accessed 8/08/2019]. 
 
NHS North West Coast Strategic Clinical Network., (2018). Palliative Care 
Guidelines in Dementia 2nd Edition Version 3.9. [online] available at 
https://www.england.nhs.uk/north/wp-
content/uploads/sites/5/2018/06/palliative-care-guidelines-in-dementia.pdf  
[accessed 01/10/ 2019]. 
 
NHS Scotland., (2017). Achieving Excellence in Pharmaceutical Care: A strategy for 
Scotland. The Scottish Government. August 2017.  
 
NHS UK., (2019). When to consider a care home. [online] available at 
https://www.nhs.uk/conditions/social-care-and-support-guide/care-services-
equipment-and-care-homes/care-homes/ [accessed 8/08/2019]. 
 
NICE (QS85)., (2015). Medicines management in care homes; quality standard. 
[online] available at: https://www.nice.org.uk/guidance/qs85 [accessed 
28/11/19]. 
 
NICE and SCIE, 2007. Dementia: A NICE–SCIE Guideline Supporting People With 
Dementia And Their Carers In Health And Social Care. [online] Scie.org.uk. Available 
at: https://www.scie.org.uk/publications/misc/dementia/dementia-
fullguideline.pdf?res=true [Accessed 20 March 2020]. 
 
NICE (SC1) (2014). Managing medicines in care homes. [Online] Available at: 
http://www.nice.org.uk/guidance/sc1/resources/guidance-managing-medicines-




NICE Key Therapeutic Topic (KTT7)., (2015). Antipsychotics in people living with 
dementia. [online] available at 
https://www.nice.org.uk/advice/ktt7/chapter/Evidence-context  [accessed 
19/02/2020]. 
NICE Pathways., (2019). Dementia assessment and overview. [online] Available at: 
https://pathways.nice.org.uk/pathways/dementia  [accessed 14/11/2019]. 
 
NICE Quality Standard QS184., (2019). Dementia quality standards. [online] 
Available at https://www.nice.org.uk/guidance/qs184  [03/07/ 2019]. 
 
Nichter, M., Nichter, M., Thompson, P., Shiffman, S. and Moscicki, A., 2002. Using 
qualitative research to inform survey development on nicotine dependence among 
adolescents. Drug and Alcohol Dependence, 68, 41-56. 
Nicieza-García, ML., Salgueiro-Vázquez, ME., Jimeno-Demuth, FJ., Manso, G., (2016). 
Beers versus STOPP criteria in polyharmacy community-dwelling older patients. 
Farmacia Hospitalaria. 40(3),150-164. 
 
Niu, H., Álvarez-Álvarez, I., Guillén-Grima, F., Aguinaga-Ontoso, I., (2017). 
Prevalence and incidence of Alzheimer's disease in Europe: A meta-analysis. 
Neurologia. 32, 523. 
Norgaard, LS., Petrovics, M., (2015). Medication reconciliation and review at sector 
transition from a psychiatric centre to residential care. International Journal of 
Clinical Pharmacy 37, 284.  
Nowrangi, M., Rao, V. and Lyketsos, C. (2011). Epidemiology, Assessment, and 
Treatment of Dementia. Psychiatric Clinics of North America, 34(2),275-294.  
 
Oakes, S., Oakes, S. L., Espino, D., Adedeji, K., Washington, F., (2010). Successful 
Implementation of an Interdisciplinary Team Approach to Reduce Psychoactive 
Medications in a Community Based Nursing Home: Tackling F-Tag 329. Journal of 
the American Medical Directors Association. 11 (3), B23 - B24. 
 
Oates, C., (2000). ‘The use of focus groups in social science research’ in Burton, D. 
(ed): Research training for social sciences. London. Sage. 
O’Brien, J. and Burns, A., (2010). Clinical practice with anti-dementia drugs: a 
revised (second) consensus statement from the British Association for 
Psychopharmacology. Journal of Psychopharmacology, 25(8), 997-1019. 
O’Brien, J., Holmes, C., Jones, M., Jones, R., Livingston, G., McKeith, I., Mittler, P., 
Passmore, P., Ritchie, C., Robinson, L., Sampson, E., Taylor, J., Thomas, A. and Burns, 
A., (2017). Clinical practice with anti-dementia drugs: A revised (third) consensus 
statement from the British Association for Psychopharmacology. Journal of 
Psychopharmacology, 31(2), 147-168. 
335 
 
O’Caoimh, R., Cornally, N., McGlade, C., Gao, Y., O’Herlihy, E., Svendrovski, A., 
Clarnette, R., Lavan, A., Gallagher, P. and William Molloy, D., (2019). Reducing 
inappropriate prescribing for older adults with advanced frailty: A review based 
on a survey of practice in four countries. Maturitas, 126, pp.1-10. 
O’Caoimh, R., Cornally, N., O’Herlihy, E., Gao, Y., Cronin, U., Clarnette, R., et al ., 
(2014). Opinions towards a consensus on use of medications in advanced 
dementia. Irish Journal of Medical Science. 183(7), Suppl 1(S312), 0021-1265. 
 
O'Connor, S.J., (2017). End-of-life care and advance care planning in Dementia. In: 
Schussler, S. and Lohrmann, C., eds. Dementia in Nursing Homes. Springer. p159 
ISBN 9783319498300 
Office of National Statistics: Population Ageing in the United Kingdom, its 
Constituent Countries and the European Union., (2012). [online] available at 
http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.go
v.uk/ons/dcp171776_258607.pdf  [accessed 11/04/2016] 
Okazaki, T., Furukawa, K., Kubo, H., Tsutsui, M., Furukawa, E., Asada, M., Yamaya, 
M., Seki, T., Iwaski, K. and Arai, H., 2006. Paralytic Ileus after discontinuation of 
cholinesterase inhibitor. Journal of the American Geriatrics Society, 54(10), 1620-
1621. 
 
Oliveira, M., Amorim, W., de Jesus, S., Heine, J., Coqueiro, H. and Passos, L., 2015. A 
comparison of the Beers and STOPP criteria for identifying the use of potentially 
inappropriate medications among elderly patients in primary care. Journal of 
Evaluation in Clinical Practice, 21(2), 320-325. 
Olsson, I., Curman, B. and Engfeldt, P., 2010. Patient focused drug surveillance of 
elderly patients in nursing homes. Pharmacoepidemiology and Drug Safety, 19(2), 
150-157. 
O'Mahony, D., O'Sullivan, D., Byrne, S., O'Connor, M. N., Ryan, C., & Gallagher, P. 
(2015). STOPP/START criteria for potentially inappropriate prescribing in older 
people: version 2. Age and ageing, 44(2), 213–218. 
https://doi.org/10.1093/ageing/afu145 
Oswald, K., 2017. Medicines optimisation in dementia: the role of the community 
pharmacy. The Pharmaceutical Journal, 299, No 7903, online | DOI: 
10.1211/PJ.2017.20203134 
Oxtoby, K., 2014. The Care Home Conundrum | Chemist+Druggist. [online] 
Chemistanddruggist.co.uk. Available at: 
https://www.chemistanddruggist.co.uk/feature/care-home-conundrum  
[Accessed 23 January 2020]. 
336 
 
Padovan, A., Agosti, C., Premi, E., Belleli, G. and Borroni, B. (2007) 'Extrapyramidal 
symptoms in Frontotemporal Dementia: Prevalence and clinical correlations', 
Neuroscience Letters, 422, 39-42. 
Paese, Paul W., Sniezek, Janet A., (1991). Influences on the appropriateness of 
confidence in judgment: Practice, effort, information, and decision-making. 
Organizational Behavior and Human Decision Processes. 48(1), 100-130. ISSN 
0749-597. 
 
Page, AT., Potter, K., Clifford, R., McLachlan, AJ., and Etherton-Beer, C., (2016). 
Medication appropriateness tool for co-morbid health conditions in dementia: 
consensus recommendations from a multidisciplinary expert panel. Internal 
Medicine Journal. 46(10), 1189–1197. doi:10.1111/imj.13215. 
Parke, B., and Hunter, K., (2017). The dementia-friendly emergency department: 
An innovation to reducing incompatibilities at the local level. Healthcare 
Management Forum. 30(1), 26-31. 
Park-Wyllie, LY., Mamdani, MM., Li, P., Gill, SS., Laupacis, A., Juurlin, DN., (2009). 
Cholinesterase inhibitors hospitalisation for bradycardia: A population based 
study. PLoS Med. 6, e1000157. 
Parsons, C. and Gamble, S., 2019. Caregivers’ perspectives and experiences of 
withdrawing acetylcholinesterase inhibitors and memantine in advanced 
dementia: a qualitative analysis of an online discussion forum. BMC Palliative Care, 
18(1). 
Parsons, C., 2017. Polypharmacy and inappropriate medication use in patients with 
dementia: an under researched problem. Therapeutic Advances in Drug Safety, 
8(1), 31-46. 
Parsons, C., and Garribles, S., (2019). Caregivers perspectives and experiences of 
withdrawing acetylcholinesterase inhibitors and memantine in advanced 
dementia: a qualitative analysis of an online discussion forum. BMC Palliative care. 
18, 6 https://doi.org/10.1186/s12904-018-0387-0 
 
Parsons, C., Hughes, CM., Passmore, AP., Lapane, KL., (2010). Withholding, 
discontinuing and withdrawing medications in dementia patients at the end of life: 
a neglected problem in the disadvantaged dying? Drugs Aging. 27(6), 435-449. 
 
Parsons, C., Johnston, S., Mathie, E., Baron, N., Machen, I., Amador, S., & Goodman, C. 
(2012). Potentially inappropriate prescribing in older people with dementia in 
care homes: a retrospective analysis. Drugs & aging, 29(2), 143–155. 
https://doi.org/10.2165/11598560-000000000-00000 
 
Parsons, C., McCorry, N., Murphy, K., Byrne, S., O'Sullivan, D., O'Mahony, D., 
Passmore, P., Patterson, S., Hughes, C., (2014). Assessment of factors that influence 
337 
 
physician decision making regarding medication use in patients with dementia at 
the end of life. International Journal of Geriatric Psychiatry. 29(3), 281–90 
 
Patel, S., and Donyai, P., (2013). Investigating care-home managers views and 
experiences of pharmaceutical services and medication reviews in older people 
using a new questionnaire. International Journal of Pharmacy Practice. 21, 108-
109. 
 
Patients Association, 2019. Care Homes Charter for Medicines (Adults). [online] 
Patients-association.org.uk. Available at: https://www.patients-
association.org.uk/Handlers/Download.ashx?IDMF=18eb2128-b0eb-426c-8649-
9daca1ece735  [Accessed 23 September 2019]. 
 
Paton, C. (2009). Dementia [PowerPoint] Prescribing For People With Dementia. 
[online] available at http://oxleas.nhs.uk/site-media/cms-
downloads/GPmaster8_-_Prescribing.in.Dementia.pdf [accessed 24/09/2019] 
 
Patterson, S., Hughes, C., Crealey, G., Cardwell, C. and Lapane, K., (2010). An 
Evaluation of an Adapted U.S. Model of Pharmaceutical Care to Improve 
Psychoactive Prescribing for Nursing Home Residents in Northern Ireland 
(Fleetwood Northern Ireland Study). Journal of the American Geriatrics Society, 
58(1),44 -53. 
Payne, R. and Duerden, M., 2015. Medicines optimisation in the care home setting. 
Prescriber, 26(9) 20-24. 
Pazan, F., Gercke, Y., Weiss, C., Wehling, M., FORTA raters., (2019). The U.S. FORTA 
(Fit fOR The Aged) list: Consensus validation of a clinical tool to improve drug 
therapy in Older Adults. Journal of the American Medical Directors Association. 0(0). 
 
Pazan, F., Weiss, C., and Wehling, M., (2018). The EURO-FORTA (Fit fOR The Aged) 
List: International Consensus Validation of a Clinical Tool for Improved Drug 
Treatment in Older People. Drugs Aging. 35, 61–71. 
https://doi.org/10.1007/s40266-017-0514-2 
 
Peikari, HR., Shah, MH., Zakaria, MS., Yasin, NM., and Ekhissi, A., (2015). The 
impacts of second-generation e-prescribing usability on community pharmacists’ 
outcomes. Research in Social and Administrative Pharmacy. 11(3), 339-351. 
Peisah, C., Strukovski, J., Wijeratne, C., Mulholland, R., Luscombe, G. and Brodaty, H., 
(2015). The development and testing of the quality use of medications in dementia 
(QUM-D): a tool for quality prescribing for behavioral and psychological symptoms 
of dementia (BPSD). International Psychogeriatrics, 27(8),1313-1322. 
Penna, R., (1990). Pharmaceutical care: pharmacy’s mission for the 1990s. 




Pfister, B., Jonsson, J. and Gustafsson, M., (2017). Drug-related problems and 
medication reviews among old people with dementia. BMC Pharmacology and 
Toxicology, 18(1). 
 
Pharmaceutical Journal, (2019). NHS England fails to fill 240 pharmacy posts in 
care homes by March 2019 deadline. The Pharmaceutical Journal 302, 7925, online 
| DOI: 10.1211/PJ.2019.20206523  
 
Pharmaceutical Services Negotiating Committee (PSNC)., (2016). NHS Community 
Pharmacy Contractual Framework Enhanced Services-Care Home (support and 
advice on storage, supply and administration of drugs and appliances). [online] 
available at: http://psnc.org.uk/services-commissioning/locally-commissioned-
services/service-specifications-and-resources/en5-care-homes/  [accessed 
11/04/2016]. 
 
Pink, Joshua., O’Brien, John., Robinson, Louise., Longson, Damien., (2018).  
Dementia: assessment, management and support: summary of updated NICE 
guidance. BMJ. 361, k2438  
 
Plum, F. (1986) The Pathophysiology of dementia, Gerontology, 32, 67-72. 
 
Poblador-Plou, B., Calderón-Larrañaga, A., Marta-Moreno, J., et al., (2014). 
Comorbidity of dementia: a cross-sectional study of primary care older patients. 
BMC Psychiatry. 14, 1–8. 
 
Poland, F., Mapes, S., Pinnock, H., Katona, C., Sorensen, S., Fox, C. and Maidment, I., 
2014. Perspectives of carers on medication management in dementia: lessons from 
collaboratively developing a research proposal. BMC Research Notes, 7(1), p.463. 
Ponjoan, A., Garre-Olmo, J., Blanch, J., Fages, E., Alves-Cabratosa, L., Martí-Lluch, R., 
Ramos, R., (2019). Epidemiology of dementia: prevalence and incidence estimates 
using validated electronic health records from primary care. Clinical epidemiology. 
11, 217–228. doi:10.2147/CLEP.S186590.   
Powell, T., and Baker, C., (2019). Dementia: policy, services and statistics. Briefing 





Praities, N., (2018). Keith Ridge: “I regret the pain, but this is a watershed moment 





Prentice, A., and Wright, D., (2014). Reducing antipsychotic drugs in care homes. 
Nursing Times. 110(22), 12–15. 
 
Press, D., and Alexander, M., (2019). Treatment of dementia. [online] available at 
https://www.uptodate.com/contents/treatment-of-dementia  [accessed 
18/10/19] last updated 16/01/2018. 
 
Primary Care Pharmacy Association., (2013). Clinical Medication Review: A 
practice Guide. [Online] available at https://pcpa.org.uk/assets/documents/PDF-
medication-review-practiceguide-2011.pdf. [Accessed 13/09/2019] 
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W. and Ferri, C (2013). The 
global prevalence of dementia: A systematic review and meta-analysis. Alzheimer's 
& Dementia, 9(1),.63-75. e2. 
Prince, M., Knapp, M., Guerchet, M., McCrone, P., Matthew, P., Comas-Herrera, A., 
and Salimkumar, D., (2014). Dementia UK: Second edition – Overview (2nd ed., p. 
61). London: Alzheimer’s Society. 
 
Prince, M., Wimo, A., Guerchet, M., Ali, GC., Wu, Yutzu., Prina, M. , (2015). World 
Alzheimer Report. The global impact of dementia: an analysis of prevalence, 
incidence, cost and trends. London: Alzheimer’s Disease International. 
PSNC., (2005). NHS Community pharmacy contractual framework enhanced 
service – Care home. [online] available at  http://psnc.org.uk/wp-
content/uploads/2013/07/en5__care_home_support1.pdf. [accessed 29/04/2017] 
 








Qato, D., Alexander, G., Conti, R., Johnson, M., Schumm, P., and Lindau, S., (2008). 
Use of prescription and over-the-counter medications and dietary supplements 
among older adults in the United States. Journal of the American Medical 
Association. 300(24), 2867. Accessed from 
http://dx.doi.org/10.1001/jama.2008.892 
 
Ramirez-Bermudez, J. (2012) 'Alzheimer's Disease: Critical Notes on the History of 
a Medical Concept', Archives of Medical Research, 43, 595-599. 
 
Rampello, L., Cerasa, S., Alvano, A., Butta, V., Raffaele, R., Vecchio, I., Cavallaro, T., 
Cimino, E., Incognito, T. and Nicoletti, F. (2004) 'Dementia with Lewy bodies: a 




Rapaport, P., Livingston, G., Hamilton, O., Turner, R., Stringer, A., Robertson, S., and 
Cooper, C. (2018). How do care home staff understand, manage and respond to 
agitation in people with dementia? A qualitative study. BMJ Open. 8(6). e022260. 
doi:10.1136/bmjopen-2018-022260 
 
Redmond, V., and Cavan, J., (2011). How to limit antipsychotic use in dementia. The 
Pharmaceutical Journal. 286, 539.  
 
Renn, BN., Asghar-Ali, AA., Thielke, S., Catic, A., Martini, SR., Mitchell, BG., and 
Kunik, ME., (2018). A Systematic Review of Practice Guidelines and 
Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia. 
The American journal of geriatric psychiatry. 26(2), 134–147. 
https://doi.org/10.1016/j.jagp.2017.09.027 
 
Riachi, M., 2016. How pharmacists can help their dementia patients. Canadian 
Pharmacists Journal / Revue des Pharmaciens du Canada, 149(2).67-69. 
 
Richmond, S., Morton, V., Cross, B., Wong, I., Russell, I., Philips, Z., Campion, P., 
(2010). Effectiveness of shared pharmaceutical care for older patients: RESPECT 
trial findings. British Journal of General Practice. 60(570), 10–19. 
http://dx.doi.org/10.3399/bjgp09x473295. 
 
Ringle, Christian M., Wende, Sven., and Becker, Jan-Michael., (2015). SmartPLS 3. 
Bönningstedt: SmartPLS. [online] available at http://www.smartpls.com  [accessed 
8/11/2017]. 
 
Ritchie, K., and Lovestone, S., (2002). The Dementias. The Lancet. 360, 1759-1765 
 
Robinson, L., Tang, E., Taylor, JP., (2015). Dementia: timely diagnosis and early 
intervention. BMJ. 350, h3029 
 
Rochon, P., Gurwitz, JH., Stall, N., Gill, S., (2018). Prescribing Cascade in a Cardiology 
Practice. Available from https://www.acc.org/latest-in-
cardiology/articles/2018/01/08/10/43/prescribing-cascade-in-a-cardiology-
practice  [accessed 21/09/19]. 
 
Roman, G. C. (2002) 'Vascular dementia may be the most common form of 
dementia in the elderly', Journal of the Neurological Sciences, 203-204, 7-10. 
 
Rosenthal M., Austin, Z., Tsuyuki, R., (2010). Are pharmacists the ultimate barrier 
to pharmacy practice change? Canadian Pharmacists Journal. 143, 37. [online] 
available at http://cph.sagepub.com/content/143/1/37  [accessed 26/11/19]. 
 
Royal College of Nursing (2012). Persistent challenges to providing quality care: 
An RCN report on the views and experiences of frontline nursing staff in 
341 
 
carehomes in England. [Online] Available at: 




Royal Pharmaceutical Society (RPS)., (2012). Keeping patients safe when they 
transfer between care providers-getting the medicines right. [online] available at: 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20ac
cess/Publications/Keeping%20patients%20safe%20transfer%20of%20care%20r
eport.pdf  [accessed 02/01/2020]. 
 
Royal Pharmaceutical Society (RPS)., (2014). Pharmacists improving care in care 




Royal Pharmaceutical Society Scotland (RPS)., (2012). Improving Pharmaceutical 
Care in Care Homes. [online] available at: 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20ac
cess/Policy%20statements/pharmacists-improving-care-in-care-homes-
scot.pdf?ver=2016-10-12-142628-923  [accessed 06/10/2013]. 
Royal Pharmaceutical Society Scotland., (2019). Putting residents at the centre of 
pharmacy care home services. [online] available at: 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20ac
cess/Policy/RPS%20Care%20Homes%20policy%202019.pdf  [accessed 
31/10/2019]. 
 
RPS. (2016a). Care home round table report: The right medicine. London: Royal 





Royal Pharmaceutical Society., (2016b). The handling of Medicines in Social Care 
[online] available at: 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20ac
cess/Support/toolkit/handling-medicines-socialcare-guidance.pdf?ver=2016-11-
17-142751-643  [accessed 29/12/19] 
 
Royal Pharmaceutical Society., (2017). Medicines optimisation briefing-Dementia 
[online] available at: 
https://www.cppe.ac.uk/wizard/files/publications/medicines_optimisation_briefi
ng-dementia-online.pdf  [accessed 23/10/2019]. 
342 
 
Royston, C., Mitchell, G., Sheeran, C., Strain, J., and Goldsmith, S., (2017). 
Optimisation of dementia care in care homes: dementia care framework 
(innovative practice). Dementia 0(0):1-9. 
 
 
RPS & CPPE (2017) Medicines optimisation briefing-Dementia [online] available 
at: 
https://www.cppe.ac.uk/wizard/files/publications/medicines_optimisation_briefi
ng-dementia-online.pdf  [accessed 28/12/2019]. 
 
RPS Scotland, 2011. RPS In Scotland’S Response To Review Of NHS Pharmaceutical 
Care Of Patients In The Community - Scotland. [online] Edingburgh: RPS Scotland, 
p.10. Available at: 
https://www.rpharms.com/Portals/0/Documents/Old%20consultations/rps-
scotland-response-to-wilson-barber-review.pdf [Accessed 15 March 2020]. 
RPS Scotland, 2019. Putting Residents At The Centre Of Pharmacy Care Home 
Services. [online] Rpharms.com. Available at: 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20ac
cess/Policy/RPS%20Care%20Homes%20policy%202019.pdf [Accessed 14 
February 2020]. 
RPS Wales, 2008. Improving Medicines Use For Care Home Residents. [online] 
Rpharms.com. Available at: 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20ac
cess/Policy%20statements/improving-medicines-use-for-care-home-residents-
(wales).pdf?ver=2016-10-13-162139-760  [Accessed 13 September 2019]. 
Rubio-Valera, M., Chen, T.F., and O'Reilly, CL., (2014). New roles for pharmacists in 
community mental health care: a narrative review. International journal of 
environmental research and public health. 11(10), 10967–10990. 
https://doi.org/10.3390/ijerph111010967. 
 
Russ, T.C., Calvert, L., and Morling, J. R., (2013). Attitudes to shared care for 
patients with dementia: A survey of general practitioners. Dementia. 12(5), 606–
618. https://doi.org/10.1177/1471301212437781. 
 
Ruths, S., Straand, J., and Nygaard, HA., (2003). Multidisciplinary medication 
review in nursing home residents: what are the most significant drug-related 
problems? The Bergen District Nursing Home (BEDNURS) study. Quality & safety in 
health care. 12(3), 176–180. doi:10.1136/qhc.12.3.176 
Ryu, SH., Ha, JH., Park, DH., Yu, J., and Livingstone, G., (2011). Persistence of 
neuropsychiatric symptoms over six months in mild cognitive impairment in 




Sackett, DL., and Wennberg, JE., (1997). Choosing the best research design for each 
question. BMJ (Clinical research ed.). 315(7123), 1636. 
https://doi.org/10.1136/bmj.315.7123.1636 
 
Saez-Benito, I., Fernades-Llimos, F., Felloto, E., et al., (2013). Evidence of the clinical 
effectiveness of cognitive pharmaceutical services for aged patients. Age and 
Ageing 42, 442-9. 
 
Sahathevan, R., Brodtmann, A., & Donnan, G. A. (2012). Dementia, stroke, and 
vascular risk factors; a review. International journal of stroke : official journal of the 
International Stroke Society, 7(1), 61–73. https://doi.org/10.1111/j.1747-
4949.2011.00731.x 
 
Sahlqvist, S., Song, Y., Bull, F., Adams, E., Preston, J. and Ogilvie, D., 2011. Effect of 
questionnaire length, personalisation and reminder type on response rate to a 
complex postal survey: randomised controlled trial. BMC Medical Research 
Methodology, 11(1). 
Sander, T., and Lee, TP., (2015). The Advantages and Disadvantages of SmartPLS 
Software. [online] available at https://www.semanticscholar.org/paper/The-
Advantages-and-Disadvantages-of-SmartPLS-Sander-
Lee/be336872a6530ae4345e509e39ffb6479d5f3ac0.  [accessed 14/03/2020]. 
 
Sawan, M., O’Donnell, LK., and Hilmer, S., (2019). Perspectives of residential aged 
care facilities’ staff on the identification and recording of residents’ medication-
related goals of care. Australasian Journal on Ageing. 00, 1-11. 
 
Schubert, C., Boustani, M., Callahan, C., Perkins, A., Carney, C., Fox, C., et al., (2006). 
Comorbidity profile of dementia patients in primary care: are they sicker? Journal 
of the American Geriatric Society. 54, 104-109. 
 
Scottish Government, 2013. Review of NHS Pharmaceutical Care Of Patients In The 






scotland/govscot%3Adocument/00430209.pdf  [Accessed 14 March 2017]. 
 
Selkoe, D., (2019). Biogen’s good news on aducanumab could ‘open the floodgates’ 
for Alzheimer’s drugs. [online] available from 
https://www.statnews.com/2019/10/23/aducanumab-news-open-floodgates-




Semple, D. and Smyth, R. (2009) Oxford Handbook of Psychiatry. 2nd Edition edn. 
Oxford: Oxford University Press, p. 128-140. 
 
Shah, S., Carey, I., Harris, T., DeWilde, S. and Cook, D. (2010). Antipsychotic 
prescribing to older people living in care homes and the community in England 
and Wales. International Journal of Geriatric Psychiatry, 26(4), 423-434. 
Sharpe, S., (2013). Future funding deals for community pharmacists will reward 
quality and service provision. The Pharmaceutical Journal. 291, 484. Accessed 
from http://dx.doi.org/10.1211/pj.2013.11129862. 
Shega, J. W., Ellner, L., Lau, D. T., & Maxwell, T. L. (2009). Cholinesterase inhibitor 
and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-
stage dementia: a survey of hospice medical directors. Journal of Palliative 
Medicine, 12(9), 779–783. https://doi.org/10.1089/jpm.2009.0059 
Showkat, N., and Parveen, H., (2017). Non-probability and probability sampling. 
[Online] Available at: 
https://www.researchgate.net/publication/319066480_Non-
Probability_and_Probability_Sampling  [accessed 14/03/2020]. 
 
Silva, C., Ramalho, C., Luz, I., Monteiro, J., and Fresco, P., (2015). Drug-related 
problems in institutionalized, polymedicated elderly patients: opportunities for 
pharmacist intervention. International Journal of Clinical Pharmacy. 37(2), 327–
334. 
 
Sinclair, I., Stanforth, L., and O'Connor, P., (1988). Factors Predicting Admission of 
Elderly People to Local Authority Residential Care. The British Journal of Social 
Work. 18(3), 251–267. https://doi.org/10.1093/oxfordjournals.bjsw.a055437 
 
Sinopoulou, V., Summerfield, P., Rutter, P., (2017). A qualitative study on 
community pharmacists' decision‐making process when making a diagnosis. J Eval 
Clin Pract. 23, 1482– 1488. https://doi.org/10.1111/jep.12837. 
 
 
Smith, D., Lovell, J., Weller, C., Kennedy, B., Winbolt, M., Young, C. and Ibrahim, J., 
2017. A systematic review of medication non-adherence in persons with dementia 
or cognitive impairment. PLOS ONE, 12(2), p.e0170651. 
 
Smith, E., and Wright, C., (2019). Etiology, clinical manifestations and diagnosis of 
Vascular Dementia. In J Wilterdink (Ed). UpToDate. Available at: 
https://www.uptodate.com/contents/etiology-clinical-manifestations-and-
diagnosis-of-vascular-dementia  [accessed 14/10/2019]. 
 
Smith, F., (2010). Conducting your pharmacy practice research: a step-by-step 




Smith, J., and Firth, J., (2011).  ‘Qualitative data analysis: the framework approach’. 
Nurse Researcher. 18(2), 52-62. 
 
Smith, W.E., Ray, M.D., and Shannon, D.M., (2002). Physicians expectation of 
pharmacists. American Journal of Health System Pharmacy. 59(1), 50-57. 
 
Snyder, M., Mican, L., Smith, T. and Barner, J. (2014). Application of STOPP Criteria 
and Beers Criteria in an inpatient psychiatric facility and impact on utilization of 
potentially inappropriate medications and adverse outcomes. Mental Health 
Clinician, 4(4), 201-206. 
Social Care Institute of Excellence (SCIE)., (2018). Delivering integrated care: the 




Sourial, N., Wolfson, C., Zhu, B., Quail, J., Fletcher, J., Karunananthan, S., Bandeen-
Roche, K., Béland, F., and Bergman, H. (2010). Correspondence analysis is a useful 
tool to uncover the relationships among categorical variables. Journal of clinical 
epidemiology, 63(6), 638–646. https://doi.org/10.1016/j.jclinepi.2009.08.008 
 
Spilsbury, K., Bake,r J., Alldred, DP., (2016). Administration of medicines in care 
homes (with nursing) for older people by care assistants: Developing evidence-
based guidance for care home providers. Summary of evidence. University of 
Leeds. 
 
Spinewine, A., Schmade, KE., Barber, N., Hughes, C., Lapane, KL., Swine, C., Hanlon, 
JT., (2007). Appropriate prescribing in elderly people: how well can it be measured 
and optimised? Lancet. 370(9582), 173-84. 
 
Stafford, A., 2020. The Pharmacist’S Role In Supporting People Living With Dementia 
In The Community. [online]  Available at: 
http://hdl.handle.net/20.500.11937/34288 [Accessed 20/03/2020]. 
Steinberg, M., Shao, H., Zandi, P., Lyketsos, CG., Welsh‐Bohmer, KA., Norton, MC., et 
al., (2008). Point and 5‐year period prevalence of neuropsychiatric symptoms in 
dementia: The Cache County Study. International journal of geriatric psychiatry. 
23(2), 170-7. 
 
Stocks, SJ., Kontopantelis, E., Webb, RT., Avery, AJ., Burns, A., and Ashcroft, DM., 
(2017). Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a 
Diagnosis of Psychosis in the Context of National Guidance and Drug Safety 
Warnings: Longitudinal Study in UK General Practice. Drug safety. 40 (8), 679–692. 
doi:10.1007/s40264-017-0538-x. 
 
Surr, C. A., Shoesmith, E., Griffiths, AW., Kelley, R., McDermid, J., and Fossey, J., 
(2019). Exploring the role of external experts in supporting staff to implement 
346 
 
psychosocial interventions in care home settings: results from the process 
evaluation of a randomized controlled trial. BMC health services research. 19(1), 
790. doi:10.1186/s12913-019-4662-4. 
 
Sury, L., Burns, K., and Brodaty, H., (2013). Moving in: Adjustment of people living 
with dementia going into a nursing home and their families. International 
Psychogeriatrics. 25(6), 867–876. 
Sutton, R. T., Pincock, D., Baumgart, D. C., Sadowski, D. C., Fedorak, R. N., & Kroeker, 
K. I. (2020). An overview of clinical decision support systems: benefits, risks, and 
strategies for success. NPJ Digital Medicine, 3, 17. 
https://doi.org/10.1038/s41746-020-0221-y 
 
Swift, A., (2018). Improving medicines optimisation for care home residents: A 
Wigan Borough CCG’s approach. Clinical Pharmacist. 10(3), online | DOI: 
10.1211/CP.2018.20204291. 
 
Szczepura, A., Wild, D., Khan, AJ., et al., (2016). Antipsychotic prescribing in care 
homes before and after launch of a national dementia strategy: an observational 
study in English institutions over a 4-year period.  BMJ Open. 6, e009882. doi: 
10.1136/bmjopen-2015-009882 
 
Taachi, J., (2019). Funding for Primary Care Networks Explained | Gponline. [online] 
Gponline.com. Available at: https://www.gponline.com/funding-primary-care-
networks-explained/article/1594716 [Accessed 16/03/2020]. 
Takahashi, S. (2006) 'Vascular dementia: possible role of the ischaemic lesions in 
mild dementia Psychogeriatrics 6(s1): 10.1111/j.1479-8301.2006. 00135.x   
Tampi, R., Tampi, D., Balachandran, S. and Srinivasan, S., 2016. Antipsychotic use in 
dementia: a systematic review of benefits and risks from meta-analyses. 
Therapeutic Advances in Chronic Disease, 7(5), pp.229-245. 
Taylor, D., (2009). Living with Medicines for Dementia - Patient and Carer 
Perspectives. London: Pharmacy Practice Research Trust [online] available at: 
https://www.researchgate.net/publication/237312214_Living_with_Medicines_fo
r_Dementia_-_Patient_and_Carer_Perspectives  [accessed 01/03/2020] 
The Pharmaceutical Journal, (2015). Giving pharmacists access to summary care 
records will improve patient care. The Pharmaceutical Journal, 285(7870). 
The Pharmaceutical Journal, (May 2019) 302, 7925, online | DOI: 
10.1211/PJ.2019.20206523 
Thompson Coon, J., Abbott, R., Rogers, M., Whear, R., Pearson, S., Lang, I., et al. 
(2014). Interventions to reduce inappropriate prescribing of antipsychotic 
medications in people with dementia resident in care homes: a systematic review. 






Thraves, L., (2016). Role of pharmacists in improving healthcare for people with 
dementia living in care homes (presentation in The Kings’s Fund: Commissioning 
person-centred care for vulnerable groups: what role does pharmacy play?). 
[Online] available at: https://www.kingsfund.org.uk/events/commissioning-
person-centred-care-vulnerable-groups-what-role-does-pharmacy-play  [accessed 
21/02/2020]. 
Tible, O.P., Riese, F., Savaskan, E,. and Von Gunten A.. (2017). Best Practice in the 
management of behavioural and psychological symptoms of dementia. Therapeutic 
Advances in Neurologic Disorders. 10(8), 297-309. 
 
Tipton, PW., and Graff-Radford, NR., (2018). Prevention of late‐life dementia: what 
works and what does not. Polish Archives of Internal Medicine. 128(5) 
 
Tommelein, E, Mehuys, E Van Tongelen, I, Petrovic, M., Somers, A, Colin, P, (2017) 
Community pharmacists’ evaluation of potentially inappropriate prescribing in 
older community-dwelling patients with polypharmacy: observational research 
based on the GheOP³S tool, Journal of Public Health, 39(3), 583–592, 
https://doi.org/10.1093/pubmed/fdw108 
 
Tommelein, E., Mehuys, E., Petrovic, M., Somers, A., Colin, P. and Boussery, K. 
(2015) Potentially inappropriate prescribing in community-dwelling older people 
across Europe: a systematic literature review. European Journal of Clinical 
Pharmacology, 71(12), 1415-1427. 
 
Tommelein, E., Petrovic, M., Somers, A., Mehuys, E., van der Cammen, T., and 
Boussery, K. (2016). Older patients' prescriptions screening in the community 
pharmacy: development of the Ghent Older People's Prescriptions community 
Pharmacy Screening (GheOP³S) tool. Journal of Public Health (Oxford, England), 
38(2), e158–e170. https://doi.org/10.1093/pubmed/fdv090 
 
Tong, A., Sainsbury, P. and Craig, J., 2020. Consolidated Criteria For Reporting 
Qualitative Research (COREQ): A 32-Item Checklist For Interviews And Focus Groups. 
[online] Available at: http://dx.doi.org/10.1093/intqhc/mzm042 [Accessed 
20/03/2017]. 
Torjesen, I., (2018). Access to patient records: Britain lags behind other countries. 
The Pharmaceutical Journal. 300(7909), online | DOI: 10.1211/PJ.2018.20204251. 
 
Truter, I., (2013). Antipsychotic drug prescribing to patients with dementia in a 
South African patient population. African Journal of Pharmacy and Pharmacology. 
7(41), 2755-2762. DOI: 10.5897/AJPP2013.3893. 
 





UK Care home, residential and nursing home search, carehome.co.uk., (2016). 
[online] available at: http://www.carehome.co.uk/care_search.cfm. [accessed 
11/04/2016] 
Urbona, G., and Kubiliene, L., (2016). Assessing the relationship between 
pharmacists’ job satisfaction and over-the-counter counselling at community 
pharmacies. International Journal of Clinical Pharmacy. 38(2), 252-260 
van Dalen-Kok, A. H., Achterberg, W. P., Rijkmans, W. E., Tukker-van Vuuren, S. A., 
Delwel, S., de Vet, H. C., Lobbezoo, F., and de Waal, M. W. (2017). Pain Assessment 
in Impaired Cognition (PAIC): content validity of the Dutch version of a new and 
universal tool to measure pain in dementia. Clinical Interventions in Aging, 13, 25–
34. https://doi.org/10.2147/CIA.S144651. 
 
van de Pol, J., Koster, E., Hövels, A., Bouvy, M., (2019). Balancing traditional 
activities and cognitive pharmaceutical services by community pharmacists: a 
work sampling study. International Journal of Clinical Pharmacy 41(4), 872–879. 
doi:10.1007/s11096-019-00852-0. 
 
Van den Bemt, PM., Idzinga, JC., Robertz, H., Kormelink, DG., and Pels, N., (2009). 
Medication administration errors in nursing homes using an automated dispensing 
system. Journal of the American Geriatrics Society. 57, 266-272 
 
van der Spek, K., Gerritsen, D., Smalbrugge, M., Nelissen-Vrancken, M., Wetzels, R., 
Smeets, C., Zuidema, S. and Koopmans, R., 2015. A reliable and valid index was 
developed to measure appropriate psychotropic drug use in dementia. Journal of 
Clinical Epidemiology, 68(8), 903-912. 
van Marum, RJ., (2017). Polypharmacy in Nursing Home Residents with Dementia. 
In: Schüssler S., Lohrmann C,. (eds). Dementia in Nursing Homes. Springer, Cham. 
 
van Mil JWF., (2019). Definitions of Pharmaceutical Care and Related Concepts. In: 
Alves da Costa F., van Mil J., Alvarez-Risco A., (eds). The Pharmacist Guide to 
Implementing Pharmaceutical Care. Springer, Cham. 
 
Varnish, J., (1998). Drug pushers or health care professionals: The public’s 
perceptions of pharmacy as a profession. International Journal of Pharmacy 
Practice. 6(1), 13–21.  http://dx.doi.org/10.1111/j.2042-7174.1998.tb00911.x. 
 
Verbeek, H., Meyer, G., Leino-Kilpi, H., Zabalegui, A., Hallberg, I., Saks, K., Soto, M., 
Challis, D., Sauerland, D. and Hamers, J. (2012) A European study investigating 
patterns of transition from home care towards institutional dementia care: the 
protocol of a RightTimePlaceCare study. BMC Public Health, 12(1). 
Waterfield, J., (2010). Is Pharmacy a knowledge-based profession? American 




Webber, J., (2015). Pharmacy and care homes. London: General Pharmaceutical 
Society (GPhC). [online] available from 
https://www.pharmacyregulation.org/sites/default/files/pharmacy_and_care_ho
mes_report_by_jo_webber_december_2015.pdf [accessed 21/10/2016] 
 
Weidmenmayer, K., Summers, R., Mackie, C., Gous, A., Everard, M., Tromp, D., 
(2006). Developing pharmacy practice: A focus on Patient Care. Geneva. World 
Health Organisation and International Pharmaceutical Federation.  
 
Wilkinson, E., (2018). Why are few pharmacies using the summary care record?. 
The Pharmaceutical Journal. 301(7918), online|DOI:10.1211/PJ.2018.20205619 
 
Willemse, BM., De Jonge, J., Smit, D., Visser, Q., Depla, MF,. and Pot AM., (2015). 
Staff’s person-centredness in dementia care in relation to job characteristics and 
job-related well-being: a cross-sectional survey in nursing homes. Journal of 
Advanced Nursing. 71(2), 404-16. doi: 10.1111/jan.12505 
 
Winit-Watjana, W., (2016). Research philosophy in pharmacy practice: necessity 
and relevance. International Journal of Pharmacy Practice. 24(6), 428-436.  
436.10.1111/ijpp.1228 
 
Wold, Herman., (1975). Path models and latent variables: The NIPALS approach. 
In: Blalock, HM., Aganbegian, A., Borodkin, FM., Boudon,R., & Capecchi, V., eds. 
Quantitative sociology: International perspectives on mathematical and statistical 
modeling. NY: Academic Press. pp. 307-357.  
 
Wolters F.J., van der Lee S.J., Koudstaal P.J., van Duijn C.M., Hofman, A., Ikram, M.K., 
Vernooij, M.W., and Ikram M.A. (2017) Parental family history of dementia in 




World Health Organization. (1992). The ICD-10 classification of mental and 
behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: 
World Health Organization. 
 
World Health Organisation (WHO) (2006) Neurological Disorders: Public Health 
Challenges, Geneva: World Health Organisation. 
 
World Health Organisation (WHO) (2012) . Dementia: A Public Health Priority. 






World Health Organisation (WHO) (2015). The epidemiology and impact of 
dementia: current state and future trends. Geneva: World Health Organization. 
Document WHO/MSD/MER/15.3, available at 
https://www.who.int/mental_health/neurology/dementia/dementia_thematicbri
ef_epidemiology.pdf  [accessed 29/02/2020]. 
 
World Health Organisation (WHO) (2017) Global action plan on the public health 
response to dementia 2017–2025. Geneva: World Health Organization. License: CC 
BY-NC-SA 3.0 IGO. 
 
World Health Organisation (WHO) (2019). Dementia. [online]  Available at: 
https://www.who.int/news-room/fact-sheets/detail/dementia  [Accessed 
18/12/2019]. 
World Population Ageing, (2009.) New York: United Nations. 
Wortmann, M. (2012). Dementia: a global health priority - highlights from an ADI 
and World Health Organization report. Alzheimer's Research & Therapy, 4(5). 
Wouters, H., Quik, E., Boersma, F., Nygard, P., Bosman, J., Bottger, W., et al. (2014) 
Discontinuing Inappropriate Medication in Nursing Home Residents (DIM-NHR 
Study): Protocol of a cluster randomised controlled trial. BMJ Open. 4, e0066082 
doi: 10.1136/bmjopen-2014-006082 
Wouters, H., Scheper, J., Koning, H., Brouwer, C., Twisk, JW., van der Meer, H,. et al. 
(2017). Discontinuing Inappropriate Medication Use in Nursing Home Residents: A 
Cluster Randomized Controlled Trial. Annals of Internal Medicine. 167. 609–617. 
doi: https://doi.org/10.7326/M16-2729 
 
Wright, D (2016). A Rapid Review Of Evidence Regarding Clinical Services 
Commissioned From Community Pharmacies. [online] Norwich: NHS England, 




Wright, D. J., Maskrey, V., Blyth, A., Norris, N., Alldred, D. P., Bond, C. M., 
Desborough, J., Hughes, C. M., & Holland, R. C. (2019). Systematic review and 
narrative synthesis of pharmacist provided medicines optimisation services in care 
homes for older people to inform the development of a generic training or 
accreditation process. The International journal of pharmacy practice, 
10.1111/ijpp.12591. Advance online publication. 
https://doi.org/10.1111/ijpp.12591 [accessed 19/10/2019] 
 
Xiao S., Wang T., Ma, X., et al. (2017). Efficacy and safety of a novel 
acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate 




Yi Mohammadi, J., Franks, K. and Hines, S. (2015). Effectiveness of professional oral 
health care intervention on the oral health of residents with dementia in 
residential aged care facilities: a systematic review protocol. JBI Database of 
Systematic Reviews and Implementation Reports, 13(10), 110-122. 
Zerafa, N. and Scerri, C., (2016). Knowledge and pharmacological management of 
Alzheimer’s disease by managing community pharmacists: a nationwide study. 
International Journal of Clinical Pharmacy, 38(6), 1416-1424. 
Zhang, Q., Kim, Y. C., & Narayanan, N. S. (2015). Disease-modifying therapeutic 
directions for Lewy-Body dementias. Frontiers in neuroscience, 9, 293. 
https://doi.org/10.3389/fnins.2015.00293 
 
Zotova, E., Nicoll, J., Kalaria, R., Holmes, C., & Boche, D. (2010). Inflammation in 
Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimer's Research 
& Therapy, 2(1), 1.  
doi: 10.1186/alzrt24  
 
Zuliani, G., Galvani, M., Sioulis, F., Bonetti, F., Prandini, S., Boari, B., Guerzoni, F., and 
Gallerani, M., (2012). Discharge diagnosis and comorbidity profile in hospitalized 
older patients with dementia. International Journal of Geriatric Psychiatry. 27, 313–
20. 
 
Zwietering, N., Westra, D., Winkens, B., Cremers, H., van der Kuy, P. and Hurkens, 
K., (2019). Medication in older patients reviewed multiple ways (MORE) study. 













Appendix 1: Theses related publications  
1. Apampa B, Navti B. Medicines optimization in the dementias. Nurse 
Prescribing. 2014; 12(11): 567- 60. 
https://doi.org/10.12968/npre.2014.12.11.557 
 
2. Navti, B., & Apampa, B. (2019). Pharmaceutical care services to people living 
with dementia in care homes: A qualitative study of community pharmacists’ 
perceptions. Dementia, 18(6), 2282–2302. 
































Appendix 2: Conference Abstracts (College of Mental Health 
Pharmacists Annual Conference October 2018, Loughborough 
United Kingdom) 
 
A. Pharmaceutical care services to people living with dementia in care 
homes: A quantitative study of community pharmacy services 
 
Bongkwati Navti B1, Manfrin A2, Apampa B2 
1 North East London NHS Foundation Trust (NELFT) and Sussex Pharmacy, School 
of Life Sciences, University of Sussex (UK) 
2 Sussex Pharmacy, School of Life Sciences, University of Sussex (UK) 
 
Background/Introduction  
Dementia poses a great challenge for health care systems worldwide, with the 
population of affected people over the age of 60 estimated to reach 2 billion by the 
year 20501. Dementia is acknowledged as being one of the strongest determinants 
of entry into residential care in people aged over 65 and up to 69% of care home 
residents are living with dementia.  
While the care home service from community pharmacies is currently provided as 
an enhanced service in the community pharmacy contractual framework, a 
Pharmacy Integration Fund (PhIF) 2 launched in 2015 is included in the new 
funding arrangements for community pharmacy in England.  
A key priority for the PhIF is to deploy pharmacists and pharmacy services to 
primary care settings including GP practices and care homes. This is a welcome 
development for care home residents, particularly those with chronic, progressive 
diseases such as dementia.  
It is therefore important to establish the nature and extent of the current 
pharmaceutical services provided to care homes including those that have 
residents living with dementia. 
Aim 
To identify the nature and assess the extent of pharmaceutical services provided to 
people living with dementia in care homes in England. 
Objectives:  
• To identify the nature of pharmaceutical services provided to care homes 
• To assess the extent of pharmacy services provided to care homes 
Methods/Design 
A questionnaire (survey) was distributed to a random sample of community 
pharmacists across England. Data were analysed using SPSS version 24. 
Categorical variables were analysed using Pearson chi square for goodness of fit. 
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Ethical approval was obtained from the University of Sussex cross-schools 
research ethics committee (C-REC). 
Results 
102 pharmacists participated in this study. 57% were female (p<0.166). A 
statistical significant difference was found within the age groups (p=0.003), the 
most represented being 25-29 years (24%), the least 55-59 years (5%) (p=0.003). 
Seventy-five percent were managers or independent pharmacists, 11% locums; 
and 5% second pharmacists (p<0.001). The majority of pharmacists (68%) 
entered the pharmacy register after 2000.  
31% of pharmacists provided services to care homes (p<0.001). Nineteen of the 
care homes had residents with dementia.  
 
Discussion and Conclusion 
The main pharmaceutical service provided by pharmacists was the dispensing of 
medicines in monitored dosage systems and delivery to the home. While the 
deployment of clinical pharmacists to care homes can greatly improve disease 
management in residents (Royal Pharmaceutical Society 2016)3, only one third of 
the pharmacists surveyed in our study provided cognitive services to care homes. 
There is thus an overwhelming need for a bespoke model of community 
pharmaceutical services for dementia patients that is responsive to patients' 
needs. However, the precise pharmaceutical care needs of people living with 
dementia in care homes still need to be clearly defined. Additionally, most of the 




1. Alzheimer's Disease International. (2016). World Alzheimer Report. Improving 
healthcare for people living with dementia: Coverage, quality and costs now and in the 
future. London. Available at: 
https://www.alz.co.uk/research/WorldAlzheimerReport2016.pdf [accessed 30 Oct. 
2016]  
2. NHS Commissioning Pharmacy Integration Fund. (2016). England.nhs.uk. Available 
at:   
https://www.england.nhs.uk/commissioning/primary-care-
comm/pharmacy/integration-fund/ Google Scholar [accessed 1 Nov. 2016]    
3. RPS. (2016). Care home round table report: The right medicine. London: Royal 
Pharmaceutical Society. Available at: 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20acces
s/Publications/Care%20Homes%20Round%20Table%20Report.pdfGoogle Scholar 







B. Pharmaceutical care in dementia: a quantitative analysis utilising path 
modelling for evaluating the relationships between knowledge, 
barriers to care, understanding and confidence of pharmacists 
providing pharmaceutical services (shortlisted for an award in the 
category of ‘original research’) 
Background/Introduction 
All healthcare professionals can play a role in dementia care; pharmacists have a 
critical role in optimising drug therapy in dementia.  
Pharmacists should be responsible for medicines use in care homes1, however 
such services will require explicit knowledge and a reduction of barriers to care2. 
The Pharmacy Integration Fund aims to support community pharmacy as it 
develops new clinical pharmacy services including services to care homes.   
Aim 
 To evaluate the relationship between knowledge, barriers, understanding and 
confidence of pharmacists providing services to dementia patients in care homes 
Objectives:  
• To identify the path coefficients between knowledge, barriers, understanding 
and confidence of pharmacists using a path model 





A postal questionnaire (survey) was distributed to a random sample of community 
pharmacists across England.  Due to the small sample size and non-parametric 
nature of the data, analysis was conducted with SmartPLS (Ver. 3.2.7), using partial 
least squares (PLS) path modelling. The analysis involved a series of ordinary 
squares regressions and bootstrapping recommended for assessing statistical 
validity (p<0.05) of non-normal variables with 500 iterations and t>1.96. Ethical 
approval was obtained from the University of Sussex cross-schools research ethics 
committee (C-REC). 
Results 
102 pharmacists completed the survey. Negative effects of the standardized path 
coefficients were found between knowledge and barriers to care (β= -0.151), and 
between barriers to care and understanding/confidence (β= -0.098). Positive 
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effect of the standardized path coefficient was found between knowledge and 
understanding-confidence (β= +0.672). A statistically significant linear 
relationship was only found between knowledge and understanding-confidence 
(t=12.70; p<0.001). The model explained 48.1% (R2=0.481) of the variance of 
understanding/confidence. Notably 91% of pharmacists surveyed were interested 
in receiving training on dementia. 
Discussion and Conclusion 
The path model demonstrates that knowledge and confidence decrease when 
barriers to care increase. Similar findings were identified in another study3. The 
results suggest a training need for pharmacists in dementia. 
 
References 
1. Royal Pharmaceutical Society (RPS). (2014). Pharmacists improving care in care homes. 
London: Royal Pharmaceutical Society (RPS). Retrieved October 5, 2015, 
from http://www.health.org.uk/sites/health/files/Shine2012_NorthumbriaHealthcar
eNHSFoundationTrust_RPSGuidancePharmacistsImprovingCareInCareHomes.pdf Goo
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https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482839/ [Accessed 29 Jun. 2018]. 
 
3. Maidment, I., Aston, L., Hilton, A., Iqbal, N., Child, A., Shaw, R. (2016). Role of 
community pharmacists in the use of antipsychotics for behavioural and psychological 





Appendix 3a: University of Sussex Certificate of Approval-
ER/BN67/1 
 






Appendix 3b: Letter of invitation to participate in the study 
 
Dear Pharmacist,        Date 
 
Pharmaceutical Care in Dementia: Exploring the views of pharmacists about 
the pharmaceutical care needs of dementia patients living in care homes 
 
I am carrying out a pilot study to explore the pharmaceutical care needs of patients 
with dementia living in care homes in England, from the perspectives of selected 
community pharmacists. A care home has identified you as a possible participant 
for this study.  
 
The study will involve a short face-to-face interview (30 minutes) that will explore 
your views about the medicines-related needs of these patients. I will also seek 
your opinion regarding the training needs of pharmacists who provide pharmacy 
services to these patients. 
 
Information obtained will be digitally recorded, transcribed verbatim and 
anonymised. Themes emerging will inform the development of a questionnaire to 
be used in the wider survey of community pharmacists involved in dementia care 
in England. I would like to assure you that any information obtained will be kept 
strictly confidential and stored securely at the School. 
 
You are formally invited to participate in this study. I will contact you by telephone 
within five working days to ascertain whether you are interested in taking part and 
to answer any questions that you may have.   
 
If you decide to participate, I will arrange a time that is convenient for you for the 
interview, and you will be sent an information pack in the post, together with a 
consent form.  Please return the signed consent form in the pre-paid envelope that 
is provided.  
 
Before the commencement of the interview, you will be given an opportunity to 
ask any questions about the study. Please note that you may withdraw from the 
study at any time if you wish to. 
 
If you have any further questions, please contact me on 07811264808 
 










Appendix 3c: Participant Information Sheet 
 
STUDY TITLE  
Pharmaceutical Care in Dementia: Exploring the views of pharmacists about the 
pharmaceutical care needs of dementia patients living in care homes  
 
Name of Researcher: Beryl B Navti  
 
You are being invited to take part in a study. Before you decide if you want to take part, 
you must understand why the study is being done and what it involves. Please take time to 
read the following information and to decide if you want to take part or not.  
 
WHAT IS THE PURPOSE OF THE STUDY?  
The purpose of this study is to explore community pharmacists’ views of community 
pharmacy services to patients with dementia in care homes in your locality. The World 
Health Organisation regards a close working relationship between primary care 
practitioners (e.g. GPs, nurses, pharmacists) as essential for appropriate care of patients. 
This study aims to find out to what extent pharmacists are contributing to the care being 
provided and how they can better meet the needs of these patients.  
 
WHY HAVE I BEEN INVITED TO PARTICIPATE?  
The study is being carried out with selected community pharmacists in your locality who 
provide services to care homes with dementia patients.. These pharmacists were 
identified by enlisting the help of care homes in the area that are registered as having 
dementia patients on the website www.carehome.co.uk  
 
DO I HAVE TO TAKE PART?  
No. It is up to you to decide whether or not to take part. Even if you agree to take part, you 
can change your mind at any time without giving any reason. If you decide not to take part 
in the study, your rights will not be affected in any way. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form.  
 
WHAT WILL HAPPEN TO ME IF I TAKE PART?  
The study will involve a short face to face interview with the researcher. You will be asked 
questions about the services you provide. The interview will take place at your pharmacy 
if this is convenient, will follow an interview schedule and should take no longer than 30 
minutes. The interview session will be recorded with your permission. Any information 
obtained will be kept strictly confidential. Quotes maybe used from interviews but these 
will be anonymised and all tapes will be deleted at the end of the study. If you agree to 
take part, you will be asked to sign a consent form.  
 
WHAT ARE THE POSSIBLE DISADVANTAGES AND RISKS OF TAKING PART? (WHERE 
APPROPRIATE)  
The only risk anticipated would be that the questions will require you to set aside a small 
portion of your time, which could be an inconvenience. However, every effort will be made 
to interview you at a time that is most convenient for you.  
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WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART?  
Answering the questions may help identify any learning needs you may have with regards 
to the pharmaceutical care of patients with dementia living in the care homes you provide 
services to. You will be provided with a summary of the results obtained from the study if 
you indicate a wish to receive this information.  
 
WILL MY INFORMATION IN THIS STUDY BE KEPT CONFIDENTIAL?  
We will not tell anyone that you have taken part in the study. Once the data from the 
interview is transcribed and analysed, the results will be used to inform the development 
of a survey instrument for a larger sample of community pharmacists. Any personal data 
collected during the course of the pilot study will only be used for academic and research 
purposes. All anonymised transcripts will be stored for 5 years after completion of the 
study and then shredded.  
 
WHAT SHOULD I DO IF I WANT TO TAKE PART?  
If you would like to take part in this study, please sign the consent form attached and 
return in the pre-paid envelope.  
 
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY?  
Information obtained will be digitally recorded and transcribed verbatim. Themes 
emerging will inform the development of a questionnaire to be used in the wider survey of 
community pharmacists involved in dementia care in England  
 
WHO IS ORGANISING THE RESEARCH?  
This study is being undertaken by the researcher who is a pharmacy student at the 
University of Sussex  
 
WHO HAS APPROVED THIS STUDY?  
This study has been approved by the Science and Technology Cross-Schools Research 
Ethics Committee (C-REC) ethical review process at the University of Sussex.  
Email: crecscitec@sussex.ac.uk 
  
CONTACT FOR FURTHER INFORMATION  
You may contact the academic supervisor at the address below.  
Dr Bugewa Apampa, Director of Pharmacy Development, School of Life Sciences University 
of Sussex, Falmer Brighton  
Tel: 01273 873756|Email: b.apampa@sussex.ac.uk 
  
THANK YOU  
















Appendix 3d: Participant consent form 
 
Participant CONSENT FORM for INTERVIEW 
 
Title of Project: 
 
Pharmaceutical Care in Dementia: Exploring the views of pharmacists about 
the pharmaceutical care needs of dementia patients living in care homes 
 
Name of Researcher: Beryl B Navti 
 
I have read and understand the information provided for the above 
study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily 
Initial 
Here 
I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving a reason and that this will not 
affect my legal rights 
Initial 
Here 
I understand that any personal information collected during the study 
will be anonymised and remain confidential 
Initial 
Here 
I understand that the interview will be digitally audio recorded and that 
this recording will be transcribed verbatim 
Initial 
Here 
I understand that verbatim quotes taken from the recording of our 
conversation may be used in publications and reports, but that these will 
be anonymised and not traceable to me 
Initial 
Here 




Name of Participant (Print) 
 
Signature          Date 
 
 
Name of Researcher (Print) 
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Appendix 3f: The Interview schedule 
 
Pharmaceutical Care in Dementia: Exploring the views of pharmacists about the 
pharmaceutical care needs of dementia patients living in care homes  
 
Interview Schedule  
 
I would like to thank you for consenting to participate in this study. Have you got any 
questions you would like to ask me about the study before we start the interview?  
Services  
1. How many care homes do you provide services to?  
2. What are the main services that you provide?  
3. What proportion of residents in the care homes suffer from dementia?  
4. What are the pharmaceutical care needs of people with dementia?  
5. Are the services you provide sufficient to cater for their needs, if so how?  
 
Medicines Optimisation  
6. What dementia medicines do you supply to these patients?  
7. What issues do you consider when dispensing prescriptions for dementia patients?  
8. What are the main adverse effects of these medicines?  
9. What clinically significant interactions would you consider during screening of 
prescriptions for dementia patients?  
10. Do you offer a medication review service to the care homes, if so, what are the 
components?  
 
Access to records  
11. Describe any barriers to pharmaceutical care provision that you may face  
12. Are you able to access patient care records in care homes? If so, how?  
 
Training  
13. Briefly explain the behavioural and psychological symptoms of dementia?  
14. Describe the knowledge and skills that you consider essential for a comprehensive 
pharmaceutical care service to dementia patients?  
15. What dementia- related training have you undertaken in the past year?  
16. Are you involved in training care home staff? If so what training do you provide?  
 
Pharmacist demographics  
17. Year of registration as pharmacist in the UK…………………………………………..  
18. Post graduate qualifications………………………………………………………………….  
19. Gender…………………………………………………………………………………………………  
20. Practice type and location…………………………………………………………………….  
21. Position held in pharmacy…………………………………………………………………….  






Appendix 3g: Consolidated criteria for reporting qualitative 
research (COREQ Guidelines) 
Domain 1: Research team and reflexivity 
1. Who conducted the interviews or the focus group? 
The interviews were conducted by the researcher (BN) 
2. What were the researcher’s credentials? 
The researcher (BN) is a qualified pharmacist with many years’ experience in the community 
pharmacy sector. 
BN has experience working with people living with dementia in care homes and BA (research 
supervisor) is an experienced pharmacy practice researcher. 
3. What was their occupation at the time of the study? 
BN is an advanced mental health pharmacist and part time PhD researcher and BA was a professor 
of pharmacy education and director of pharmacy at the University of Sussex. 
4. Was the researcher male or female? 
Female 
5. What experience or training did the researcher have? 
BN is an advanced mental health pharmacist experienced in dementia care and completed a module 
at the Brighton and Sussex Medical School on research methods. BA (research supervisor) has 
conducted numerous qualitative research projects in her capacity as pharmacy educator and 
academic supervisor. 
6. Was a relationship established prior to study commencement? 
BN was personally acquainted with one of the study participants in the Thurrock arm of the study 
but did not know any of the Kent participants prior to the commencement of the study. Full 
informed consent was obtained. BN conducted the interviews and formally introduced herself and 
the topic before the interview this included explaining her current role in the project. 
7. What did the participants know about the researcher? 
The participants knew that BN was a pharmacist, and a postgraduate student at the University of 
Sussex, and that BA was her academic supervisor. 
8. What characteristics were reported about the interviewer/facilitator? 
BN reported that she was working as a pharmacist and a postgraduate student at the University of 
Sussex. BA was reported as the academic supervisor who could be contacted for further 
information on the study. This information was included in the participant information sheet 
provided to participants prior to them consenting to take part in the study. 
 
Domain 2: Study design 
9. What methodological orientation was stated to underpin the study? 
An exploratory, qualitative study was conducted face-to-face semi-structured interviews. 
Data were analysed using a thematic framework approach for sorting, categorisation and 
interpretation of recorded interviews. 
10. How were participants selected? 
Pharmacists were eligible if they worked in pharmacies that provide services to care homes 
catering for people with dementia or have a mixed clientele which include patients with dementia. 
The pharmacies were eligible if they were in the geographical area chosen for the study. 
11. How were participants approached? 
Care homes in the Thurrock and Kent areas that have people living with dementia, or a mixture of 
dementia and non-dementia patients were identified by searching the website, 
http://www.carehome.co.uk/ (2014). This lists a database of care homes within England and Wales 
by post code, as well as by the nature of services provided. The dementia care homes in the selected 
areas were identified via this website. The Thurrock and Kent areas were selected for this study for 
convenience purposes. 
BN contacted the identified care homes by telephone to ascertain the pharmacy responsible for 
their pharmaceutical services. The contact details of the pharmacies were then confirmed through 
the NHS Choices website (2014) and pharmacists working in the registered pharmacies identified 
by the care homes were contacted by BN and invited to participate in the study. 
Participants were informed that they were selected because they delivered pharmaceutical services 
to care home(s) that had residents living with dementia. They could contact either BN or BA at any 




12. How many participants were in the study? 
There were 16 pharmacists (15 community pharmacists and one primary care pharmacist). 
13. How many people refused to participate or dropped out? 
One participant dropped out after obtaining more detail about the study. 
14. Where was the data collected? 
Each participant was contacted to arrange a face-to-face interview to be held in the pharmacy 
premise’s consulting room, at a time of their convenience. 
15. Was anyone else present besides the participants and researchers? 
No-one else was present, but there were constant interruptions as participants often had to stop 
recording to deal with queries and conduct clinical checks of prescriptions within the pharmacy. 
16. What are the important characteristics of the sample? 
Pharmacists selected to participate worked in pharmacies that provided pharmaceutical services to 
care homes that had residents living with dementia, within the localities chosen for the study. 
17. Were questions, prompts, guides provided by the authors? Was it pilot tested? 
The interview schedule consisted of a combination of open ended and closed questions. The open 
ended questions enabled participants to express themselves without being led by the researcher. 
The questions were not piloted. 
18. Were repeat interviews carried out? 
No interviews were repeated. 
19. Did the research use audio or visual recording to collect the data? 
An audio recorder was used to record the interviews. Data were transcribed verbatim. 
20. Were field notes made during and/or after the interview? 
When participants raised issues not covered by the interview schedule, notes were made during the 
interviews. 
21. What was the duration of the interviews? 
There was no formal restriction on the duration of the interviews, but BN and BA agreed that 
interviews would last on average 20–30 minutes. During the study, the shortest interview last 10 
minutes and the longest 34 minutes. 
22. Was data saturation discussed? 
Data saturation was reached in both localities of the study and discussed and agreed between the 
researcher and research supervisor. 
23. Were transcripts returned to participants for comment and/or correction? 
Transcripts were not returned to participants but emerging themes were discussed between the 
researcher and research supervisor 
A note was taken of all participants who wanted to be sent the report once the study was 
completed. 
 
Domain 3: Analysis and findings 
24. How many data coders coded the data? 
BA independently reviewed the transcripts then met with BN for comparison of findings. 
Disagreements on the interpretation and analysis of the data were then discussed between BN and 
BA until consensus was achieved. BN rearranged data according to identified themes and discussed 
with BA before mapping and interpretation. 
25. Did authors provide a description of the coding tree? No. 
26. Were themes identified in advance or derived from the data? 
Themes were derived from the data. Four main themes emerged from the data. 
27. What software, if applicable, was used to manage the data? 
No software was used. 
28. Did participants provide feedback on the findings? 
Participants who requested feedback on the data were given a copy of the final report but none 
provided feedback. 
29. Were participant quotations presented to illustrate the themes/findings? Was each quotation 
identified? 
Extracts from the transcripts were quoted in the results section verbatim from the recordings 
during the interviews. 
30.Was there consistency between the data presented and the findings? 
Yes there was consistency between the data presented and the findings. 
31. Were major themes clearly presented in the findings? 
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Four major themes were elicited from the data and presented in the results of the study in named 
sub-sections. 
32. Is there a description of diverse cases or discussion of minor themes? 
Yes, diverse cases have been discussed and differences between levels of practice between 












































































Appendix 4b: Participants information sheet-questionnaire 
survey 
 
PARTICIPANT INFORMATION SHEET 
 
STUDY TITLE: PHARMACEUTICAL CARE IN DEMENTIA: EXPLORING THE VIEWS OF 
PHARMACISTS ABOUT THE PHARMACEUTICAL CARE NEEDS OF PEOPLE LIVING WITH 
DEMENTIA 
 
Name of Researcher: Beryl B Navti 
 
You are being invited to take part in a study. Before you decide if you want to take part, 
you must understand why the study is being done and what it involves. Please take time 
to read the following information. Ask if anything is not clear or if you would like more 
information. Please take time to read the following information carefully'. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
The purpose of this study is to explore community pharmacists’ views of community 
pharmacy services to patients with dementia in care homes in your locality. The World 
Health Organisation regards a close working relationship between primary care 
practitioners (e.g. GPs, nurses, pharmacists) as essential for appropriate care of 
patients. This study aims to find out to what extent pharmacists are contributing to the 
care being provided and how they can better meet the needs of these patients 
 
WHY HAVE I BEEN INVITED TO PARTICIPATE? 
You have been invited because you are a community pharmacist registered to practice 
in England. 
 
DO I HAVE TO TAKE PART? 
'It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep. If you decide to take part you are still free 
to withdraw at any time and without giving a reason'. Answering the questionnaire will 
indicate you have consented to take part in the survey. 
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
The study will involve a postal questionnaire with randomly selected community 
pharmacists registered with the General Pharmaceutical Council who provide services 
in England. You will be asked questions about the services you provide. All 
questionnaires will be anonymised and you will not be identified in any way. 
 
WHAT ARE THE POSSIBLE DISADVANTAGES AND RISKS OF TAKING PART? (WHERE 
APPROPRIATE) 
The only risk anticipated would be that the questions will require you to set aside a 
small portion of your time, which could be an inconvenience 
 
WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? 
Answering the questions may help identify any learning needs you may have with 
regards to the pharmaceutical care of patients with dementia 
 
WILL MY INFORMATION IN THIS STUDY BE KEPT CONFIDENTIAL? 
We will not collect any person identifiable information, nor inform anyone you have 
taken part in the study. All anonymised questionnaires will be kept for 5 years and then 
shredded. 
 
WHAT SHOULD I DO IF I WANT TO TAKE PART? 
If you decide to take part in this study, please respond to the questionnaire and return it 




WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY? 
Responses to the questionnaire will be analysed and the resulting data reported as part 
of a thesis on the pharmaceutical care of people with dementia 
 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
This study is being funded by the University of Sussex 
 
WHO HAS APPROVED THIS STUDY? 
 
This project has been looked at and approved by the University of Sussex Research 
Ethics Committee , the Cross-Schools Research Ethics Committee (C-REC). 
 
CONTACT FOR FURTHER INFORMATION 
You may contact the academic supervisor at the address below. 
Dr Buge Apampa, Director of Pharmacy Development, School of Life Sciences University 


















































































































Appendix 5f: COnsolidated criteria for REporting Qualitative 
research check list COREQ-care home staff study 
 
Domain 1: Research team and reflexivity 
1. Who conducted the interviews or the focus group? 
The interviews were conducted by the researcher (BN) 
2. What were the researcher’s credentials? 
The researcher (BN) is a qualified pharmacist with many years’ experience in the community 
pharmacy sector. 
BN has experience working with people living with dementia in care homes and BA (research 
supervisor) is an experienced pharmacy practice researcher. 
3. What was their occupation at the time of the study? 
BN is an advanced mental health pharmacist and part time PhD researcher and BA was a professor of 
pharmacy education and director of pharmacy at the University of Sussex. 
4. Was the researcher male or female? 
Female 
5. What experience or training did the researcher have? 
BN is an advanced mental health pharmacist experienced in dementia care and completed a module at 
the Brighton and Sussex Medical School on research methods. BA (research supervisor) has conducted 
numerous qualitative research projects in her capacity as pharmacy educator and academic 
supervisor. 
6. Was a relationship established prior to study commencement? 
BN was not acquainted with any of the study participants. Full informed consent was 
obtained. BN conducted the interviews and formally introduced herself and the topic before 
the interview this included explaining her current role in the project. 
7. What did the participants know about the researcher? 
The participants knew that BN was a pharmacist, and a postgraduate student at the University of 
Sussex, and that BA was her academic supervisor. 
8. What characteristics were reported about the interviewer/facilitator? 
BN reported that she was working as a pharmacist and a postgraduate student at the University of 
Sussex. BA was reported as the academic supervisor who could be contacted for further information on 
the study. This information was included in the participant information sheet provided to participants 




Domain 2: Study design 
9. What methodological   was stated to underpin the study? 
An exploratory, qualitative study was conducted face-to-face semi-structured interviews. 
Data were analysed using a thematic analysis approach for sorting, categorisation and 
interpretation of recorded interviews. 
10. How were participants selected? 
Care home staff were eligible to participate if they worked in care homes located in Thurrock, Essex, 
which catered for people with dementia. 
11. How were participants approached? 
A purposive sample of care homes in Thurrock, Essex, that have dementia patients was identified by 
searching the website 
https://www.cqc.org.uk/search/site/care%20homes?sort=default&distance=15&mode=html&f%5B0
%5D=im_field_popular_services%3A3668  (CQC) (2017). BN contacted the identified care homes by 
telephone to ascertain the pharmacy responsible for their pharmaceutical services. The contact details 
of the pharmacies were then confirmed through the NHS Choices website (2014) and pharmacists 
working in the registered pharmacies identified by the care homes were contacted by BN and invited 
to participate in the study. 
Participants were informed that they were selected because they worked in care homes that had 
residents with dementia 
12. How many participants were in the study? 
There were 11 care home staff 
13. How many people refused to participate or dropped out? 
None 
14. Where was the data collected? 
Each participant was interviewed at the care home they worked in, in a quiet room. 
15. Was anyone else present besides the participants and researchers? 
No-one else was present, but there were occasional interruptions as participants often had to stop 
recording to deal with queries or care home residents needing assistance 
16. What are the important characteristics of the sample? 
Care home staff selected to participate worked in care homes that provided residential care or nursing 
to people living with dementia, within the localities chosen for the study. 
17. Were questions, prompts, guides provided by the authors? Was it pilot tested? 
The interview schedule consisted of a combination of open ended and closed questions. The open-
ended questions enabled participants to express themselves without being led by the researcher. The 




18. Were repeat interviews carried out? 
No interviews were repeated. 
19. Did the research use audio or visual recording to collect the data? 
An audio recorder was used to record the interviews. Data were transcribed verbatim by a third party 
translation service 
20. Were field notes made during and/or after the interview? 
When participants raised issues not covered by the interview schedule, notes were made during the 
interviews. 
21. What was the duration of the interviews? 
There was no formal restriction on the duration of the interviews but the researcher aimed for a 20-30 
minute interview 
22. Was data saturation discussed? 
Data saturation was reached in the study and discussed and agreed between the researcher and 
research supervisor. 
23. Were transcripts returned to participants for comment and/or correction? 
Transcripts were not returned to participants, but emerging themes were discussed between the 
researcher and research supervisor 
A note was taken of all participants who wanted to be sent the report once the study was completed. 
Domain 3: Analysis and findings 
24. How many data coders coded the data? 
Two: The academic supervisor independently reviewed and coded the scripts and the researcher (BN) 
also did, then both met for comparison of findings. 
Disagreements on the interpretation and analysis of the data were then discussed between BN and BA 
until consensus was achieved. BN rearranged data according to identified themes and discussed with 
BA before mapping and interpretation. 
25. Did authors provide a description of the coding tree? No. 
26. Were themes identified in advance or derived from the data? 
Themes were derived from the data. Four main themes emerged from the data. 
27. What software, if applicable, was used to manage the data? 
No software was used. 
28. Did participants provide feedback on the findings? 




29. Were participant quotations presented to illustrate the themes/findings? Was each 
quotation identified? 
Extracts from the transcripts were quoted in the results section verbatim from the recordings during 
the interviews. 
30.Was there consistency between the data presented and the findings? 
Yes there was consistency between the data presented and the findings. 
31. Were major themes clearly presented in the findings? 
Four major themes were elicited from the data and presented in the results of the study in named sub-
sections. 
32. Is there a description of diverse cases or discussion of minor themes? 
Yes, diverse cases have been discussed and differences between levels of practice between participants 


























Appendix 6b: STOPP/ START Criteria Version 2  
(Denis O’Mahony, David O’Sullivan, Stephen Byrne, Marie Noelle O’Connor, Cristin Ryan, Paul 
Gallagher, 2015) 
STOPP: Screening Tool of Older People’s Potentially Inappropriate Prescriptions 
The following drug prescriptions are potentially inappropriate in persons aged 65 years of 
age and older: 
Section A: Indication of medication 
1. Any drug prescribed without an evidence-based clinical indication. 
2. Any drug prescribed beyond the recommended duration, where treatment duration is well defined. 
3. Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors, 
anticoagulants (optimisation of monotherapy within a single drug class should be observed prior to 
considering a new agent). 
Section B: Cardiovascular System 
1. Digoxin for heart failure with normal systolic ventricular function (no clear evidence of benefit). 
2. Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure). 
3. Beta-blocker in combination with verapamil or diltiazem (risk of heart block). 
4. Beta blocker with bradycardia (< 50/min), type II heart block or complete heart block (risk of complete 
heart block, asystole). 
5. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias (higher risk of 
side-effects than beta-blockers, digoxin, verapamil or diltiazem). 
6. Loop diuretic as first-line treatment for hypertension (safer, more effective alternatives available). 
7. Loop diuretic for dependent ankle oedema without clinical, biochemical evidence or radiological 
evidence of heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and /or 
compression hosiery usually more appropriate). 
8. Thiazide diuretic with current significant hypokalaemia (i.e. serum K+ < 3.0 mmol/l), 
hyponatraemia (i.e. serum Na+ < 130 mmol/l) hypercalcaemia (i.e. corrected serum calcium > 
2.65 mmol/l) or with a history of gout (hypokalaemia, hyponatraemia, hypercalcaemia and gout can 
be precipitated by thiazide diuretic). 
9. Loop diuretic for treatment of hypertension with concurrent urinary incontinence (may exacerbate 
incontinence). 
10. Centrally-acting antihypertensives (e.g. methyldopa, clonidine, moxonidine, rilmenidine, guanfacine), 
unless clear intolerance of, or lack of efficacy with, other classes of antihypertensives 
(centrally-active antihypertensives are generally less well tolerated by older people than younger 
people). 
11. ACE inhibitors or Angiotensin Receptor Blockers in patients with hyperkalaemia. 
12. Aldosterone antagonists (e.g. spironolactone, eplerenone) with concurrent potassium- conserving 
drugs (e.g. ACEI’s, ARB’s, amiloride, triamterene) without monitoring of serum potassium (risk of 
dangerous hyperkalaemia i.e. > 6.0 mmol/l – serum K should be monitored regularly, i.e. at least 
every 6 months). 
13. Phosphodiesterase type-5 inhibitors (e.g. sildenafil, tadalafil, vardenafil) in severe heart failure 
characterised by hypotension i.e. systolic BP < 90 mmHg, or concurrent nitrate therapy for angina 
(risk of cardiovascular collapse). 
Section C: Antiplatelet/Anticoagulant Drugs 
1. Long-term aspirin at doses greater than 160mg per day (increased risk of bleeding, no evidence for 
increased efficacy). 
2. Aspirin with a past history of peptic ulcer disease without concomitant PPI (risk of recurrent peptic 
ulcer ). 
3. Aspirin, clopidogrel, dipyridamole, vitamin K antagonists, direct thrombin inhibitors or factor Xa 
inhibitors with concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, bleeding 
diathesis, recent non-trivial spontaneous bleeding) (high risk of bleeding). 
4. Aspirin plus clopidogrel as secondary stroke prevention, unless the patient has a coronary stent(s) 
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inserted in the previous 12 months or concurrent acute coronary syndrome or has a high grade 
symptomatic carotid arterial stenosis (no evidence of added benefit over clopidogrel monotherapy). 
5. Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in 
patients with chronic atrial fibrillation (no added benefit from aspirin) 
6. Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in 
patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from 
dual therapy). 
7. Ticlopidine in any circumstances (clopidogrel and prasugrel have similar efficacy, stronger evidence and 
fewer side-effects). 
8. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first deep venous thrombosis 
without continuing provoking risk factors (e.g. thrombophilia) for > 6 months, (no proven added benefit). 
9. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first pulmonary embolus 
without continuing provoking risk factors (e.g. thrombophilia) for > 12 months (no proven added 
benefit). 
10. NSAID and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in combination 
(risk of major gastrointestinal bleeding). 
11. NSAID with concurrent antiplatelet agent(s) without PPI prophylaxis (increased risk of peptic ulcer 
disease). 
Section D: Central Nervous System and Psychotropic Drugs 
1. TriCyclic Antidepressants (TCAs) with dementia, narrow angle glaucoma, cardiac conduction 
abnormalities, prostatism, or prior history of urinary retention (risk of worsening these conditions). 
2. Initiation of TriCyclic Antidepressants (TCAs) as first-line antidepressant treatment (higher risk of adverse 
drug reactions with TCAs than with SSRIs or SNRIs). 
3. Neuroleptics with moderate-marked antimuscarinic/anticholinergic effects (chlorpromazine, 
clozapine, flupenthixol, fluphenzine, pipothiazine, promazine, zuclopenthixol) with a history of 
prostatism or previous urinary retention (high risk of urinary retention). 
4. Selective serotonin re-uptake inhibitors (SSRI’s) with current or recent significant hyponatraemia 
i.e. serum Na+ < 130 mmol/l (risk of exacerbating or precipitating hyponatraemia). 
5. Benzodiazepines for ≥ 4 weeks (no indication for longer treatment; risk of prolonged sedation, 
confusion, impaired balance, falls, road traffic accidents; all benzodiazepines should be withdrawn 
gradually if taken for more than 4 weeks as there is a risk of causing a benzodiazepine withdrawal 
syndrome if stopped abruptly). 
6. Antipsychotics (i.e. other than quetiapine or clozapine) in those with parkinsonism or Lewy Body Disease 
(risk of severe extra-pyramidal symptoms). 
7. Anticholinergics/antimuscarinics to treat extra-pyramidal side-effects of neuroleptic medications 
(risk of anticholinergic toxicity), 
8. Anticholinergics/antimuscarinics in patients with delirium or dementia (risk of exacerbation of cognitive 
impairment). 
9. Neuroleptic antipsychotic in patients with behavioural and psychological symptoms of dementia 
(BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased 
risk of stroke). 
10. Neuroleptics as hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, 
hypotension, extra-pyramidal side effects, falls). 
11. Acetylcholinesterase inhibitors with a known history of persistent bradycardia (< 60 beats/min.), 
heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate 
such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and 
injury). 
12. Phenothiazines as first-line treatment, since safer and more efficacious alternatives exist 
(phenothiazines are sedative, have significant anti-muscarinic toxicity in older people, with the exception 
of prochlorperazine for nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and 
levomepromazine as an anti-emetic in palliative care). 
13. Levodopa or dopamine agonists for benign essential tremor (no evidence of efficacy) 




Section E: Renal System 
The following drugs are potentially inappropriate in older people with acute or chronic kidney disease with 
renal function below particular levels of eGFR (refer to summary of product characteristics 
datasheets and local formulary guidelines) 
1. Digoxin at a long-term dose greater than 125µg/day if eGFR < 30 ml/min/1.73m2 (risk of digoxin toxicity 
if plasma levels not measured). 
2. Direct thrombin inhibitors (e.g. dabigatran) if eGFR < 30 ml/min/1.73m2 (risk of bleeding). 
3. Factor Xa inhibitors (e.g. rivaroxaban, apixaban) if eGFR < 15 ml/min/1.73m2 (risk of bleeding). 
4. NSAID’s if eGFR < 50 ml/min/1.73m2 (risk of deterioration in renal function). 
5. Colchicine if eGFR < 10 ml/min/1.73m2 (risk of colchicine toxicity). 
6. Metformin if eGFR < 30 ml/min/1.73m2 (risk of lactic acidosis). 
 
Section F: Gastrointestinal System 
Prochlorperazine or metoclopramide with Parkinsonism (risk of exacerbating Parkinsonian symptoms). 
1. PPI for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full therapeutic dosage for > 8 
weeks (dose reduction or earlier discontinuation indicated). 
2. Drugs likely to cause constipation (e.g. antimuscarinic/anticholinergic drugs, oral iron, opioids, 
verapamil, aluminium antacids) in patients with chronic constipation where non- constipating 
alternatives are available (risk of exacerbation of constipation). 
3. Oral elemental iron doses greater than 200 mg daily (e.g. ferrous fumarate> 600 mg/day, ferrous sulphate 
> 600 mg/day, ferrous gluconate> 1800 mg/day; no evidence of enhanced iron absorption above these 
doses). 
Section G: Respiratory System 
1. Theophylline as monotherapy for COPD (safer, more effective alternative; risk of adverse effects due to 
narrow therapeutic index). 
2. Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate-
severe COPD (unnecessary exposure to long-term side-effects of systemic corticosteroids and 
effective inhaled therapies are available). 
3. Anti-muscarinic bronchodilators (e.g. ipratropium, tiotropium) with a history of narrow angle 
glaucoma (may exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention). 
4. Benzodiazepines with acute or chronic respiratory failure i.e. pO2 < 8.0 kPa ± pCO2 > 6.5 kPa (risk of 
exacerbation of respiratory failure). 
Section H: Musculoskeletal System 
1. Non-steroidal anti-inflammatory drug (NSAID) other than COX-2 selective agents with history of 
peptic ulcer disease or gastrointestinal bleeding, unless with concurrent PPI or H2 antagonist (risk of 
peptic ulcer relapse). 
2. NSAID with severe hypertension (risk of exacerbation of hypertension) or severe heart failure (risk of 
exacerbation of heart failure). 
3. Long-term use of NSAID (>3 months) for symptom relief of osteoarthritis pain where paracetamol 
has not been tried (simple analgesics preferable and usually as effective for pain relief). 
4. Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthrtitis (risk of systemic 
corticosteroid side-effects). 
5. Corticosteroids (other than periodic intra-articular injections for mono-articular pain) for osteoarthritis 
(risk of systemic corticosteroid side-effects). 
6. Long-term NSAID or colchicine (>3 months) for chronic treatment of gout where there is no 
contraindication to a xanthine-oxidase inhibitor (e.g. allopurinol, febuxostat) (xanthine- oxidase 
inhibitors are first choice prophylactic drugs in gout). 
7. COX-2 selective NSAIDs with concurrent cardiovascular disease (increased risk of myocardial 
infarction and stroke). 
8. NSAID with concurrent corticosteroids without PPI prophylaxis (increased risk of peptic ulcer disease). 
9. Oral bisphosphonates in patients with a current or recent history of upper gastrointestinal disease i.e. 
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dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding 
(risk of relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture). 
Section I: Urogenital System 
1. Antimuscarinic drugs with dementia, or chronic cognitive impairment (risk of increased confusion, 
agitation) or narrow-angle glaucoma (risk of acute exacerbation of glaucoma), or chronic prostatism (risk of 
urinary retention). 
2. Selective alpha-1 selective alpha blockers in those with symptomatic orthostatic hypotension or 
micturition syncope (risk of precipitating recurrent syncope). 
Section J. Endocrine System 
1. Sulphonylureas with a long duration of action (e.g. glibenclamide, chlorpropamide, glimepiride) 
with type 2 diabetes mellitus (risk of prolonged hypoglycaemia). 
2. Thiazolidenediones (e.g. rosiglitazone, pioglitazone) in patients with heart failure (risk of exacerbation 
of heart failure). 
3. Beta-blockers in diabetes mellitus with frequent hypoglycaemic episodes (risk of suppressing 
hypoglycaemic symptoms). 
4. Oestrogens with a history of breast cancer or venous thromboembolism (increased risk of recurrence). 
5. Oral oestrogens without progestogen in patients with intact uterus (risk of endometrial cancer). 
6. Androgens (male sex hormones) in the absence of primary or secondary hypogonadism (risk of 
androgen toxicity; no proven benefit outside of the hypogonadism indication). 
Section K: Drugs that predictably increase the risk of falls in older people 
1. Benzodiazepines (sedative, may cause reduced sensorium, impair balance). 
2. Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism). 
3. Vasodilator drugs (e.g. alpha-1 receptor blockers, calcium channel blockers, long-acting nitrates, ACE 
inhibitors, angiotensin I receptor blockers, ) with persistent postural hypotension i.e. recurrent drop in 
systolic blood pressure ≥ 20mmHg (risk of syncope, falls). 
4. Hypnotic Z-drugs e.g. zopiclone, zolpidem, zaleplon (may cause protracted daytime sedation, 
ataxia). 
Section L: Analgesic Drugs 
1. Use of oral or transdermal strong opioids (morphine, oxycodone, fentanyl, buprenorphine, diamorphine, 
methadone, tramadol, pethidine, pentazocine) as first line therapy for mild pain (WHO analgesic ladder 
not observed). 
2. Use of regular (as distinct from PRN) opioids without concomitant laxative (risk of severe constipation). 
3. Long-acting opioids without short-acting opioids for break-through pain (risk of persistence of severe 
pain). 
Section N: Antimuscarinic/Anticholinergic Drug Burden 
1. Concomitant use of two or more drugs with antimuscarinic/anticholinergic properties (e.g. bladder 
antispasmodics, intestinal antispasmodics, tricyclic antidepressants first generation antihistamines) 




















START: Screening Tool to Alert to Right Treatment (START), version 2. 
 
Unless an elderly patient’s clinical status is end-of-life and therefore requiring a more palliative focus 
of pharmacotherapy, the following drug therapies should be considered where omitted for no valid 
clinical reason(s). It is assumed that the prescriber observes all the specific contraindications to 
these drug therapies prior to recommending them to older patients. 
Section A: Cardiovascular System 
1. Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors in the presence of chronic 
atrial fibrillation. 
2. Aspirin (75 mg – 160 mg once daily) in the presence of chronic atrial fibrillation, where Vitamin K 
antagonists or direct thrombin inhibitors or factor Xa inhibitors are contraindicated. 
3. Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) with a documented history of 
coronary, cerebral or peripheral vascular disease. 
4. Antihypertensive therapy where systolic blood pressure consistently > 160 mmHg and/or diastolic blood 
pressure consistently >90 mmHg; if systolic blood pressure > 140 mmHg and 
/or diastolic blood pressure > 90 mmHg, if diabetic. 
5. Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease, 
unless the patient’s status is end-of-life or age is > 85 years. 
6. Angiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure and/or documented 
coronary artery disease. 
7. Beta-blocker with ischaemic heart disease. 
8. Appropriate beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) with stable systolic heart 
failure. 
Section B: Respiratory System 
1. Regular inhaled 2 agonist or antimuscarinic bronchodilator (e.g. ipratropium, tiotropium) for mild to 
moderate asthma or COPD. 
2. Regular inhaled corticosteroid for moderate-severe asthma or COPD, where FEV1 <50% of predicted value 
and repeated exacerbations requiring treatment with oral corticosteroids. 
3. Home continuous oxygen with documented chronic hypoxaemia (i.e. pO2 < 8.0 kPa or 60 mmHg or 
SaO2 < 89%). 
Section C: Central Nervous System& Eyes 
1. L-DOPA or a dopamine agonist in idiopathic Parkinson’s disease with functional impairment and resultant 
disability. 
2. Non-TCA antidepressant drug in the presence of persistent major depressive symptoms. 
3. Acetylcholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine) for mild- moderate 
Alzheimer’s dementia or Lewy Body dementia (rivastigmine). 
4. Topical prostaglandin, prostamide or beta-blocker for primary open-angle glaucoma. 
5. Selective serotonin reuptake inhibitor (or SNRI or pregabalin if SSRI contraindicated) for persistent 
severe anxiety that interferes with independent functioning. 
6. Dopamine agonist (ropinirole or pramipexole or rotigotine) for Restless Legs Syndrome, once iron 
deficiency and severe renal failure have been excluded 
Section D: Gastrointestinal System 
1. Proton Pump Inhibitor with severe gastro-oesophageal reflux disease or peptic stricture requiring 
dilatation. 
2. Fibre supplements (e.g. bran, ispaghula, methylcellulose, sterculia) for diverticulosis with a history of 
constipation. 
 
Section E: Musculoskeletal System 
1. Disease-modifying anti-rheumatic drug (DMARD) with active, disabling rheumatoid disease. 




3. Vitamin D and calcium supplement in patients with known osteoporosis and/or previous fragility 
fracture(s) and/or (Bone Mineral Density T-scores more than -2.5 in multiple sites). 
4. Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate, strontium ranelate, teriparatide, 
denosumab) in patients with documented osteoporosis, where no pharmacological or clinical status 
contraindication exists (Bone Mineral Density T-scores ->2.5 in multiple sites) and/or previous history of 
fragility fracture(s). 
5. Vitamin D supplement in older people who are housebound or experiencing falls or with osteopenia 
(Bone Mineral Density T-score is > -1.0 but < -2.5 in multiple sites). 
6. Xanthine-oxidase inhibitors (e.g. allopurinol, febuxostat) with a history of recurrent episodes of 
gout. 
7. Folic acid supplement in patients taking methotexate. 
 
Section F: Endocrine System 
   1. ACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE inhibitor) in diabetes with evidence of    
renal disease i.e. dipstick proteinuria or microalbuminuria (>30mg/24 hours) with or without serum 
biochemical renal impairment. 
Section G: Urogenital System 
1. Alpha-1 receptor blocker with symptomatic prostatism, where prostatectomy is not considered 
necessary. 
2. 5-alpha reductase inhibitor with symptomatic prostatism, where prostatectomy is not considered 
necessary. 
3. Topical vaginal oestrogen or vaginal oestrogen pessary for symptomatic atrophic vaginitis. 
 
Section H: Analgesics 
1. High-potency opioids in moderate-severe pain, where paracetamol, NSAIDs or low-potency opioids are not 
appropriate to the pain severity or have been ineffective. 
2. Laxatives in patients receiving opioids regularly. 
 
Section I: Vaccines 
1. Seasonal trivalent influenza vaccine annually 










Appendix 6c: NICE guidelines dementia (CG42): excerpt from 
section 1.7 
Dementia: supporting people with dementia and their carers in health and 
social care (NICE guidelines CG42) 
(https://www.nice.org.uk/guidance/cg42) 
 Non-cognitive symptoms include hallucinations, delusions, anxiety, marked agitation and 
associated aggressive behaviour. ‘Behaviour that challenges’ encompasses a wide range of 
difficulties that are often experienced by people with dementia and that may have an effect on those 
who provide care. It may include aggression, agitation, wandering, hoarding, sexual disinhibition, 




1.7.1: Non-pharmacological interventions for non-cognitive symptoms and 
behaviour that challenges 
1.7.1.1 People with dementia who develop non-cognitive symptoms that cause them 
significant distress or who develop behaviour that challenges should be offered an 
assessment at an early opportunity to establish likely factors that may generate, aggravate or 
improve such behaviour. The assessment should be comprehensive and include: 
• the person’s physical health 
• depression 
• possible undetected pain or discomfort 
• side effects of medication 
• individual biography, including religious beliefs and spiritual and cultural identity 
• psychosocial factors 
• physical environmental factors 
• behavioural and functional analysis conducted by professionals with specific skills, in 
conjunction with carers and care workers. 
Individually tailored care plans that help carers and staff address the behaviour that 
challenges should be developed, recorded in the notes and reviewed regularly. The 
frequency of the review should be agreed by the carers and staff involved and written in the 
notes. 
1.7.1.2 For people with all types and severities of dementia who have comorbid 
agitation, consideration should be given to providing access to interventions tailored to 
the person’s preferences, skills and abilities. Because people may respond better to 
one treatment than another, the response to each modality should be monitored and 
the care plan adapted accordingly. Approaches that may be considered, depending on 
availability, include: 
• aromatherapy 
• multisensory stimulation 
• therapeutic use of music and/or dancing 
• animal-assisted therapy 
• massage. 
These interventions may be delivered by a range of health and social care staff and 
volunteers, with appropriate training and supervision. The voluntary sector has a 
particular role to play in delivering these approaches. Health and social care staff in the 
NHS and social care, including care homes, should work together to ensure that some 
of these options are available, because there is some evidence of their clinical 








Appendix 6d: Drug Interactions 
A. Drug interactions between Acetylcholinesterase Inhibitors and other 
medications (see current BNF and Stockley’s Drug Interactions for up to 
date list of interactions) 
◼ Probably clinically insignificant; no dose adjustment of anticholinesterase needed unless 
adverse side effects (e.g nausea and vomiting) are experienced. 
❖ Probably clinically insignificant; no dose increase of anticholinesterase needed but use with 
care 
● Probably clinically significant increase; a lower anticholinesterase maintenance dose might be 
appropriate. 
 Monitor concurrent use if adverse effects occur or if there is treatment failure 










Increase level of donepezil 
and may increase risk of 
bradycardia ◼/⚫ 
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 Interaction unlikely 
Fluoxetine 
Increases level of donepezil  
◼ 
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Increases levels of 
galantamine by 40%    ⚫ 
Interaction unlikely 
Quinidine 
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Might oppose levels of 
galantamine opposite effect 
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B. Drug interactions between Memantine and other medications 
(refer to most recent BNF for up to date list of drug interactions) 
 
◼: Clinically possibly significant. Monitor for adverse effects. 







Interacting drug Effect Comments 
General anaesthetics: 
KETAMINE 
Increased risk of adverse CNS reactions (e.g psychosis) when memantine 
given with ketamine.  X 
Avoid concurrent use 
Analgesics: 
DEXTROMETHORPHAN 
Increased risk of CNS toxicity when memantine given with 
dextromethorphan because they have similar modes of action X 
Avoid concurrent use 
Dopaminergics: 
AMANTADINE 
Increased risk of CNS toxicity when memantine given with amantadine 
because they are chemically related X 
Avoid concurrent use 
Anticoagulants: 
WARFARIN 
Memantine may enhance anticoagulant effect of warfarin (cases of raised 
INR reported when patients on warfarin given memantine)     ◼ 
Increase frequency of INR 
monitoring if memantine 




Memantine may reduce effect of primidone  and barbiturates◼ Monitor for seizures 
Anticholinergics 
(Antimuscarinics) 
Memantine may enhance effect of anticholinergic drugs ◼ 
Monitor for worsening 
confusion and 
anticholinergic effects, 
and adjust treatment 
accordingly 
Antipsychotics Memantine may reduce effect of antipsychotic drugs ◼ 
Monitor that concurrent 
use to ensure 
antipsychotic effect 





Memantine possibly enhances effects of dopaminergics and selegiline◼ 
Dopaminergic side effects 
may increase, Monitor 





Memantine possibly modifies effects of baclofen and dantrolene ◼ 
Monitor for adverse 






These share a renal pathway of elimination and may reduce rate of clearance 
of memantine potentially leading to higher plasma levels of memantine ◼ 
Monitor for any increased 




Appendix 6e: Anticholinergic Cognitive Burden Scale (ACB) 
(adapted) 
  Anticholinergic drugs can oppose the action of acetylcholine and lead to increased confusion, making     
the addition of acetylcholinesterase drugs (aimed at increasing acetylcholine and improving 
cognition)  ineffective. Each definite anticholinergic medication could increase risk of cognitive 
impairment by 46% over 6 years (Campbell et al 2010). Cumulative ACB score>3 is considered 
clinically relevant 
Drug class with 
anticholinergic 
effects 
Examples of drug and level of anticholinergic effect on Anticholinergic Cognitive Burden Scale 
(1=possible, 2,3=definite) 





































Anxiolytics   Alprazolam 
Diazepam 








Antiepileptics  Carbamazepine 
Oxcarbazepine 
 
Antiplatelet   Dipyridamole 































Gout   Colchicine 
Respiratory   Theophylline 
Skeletal muscle 
relaxants 
Methocarbamol   
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Appendix 6f: Pharmaceutical care plans 


























































Appendix 7e: Case studies for testing usability of DEMENTIAS 
toolkit 
 
Case Study 1 
Peter is 75 and has been diagnosed with Alzheimer’s disease and has a MMSE 22. He lives 
in a care home because he is no longer able to look after himself at home. 
Current medication: 
Atenolol for hypertension 
Salbutamol for asthma PRN 
Fluoxetine for depression 
Amitriptyline for back pain and to help him sleep 
 




He doesn’t take any other medication bought over the counter. 
Please use the Dementias Toolkit to review Peter’s medication and to make 
recommendations for changes that can be considered by the GP for medication review and to 
determine whether an anticholinesterase inhibitor (donepezil, galantamine or rivastigmine) 
can be safely prescribed and formulate a pharmaceutical care pla 
Case Study 2: 
Mrs Carter is an 81 year old woman with severe AD dementia.  
He has been living alone for the 6 years since his wife died and has now been admitted in a 
nursing home.  
She has a male keyworker/main carer who attends to her welfare and she is completely 
dependent on carers for her personal care and every day needs. 
She is generally amiable with her main carer but has been known to throw her food at him 
on occasions out of the blue. 
Recently her carer started taking one day off a week, replaced by a young female staff 
member and on this one day of the week, Mrs Carter becomes verbally abusive, aggressive 
and resistant to personal care. GP has prescribed Olanzapine 2.5mg daily to deal with this 
behaviour. 
Mrs Carter is also taking Memantine 10mg daily for her dementia and has been prescribed 
co-codamol 30/500 for pain following a recent assessment by the geriatrician. 
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She has no other co-morbidities, having been quite healthy before being diagnosed with 
dementia, however, the care staff has observed that for the past three months, Mrs 
Carter’s mood has dipped significantly, she has lost her appetite, no longer wants to 
socialise with other residents and become very anxious. 
Please evaluate the usefulness of the toolkit for reviewing Mrs Carter’s medication. 
ANSWERS: 
Case study 1- Guide to identification of drug therapy problems 
Aspects of DEMENTIAS toolkit 
 
• Amitriptyline has a high anticholinergic burden (see ACB scale) and would impair 
the useful effects of an anticholinesterase drug, so should be stopped. 
• As amitriptyline was helping him sleep, Peter is observed for insomnia, and if 
necessary, another hypnotic can be prescribed. 
• An anticholinesterase inhibitor can be added as per NICE dementia guidelines, but 
this may cause bradycardia as with his atenolol (see STOPP/START tool), though 
the two can be used safely. If an anticholinesterase drug is to be started, his cardiac 
function should be monitored, and the dose of atenolol reduced if necessary.  
• Adding an anticholinesterase drug may cause his asthma control to worsen (see 
interactions), so his respiratory function should be monitored, and appropriate 
action taken if necessary, either by increasing the asthma treatment or reducing/ 
stopping the anticholinesterase drug safely. 
• An anticholinesterase drug is worthwhile, feasible, and safe with the monitoring 
put in place so it can be added if all other person-centred considerations have been 
made 
• Drug-drug interaction between donepezil and fluoxetine, increasing their levels.  
• Rivastigmine doesn’t interact, so potential anticholinesterase inhibitor of choice. 
Pharmaceutical care issue 
identified using toolkit 
Description  
D (Drugs prescribed) 
Patient prescribed 
Amitriptyline 
Amitriptyline, Atenolol, Fluoxetine, Salbutamol 
inhaler 
Evidence NICE guidelines for: Dementia, hypertension, 
depression in adults 
Co-Morbidity Patient suffers from insomnia, asthma, high blood 
pressure, pain, lack of sleep 
Side Effects Amitriptyline has anti-cholinergic side effects 
Neuropsychiatric symptoms Depression 
Type of dementia Alzheimer’s disease (MMSE = 22) 
Interactions Drug-drug interaction between fluoxetine and 
donepezil 
Anticholinergic burden Check anticholinergic burden scale 
Simplify/stop/switch? Query Amitriptyline 
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Case study 2- considerations from toolkit for inclusion in pharmaceutical care plan 
 
• Only Risperidone is licensed for treating aggression in person with dementia 
• Co-codamol has codeine which can cause constipation, particularly problematic for 
people with dementia and can lead to agitation and aggression 
• Depression common in people with dementia, this patient’s low mood should be 
investigated. 
• Potential drug-drug interaction between olanzapine and memantine 








issue from toolkit 
Description  
D (Drugs prescribed) 
 
Memantine, Olanzapine, Co-codamol 
Evidence NICE guidelines for: Dementia 
Co-Morbidity Query low mood 
Side Effects Co-codamol can cause constipation 
Neuropsychiatric 
symptoms 
Aggression (see NICE guideline, Dementia). Is olanzapine 
evidence based? 
Type of dementia Alzheimer’s disease  
Interactions Drug-drug interaction between memantine and 
olanzapine, check if clinically significant 
Anticholinergic burden Check anticholinergic burden scale, co-codamol has 
codeine, check ACB score 
Simplify/stop/switch? Consider switching co-codamol 
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Appendix 7f: NICE guidelines NG97 excerpt (replaces Appendix 6c 
in toolkit) 
NICE Guidelines NG97: Dementia: assessment, management and support for 
people living with dementia and their carers 
1.7 Managing non-cognitive symptoms  
https://www.nice.org.uk/guidance/ng97/chapter/Recommendations#mana
ging-non-cognitive-symptoms 
Agitation, aggression, distress and psychosis 
1.7.1 Before starting non-pharmacological or pharmacological treatment for distress in people living with 
dementia, conduct a structured assessment to: 
•explore possible reasons for their distress and 
•check for and address clinical or environmental causes (for example pain, delirium or inappropriate care). 
1.7.2 As initial and ongoing management offer psychosocial and environmental interventions to reduce 
distress in people living with dementia. 
1.7.3 Only offer antipsychotics or people living with dementia who are either:  
•at risk of harming themselves or others or 
• experiencing agitation, hallucinations or delusions that are causing them severe distress. 
1.7.4 Be aware that for people with dementia with Lewy bodies or Parkinson's disease dementia, 
antipsychotics can worsen the motor features of the condition, and in some cases cause severe antipsychotic 
sensitivity reactions. For more guidance, see the advice on managing delusions and hallucinations in the NICE 
guideline on Parkinson's disease. Be aware that interventions may need to be modified for people living with 
dementia. 
1.7.5 Before starting antipsychotics, discuss the benefits and harms with the person and their family members 
or carers (as appropriate). Consider using a decision aid to support this discussion. NICE has produced a 
patient decision aid on antipsychotic medicines for treating agitation, aggression and distress in people living 
with dementia. 
1.7.6 When using antipsychotics: 
• use the lowest effective dose and use them for the shortest possible time 
• reassess the person at least every 6 weeks, to check whether they still need medication.  
1.7.7 Stop treatment with antipsychotics:  
• if the person is not getting a clear ongoing benefit from taking them and 
• after discussion with the person taking them and their family members or carers (as appropriate). 
1.7.8 Ensure that people living with dementia can continue to access psychosocial and environmental 
interventions for distress while they are taking antipsychotics and after they have stopped taking them. 
1.7.9 For people living with dementia who experience agitation or aggression, offer personalised activities to 
promote engagement, pleasure and interest. 
1.7.10 Do not offer valproate to manage agitation or aggression in people living with dementia, unless it is 
indicated for another condition. 
 
Depression and anxiety 
1.7.11 For people living with mild to moderate dementia who have mild to moderate depression and/or 
anxiety, consider psychological treatments. 
1.7.12 Do not routinely offer antidepressants to manage mild to moderate depression in people living with 
mild to moderate dementia, unless they are indicated for a pre-existing severe mental health problem. 
 
Sleep problems 
1.7.13 Do not offer melatonin to manage insomnia in people living with Alzheimer's disease. 
1.7.14 For people living with dementia who have sleep problems, consider a personalised multicomponent 






















Name of Care Home:  Care Home Code (For research 
purposes): 
Address: 
Telephone: Manager: Manager’s email: 
Type of Care Home (Circle appropriate category): 
(a) Residential                                                                                      b) Nursing 
No. of residents: No. of dementia patients 
(diagnosed): 
No. of dementia patients  

















Age: Date of Birth: Gender: M/F Code: 
Weight: Height: BMI: Ethnicity: 
Date of admission into home: Religion GP: GP address: 
Dementia subtype: 
Mobility: 
Please state any other diseases patient has: 
























List cognitive tests conducted: 
Risk assessments:  
Physical health checks: 
Allergies Medication: 
Adverse reactions to drugs in the past: 












































































      
      
      
      
      
      
      
      









































Appendix 7h: Permission to add online Anticholinergic Burden 









Appendix 7i: COnsolidated criteria for REporting Qualitative 
research check list COREQ-pharmacists’ focus group study 
 
Domain 1: Research team and reflexivity 
1. Who conducted the interviews or the focus group? 
The focus group was moderated by the researcher (BN) 
2. What were the researcher’s credentials? 
The researcher (BN) is a qualified pharmacist with many years’ experience in the community 
pharmacy sector. 
BN has experience working with people living with dementia in care homes  
3. What was their occupation at the time of the study? 
BN is an advanced mental health pharmacist and part time PhD researcher and BA was a professor of 
pharmacy education and director of pharmacy at the University of Sussex. 
4. Was the researcher male or female? 
Female 
5. What experience or training did the researcher have? 
BN is an advanced mental health pharmacist experienced in dementia care and completed a module at 
the Brighton and Sussex Medical School on research methods. BA (research supervisor) has conducted 
numerous qualitative research projects in her capacity as pharmacy educator and academic 
supervisor. 
6. Was a relationship established prior to study commencement? 
BN belonged in a pharmacist collaboration forum with two  participants. Full informed 
consent was obtained. BN moderated the focus group discussions and formally introduced 
herself and the topic before the discussions started explaining her and the aim of the focus 
group. 
7. What did the participants know about the researcher? 
The participants knew that BN was a specialist pharmacist, and a postgraduate student at the 
University of Sussex, and that BA was her academic supervisor. 
8. What characteristics were reported about the interviewer/facilitator? 
BN reported that she was working as a pharmacist and a postgraduate student at the University of 
Sussex. The group was informed that the study was supervised by BA the academic supervisor who 
could be contacted for further information on the study. This information was included in the 





Domain 2: Study design 
9. What methodological   was stated to underpin the study? 
A focus group qualitative approach was used  
Data were analysed using a thematic analysis approach for sorting, categorisation and 
interpretation of recorded interviews. 
10. How were participants selected? 
Pharmacists working in the community pharmacy, care home or mental health sector were selected 
11. How were participants approached? 
Participants were invited from NHS England Pharmacy Integration Programme, through the "Future 
NHS Collaboration Platform" 
(https://future.nhs.uk/connect.ti/system/login?nextURL=%2Fconnect%2Eti%2FPharmacyIntegratio
n%2Fgrouphome), where the researcher is a member 
12. How many participants were in the study? 
There were 7 
13. How many people refused to participate or dropped out? 
None 
14. Where was the data collected? 
A conference room was booked in a hotel within easy reach of all participants 
15. Was anyone else present besides the participants and researchers? No 
16. What are the important characteristics of the sample? 
Participants worked in care home environments or hospital settings where they regularly delivered or 
witnessed care to people living with dementia 
17. Were questions, prompts, guides provided by the authors? Was it pilot tested? 
The focus group discussion was directed by questions and prompts from the researcher, guided by the 
views of the participants on the toolkit being reviewed. Toolkit was not piloted but it was reviewed by 
the academic supervisor 
18. Were repeat interviews carried out? No 
19. Did the research use audio or visual recording to collect the data? 
An audio recorder was used to record the interviews. Data were transcribed verbatim by a third-party 
translation service 
20. Were field notes made during and/or after the interview? 




21. What was the duration of the interviews? 
The focus group study took approximately one hour to complete 
22. Was data saturation discussed? 
Data saturation was reached in the study when participants had reviewed the toolkit and had no more 
comments to make about it.  
23. Were transcripts returned to participants for comment and/or correction? 
Transcripts were not returned to participants, but themes were discussed between the researcher and 
research supervisor 
A note was taken of all participants who wanted to be sent the report once the study was completed. 
Domain 3: Analysis and findings 
24. How many data coders coded the data? 
Two: The academic supervisor independently reviewed and coded the scripts and the researcher (BN) 
also did, then both met for comparison of findings. 
Disagreements on the interpretation and analysis of the data were then discussed between BN and BA 
until consensus was achieved. BN rearranged data according to identified themes and discussed with 
BA before mapping and interpretation. 
25. Did authors provide a description of the coding tree? No. 
26. Were themes identified in advance or derived from the data? 
Themes were derived from the data.  
27. What software, if applicable, was used to manage the data? No  
28. Did participants provide feedback on the findings? No 
29. Were participant quotations presented to illustrate the themes/findings? Was each 
quotation identified? 
Extracts from the transcripts were quoted in the results section verbatim from the recordings obtained 
during the focus group discussions 
30.Was there consistency between the data presented and the findings? 
Yes, there was consistency between the data presented and the findings. 
31. Were major themes clearly presented in the findings? 
Three major themes were elicited from the data and presented in the results of the study in named 
sub-sections. 
32. Is there a description of diverse cases or discussion of minor themes? 
Yes, diverse cases have been discussed and differences between levels of practice between participants 
within the same locality and between the two localities studied have been discussed in the findings. 
